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PhD abstract
PhD abstract
Quorum sensing, the phenomenon in which bacteria express their genes in a cell density-
dependent manner, plays a pivotal role in the production of several secondary metabolites.
Gram-negative bacteria rely mostly on N-acylated-L-homoserine lactones (AHLs) for this type
of regulation. Besides communication between bacteria, AHLs are also involved in bacteria-
plant interactions (the so-called interkingdom signaling). Cyclic lipopeptides are an example of
a class of secondary metabolites with interesting activities, in which quorum sensing can play
an important regulating role. The overall goal of this PhD research was to study the role of a
certain class of AHLs, N-(3-hydroxyacyl)-L-homoserine lactones, in nature.
In a first part of this PhD thesis several isotope-labelled AHLs, belonging to all three major
classes of AHLs, were synthesized. To further extend the possible applications of these com-
pounds, two important AHL-degradation products, a tetramic acid and a N-acyl-L-homoserine
were synthesized departing from these deuterated compounds. To aid their application as inter-
nal standards in isotope dilution mass spectrometry, the MS fragmentation pattern was studied
extensively. The isotope-labelled AHLs can be used as well as a tool to study the metabolization
of the fatty acid side chain of AHLs.
In a second part, the spontaneous rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones,
which proved to be very unlikely, was investigated. This investigation resulted however in the
successful development of a synthetic entry toward 1,4-oxazepane-2,5-diones, which are ex-
tremely difficult to synthesize due to the presence of a lactam with a preference for the trans-
conformation and a labile lactone moiety in one ring structure. However, some of the reported
natural products with such a 1,4-oxazepane-2,5-dione core display interesting biological activi-
ties. By applying the disclosed methodology on the synthesis of the natural product serratin, the
incorrect structural assignment of this compound was identified.
The following two research parts aimed to gain a better understanding of the biocontrol ac-
tivity of Pseudomonas species CMR12a and more specific the role of quorum sensing. There-
fore, the effect of one of its quorum sensing signal molecules, N-(3-hydroxydodecanoyl)-L-
homoserine lactone, on plant growth was studied. However, no direct growth promoting ef-
fect could be observed. No growth promoting or inhibiting effects were observed either for a
tetramic acid, which is formed via the rearrangement of an oxo-AHL. On the other hand, as
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an antifungal effect was found for this compound, which has already known algicidal effects,
the use in hydroculture could form an interesting application, although further research is re-
quired. Subsequently, the profound effect of another QS signal molecule of this Pseudomonas
strain, N-(3-hydroxyoctanoyl)-L-homoserine lactone, on its cyclic lipopeptide production was
demonstrated. It was hypothesized that quorum sensing plays a crucial role in determining the
swarming behavior of this Pseudomonas sp. CMR12a. The influence of QS goes via an ele-
gant fine-tuning of the ratio of the two produced CLPs, orfamide and sessilin, via the control of
orfamide production.
2
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Introduction and goals
For many years, researchers thought of bacteria as individual cells, unable to interact with one
another. However, this view changed dramatically with the discovery of population density-
dependent light production by the marine bacterium Vibrio fischeri some decades ago.1 Indi-
vidual cells of V. fischeri do not produce light, but when accumulated in high cell densities such
as in the light organ of the Hawaiian bobtail squid Euprymna scolopes, bioluminescence is ob-
served (Figure 1.1, left). By providing a nutrient-rich environment, the squid can benefit from
this bioluminescence to counter-illuminate itself and hide its silhouette from predators on clear
nights.2 The pineapplefish (Cleidopus gloriamaris) uses a similar light organ as a spot to search
for prey at night and to communicate with its own kind (Figure 1.1, right).2
Figure 1.1. Bioluminescence in marine organisms. Left: Euprymna scolopes. Right: Cleidopus gloriamaris.2
Because this type of gene regulation is linked to the population density or quorum, the term
‘quorum sensing’ (QS) was used to describe this phenomenon. First thought to be restricted to
a limited number of bacteria, QS was later on found to be present in many other bacteria. To
communicate with each other, the bacteria rely on small, diffusible signal molecules, termed
autoinducers. Once a certain threshold concentration of these autoinducers is reached, several
phenotypes can be activated. A chemically diverse array of these autoinducers is known (Fig-
ure 1.2). One of the most studied types are N-acylated-L-homoserine lactones (AHLs), which
are used by Gram-negative bacteria. The general structure of an AHL consists of a homoserine
lactone ring coupled to a variable N-acyl chain. This acyl chain can contain four to eighteen car-
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bon atoms and the third carbon atom can be unfunctionalized (C4-C18 1) or carry a hydroxy-
(HO4-HO18 2) or oxo-group (oxo4-oxo18 3).2,3 Recently, an AHL 4 lacking the typical acyl
chain but with a p-coumaryl group instead was discovered, expanding the range of possible
AHLs.4 AHL-Mediated QS has been observed in more than 70 genera of Gram-negative pro-
teobacteria. Several other QS signal molecules are known, for example Streptomyces species use
γ-butyrolactones 5 as signal compounds. Pseudomonas aeruginosa uses 2-heptyl-3-hydroxy-
4(1H)-quinolone, named Pseudomonas quinolone signal (6) (PQS), as an additional autoin-
ducer beside AHLs. Some other QS signal molecules are derived solely from fatty acids such as
the diffusible signal factor (7) (DSF) used by Xanthomonas or 3-hydroxypalmitate methyl ester
8 which is used by Ralstonia.5 Gram-positive bacteria rely on cyclic peptides such as autoin-
ducing peptide III (9) (AIP-III) to coordinate their gene expression in a cell density-dependent
manner. Furanosyl borate diester or autoinducer-2 (10) (AI-2) is used as a signal molecule
in interspecies cell-to-cell communication, although there remains some controversy about its
function.5 In this PhD thesis the focus will be on AHL-mediated QS.
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Figure 1.2. Some examples of QS signal molecules, demonstrating the diversity of compounds used as QS signals
by bacteria.
QS enables bacteria to express certain genes under the right conditions, e.g. only inducing light
production when a sufficient quorum is reached to generate a strong light signal or delay viru-
lence until sufficient bacteria are present to overwhelm the host and mount a successful infec-
tion.2 Instead of sensing the population density, it has been argued that autoinducers could be
used to determine whether secreted compounds move rapidly away from the cell in a process
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called diffusion sensing. As a high diffusion rate corresponds to a low concentration of signal
molecules and vice versa, bacteria can determine whether it is advantageous to excrete certain
enzymes or metal chelators.6,7 Both concepts are unified in the efficiency sensing theory, postu-
lating that bacteria sense the combination of cell density, spatial distribution and mass transfer
to fine-tune their actions.8 AHLs themselves can also have another function than solely sig-
naling. N-(3-Oxoacyl)-L-homoserine lactones 3 for example can rearrange to tetramic acids 11
(Scheme 1.1) with interesting bioactivity such as iron chelation and antimicrobial activity.9
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Scheme 1.1. Rearrangement of N-(3-oxoacyl)-L-homoserine lactones 3 to tetramic acids 11.
QS Plays a pivotal role in both pathogenic and symbiotic bacteria-host interactions. Processes
regulated by QS include bioluminescence, conjugation, pigment production, antibiotic produc-
tion, virulence, root nodulation, motility, biofilm formation, etc.2,3 Several clinically relevant
pathogens, e.g. Pseudomonas aeruginosa, rely on QS systems to regulate their virulence. There-
fore, a great interest exists to use QS as a novel target to tackle bacterial infections.2 As the
emergence of resistant bacteria poses a rising threat to the effectiveness of antibiotics, QS could
form an interesting target to combat several bacterial pathogens. Unlike traditional antibiotics,
no harsh selective pressure for development of resistance is applied by QS inhibitors as QS is not
essential for microbial survival.10,11 Several natural and synthetic compounds exist which are
able to interfere with QS.5,12,13 Alternatively, several enzymes such as lactonases and acylases
(also referred to as amidases) are able to degrade AHLs.5
When Alexander Fleming serendipitously discovered penicillin in 1928, by observing that a
contaminating Penicillium fungus was able to kill the cultured bacteria, mankind had finally
the powerful means to combat bacterial infections.14 After the penicillins (belonging to the β-
lactam group), many other classes of antibiotics have been discovered between 1940 and 1970
(the golden age of antibiotics). After the 1970s the pipeline with new antibiotics started to run
dry (Figure 1.3). However, already in 1960 the first resistant bacterial strains occurred and due
to misuse and over-usage of antibiotics, the number of resistant human pathogens is increasing.
This causes the urgent need to find new antibiotics, able to circumvent the resistance of these
bacteria. Rather than derivatives of known compound classes, totally new scaffolds are preferred
as they could have a totally new target for which bacteria have not yet acquired resistance. One
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example of such a class with presumably a different mode of action are the lipopeptides. The
use of these compounds as antibiotics was approved in 2003.15,16
Figure 1.3. Antibiotic discovery time line. Reprinted from Lewis, 2012.15
Cyclic lipopeptides (CLPs) are a diverse class of compounds composed out of a fatty acid tail
linked to an oligopeptide moiety. This oligopeptide contains 7-25 amino acids and 4-14 of these
residues form a cyclic structure. As these compounds are synthesized non-ribosomally, unusual
amino acids, such as D-amino acids, β-amino acids and N-methylated amino acids, can often
be found in these compounds. As an example of a CLP, the structure of the commercial CLP-
antibiotic daptomycin (12) is represented in figure 1.4.17,18
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Figure 1.4. Chemical structure of the CLP-antibiotic daptomycin (12).
The Pseudomonas genus represents an interesting source for CLPs.18,19 These Gram-negative
bacteria can be found in many different niches and some are plant- and human-pathogenic
whereas other strains can promote plant growth and offer protection against pathogens. The
CLPs produced by these bacteria can serve several purposes such as biofilm formation, viru-
lence, motility, etc.20 Although the production of some CLPs is AHL-controlled,21–25 these are
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the exception rather than the rule.
The overall structure of this PhD research is schematically presented in scheme 1.2 and the
different goals are discussed hereafter. The main goal is to obtain a better understanding of the
role of N-(3-hydroxyacyl)-L-homoserine lactones 2 in nature.
To be able to study the metabolization of these AHLs, a first goal is to develop a protocol
to synthesize isotope-labelled AHLs. In order to use these labelled AHLs to study the meta-
bolization of the fatty acid side chain, the isotope label will be included in the acyl chain of
the AHL. To be able to synthesize a broad library of tailor-made deuterated AHLs, the goal is
to construct a robust synthetic route toward different AHLs starting from one, easily accessible
deuterated building block.
A second research interest is to study the reactivity of these QS signal molecules 2. It is known
that N-(3-oxoacyl)-L-homoserine lactones 3 can rearrange to tetramic acids 11 (Scheme 1.1)
with fascinating biological properties. The goal of this part of the thesis is to evaluate if HO-
AHLs 2 can participate in a similar rearrangement wherein the hydroxy group attacks the lac-
tone to form a 1,4-oxazepane-2,5-dione. Several natural products, such as serratin, containing
such a seven-membered core have been reported. The conditions required for such a rearrange-
ment to occur will be scrutinized.
Subsequently the biological activity of N-(3-hydroxyacyl)-L-homoserine lactones 2 will be in-
vestigated. The promising biocontrol strain Pseudomonas sp. CMR12a possesses two QS sys-
tems using HO-AHLs 2. In previous research, it was found that one of its QS molecules had
growth stimulatory effects on lettuce plants. Therefore, to fully understand the biocontrol prop-
erties of this strain, these growth stimulatory effects of AHLs on plants will be studied in the
third part of this PhD research. Pseudomonas sp. CMR12a produces two types of CLPs which
play an important role in its biocontrol capacity. The regulation of this CLP-production will
therefore be subject of a thorough investigation as well. The role of AHLs in this regulation will
be evaluated. To test if the fatty acid moieties of certain AHLs get recycled into the CLPs, the
isotope-labelled AHLs which were synthesized in the first part of this research work, will be
used.
To give the reader a better insight in AHL-mediated QS, a short overview of this type of QS is
presented in the literature overview. Also the interplay between plants and AHLs will be dis-
cussed. In the second part of the literature overview, the different types of CLPs are mentioned,
followed by the biosynthesis of CLPs, with special attention for the (QS) regulation of CLP
production.
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Scheme 1.2. Schematic representation of the structure of this PhD research.
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Chapter 2
Literature overview
2.1 Quorum sensing
2.1.1 N-Acyl-L-homoserine lactone (AHL) regulated quorum sensing
To coordinate their behavior in a cell density-dependent manner, Gram-negative bacteria mostly
rely on N-acylated-L-homoserine lactones (AHLs). A general representation of a system reg-
ulated by AHL-mediated QS is depicted in figure 2.1.2 This QS system typically consists of
two components: a LuxI-homologue responsible for the synthesis of the AHL, and a LuxR-
homologue which detects the AHL and stimulates the translation of genes preceded by a so-
called lux-box. Some bacteria contain more than one QS system. P. aeruginosa for exam-
ple possesses LasI/LasR and RhlI/RhlR which control biofilm formation and exoenzyme and
virulence-factor synthesis in a hierarchical manner.3
Figure 2.1. A representation of a typical LuxI/LuxR QS circuit. Small circles represent AHLs. 5’-MTA: 5’-
methylthioadenosine, ACP: acyl carrier protein, SAM: S-adenosyl-L-methionine. Figure reprinted from Fuqua and
Greenberg, 2002.2
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AHLs are produced by a LuxI-type protein starting from S-adenosyl-L-methionine (SAM) and
an acylated acyl carrier protein (acyl-ACP) as substrates.3,26 The acyl-ACP, 3-oxoacyl-ACP and
3-hydroxyacyl-ACP are intermediates of the fatty acid metabolism, explaining the fact that the
majority of AHLs has an acyl chain with an even number of carbon atoms.26,27 However, some
AHLs with an odd acyl chain are known.28,29 The link between fatty acid metabolism and AHL-
synthesis in the case of P. aeruginosa, is represented in figure 2.2.27
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Figure 2.2. The link between the biosynthesis of fatty acids and AHLs in P. aeruginosa. ACC: acetyl-CoA-
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The LuxI-enzyme catalyzes the nucleophilic attack of the amino group of SAM 13 on the
acyl chain loaded onto the ACP. Subsequently, a lactonization occurs and the AHL and 5’-
methylthioadenosine (5’-MTA) 14 are released from the enzyme (Figure 2.3). The size of the
hydrophobic pocket of the LuxI-enzyme determines the length of the acyl chain and conse-
quently the AHL that is synthesized. Also the functionality of the acyl chain on the 3-position
is determined by hydrogen bonding inside this hydrophobic pocket, allowing different LuxI-
homologues to synthesize different AHLs from the same acyl-ACP pool.30–32 Whereas short-
chain AHLs can diffuse freely out of the cells, long-chain AHLs rely on active transport to
be excreted.33 In the supernatant of planktonic P. aeruginosa cultures, grown at 37 ◦C under
shaking conditions, concentrations of 1 to 10 µM of oxo12 3i are observed.34,35 However, in P.
aeruginosa biofilms, concentrations as high as 600 µM have been measured.34
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The LuxR-homologue contains two structurally different domains connected by a linker do-
main: a DNA-binding and an AHL-binding domain. When a certain threshold concentration is
reached, the AHL binds to the LuxR-homologue. Without the AHL ligand, LuxR proteins are
typically unstable and degrade rapidly. By binding to the AHL, a large conformational change
occurs and the DNA-binding domain of the LuxR-protein is exposed, allowing interaction with
the dyad symmetric lux-box. Typically LuxR-protein dimerization is also promoted upon bind-
ing an AHL and those multimers bind the promoter DNA sequences and cause transcription of
certain target genes (Figure 2.1).3,12,32 Whereas many R-proteins act as transcriptional activator,
some function rather as a repressor, blocking the transcriptional activation of certain genes by
RNA polymerase in the absence of a sufficient amount of AHLs.12 Also the expression of the
LuxI-proteins is stimulated by AHL-bound LuxR-proteins, hence explaining the name autoin-
ducer.13
2.1.2 Quorum quenching
There are several phenomena and mechanisms which are able to interfere with quorum sensing
(Figure 2.1).10 To describe all these processes that are able to disrupt quorum sensing, the term
quorum quenching is used.5 In this section, only abiotic and enzymatic degradation of the AHL
signal molecules will be discussed.
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Scheme 2.1. Different strategies to interfere with QS. The small squares represent QS signal molecules. (A) Inhi-
bition of QS signal generation. (B) Application of QS antagonists to prevent signal transduction. (C) Inactivation
of the QS signal molecules. (D) Premature activation of QS via the application of QS agonists. Figure reprinted
from Defoirdt et al.10
2.1.2.1 Abiotic degradation
The lactonolysis of AHL-molecules occurs spontaneously in aquatic solutions to produce the
corresponding N-acyl-L-homoserines 15.7 Short-chain AHLs degrade faster than long-chain
AHLs and this degradation goes faster at higher temperature and higher pH.7,36 For example
the half-life of C6 1c at pH 5.5 and 20 ◦C is over 8 d whereas at pH 8.5 and 20 ◦C, this is
less than 6 h.37 As the lactone ring is crucial for signal recognition, all QS activity is lost after
this hydrolysis. However, at low pH these ring-opened AHLs 15 can cyclize again, albeit to a
limited extent (Scheme 2.2).36,38
A second type of abiotic degradation can occur upon reaction with oxidized halogen antimi-
crobials. These compounds are able to inactivate oxo-AHLs 3, but are inactive toward unsub-
stituted ones (Scheme 2.2). This deactivation is caused by reaction of the oxo-AHL 3 with
two hypobromous or hypochlorous acid molecules, followed by the cleavage of the resulting
N-(2,2-dihalo-3-oxoacyl)-L-homoserine lactones 16.39,40
Oxo-AHLs 3 can be degraded via another route as well (Scheme 2.2). Instead of lactonolysis,
an intramolecular Claisen-like rearrangement leads to tetramic acids 11. These rearrangement
products 11 exhibit antimicrobial activity against Gram-positive bacteria (EC50: 8-55 µM), pre-
sumably by causing cell lysis after interaction with the cell membrane.9,41 Tetramic acids 11 can
bind iron in a 3:1 complex and can function as primordial siderophores.9 Although at neutral pH
in aqueous medium, the reaction rate to form the ring-opened degradation product 15 is three-
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fold higher than the formation rate of tetramic acid, tetramic acids 11 are stable compounds and
can accumulate in the environment.9 For example, in sputum samples of cystic fibrosis patients,
oxo12 3i was detected in concentrations ranging from 20 nM to 7 µM, whereas the correspond-
ing tetramic acid was found in concentrations of 13-900 nM.42
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2.1.2.2 Enzymatic degradation
There are four classes of AHL-inactivating enzymes known (Scheme 2.2). They can be pro-
duced by organisms lacking an AHL-regulated QS system to gain a competitive advantage over
AHL-producers. Alternatively, it has been suggested that some Gram-positive bacteria inacti-
vate oxo-AHLs 3 to prevent the formation of the toxic tetramic acids 11. Also utilization of
AHLs as a carbon and nitrogen source is a possibility. Some AHL-producers are able to in-
activate their own signals as well, either to recycle them as nutrients or to remove old signals
(signal clearance).5 However, it must be kept in mind that AHL-degradation might not be the
primary role of all these enzymes, as several other compounds can function as substrate for
these enzymes.43
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Lactonases
Lactonases are enzymes that catalyze the opening of the homoserine lactone ring and typically
display a broad substrate specificity (Scheme 2.2). The first lactonase that was reported, AiiA,
can be found in several Bacillus strains.44 Transgenic tobacco plants expressing this enzyme
were more resistant toward the soft root rot disease caused by Pectobacterium carotovora, which
uses oxo6 3c to regulate its virulence by the production of cell wall degrading enzymes.45
Agrobacterium tumefaciens produces two lactonases, AiiB and AttM, which are able to degrade
its own AHL oxo8 3e. Added AHLs cannot be used as the sole carbon or nitrogen source. A
clearing function, to prevent premature activation of the QS operon, is therefore proposed to
describe the biological role of these enzymes in A. tumefaciens.5,46
Paraoxonases degrade AHLs in a similar manner and rely on a metal ion in the active site to
make the carbonyl carbon atom more electrophilic. These enzymes can be found in serum and
tracheal epithelial cells of mammals and efficiently inactivate long-chain AHLs.5,47
During a screening of 16 fungal isolates, lactonase activity was discovered in two of these
forest root-associated fungi.48 The basidiomycetous yeast Trichosporon loubieri, isolated from
tropical wetland waters, displayed a similar lactonase activity toward AHL with an acyl chain
ranging from 4 to 10 carbon atoms.49
Acylases or amidases
Acylases or amidases cleave the AHL irreversibly at the amide bond and release a homoserine
lactone 19 and a fatty acid 18 (Scheme 2.2). Whereas lactonases target the common lactone
core, acylases can be acyl chain length specific. Variovax paradoxus VAI-C cleaves AHLs via an
acylase enzyme, and can use AHLs as the only carbon and nitrogen source.50 A Ralstonia strain
isolated from a mixed biofilm, contains the AiiD enzyme which has a similar AHL-inactivation
mechanism.51 Both long and short-chain AHLs can be metabolized by these strains.50,51
Also P. aeruginosa displays AHL-acylase activity but only for AHLs with an acyl chain com-
posed of eight or more carbon atoms.52 This preference for long-chain AHLs might be linked
with one of its own QS signal compounds, oxo12 3i. Pseudomonas strains expressing this type
of enzyme are able to use AHLs as the sole carbon and energy source.5,53 Porcine kidney acy-
lase I belongs to this class of AHL-degrading enzymes as well.5 Also plants contain enzymes,
fatty acid amide hydrolases (FAAH), with similar activity (vide infra).54,55
Haloperoxidases
This third class of enzymes is able to inactivate oxo-AHLs 3 via a similar mechanism as ox-
idized halogen antimicrobials (Scheme 2.2). The electrophilic halogenation of oxo-AHLs 3 is
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hydrogen peroxide dependent and the active site of these enzymes typically relies on vana-
dium.56 The resulting N-(2,2-dihalo-3-oxoacyl)-L-homoserine lactones 16 still display QS ac-
tivity, so the cleavage of the acyl chain to yield a N-(2,2-dihaloacetyl)-derivative 22 is the crucial
step leading to a complete loss of QS activity.57
These enzymes are often encountered in marine organisms, for example in the brown alga Lami-
aria digitata,40 the benthic diatom Nitzschia cf pellucida,57 and the red alga Delisea pulchra,58
and are associated with the prevention of microbial fouling by inhibiting QS regulated biofilm
formation.40 However, haloperoxidases have also been found in terrestrial fungi such as Curvu-
laria inaequalis,59 although the inactivation of QS signal molecules by these fungal enzymes
has yet to be reported.
Oxidoreductases
Reductases will convert the keto functionality of oxo-AHLs 3 to a hydroxy group. The resulting
HO-AHL 2 are sometimes still active but often display a strongly reduced activity. The Gram-
positive bacterium Rhodococcus erythropolis W2 uses such a reductase to convert oxo-AHLs
with an acyl chain of at least eight carbon atoms to the corresponding HO-derivatives. This strain
also contains an acylase, enabling it to use AHLs as the sole carbon and nitrogen source.60
Cytochrome oxidases can be found in bacteria, archaea and eukaryotes and catalyze the oxi-
dation of the acyl chain to form hydroxylated products 20 (Scheme 2.2). Cytochrome P450
monooxygenase from Bacillus megaterium efficiently oxidates AHLs at the ω-1, ω-2 or ω-3
carbon atom of the acyl chain. The resulting hydroxylated AHLs 20a–c still retain QS activity,
albeit strongly reduced compared to native AHLs 17. AHL-degradation products 15 and 18 can
be hydroxylated as well by these enzymes.61
2.1.3 Interkingdom signaling
Prokaryotes and eukaryotes have coexisted and interacted for a very long time, exposed to
each other’s soluble signal compounds. As a consequence, organisms of both kingdoms have
learned to perceive and react to these different compounds in a phenomenon called interking-
dom signaling (Figure 2.4). It is an intriguing observation that Pseudomonas species found in
the plant rhizosphere produce AHLs more often than their counterparts found in bulk soil.62
AHL-mediated QS also regulates several traits associated with plant-bacteria interactions such
as biofilm formation, virulence factor production, nodulation, synthesis of degradative enzymes,
etc.63 As the infection of several eukaryotic hosts often depends on AHL-mediated QS, detect-
ing these AHL molecules could give a distinct advantage.47,64 It is therefore not surprising that
plants can ‘eavesdrop’ on the bacterial cross-talk via AHLs and respond in sophisticated ways.
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On the other hand, plants can also actively influence this communication via the excretion of
compounds with AHL-mimicking or QS-disturbing activity (Figure 2.4).64
Figure 2.4. Different responses of plants to AHLs. The perception of AHLs can lead to the secretion of AHL-
mimics into the rhizosphere. Some compounds out of the exudates, such as p-coumaric acid, can be included
into bacterial AHLs. Also AHL-uptake and transportation inside the plant, or degradation via enzymes can occur.
Alternatively, AHLs can induce salicylic acid (SA) accumulation in roots and shoots, which is suggested to mediate
systemic resistance to pathogens. AHLs can also induce morphological changes and influence root elongation, root
hair formation, and lateral root density.65
2.1.3.1 Effect of AHLs on plants
That plants are able to detect AHLs was confirmed when model legume Medicago truncatula
was treated with AHLs and more than 150 proteins were differently accumulated. These pro-
teins were linked with stress and plant defense, protein degradation or processing and various
primary metabolic activities. Also auxin-inducible and chalcone synthase genes were activated.
Exposure to oxo16:1 3l, a native AHL of symbiont Sinorhizobium meliloti, led to a different
response than when oxo12 3i was tested (Appendix, Table 8.1).66 This specific response to
different AHLs was also observed when the effect of AHLs on nodulation was studied. Out
of several AHLs tested on M. truncatula, only oxo14 3k, which is one of the native AHLs of
its symbiont S. meliloti, could enhance the formation of nodules on the roots. The increased
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nodulation caused by oxo14 3k was not observed in legumes alfalfa (Medicago sativa) and
white clover (Trifolium repens), showing that the response of plants toward AHLs can be highly
specific.67
One of the most astonishing effects of AHLs on plants is a clear change in plant morphology.
Depending on the structure, AHLs can exert a different effect on the root architecture. When
Arabidopsis thaliana was treated with 10 µM of C4 1a or C6 1c in a floating hydrophonic sys-
tem, a 1.2-fold increase in root length was observed (Appendix, Table 8.1). This root growth
promoting effect was linked to a change in the auxin/cytokinin ratio. Application of 10 µM C8
1e, C12 1i and C14 1k had no effect whereas C10 1g had a negative influence on root growth.68
When A. thaliana was treated with 10 µM C4 1a, C6 1c, oxo6 3c, C8 1e and oxo8 3e in an ex-
perimental set-up with agar plates, a significant root elongation was observed as well.69–72 This
promotion was because of increased cell division activity in the meristem zone and enhanced
cell elongation in the elongation zone of the roots.73 However, a high (100 µM) concentration of
oxo6 3c and oxo8 3e resulted in a reduction of the root length.71 Genetic analysis revealed that
GCR1, a G-protein-coupled receptor (GPCR), and Gα subunit GPA1 were involved. G-Protein
signaling is linked to several plant growth and development processes which transduce environ-
mental signals into the cell.71 Recent research suggests that the Ca2+ binding protein calmodulin
participates in the root stimulatory effect of oxo6 3c on A. thaliana as well.72,74 Application of
C4 1a caused an increase of the cytosolic free Ca2+ concentration, supporting this hypothesis.74
It was also shown that the root stimulatory effect of oxo6 3c depends on an active AtMYB44
protein. This transcriptional factor is associated with plant development and defense responses
to pathogens and environmental stress and can induce auxin- and cytokinin-related genes.73 All
these data combined led to the hypothesis that GCR1 and GCR2 could be candidate receptors
for AHLs in A. thaliana. Interaction of AHLs with these GPCRs will activate the heterotri-
meric G-protein. Subsequently, the activated Gα subunit opens the Ca2+ channels which leads
to an increase of intracellular free Ca2+ which in its turn activates calmodulin. Calmodulin then
triggers the downstream cascades leading to the final specific cellular reaction.72,74
Whereas short-chain AHLs seem to stimulate root growth, no effect or a negative effect was
observed for AHLs with a longer acyl chain.68–72 In a study performed by Ortíz-Castro et al.,
a dose-dependent inhibitory effect on root length of A. thaliana was observed for C8 1e, C10
1g, C12 1i and C14 1k (Appendix, Table 8.1).54 Compound C10 1g had the strongest inhibitory
effect (80% reduction at a concentration of 48 µM) on primary root growth. This reduction
is caused by affecting cell division in the meristem and is independent of auxin-signaling.54
Also calmodulin was not involved in the inhibition of primary root growth when long-chain
17
Literature overview
AHLs are applied.72 The reduced primary root length was accompanied by a shift toward a
more branched root system. This could provide a larger surface area for bacterial colonization.
Longer-chain AHLs such as C12 1i also stimulated root hair formation.54 Remarkably, in their
set-up (seeds germinated and grown on AHL-containing agar plates, AHL concentration range
12-192 µM) no effect was observed for C4 1a, C6 1c or oxo6 3c. These differences in acti-
vity compared to other studies could be explained by the fact that the A. thaliana plants were
germinated on AHL-containing medium, unlike other studies where the seeds were germinated
first in the absence of AHLs and then transferred to AHL-containing medium. So not only the
effect of AHLs on root elongation but also on germination and root development should be taken
into account. It is striking that plants produce several compounds with a structural similarity to
AHLs, for example N-acyl ethanolamines (NAE) 23 and alkamides 24 (Figure 2.5). These plant
signals control germination and can alter root and shoot system architecture.54,75,76 Therefore,
the same AHL-treatment was applied on plants overexpressing a fatty acid amide hydrolase
(FAAH) enzyme, responsible for the hydrolysis of NAEs, and a diminished sensitivity toward
AHLs was observed as well.54 An A. thaliana mutant that was resistant to the effect of the
alkamide N-isobutyl decanamide 24a, which inhibits primary root growth and stimulates lateral
root formation in wild type plants, was resistant as well to the inhibitory effect of C10 1g.77
This suggests that plants may share a common pathway to perceive NAEs and AHLs for root
development.
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Figure 2.5. Structural similarities between C10 1g and plant constituents N-ethanol decanamide (NAE10:0) 23a
and N-isobutyl decanamide 24a.
Although C10 1g had a strong effect on A. thaliana, it is devoid of activity on mung bean (Vigna
radiata). However, the analogue with the 3-oxo-substituent, oxo10 3g, strongly induces the
formation of adventitious roots. This compound 3g stimulates basipetal auxin transport which
causes adventitious root formation via hydrogen peroxide- and nitrogen monoxide-dependent
cyclic GMP signaling.78 In the case of barley (Hordeum vulgare), a monocotyledon, both C8
1e and C12 1i were able to stimulate plant growth and a branched root architecture. This lateral
root stimulation was linked to NO-accumulation that was induced by all AHLs. Whereas only
10 µM but not 1 or 100 µM of C6 1c and C8 1e stimulated K+ uptake in root cells, the same
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effect was observed in all (1, 10 and 100 µM) concentrations tested for C12 1i (Appendix, Table
8.1).79
Palmer and colleagues found that AHLs elicited a biphasic growth response in A. thaliana and
M. truncatula seedlings. Whereas all (both short and long-chain) AHLs tested caused longer pri-
mary roots in submicromolar concentrations, a significant reduction was observed when higher
(> 50 µM) concentrations were used. The sensitivity of A. thaliana to an AHL increased with
the acyl chain length, but the functionality did not play an important role, as C12 1i, HO12
2i and oxo12 3i had a very similar effect (Appendix, Table 8.1). Stereochemistry, on the other
hand, played a crucial role, shown by the fact that the unnatural D-stereomer of oxo12 3i failed
to cause any growth effects. Also p-coumaryl-HL 4 was devoid of activity. The ring-opened
form of oxo12 had a similar activity as oxo12 3i, suggesting that an intact lactone ring is not
required for AHL-induced plant growth modification. Contrastingly, in bacteria the lactone ring
is an absolute requirement for activity. When several AHL-degradation products were tested, a
biphasic growth effect similar to the pattern observed for long-chain AHLs, was observed for
L-homoserine (HSe) 25.55 The effect of AHL-degradation products on plants was also noted by
Joseph et al. Whereas no difference in stomatal conductance (a measure for stomatal opening)
and transpiration was observed after application of 10 nM oxo6 3c to bean plants (Phaseolus
vulgaris), an increase of 20 to 30% was caused by 10 nM homoserine lactone 19 or HSe 25
(Appendix, Table 8.1). Both bacteria and plant benefit from this effect: while the microorgan-
ism gets more access to mineral nutrients carried by soil moisture toward the root, the plant can
increase mineral uptake, increase the cooling of leaves and improve photosynthetic efficiency.80
HSe 25 is formed after AHL amidolysis by plant-derived fatty acid amide hydrolase (FAAH),
followed by lactonolysis (Figure 2.6). FAAH-Deficient seedlings were found to be resistant to
the effects of AHLs but showed altered root lengths when L-HSe 25 was applied. This confirms
the hypothesis that the growth modulating effect was linked with an AHL-degradation product,
although these results contrast with those reported by Ortíz-Casto et al.54,55 The fact that D-
AHLs and short-chain AHLs were not as efficient substrates for FAAH as long-chain AHLs
corroborates the difference in activity observed for AHLs with different acyl chain lengths. The
second degradation product, the fatty acid 18, did not have an effect on the root growth. Also
the unnatural D-isomer of HSe 25 was inactive. As FAAHs are especially active during the ger-
mination and seedling phase, this could explain different results obtained when testing plants
in different development phases. At low bacterial and AHL-densities, only low concentrations
of L-HSe 25 are present which stimulate plant transpiration and thereby encourage growth,
whereas high AHL concentrations lead to high HSe 25 concentrations which may alert the
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plant and inhibit growth by stimulating ethylene production.55
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Figure 2.6. FAAH-Catalyzed degradation of AHLs 17 to homoserine lactone 19 (HL) and a fatty acid 18. The
homoserine lactone can hydrolyze to homoserine 25 (HSe).
A stereospecific response of plants toward AHLs was also apparent when two isomers of oxo8
3e were applied to sugar cane (Saccharum officinarum). Whereas both compounds led to the
formation of more stretched root cells, the L-enantiomer caused a larger increase in the sprouting
of roots compared to the D-enantiomer (Appendix, Table 8.1).81
Besides morphological changes, AHLs can also lead to induced systemic resistance (ISR) in
plants. This induced systemic resistance causes plants to strengthen their defense mechanisms
as a preparation for contact with pathogens or stress. By applying AHLs in a process called
priming, plants are brought to this state of increased resistance and can respond stronger and
faster to future threats.82 When AHL-producing strains were present in the tomato (Lycoper-
sicon esculentum) rhizosphere, an enhanced resistance to the fungal leaf pathogen Alternaria
alternata was observed. AHL-mutants lacked this ability. The effect could be mimicked via
the application of synthetic AHL standards.83 This enhanced resistance caused by AHLs relies
on the induction of salicylic acid (SA)- and ethylene-dependent defense genes.83 However, no
such enhanced resistance was observed when A. thaliana was treated with C6 1c.68 For this
plant, mainly longer-chain AHLs (C12 1i, oxo14 3k) were able to offer such protection.69,70
This AHL-induced resistance seems to rely on mitogen-activated protein kinases (MPAKs).
These proteins play an important role in the first steps of pathogen perception and induction
of defense mechanisms.69 When tested on A. thaliana, oxo14 3k could influence plant defense
via an oxylipin/SA-dependent signaling pathway leading to cell wall strengthening by stimula-
ting callose deposition, accumulation of phenolic compounds and lignification. A second effect
was the increase of stomatal closure when exposed to a pathogen.82,84 The application of AHL-
producing bacteria as a soil amendment is currently being investigated.84,85
It is difficult to draw definitive conclusions about the effect of AHLs on plants in general as
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most of the studies have been performed with the economically not-important plant A. thaliana.
As this is a small plant with a short life-cycle and which can easily be grown, A. thaliana is
perfectly suited to study the effect of AHLs in a profound, standardized manner. However be-
cause of the different experimental set-ups (hydrophonic system, agar plates, different methods
of AHL application) and experimental parameters (age of seedlings, contact time with AHLs,
AHL concentration range, stereochemistry of the AHLs used) there are already conflicting re-
sults for this one plant species (Appendix, Table 8.1). However, the general trend observed in
most cases is that short-chain AHLs (an acyl chain containing six or less carbon atoms) in a
concentration lower than 10 µM tend to promote primary root elongation, partially by shifting
the hormonal (auxin/cytokinin) balance.68,70–72,78 Long-chain AHLs (an acyl chain with ten car-
bon atoms or more) typically inhibit primary root growth and stimulate the formation of lateral
roots and root hairs.54,70 Not only the acyl chain length but also the dose and stereochemistry
play a crucial role. Short-chain AHLs can also inhibit root growth at higher (> 10 µM) concen-
trations.55 On the other hand, AHLs with a longer acyl chain (e.g. C12 1i, C14 1k) can stimulate
induced systemic resistance (AHL-priming).69,82,84,86 The exact mechanism by which AHLs ex-
ert their effect is not yet fully understood, although for the growth stimulatory effect G-protein
receptors seem to be involved. The inhibitory effect seems to be linked with an elevated ethylene
concentration, which is caused by the FAAH-mediated AHL-degradation product HSe 25.
AHLs can also have an influence on the reproductive behavior of some algae. Culture filtrates
of several AHL-producing isolates and pure C4 1a and C6 1c (2-10 µM) standards stimulated
the red macroalga Gracilaria dura to release its carpospores, whereas longer-chain AHLs C8
1e, C10 1g and oxo12 3i were inactive.87 A similar effect was observed for C4 1a on the
release of spores of red algal epiphyte Acrochaetium sp., albeit at high concentrations (100 µM).
This effect on spore release was not observed in a second red alga (Sahlingia subintegra).88
Zoospores of the green alga of the Enteromorpha genus use the presence of AHLs to detect
biofilms suited to settle upon. These zoospores only adhere to AHL-liberating strains.89
2.1.3.2 Effect of plants on QS signaling
AHLs can influence plants in several ways, but plants can interfere with bacterial signaling as
well. Several plant-derived compounds that are able to inhibit quorum sensing are known (Fig-
ure 2.7).5,13 A true inhibitor disturbs QS without affecting bacterial growth. One of the most
studied examples is the production of halogenated furanones 26 by the macro-alga Delisea pul-
chra. These compounds have a certain structural similarity with AHLs and bind to the AHL
receptor proteins and enhance degradation of these proteins.90,91 Iberin (27), an isothiocyanate,
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was isolated from horseradish (Armoracia rusticana) and is extremely effective in inhibiting QS
in P. aeruginosa.92 Also garlic (Allium sativum) contains compounds 28a and 28b which solely
inhibit QS.93 Cinnamaldehyde (29), which can be isolated from the essential oil of cinnamon,
interferes at subinhibitory concentrations with the action of short-chain AHLs whereas QS re-
lying on long-chain AHLs is not affected.94 The naturally occurring furocoumarins bergamottin
(30a) and dihydroxybergamottin (30b) were isolated from grapefruit juice and inhibit QS with-
out interfering with bacterial growth.95 Also the flavan-3-ol catechin (31), present in the bark of
bushwillow Combretum albiflorum, has a negative impact on QS.96 As this small selection of
plant-derived quorum sensing inhibitors already displays a large structural diversity, different
parts of the QS system might be targeted by these compounds, although the exact mechanism
is often not yet known.
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Figure 2.7. Structures of several QS inhibitors isolated from plants and macro-alga.
For several plant extracts, QS inhibiting or stimulating activity has been observed but the ac-
tive components were not identified yet.92,97–99 The methanolic extract of radish (Raphanus
sativus), tarragon (Artemisia dracunculus) and hollyhock (Althea officinalis) showed QS inhi-
bition, whereas white clover (Trifolium repens) showed QS stimulation.98 The extract of several
pepper species has QS inhibitory activity as well, but the active compounds have not been iden-
tified yet.97 Also rice plant (Oryza sativa) extracts contain compounds that can activate several
AHL reporter strains, although the involvement of certain endophytic bacteria could not be
ruled out. These AHL-mimics are sensitive to the AiiA lactonase, so presumably contain an
AHL-related lactone core.99 Exudates from pea (Pisum sativum) seedlings contained several
unidentified compounds that could influence AHL-regulated behavior in some reporter strains
without altering the bacterial growth. Unlike AHLs, the active compounds from the pea seedling
exudate could not be extracted with chloroform or ethyl acetate. The methanol extract on the
other hand contained the majority of the QS activity. This difference points to a different chemi-
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cal nature of the active compounds compared to bacterial AHLs. Also seedlings of crown vetch
(Coronilla varia) were able to inhibit a reporter strain, whereas exudates of lettuce (Lactuca
sativa) and A. thaliana proved to be inactive.100 This presence of QS-influencing compounds
was also detected in M. truncatula seedlings.101 Importantly, when M. truncatula was exposed
to AHLs, the excretion of QS signal-mimicking compounds was increased.66
To respond to plant signals, several plant-associated bacteria posses LuxR-like proteins with
the characteristic AHL-binding domain but without a cognate LuxI-protein. These proteins are
called orphan LuxRs or LuxR solos and can be used to eavesdrop on neighboring bacteria but
can also bind and respond to plant compounds rather than AHLs. These LuxR solos lack some
conserved residues in the AHL-binding pocket compared to classical LuxRs.86,102
In some rare occasion, components of the root exudates can even be incorporated in the AHL-
signal. p-Coumaric acid is produced by plants as a precursor of lignin and can exert QS in-
hibiting activity. The photosynthetic bacterium Rhodopseudomonas palustris however relies on
plant-derived p-coumaric acid to synthesize its p-coumaryl-AHL 4 (Figure 1.2).4,65
AHL-Degradation can be effectuated as well by plants. When the root systems of the legumes
clover (Trifolium pratense) and Lotus corniculatus were incubated with C6 1c, a rapid degrada-
tion of the signal molecule was observed. This disappearance was non-existent when the root
system of the monocots corn (Zea mays) and wheat (Triticum aestivum) was tested. As this
degradative activity was absent after boiling, presumably one or more enzymes are involved.37
When barley and yam bean (Pachyrhizus erosus) were treated with AHLs, a stronger AHL de-
crease was observed in the rhizosphere of the legume yam bean compared to barley. This could
be explained by the fact that legumes such as bean and clover are naturally exposed to multiple
AHLs during their symbiosis with rhizobia, whereas monocots such as barley, corn and wheat
do not have such interactions.103,104 After treatment of yam bean and barley with C6 1c, C8 1e
and C10 1g, all three AHLs were detected in root extracts of both plants. In the shoots of barley
on the other hand, only C6 1c and C8 1e were detectable, whereas only C6 1c was found in
yam bean shoots. Importantly, AHLs with the unnatural D-configuration showed a reduced up-
take by barley and yam bean.103 It was found that AHLs with a longer side chain (e.g. C10 1g)
were degraded faster than their short-chain counterparts.104 Accumulation of C6 1c in shoots
and C10 1g in roots was also shown for A. thaliana.68,69 However, when the uptake of C8 1e
and C10 1g was evaluated with more sensitive methods, applying radioactive isotope-labeled
AHLs and biosensors, both C8 1e and C10 1g could be detected in the shoots, albeit in limited
amounts for C10 1g. It was shown that ABC transporters are involved in the AHL-uptake and
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that the transport occurs mainly via the central cylinder.105 So whereas short-chain AHLs can be
transported throughout the plant, long-chains AHL are transported as well but only to a limited
extent inside the plant and accumulate mainly in the roots.69,105
2.2 Cyclic lipopeptides
2.2.1 Introduction
The general structure of a cyclic lipopeptide (CLP) consists of a lipid tail connected to an
oligopeptide (Figure 2.8 and 2.9). CLPs containing a lactone in the cyclic core are called depsi-
peptides. These versatile compounds are synthesized by non-ribosomal peptide synthetases
(NRPS). The combination of a polar amino acid (AA) head linked to a lipophilic fatty acid
tail gives these amphiphilic compounds interesting activities (vide infra). The cyclic character
is often a prerequisite for the (bio)activity.106,107 For example linear analogues of surfactin lack
the hemolytic activity that is present in the cyclic analogues.107 The cyclization itself reduces
conformational freedom, constraining the structure and thereby ensuring a proper interaction
with the dedicated target.17 Not only the cyclic character gives these compounds interesting
properties, often unusual AAs can be found in CLPs. Several databases containing all the dif-
ferent (> 500) monomers found in non-ribosomal peptides are available.108 The presence of
D-AAs and N-methylated AAs constrains the conformation to aid cyclization and furnishes a
higher stability against proteolytic digestion, although they can still be degraded by several
other microorganisms.109,110 The length of the fatty acid tail linked to the oligopeptide moiety
can also have a profound effect on the activity of the CLP.106
CLPs are produced mostly by bacteria belonging to soil-dwelling or plant-associated Pseu-
domonas, Bacillus, Actinomyces, Serratia and Streptomyces genera, but CLP-producing organ-
isms have been found in other habitats as well.20 Especially the CLPs produced by the first two
genera have been studied extensively.
In this work, first the different types of CLPs are discussed, followed by the biosynthesis. Fur-
ther on the natural functions and possible commercial applications are mentioned.
2.2.2 Classification
2.2.2.1 Pseudomonas CLPs
Based on structural similarities, the CLPs produced by Pseudomonas can be divided into six
major groups (Figure 2.8 and Table 2.1).18–20
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Figure 2.8. Chemical structure of the CLPs putisolvin I (32), tensin (33), syringopeptin 25A (34), syringotoxin B
(35) and viscosin (36) which are produced by Pseudomonas sp.20,111 The stereochemistry of putisolvin I (32) is
predicted based upon sequence analysis.23
Viscosin group
The CLPs of this group are composed out of nine amino acids and are mostly linked to a
β-hydroxydecanoyl moiety. The macrolactone is formed via an esterification between the car-
boxylic acid group of the C-terminal amino acid and the hydroxy group of the D-aThr residue.19,112
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The production of this type of CLP seems to be associated with several fluorescent pseudo-
monads from different habitats, including rhizosphere, soil, phyllosphere and marine environ-
ments.113 Also the white line-inducing principle (WLIP) belongs to this group. Pseudomonads
producing WLIP used to be classified in the ill-defined P. reactans group. When a WLIP-
producing strain is confronted with tolaasin on a solid medium, a white precipitate originates.114
Besides WLIP, following CLPs belong to the viscosin group: viscosin (36), massetolide, vis-
cosinamide, pseudodesmin and pseudophomin (Table 2.1).19,112
Syringomycin group
This group is named after virulence factor syringomycin produced by P. syringae pv. syringae.18
CLPs from this heterogenic group contain 9 AAs, including unusual AAs such as homoserine
(Hse), 2,4-diaminobutyric acid (Dab), 2,3-dehydroaminobutyric acid (Dhb), ornithine (Orn), 3-
hydroxyaspartic acid (Asp(3-HO)) and 4-chlorothreonine (Thr(4-Cl)). The N-terminal amino
acid is linked to a β-hydroxy or 3,4-dihydroxy fatty acid containing 10, 12 or 14 carbon
atoms. The cyclic core of these lipodepsinonapeptides is formed via a cyclization between
the N-terminal Ser and the C-terminal Thr(4-Cl). Examples are the phytotoxic syringomycins,
syringostatins and syringotoxin B (35) and the antifungal pseudomycin and ecomycin (Table
2.1).19,113,115
Amphisin group
Amphisin, tensin (33), lokisin, pholipeptin, hodersin and arthrofactin are members of this group
(Table 2.1). The typical structure consists of 11 amino acids coupled to a β-hydroxydecanoic
acid tail. The lactone ring of these lipoundecapeptides is formed between the C-terminal amino
acid and the hydroxy group of the L-Thr or D-aThr residue located at position three.19
Putisolvin group
These CLPs have a 12 AAs peptide chain coupled to a hexanoic fatty acid tail. The only mem-
bers of this group are putisolvin I (32) and II (Table 2.1).18
Tolaasin group
CLPs belonging to this group contain 19-25 AAs, often including unusual AAs (e.g. Hse, Dab,
Dhb). The lipid moiety is typically β-hydroxydecanoic acid although exceptions are possible in
this diverse group. The peptide is cyclized via a lactone formed between the C-terminal amino
acid and the aThr residue. The cyclic moiety consists of 5-8 AAs.113 Corpeptin, fuscopeptin and
tolaasin are examples of CLPs belonging to this group (Table 2.1). Most of these CLPs possess
phytotoxic properties.19,113
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Syringopeptin group
CLPs in this group contain 22 or 25 AAs and the N-terminal AA is acylated with a β-hydroxy-
decanoic acid or β-hydroxydodecanoic acid (Table 2.1). The lactone bond is formed between
the C-terminal Tyr residue and the hydroxy group of aThr.115 The system responsible for the
biosynthesis of syringopeptin (34) is the largest prokaryotic NRPS described so far (74 kb - 22
modules).111,116
‘Orphan’ CLPs
In recent years, several other CLPs have been discovered with structural features different from
the main groups. One example are the orfamides, identified by mining of the P. fluorescens Pf-5
genome.117 These depsidecapeptides contain 10 AAs coupled to a β-hydroxydecanoic acid or
β-hydroxydodecanoic acid tail and resemble CLPs of the viscosin group (Table 2.1). Another
example is entolysin containing 14 AAs with the lactone ring formed between the C-terminal
carboxy group and the hydroxy group of a Ser residue on the tenth position. Its fatty acid
tail consists of a β-hydroxydecanoic acid.118 Very recently the lipotetradecadepsipeptide xan-
tholysin was discovered, with an octacyclic core.112 Sometimes, orfamides and entolysins are
regarded as new groups of CLPs, bringing the total number of different groups of Pseudomonas
CLPs to at least eight.
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2.2.2.2 Bacillus CLPs
Most Bacillus CLPs are classified in one of the following three groups: the surfactin, iturin and
fengycin family (Figure 2.9 and Table 2.2).
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Figure 2.9. Chemical structure of the CLPs surfactin (37), iturin A (38), fengycin A (39) and polymyxin B1 (40)
which are produced by Bacillus sp.
Surfactin family
These heptapeptides are interlinked with a β-hydroxy fatty acid containing 12 to 16 carbon
atoms and typically have a powerful biosurfactant activity.121 The macrolactone is formed be-
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tween the C-terminal peptide and the β-hydroxy fatty acid. The main representative of this
family, surfactin (37) itself, was discovered in 1968 in the culture broth of a Bacillus subtilis
and has received a lot of attention since.122,123 Other examples of CLPs belonging to this group
are esperin, lichenysin and pumilacidin (Table 2.2).
Iturin family
Members of this group are characterized by a β-amino fatty acid moiety of 14 to 17 carbon
atoms linked to a cyclic heptapeptide macrolactam. These CLPs are synthesized by a hybrid
PKS/NRPS-system. The main variants within this group are iturin A (38) and C, bacillomycin
D, F, L and LC (also called bacillopeptin) and mycosubtilin (Table 2.2).121
Fengycin family
This group consists of decapeptides with a β-hydroxytetradecanoic to β-hydroxyoctadecanoic
fatty acid tail. The macrolactone is formed between the hydroxy group of a Tyr-residue and
the C-terminal amino acid. Representative CLPs are fengycin A (39) and B (also referred to as
plipastins depending on the configuration of the Tyr-residues) (Table 2.2).121
Others
The antibiotic polymyxins are cationic CLPs with a remarkable Dab-content. Polymyxin B
(40) and E (also known as colistin) are both produced by the soil bacterium Bacillus polymyxa.
Polymyxin M (mattacin) on the other hand is produced by Paenibacillus kobenis (Table 2.2).124
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Table 2.2: Different structural groups of CLPs produced by Bacillus and primary structures of representatives of
each group. Based on Ongena et al. and Roongsawang et al.116,121 Residues involved in cyclization are marked
with an asterisk (*). Abbreviations used: aThr: allo-threonine, Dab: 2,4-diaminobutyric acid, Orn: ornithine.
For the other common AAs the standard three-letter abbreviations are used. aiFA9: anteiso-nonanoic acid (6-
methyloctanoic acid), iFA8: iso-octanoic acid (6-methylheptanoic acid). a The major β-hydroxy fatty acids encoun-
tered are iso- and anteiso-HOFA13, n- and iso-HOFA14, iso- and anteiso-HOFA15. b The major β-hydroxy fatty
acids encountered are anteiso-HOFA15, n- and iso-HOFA16, n- and anteiso-HOFA17. c The major β-amino fatty
acids encountered are n-NH2FA14, iso- and anteiso-NH2FA15 and n- and iso-NH2FA16 and anteiso-NH2FA17.121
Name FA 1 2 3 4 5 6 7 8 9 10
Surfactin familya
Surfactin (37) HOFA* L-Glu L-Leu/Val/Ile D-Leu L-Val/Ala/Leu/Ile L-Asp D-Leu L-Leu/Val/Ile*
Lichenysin HOFA* L-Gln/Glu L-xLeu D-Leu L-Val/Ile L-Asp D-Leu L-Ile/Val*
Surfactant BL86 HOFA* L-Glx L-Leu D-Leu L-Val L-Asx D-Leu L-Ile/Val*
Pumilacidin HOFA* L-Glu L-Leu D-Leu L-Leu L-Asp D-Leu L-Ile/Val*
Esperin HOFA* L-Glu L-Leu D-Leu L-Val L-Asp* D-Leu L-Leu
Fengycin familyb
Fengycin A (39) HOFA L-Glu D-Orn D-Tyr* D-aThr L-Glu D-Ala L-Pro L-Gln L-Tyr L-Ile*
Fengycin B HOFA L-Glu D-Orn D-Tyr* D-aThr L-Glu D-Val L-Pro L-Gln L-Tyr L-Ile*
Plipastatin A HOFA L-Glu D-Orn L-Tyr* D-aThr L-Glu D-Ala L-Pro L-Gln D-Tyr L-Ile*
Plipastatin B HOFA L-Glu D-Orn L-Tyr* D-aThr L-Glu D-Val L-Pro L-Gln D-Tyr L-Ile*
Iturin familyc
Iturin A (38) NH2FA* L-Asn D-Tyr D-Asn L-Gln L-Pro D-Asn L-Ser*
Iturin C NH2FA* L-Asp D-Tyr D-Asn L-Gln L-Pro D-Asn L-Ser*
Bacillomycin D NH2FA* L-Asn D-Tyr D-Asn L-Pro L-Glu D-Ser L-Thr*
Bacillomycin F NH2FA* L-Asn D-Tyr D-Asn L-Gln L-Pro D-Asn L-Thr*
Bacillomycin L NH2FA* L-Asn D-Tyr D-Asn L-Ser L-Gln D-Ser L-Thr*
Bacillomycin LC NH2FA* L-Asn D-Tyr D-Asn L-Ser L-Glu D-Ser L-Thr*
Mycosubtilin NH2FA* L-Asn D-Tyr D-Asn L-Gln L-Pro D-Ser L-Asn*
Other
Polymyxin B1 (40) aiFA9 L-Dab L-Thr L-Dab L-Dab* L-Dab D-Phe L-Leu L-Dab L-Dab L-Thr*
Polymyxin B2 iFA8 L-Dab L-Thr L-Dab L-Dab* L-Dab D-Phe L-Leu L-Dab L-Dab L-Thr*
Polymyxin E aiFA8 L-Dab L-Thr L-Dab L-Dab* L-Dab D-Leu L-Leu L-Dab L-Dab L-Thr*
Polymyxin M aiFA8 L-Dab L-Thr L-Dab L-Dab* L-Dab D-Leu L-Thr L-Dab L-Dab L-Thr*
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2.2.2.3 Relevant CLPs produced by other microorganisms
Streptomyces sp.
Daptomycin (12) is a semi-synthetic CLP with potent antibacterial activity, produced by Strep-
tomyces roseosporus (Figure 2.10). The CLP produced by the microorganism is first deacylated
via a deacylase enzyme and then condensed with decanoic acid. Alternatively, decanoic acid
can be added to the fermentation medium leading to a direct incorporation.125 Daptomycin (12)
harbors interesting antibiotic activity (vide infra). The calcium-dependent antibiotic (CDA) is
produced by Streptomyces coelicolor.
Serratia sp.
Also Serratia produces several CLPs. The best known are serrawettin W2 (41) by Serratia
marcescens MG1 and the antimycobacterial serratamolides (42) (Figure 2.10).126
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Figure 2.10. Chemical structure of serrawettin W2 (41), daptomycin (12) and serratamolide A (42a).
2.2.3 Biosynthesis
CLPs are synthesized by large, multifunctional enzymes called non-ribosomal peptide syn-
thetases (NRPS). NRPS consist of different sections, called modules, each responsible for the
recognition, activation, modification and incorporation of one specific AA building block into
the final product. In most cases the sequence and number of modules correlates with the AA
sequence of the CLP (colinearity rule). During its synthesis, the elongating peptide moves from
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one module to the following, mimicking an assembly-line. A module is further subdivided into
different domains effectuating substrate recognition, activation, binding, modification, elonga-
tion and release.17,18 Ten different types of domains are known.17 The most important domains
are described in detail below.
Overall, three types of modules can be distinguished: initiation, elongation and termination
modules. Initiation modules consist of an adenylation and thiolation domain, responsible for the
selection and binding of the first amino acid.127 Also the N-acylation of the first amino acid is
typically catalyzed in the initiation module by a condensation domain.128 Elongation modules
always contain a condensation, adenylation and thiolation domain but editing domains may
be present as well. Termination modules contain a condensation, adenylation, thiolation and a
thioesterification domain, required for the release and possible cyclization of the oligopeptide.
2.2.3.1 Adenylation (A) domain
The adenylation (A) domain is responsible for AA recognition and activation. The carboxylic
acid of the AA is activated via a Mg2+-dependent hydrolysis of ATP, yielding the correspond-
ing amino acyl-O-adenylate and pyrophosphate (Figure 2.11).17 As a consequence of the non-
ribosomal synthesis, CLPs can contain not only the 20 common, proteinogenic AAs but differ-
ent building blocks as well.17 The large diversity of building blocks of CLPs is explained by
the existence of a wide structural variety of A domains.17 Based on the analysis of the primary
sequence of the binding pocket of the A domain, its selectivity can be predicted employing the
non-ribosomal code.127,129–132 Via selective mutation it is possible to alter the selectivity of the
A domain and construct new peptide analogues.129,133 The substrate flexibility of certain A do-
mains can give rise to the biosynthesis of several structural variants of a certain CLP or even
allow the incorporation of added, unnatural amino acids.18,117,134–136
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Figure 2.11. A Domain-catalyzed recognition and activation of the selected amino acid at the expense of ATP to
yield the amino acyl-O-AMP. Figure adapted from Sieber et al.17
2.2.3.2 Thiolation (T) or peptidyl carrier protein (PCP) domain
Downstream of the A domain, the activated amino acyl-O-adenylate is covalently bound to the
thiol group of the 4’-phosphopantetheinyl (ppant) co-factor, linked to a serine residue of the
thiolation (T) domain. Therefore, to activate a T domain, it must be posttranslationally mod-
ified to obtain this 20 Å long phosphopantetheinyl arm, derived from coenzyme A. This mo-
dification from unactive apo- to functional holo-form is catalyzed by 4’-phosphopantetheinyl
transferases (PPTase) and is Mg2+-dependent (Figure 2.12).127,137,138 The thioesterification be-
tween the activated amino acid and the ppant co-factor is catalyzed by the A domain. After this
step, the substrate is covalently bound to the enzyme. The T domains are responsible for pass-
ing the substrate from one catalytic center to the next throughout the NRPS assembly line.17
The thioesters employed by NRPS are more reactive than the tRNA-bound ester intermediates
which are used in ribosomal peptide synthesis, because of lower mesomeric stabilization of the
thioester compared to the ester.17
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Figure 2.12. Posttranslational modification of the T domain with its ppant co-factor by a phosphopantheinyltrans-
ferase (PPTase). The phosphopantheine moiety is transferred from coenzyme A to a conserved serine residue of
the T domain. Then the activated amino acid moiety is covalently attached to the thiol group of the ppant co-factor
of the T domain. This loading of the T domain is catalyzed by the A domain. Figure based on Lambalot et al.,
Sieber et al. and Fischbach et al.17,137,138
2.2.3.3 Condensation (C) domain
Condensation (C) domains catalyze the peptide bond formation via nucleophilic attack of the
α-amino group of the downstream PCP-bound AA, positioned in the acceptor site, on the as
a thioester activated carboxylic acid part of the upstream PCP-bound AA, positioned in the
donor site (Figure 2.13). The resulting peptide then serves as the donor substrate in a subse-
quent condensation catalyzed by the C domain of the next module.17,127,128 Although C domains
exhibit a high selectivity for the nucleophilic (acceptor) substrate, the electrophilic (donor) sub-
strate is hardly differentiated.139 However, when an epimerization domain is present (see section
2.2.3.5), the C domain is responsible for the selection of the donor substrate with the correct
stereochemistry.128,140
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Figure 2.13. Peptide bond formation catalyzed by the C domain. The nucleophilic amine of the amino acid moiety
in the acceptor (a) site attacks the electrophilic thioester of the amino acid moiety accommodated in the donor (d)
site. The resulting peptide can subsequently act as the electrophile in the donor site of the next C domain. Figure
adapted from Sieber et al.17,127
2.2.3.4 Thioesterase (TE) domain
Finally, to reactivate the multienzyme complex for another synthetic cycle, the thioesterase (TE)
domain cleaves the oligopeptide at the end of the assembly line in the termination module. To
achieve this release, a conserved serine residue of the active site of the TE domain attacks the
T domain-bound peptidyl thioester, forming a peptide-O-TE intermediate.127 Subsequently, the
peptide can be released from this serine moiety either by hydrolysis, to yield a linear peptide,
or by an intramolecular nucleophilic attack, yielding a CLP (Figure 2.14). Whether a cyclic or
a linear LP is released is determined by the oxyanion hole. The negatively charged intermediate
formed during the release reaction is stabilized by two amide bonds. In the case of a TE domain
that is producing CLPs, a rigid proline residue can be found next to one of these amides, whereas
for the other type of TE domain, a more flexible glycine residue is present, easing the entry of
a water molecule that is required for hydrolysis.141 The cyclization always includes the C-
terminal end of the peptide, side-chain to side-chain cyclizations have not been observed.17,141
The macrocyclization catalyzed by TE domains occurs stereo- and regioselective.142,143 The
presence and type of the fatty acid tail can exert a profound effect on the regioselectivity of
this cyclization catalyzed by the TE domain.143 TE domains also control the oligomerization of
identical peptide units during iterative peptide synthesis.144
Macrocyclization is difficult to achieve via chemical synthesis without the application of many
protecting groups, which is often accompanied with low yields. Excised TE domains can be
used for chemoenzymatic synthesis. A linear precursor is first synthesized via solid-phase pep-
tide chemistry, followed by selective and efficient cyclization catalyzed by an excised TE do-
main.17,141–143
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2.2.3.5 Editing domains
When the substrate is linked to the T domain, different modifications can take place, catalyzed
by the non-essential editing domains.
Epimerization (E) and condensation/epimerization (C/E) domain
A striking feature of many CLPs is the presence of one or more D-AAs. A possibility for the
inclusion of D-AAs is selective incorporation by the A domain of D-AAs provided by an external
racemase.145 A more prevalent way is through the use of E domains. E Domains epimerize the
Cα-carbon of the amino acid linked to the ppant co-factor of the T domain, delivering a D/L-
mixture.17,140 Subsequently, the downstream C domain enantioselectively selects the product
with the desired stereochemistry.127,128,140
However, sometimes there are discrepancies between the stereochemistry of the final peptide,
containing D-AAs, and the corresponding NRPS, lacking E domains. Typically, these NRPS
possess condensation domains with a dual catalytic activity: both condensation and epimeriza-
tion are effectuated by these domains. These are called C/E domains and epimerize the AA
loaded on the T domain of the preceding module. This type of domain can be recognized by the
elongated His motif.146 E Domains have been found in Gram-positive bacteria such as Bacillus,
but typically not in the Gram-negative Pseudomonas species, as they contain C/E domains.
Methyltransferase (MT) domain
Another type of modification is N- or C-methylation of the substrate. This domain relies on
S-adenosyl-L-methionine (SAM) as the methyl donor.127
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(Hetero)cyclization (Cy) domain
This is the only type of editing domain that can replace one of the core domains of the NRPS.127
When replacing a C domain, this unit catalyzes the formation of oxazoline and thiazoline rings
out of Ser/Thr or Cys respectively.17,147
Oxidation (O) and Reduction (R) domain
The oxidation state of oxazoline and thiazoline rings can be modified via oxidation (Ox) or
reduction (R) domains.127 In the absence of a TE domain, C-terminal R domains can also reduce
the thioester linked to the T domain, thereby releasing the linear oligopeptide as an aldehyde or
alcohol.144
Formyltransferase (F) domain
N-Formylation is effectuated by the N-formyltetrahydrofolate-dependent F domain.17,148
2.2.3.6 Fatty acid introduction
An additional condensation (C1) domain preceding the A domain of the initiation module is
involved in the N-acylation of the first amino acid with the lipid moiety (also known as lipoini-
tiation).128,135,149,150
In the case of surfactin (37), the CoA-activated β-hydroxy fatty acid is transferred with a high
specificity to the T domain-bound amino acid. The activation of the β-hydroxy fatty acid itself is
catalyzed by a fatty acyl CoA ligase.149 The calcium-dependent antibiotic (CDA) CLP follows
a quite similar mode of fatty acid introduction, only using a fatty acid tethered to ACP instead
of CoA.150 A third mechanism of fatty acid introduction is found in mycosubtilin, produced by
a hybrid PKS/NRPS synthase. During its biosynthesis, palmitic acid is loaded onto the first A
domain of the polyketide synthase part, then condensed with malonyl-CoA and the resulting
β-keto thioester is reductively aminated to give the β-amino fatty acid moiety that is charac-
teristic for CLPs belonging to the iturin group. This fatty acid tail is then presumably passed
on to the NRPS part.151 The hydroxy fatty acids themselves could be produced by the primary
metabolism (type II fatty acid synthase systems).117
As an example of the complete NRPS-assembly line, the ten modules responsible for the syn-
thesis of the CLP orfamide A are represented in figure 2.15.18
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Figure 2.15. NRPS Organization for the biosynthesis of the CLP orfamide A.18
2.2.3.7 Comparison ribosomal - non-ribosomal peptide synthesis
In ribosomal peptide synthesis, a tRNA synthetase selects and activates the AA at the expense
of ATP, yielding an amino acyl-O-adenylate. Although an identical mechanism is followed by
the A domains, both type of enzymes evolved independently. In case of the ribosomal peptide
synthesis, the activated AA is subsequently loaded onto a tRNA via an ester bond, which then
goes to the ribosome for mRNA-directed protein biosynthesis. During non-ribosomal peptide
synthesis, the activated AA is transferred to a T domain and then further passed on through the
NRPS assembly line.127,152
Due to the need for precision in primary metabolism, several proofreading mechanisms are
included in ribosomal synthesis, which are absent in NRPS.127,152 On the other hand, NRPS can
use several hundreds of substrates, whereas ribosomal synthesis is normally restricted to the 20
proteinogenic AAs.127
2.2.4 Regulation of CLP production
In response to several abiotic conditions (temperature, pH, oxygen, etc.), nutritional factors (car-
bon, nitrogen and trace elements) and sometimes even plant signal molecules, a complex genetic
network regulates the CLP production.113 Known CLP regulatory genes and mechanisms are
discussed below.
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2.2.4.1 Regulation of CLP production in Pseudomonas
GacS/GacA
The production of CLPs is subjected to complex regulatory circuits. In Pseudomonas species,
the GacS/GacA (Global activator) two-component system is often a crucial element and func-
tions as a master switch (Table 2.3).115,116,118,136,153–159 Nutritional factors and specific plant
phenolic glycosides were able to activate the synthesis of syringomycin in P. syringae pv.
syringae.115 Exudates from sugar beet seeds were also able to activate amphisin production
in Pseudomonas sp. DSS73 via triggering the GacS/GacA two-component system. GacS is a
transmembrane protein, functioning as a histidine sensor kinase, which is activated by autophos-
phorylation in response to environmental stimuli and then phosphorylates its cognate response
regulator GacA.115,153,154 GacA in its turn activates the expression of certain target genes speci-
fying small noncoding RNAs. These RNAs are characterized by repeated CGA motifs essential
for binding small RNA-binding proteins (RsmA) that act as translational repressors of target
mRNAs.118,160 In this manner, activation of Gac titrates the repressors away. Besides many sec-
ondary metabolites, also the production of AHLs is typically GacS/GacA-regulated.161
LuxR-type transcriptional regulators
LuxR-type regulators are found in the flanking regions of most NRPS genes present in Pseu-
domonas (Table 2.3).114,157,162 These transcriptional regulators contain a DNA-binding helix-
turn-helix motif but lack an AHL-binding or response regulator domain.162
LuxR-type regulators SalA and SyrF regulate syringomycin and syringopeptin (34) production
in P. syringae pv. syringae. SalA is suspected to interact with the syrF promoter and SyrF then
binds and activates the promoter of the target NRPS.153,157,163 ViscAR and ViscBCR regulate
viscosin (36) production in P. fluorescens SBW25,162 and the similar MassAR and MassBCR
transcriptional regulators control massetolide biosynthesis in P. fluorescens SS101.136 EtlR con-
trols entolysin biosynthesis in P. entomophila,118 and ArfF arthrofactin production in Pseu-
domonas sp. MIS38.164 Also the production of white line-inducing principle (WLIP), a mem-
ber of the viscosin CLP group, by rice rhizosphere isolate P. putida RW10S2 is activated by the
LuxR family regulator WlpR and is not controlled by the present PmrI/PmrR QS system.114
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Table 2.3: Regulation of CLP production. Adapted and extended from Raaijmakers et al.113,162
CLP Microorganism Regulators involved AHLs
Amphisin 154,155 Pseudomonas sp. DSS73 GacS/GacA -
Arthrofactin 164 Pseudomonas sp. MIS38 GacS/GacA, ArfF, heat shock protein HtpG and stress
factor spoT
-
Cormycin A 24,25 P. corrugata CFBP5454 QS: PcoI/PcoR, RfiA C6 1c, C8 1e, oxo6 3c
Corpeptin A & B 24,25 P. corrugata CFBP5454 QS: PcoI/PcoR, RfiA C6 1c, C8 1e, oxo6 3c
Corpeptins 25 P. mediterranea CFBP5447 QS: PmeI/PmeR, RfiA C6 1c, C8 1e, oxo6 3c
Entolysin 118 P. entomophila GacS/GacA, EtlR -
Massetolide A 136,165 P. fluorescens SS101 GacS/GacA, MassAR and MassBCR, serine protease
ClpP
-
Putisolvin I (32) & II 22,23,156 P. putida PCL1445 GacS/GacA, PsoR, heat shock proteins DnaK, DnaJ and
GrpE, QS: PpuI/RsaL/PpuR
oxo10 3g, oxo12 3i
Serrawettin W2 (41) 126,166 Serratia marcescens MG1 SwrI/SwrR C4 1a, C6 1c
Syringopeptin (34) 157 P. syringae pv. syringae
B301D
GacS/GacA, SalA, SyrG, SyrF -
Syringomycin 115,153,157 P. syringae pv. syringae
B301D
GacS/GacA, SalA, SyrG, SyrF -
Viscosin (36) 21 P. fluorescens 5064 HO8 2e
Viscosin (36) 131,162 P. fluorescens SBW25 GacS/GacA, ViscAR and ViscBCR -
WLIP 114 P. putida RW10S2 GacS/GacA, WlpR -
Xantholysin 112 P. putida BW11M11 XtlR -
Regulation by AHL-mediated QS
AHL-Mediated QS controls several bacterial traits but only in a limited number of cases AHLs
play an important regulating role in CLP production (Table 2.3). During the screening for
biosurfactant producing strains in the sugar beet rhizosphere, only three out of 80 surfactant-
producing isolates were able to synthesize AHLs.155 True LuxR analogues such as LuxR itself,
LasR, RhlR, and PhzR contain an AHL-binding domain.
The involvement of AHL-mediated QS in the control of viscosin (36) production by broccoli
pathogen P. fluorescens 5064 was hinted by the fact that biosurfactant production only started
at high cell densities in the late exponential growth phase. The corresponding AHL is HO8
2e.21 Another example is the PpuI/RsaL/PpuR QS-system regulating putisolvin I (32) and II
synthesis in P. putida PCL1445. These CLPs are produced at late exponential growth phase as
well. LuxI and LuxR homologues PpuI and PpuR are responsible for AHL (oxo10 3g and oxo12
3i) production and recognition, whereas RsaL acts as a repressor of PpuI and PpuR. Mutation
in the ppuI and ppuR genes causes a reduced putisolvin production, whereas rsaL mutation
gives rise to overproduction of both AHLs and putisolvin.22 Besides the AHL-mediated QS
regulation,22 also the LuxR-type regulator PsoR was shown to be involved.23 Tomato pathogen
P. corrugata contains the PcoI/PcoR QS-system controlling the synthesis of CLPs corpeptin A
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and B and cormycin A as virulence factors.24,25 A similar regulation is also found in the closely
related P. mediterranea (containing the PmeI/PmeR operon).25 P. corrugata contains as well a
LuxR-family type regulator, designated RfiA, for which the downstream regulatory rfiA gene is
co-transcribed with pcoI.24
Other types of regulators
Besides LuxR analogues or LuxR-type regulators, other proteins can be involved as well. Ser-
ine protease ClpP (caseinolytic protease) regulates massetolide biosynthesis via influencing the
expression of LuxR-type transcriptional-regulatory genes in the plant-growth stimulating strain
P. fluorescens SS101. ClpP typically plays a crucial role in intracellular refolding and degra-
dation of proteins. It was postulated that ClpP degrades proteins that repress or interfere with
the transcription of the massetolide-regulatory gene. Also an influence on the citric acid cycle
and amino acid metabolism cannot be excluded. It was shown that ClpP regulates massetolide
biosynthesis independent of the GacA/GacS-controlled regulation.165
Heat shock proteins DnaK, DnaJ and GrpE were shown to be involved in the regulation of the
biosynthesis of putisolvin in P. putida PCL1445 at low temperatures. These proteins may be
required for proper folding of other positive regulators or the synthetic machinery.156 Also heat
shock protein HtpG is involved in regulating the synthesis of arthrofactin, but the mechanism
of its involvement is not entirely clear yet. Also the SpoT stress factor, which is responsible
for the hydrolysis of guanosine 3’,5’-bispyrophosphate (ppGpp) and synthesis of guanosine
3’-diphosphate,5’-triphosphate (pppGpp), seems to play a role in arthrofactin synthesis.164
2.2.4.2 Regulation of CLP production in other bacteria
Serratia
Serratia marcescens MG1 (previously designated as S. liquefaciens) produces serrawettin W2
(41) (Figure 2.10). This production is controlled by the SwrI/SwrR quorum sensing system
and its cognate AHLs C4 1a and C6 1c.126,166 In swrI-mutant MG44, unable to swarm, the
serrawettin W2 (41) production and thus the swarming phenotype could be restored by the
addition of C4 1a.126,166 Besides the QS regulated CLP-production, stimulation of the flhDC
master operon which controls swarmer cell differentiation (cell elongation, multinucleation and
hyperflagellation), is needed as well to achieve swarming. Also nutrient status plays a crucial
rol.167
Bacillus
Surfactin (37) production is regulated by the two-component system ComA/ComP in a cell-
density dependent manner via the peptide pheromone ComX among many other components.
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ComA is phosphorylated by protein kinase ComP in response to perception of ComX. The
activated ComA then binds to the promoter region.20,116,168
2.2.5 Natural functions
The main natural functions associated with CLPs are antagonism, motility and surface attach-
ment (Figure 2.16).20 The structure of a CLP determines the activity, small structural changes
in the peptide core or lipid tail can change the physicochemical properties and interaction with
membranes.106,123,134,136,162
Figure 2.16. Different natural functions of CLPs. Figure from Raaijmakers et al.20
Microbial warfare
The antagonistic effects of many CLPs grant a competitive advantage to the producing organism
over coexisting microorganisms. By disintegrating membranes, CLPs can exhibit inhibitory ef-
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fects against bacteria, viruses, fungi and oomycetes.19,20,113,169 The limited activity of CLPs
against Gram-negative bacteria has been ascribed to the protective effects of the outer mem-
brane, although there are exceptions.19,112,170 The mode of action consists of the formation of
channels in the membrane. The resulting pores increase the influx of H+ and Ca2+ and the efflux
of K+, causing a collapse of the membrane pH gradient, although some CLPs act rather as a
non-specific detergent than as a pore-forming toxin.19,115,170,171 To fully assess the antagonistic
effect of a CLP, studies with the isolated CLP or with non-producing or overproducing mutants
are required, besides the evaluation of the level of CLP-production in vitro.121
Protection against predation
Both surfactin (37), produced by Bacillus, and serrawettin W2 (41), produced by Serratia mar-
cescens, were able to fend of the nematode Caenorhabditis elegans from feeding on the bacterial
colonies.172 Also viscosin (36) produced by P. fluorescens SBW25 and massetolide produced by
P. fluorescens SS101 offer both species protection against predation by the amoeba Naegleria
americana.173
Motility
CLPs can influence the wettability of surfaces, helping the bacteria spread across these sur-
faces.19,113,121,155 Surfactin (37) for example can lower the surface tension of water from 71 to
27 mN/m at concentrations as low as 20 µM.123 Viscosin (36) has a comparable effect on the
surface tension.19 As a consequence, several CLPs are indispensable for the producing microor-
ganism to swarm, e.g. massetolide A,136 amphisin,155 entolysin,118 and serrawettin W2 (41).126
Benefits of increased bacterial mobility include better nutrient acquisition, avoiding predators
and toxic substances and access to new colonization sites.155
Biofilm formation
Biofilms can protect the inhabiting bacteria against undesired elements such as antibiotics and
predators. CLPs can play an important role during the attachment phase and the formation of
biofilm as demonstrated by the tendency of CLP-mutants to form differently structured biofilms.
The structure of the CLP plays an important role: whereas some CLPs such as massetolide A,
positively stimulate the formation of a thick, structured biofilm,136 other CLPs (e.g. putisolvin
I (32) and II) dissipate existing biofilms.22,174,175 The orientation of the CLP plays a crucial role
in the final effect. When the hydrophobic moiety of CLP is embedded into the bacterial cell sur-
face, leaving the hydrophilic part of the CLP exposed, only attachment to hydrophilic surfaces
is possible. On the other hand, when the hydrophobic part remains exposed, only attachment to
hydrophobic surfaces is possible.176 This effect was suggested by the observation that a rham-
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nolipid surfactant increased the cell hydrophobicity of some P. aeruginosa strains and hence
the rate of octadecane degradation.177 On the other hand, when a serratamolide (42) biosurfac-
tant was added to a Serratia marcescens culture, a reduction of cell surface hydrophobicity was
observed, presumably caused by blocking the hydrophobic sites.178 The final effect depends on
the initial bacterial surface hydrophobicity as well. Whereas surfactin (37) was able to increase
the hydrophobicity of a hydrophilic B. subtilis strain, a decrease in cell surface hydrophobicity
of a hydrophobic strain was observed.179
Chelation and emulsification
The emulsifying properties of CLPs increase the solubility of hydrophobic nutrients, enhancing
the growth.19 Also several metal ions can be chelated, granting protection against the toxic
effects of certain metals or enabling sequestration of trace metals as micronutrients.20 Structural
elements play a crucial role, the replacement of a Glu-residue in surfactin (37) with Gln yields
lichenysin with better chelation properties for Ca2+ and Mg2+.180
Phytotoxicity
Several CLPs have a phytotoxic activity. Syringomycin and syringopeptin (34) of P. syringae
interact with the plant plasma membrane leading to pore formation thereby enabling transmem-
brane passage of K+, H+ and Ca2+-ions. This eventually induces necrosis of plant tissues.115
Also the biosurfactant properties of CLPs contribute indirectly to the virulence by helping bacte-
ria spread and solubilizing plant protective wax layers, having a synergistic effect with cell wall
degrading enzymes.19,113 The CLPs corpeptin A and B and cormycin A are the major virulence
factors of tomato pathogens P. corrugata and P. mediterranea.24,25
2.2.6 Commercial applications of bacterial CLPs
Biosurfactants can be applied in a broad range of industrial applications such as oil recovery,
bioremediation, wetting and emulsification. The main advantage compared to the synthetic al-
ternatives are their biodegradability and lower toxicity. However, not all CLPs can be used as
such. Sometimes the (cyto)toxicity of some CLPs prevents their use for certain (clinical) appli-
cations. Also instability can impede industrial application of some CLPs.109 Another limitation
is the rather low level of CLP production. To offer an economically viable alternative for non-
renewable, synthetic compounds, CLPs should be produced with a high productivity and on
inexpensive substrates. Also the downstream processing should be limited.181,182 Surfactin (37)
is often extracted from the culture broth via acid precipitation, recrystallization and organic
solvent extraction. However, several impurities are co-extracted, causing the need for a chro-
matographic separation step.123 Another option is the foam fractionation technique, exploiting
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the surfactant properties of surfactin (37). The CLP is recovered from the collapsed foam via
acid-induced precipitation.183
Cosmetic industry
Besides their environmentally friendly and renewable image, many CLPs possess a low human
toxicity, allowing their application for cosmetic products. Several CLPs, such as surfactin (37),
serrawettin and iturin are suitable to be used as emulsifiers in skin preparations.184 Surfactin (37)
can be included in cleansing cosmetics as well. These products show an excellent washability
combined with an extremely low skin irritation.185,186 The Japanese company Kaneka offers
surfactin (37) on the market for cosmetic applications.187 The antimicrobial properties of many
CLPs can also aid to increase the product preservation.186
Soil remediation
Biosurfactants can be applied for soil remediation. By solubilizing the pollutants, their environ-
mental degradation is enhanced. The CLP surfactin (37) was able to enhance diesel biodegra-
dation at a concentration of 40 mg/L. On the other hand, a concentration of 400 mg/L halted
biodegradation, presumably due to the antibiotic properties of this CLP.188 Also the biodegrada-
tion of the chlorinated pesticide endosulfan was enhanced in the presence of surfactin (37).189
Aliphatic and aromatic hydrocarbons degraded more quickly as well in the presence of this
CLP.190 The increased degradation of aromatic compounds is caused by increasing contact with
air to speed up oxidation.191 The solubilizing properties of CLPs toward hydrocarbons can also
be exploited for the mobilization of oil, for example entrapped in sandstone cores, thereby en-
abling oil recovery.192,193
The metal chelating properties of several CLPs can be exploited for the removal of heavy metals
from contaminated soil.191 Surfactin (37) succeeded in removing Zn and Cu by sorption at the
soil interface and metal complexation.194 Alternatively, blowing with air, causes the metal-CLP
complex to foam, allowing easy removal from the soil.195
Pharmaceutical applications
CLPs represent an underexplored class of natural products with promising antibacterial activity
to confront the emergence of multi-resistant human pathogens. Several CLPs with antibiotic
activity have been described.110 A strong advantage of CLPs as antimicrobial agents is their
rapid bactericidal effect and a minimal induction of resistance because of the fact that the entire
membrane is targeted, which is difficult to redesign.124 Limitations are the limited solubility and
potential toxicity because of the unspecific mode of action.124 Most CLPs are only active against
Gram-positive bacteria. The Gram-negative outer membrane or peptidoglycan layer presumably
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denies the CLP access to the plasma membrane.19,170
A famous example of a CLP-type antibiotic is daptomycin (12), produced by the Gram-positive
bacterium Streptomyces roseoporous and currently used as a last resort antibiotic against methi-
cillin-resistant Staphylococcus areus (MRSA) and vancomycin-resistant Enterococci (VRE).
This anionic CLP is since its FDA approval in 2003 commercially marketed as Cubicin. The
currently accepted mode of action involves Ca2+-dependent binding to the cytoplasmic bacterial
membrane followed by a perturbation of the membrane in a detergent-like manner.124,196,197
For infections caused by Gram-negative bacteria, polymyxins are an interesting option. These
cationic CLPs have an affinity for a lipopolysaccharide (LPS) component of the outer cell mem-
brane of Gram-negative bacteria. Polymyxin B (40) and E (= colistin) are already in clinical
use, but high doses are accompagnied with neurotoxic and nephrotoxic effects.197 Currently,
two polymyxins developed by an optimization program of Northern Antibiotics are undergoing
late stage preclinical development.124
Another encouraging example is Pseudomycin B. This CLP is effective against the human-
pathogenic yeasts Candida albicans and Cryptococcus neoformans but has an irritating effect
and can cause necrosis of the treated tissue, hindering practical applications. However, pseu-
domycin analogues have been synthesized that retained the antibiotic effect but with a strongly
reduced toxicity to the experimental animals.198
Several other CLPs are known with weak to moderate in vitro antibacterial activity.110 Masse-
tolide A and viscosin (36) exhibit in vitro antimicrobial activity against tuberculosis causative
agent Mycobacterium tuberculosis.18,19,134,136 B. megaterium is inhibited by corpeptin and syrin-
gopeptin 22A and 25A (34).19 Surfactin (37) exhibits antibacterial activity against Mycoplasma
but its cytotoxicity against erythrocytes hinders its medical application.169
Some CLPs possess antiviral activity as well. Surfactin (37) is active against some enveloped
viruses, such as herpes- and retroviruses.169,199 Because of its hemolytic activity, clinical appli-
cation is limited to local treatment.199 Also viscosin (36) has in vitro antiviral activity against
enveloped human-pathogenic viruses (e.g. infectious bronchitis virus, influenza virus and New-
castle disease virus). The high MIC values suggest a non-specific detergent effect, acting on the
lipid envelope of the virus.19
Other medical applications
Surfactin (37) is a valuable inhibitor of fibrin clot formation, but further research is required to
determine the applicability of this compound 37.110,122
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Crop protection - fungicides
CLPs have a great potential to be used as environmentally friendly alternatives for chemical
plant protection agents currently in use against several agricultural diseases. One option would
be to use the CLP as such, whereas another possibility is using the CLP-producing microorgan-
ism itself. The spore-forming ability of Bacillus is in this point of view a huge advantage.121
Several CLPs produced by Pseudomonas have been reported to play a role in biological control
of several plant pathogens as well.200 Some examples are xantholysin against Xanthomonas
sp. and Rhizoctonia solani,112 viscosin (36) against Phytophthora infestans,131 and sessilin
and orfamide against R. solani.201,202 Orfamides and massetolides have also a destructive ef-
fect on the zoospores of many Oomycete plant pathogens (Pythium ultimum and Phytophthora
porri).117,131,203
Antifouling
Several CLPs are able to desintegrate biofilms and prevent biofilm formation. Besides the in-
dustrially relevant biofouling, biofilms are medically relevant as well, as they grant resistance
against added antibiotics. It was shown that the addition of the B. subtilis CLP surfactin (37)
was able to disperse the biofilm formed in urethral catheters by Salmonella enterica, E. coli,
and Proteus mirabilis. Biofilms formed by P. aeruginosa remained unaffected.174
2.3 Concluding remarks
Although a lot of research has been performed on QS, interkingdom signaling is only an emerg-
ing field of research. The effect of AHLs on plants, and plants on QS is clear, but there is still
a lot of debate about the exact mechanism of action. Sometimes differing (or even contrasting)
effects can be observed for one AHL depending on the experimental set-up (plant species, agar
plates or liquid medium, duration of the treatment, AHL contact before or after germination,
etc.). Careful in vitro and in vivo experiments with different plant species are required to draw
conclusions and perhaps allow the use of AHLs for commercial applications.
CLPs fulfill several crucial functions for the producing organism. As is the case for many sec-
ondary metabolites, their production is subjected to many complex regulatory circuits. A better
understanding of this regulation could help increase CLP-production to make them even more
competitive alternatives for some surfactants used today. Besides the application as pure surfac-
tants, CLPs could be applied in several other markets such as cosmetic industry, pharmaceutical
industry, crop protection, soil remediation, etc.
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Chapter 3
Results and discussion
3.1 Synthesis and analysis of stable isotope-labelled N-acyl-L-homoserine
lactones
Abstract
Aliphatic aldehydes were deuterated at the α-position via a base-catalyzed exchange reaction
with D2O. These deuterated building blocks were used for the synthesis of labelled analogues of
quorum sensing signal molecules belonging to the three major classes of naturally occurring N-
acylated homoserine lactones (AHLs), with the label on a non-enolizable and therefore stable
position. Besides the application of these stable isotope-labelled AHLs as labelled standard
for quantitative analysis via isotope dilution mass spectrometry, these compounds can be used
to study the metabolic fate of the fatty acid tail of the AHL-molecule. These isotope-labelled
compounds were fully characterized and used to synthesize the deuterated analogues of two
commonly occurring AHL-degradation products, a tetramic acid and a ring opened N-acyl -L-
homoserine.
Graphical abstract
O
N
H
O
O
O
H
O
R
H H
H
O
R
D D
O
N
H
O
O
OH
R
R
O
N
H
O
O
R
D D
DD
D D
Keywords
AHL, quorum sensing, fatty acid, isotope labelling, tetramic acid, isotope dilution, GC-MS
Reference
Ruysbergh, E., Stevens, C. V., De Kimpe, N., Mangelinckx, S. Synthesis and analysis of stable
isotope-labelled N-acyl homoserine lactones. RSC Adv. 2016, 6, 73717-73730.
51
Results and discussion
3.1.1 Introduction
Although the AHL-concentration inside a biofilm can reach as high as 600 µM, only concen-
trations in the nM range are typically encountered in the effluent leaving flow cells covered
with biofilm.34 To detect these trace amounts of AHLs, sensitive detection methods are needed.
One possible method is via the application of biosensors, such as Agrobacterium tumefaciens
NT1,204 Chromobacterium violaceum CV026,205 and Escherichia coli JB523206 (Table 3.1).
The detection relies on a phenotypic response such as enzyme secretion, pigment production or
bioluminescence when the threshold concentration of AHLs is exceeded.207
Table 3.1: Biosensors commonly used for AHL-detection.
Biosensor Phenotype AHL-sensitivity
A. tumefaciens NT1204 β-galactosidase production C6 1c - C14 1k, oxo4 3a - oxo14 3k, HO6 2c
- HO10 2g
C. violaceum CV026205 purple pigment production C4 1a - C8 1e, oxo4 3a - oxo8 3e
C. violaceum CV026205 inhibition of purple pigment
production
C10 1g - C14 1k, oxo10 3g - oxo14 3k
E. coli JB523206 gfp-production C4 1a - C10 1g, oxo6 3c - oxo12 3i
Although detection of sub-picomole amounts of AHLs is feasible, the possible interference by
artefacts, such as medium-derived diketopiperazines,208 and the need to use multiple biosensor
strains in parallel for complete coverage of all AHLs (Table 3.1), has prompted researchers
to develop multiple techniques for instrumental AHL-detection and identification.35,38,209,210 To
obtain reliable results and exact quantification, an internal standard needs to be included in these
analyses. The use of odd-chain AHLs as internal standard was abandoned after the discovery of
odd-chain AHL-producing bacteria.28,29
Several groups have reported the synthesis of isotope-labelled AHLs 43-52 (Figure 3.1) which
can be used as internal standards.34,42,211–217 In the case of isotope dilution mass spectrometry
(IDMS), the spike compound should be chemically identical with the analyte. As the isotope-
labelled compound acts as an internal standard, compensating for losses during sample isolation
and analysis, the mass difference between the isotope and the analyte should not be too high, to
avoid possible isotope effects.218 Besides the application as a standard, isotope-labelled com-
pounds are often used in absorption, distribution, metabolism and excretion (ADME) studies
and to study reaction mechanisms.219 Hereby, mostly a 1:1 mixture of non-labelled and isotope-
labelled compounds is used, to create a recognizable mass spectral ion pattern to study the in
vitro and in vivo metabolic dispersion.219–222 However, no methodology is available to syn-
thesize AHLs belonging to the major different classes with an isotope label in the acyl chain,
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starting from one, easily available deuterated building block.
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Figure 3.1. Isotope-labelled AHL-analogues 43,34 44,211 45a–c,212 46a–h,213 47a–c,214 48a–e,215 49,216 50, 51,42
and 52,217 described in the literature.
3.1.2 Synthesis of unlabelled AHLs
To be able to compare the chemical properties and spectral data of the labelled analogues with
the natural AHLs, a broad library of unlabelled, natural AHLs was synthesized. The common
building block of all AHLs, the homoserine lactone unit, was prepared as hydrogen bromide
salt 53 via reaction of L-methionine with bromoacetic acid.93 AHLs 1 without a functionality
at the 3-position of the N-acyl chain were prepared in a straightforward manner by coupling
the homoserine lactone hydrobromide 53 with the appropriate acid chloride 54 under Schotten-
Baumann reaction conditions (Scheme 3.1).223
53
Results and discussion
Cl
O 2.6 equiv Na2CO3
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H2NHBr . RR +
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Scheme 3.1. Synthesis of natural AHLs 1a–i,k.
To synthesize β-hydroxy esters 55a–i, a Reformatsky reaction between aldehydes 56a–i and
ethyl bromoacetate 57 was performed (Scheme 3.2).224–226 To obtain β-hydroxy fatty acids 58a–
i, two procedures were used to hydrolyze these esters 55a–i. Whereas sodium hydroxide in a
water:methanol mixture gave satisfying results for the shorter-chain derivatives 58a–e, too much
(up to 25%) of the unreacted ester was remaining for the longer-chain derivatives. Therefore, an
alternative procedure with lithium hydroxide in a tetrahydrofuran:methanol:water mixture was
used.225 An 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated coupling reac-
tion of fatty acids 58a–i with L-homoserine lactone hydrobromide 53 yielded the desired HO-
AHLs 2c–k (Scheme 3.2).227
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1.3 equiv Zn
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Scheme 3.2. Synthesis of natural HO-AHLs 2c–k.
To prepare oxo-AHLs 3c–g,i–k, the required acid chloride 54a–e,g–i was condensed quanti-
tatively with Meldrum’s acid, whereafter a nucleophilic attack of L-homoserine lactone, gen-
erated from the hydrobromide salt 53 with triethylamine, across the resulting adduct 59 gave
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oxo-AHLs 3c–g,i–k.223,228 Alternatively, an EDC-mediated coupling between β-oxo fatty acids
and L-homoserine lactone hydrobromide 53 was evaluated to synthesize oxo-AHLs 3, but only
disappointing yields were obtained.
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Scheme 3.3. Synthesis of natural oxo-AHLs 3c–g,i–k.
3.1.3 Synthesis of a monodeuterated HO-AHL
Since secondary metabolites are quite expensive to synthesize in terms of energy and used
materials, it is tempting to speculate that certain elements of these metabolites are reused. Sev-
eral enzymes are known that are able to degrade AHLs.10 Haloperoxidases for example are
able to halogenate N-(3-oxoacyl)-L-homoserine lactones 3 in a hydrogen peroxide-dependent
manner.40,57,58 Subsequent cleavage of the halogenated acyl chain yields N-(α,α-dihaloacetyl)-
L-homoserine lactone and a fatty acid.57 Therefore, to study the metabolic fate of the fatty
acid side chains, it was decided to include the isotope label in the acyl side chain of the AHL-
molecule. When the isotope label is included in the lactone ring (analogues 45 and 46), all
classes of AHLs can easily be accessed.212,213 However, studies to investigate the metaboliza-
tion of the fatty acid side chain are impossible with these analogues. To include the label in
the side chain (analogues 44, 47 and 52), most synthetic routes rely on the use of rather ex-
pensive deuterated fatty acids.211,214,217 A metal-catalyzed reduction of terminally unsaturated
AHLs with sodium borodeuteride to include the isotope label (analogues 48) has been reported
as well.215
No analogues of N-(3-hydroxyacyl)-L-homoserine lactones 2 with an isotope label in the acyl
chain have been reported in literature yet. The synthesis of this type of compounds was therefore
the first goal. In a first approach, β-ketoester 62 was synthesized in excellent yield by reacting
undecanone 60 with diethyl carbonate 61 in the presence of sodium hydride, followed by a
sodium hydroxide-mediated hydrolysis to yield β-oxododecanoic acid 63 (Scheme 3.4).229 The
deuterium label was introduced via a reduction of the keto function with sodium borodeuteride
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to afford deuterated β-hydroxy fatty acid 64 with a deuterium incorporation of 89% at the
carbon atom bearing the hydroxy moiety.230 An EDC-mediated coupling with L-homoserine
lactone hydrobromide 53 yielded the desired N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine
lactone 65.227
dry THF, N2, ∆, o.n.
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C9H19
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C9H19
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O O
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H2N
60 61 62
63 64
53
65
Scheme 3.4. Synthesis of N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine lactone 65. The deuterium content was
determined by ESI-MS.
Only the class of AHLs bearing the hydroxy group is accessible via this route. The introduction
of only one deuterium atom causes a mass shift of one unit. The natural presence of the heavy
isotopes of mainly carbon, oxygen, nitrogen and hydrogen, gives rise to the presence of a mass
(M+1) one unit higher than the expected parental mass (M). The abundance of this M+1 can be
as high as 20% of the parental mass M for molecules with a molecular weight of 300 Da, hin-
dering the application of these monodeuterated compounds as standards, but they can be useful
to study the fragmentation patterns during GC-MS-analysis. Although M+2 is naturally present
as well, even for the AHLs with the highest mass, the abundancy never exceeds 3% of the pres-
ence of the parental mass M, resulting in less interference with peaks of a dideuterated labelled
compound. Noteworthy, dideuterated AHL-analogues 46a–h were applied as internal standards
in an isotope dilution tandem mass spectrometric method.213 Therefore, a more general route
was developed to gain access to the dideuterated analogues of all different types of AHLs.
3.1.4 Synthesis of dideuterated AHLs
Aliphatic aldehydes 56c,d,g,h were deuterated at the α-position via a 4-(N,N-dimethylamino)
pyridine (DMAP)-catalyzed H/D-exchange reaction with D2O (Scheme 3.5).231 This mild cata-
lysis only allows selective deuterium introduction at the acidic α-position. Due to the formation
of HDO and H2O during this exchange reaction, complete deuteration is impossible. Therefore,
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to get a higher degree of deuterium incorporation than 68-86%, obtained after one iteration,
a second treatment with D2O was applied, yielding aldehydes 66b–d with a satisfactory deu-
terium incorporation of 93-95%. To achieve a deuterium incorporation higher than 95%, a third
iteration with D2O should be included. However, as in IDMS the focus goes to the alteration of
the ratio of two isotopes (labelled compared to non-labelled), the incomplete deuterium incorpo-
ration will not hinder the applicability, as long as the isotope ratio of the standard is determined
in a parallel analysis.218,232,233
H
1) 0.1 equiv DMAP
    D2O, 100 °C, 1 h
    71-97%, 
    D-incorp.: 68-86%
2) 0.1 equiv DMAP
    D2O, 100 °C, 1 h
O
R
H
O
R
D D
          (R = C4H9, 65%, D-incorp.: 86% (one iteration))
          (R = C5H11, 69%, D-incorp.: 93% (two iterations))
          (R = C8H17, 93%, D-incorp.: 95% (two iterations))  
          (R = C9H19, 90%, D-incorp.: 93% (two iterations))
56c
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56g
56h
66a
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66c
66d
Scheme 3.5. Synthesis of α,α-dideuterated aldehydes 66a–d as deuterated building blocks. The deuterium content
was determined via 1H NMR.
Further elaboration of these deuterated aldehydes 66 toward unfunctionalized fatty acids was
evaluated. Because the α-position of a carbonyl group is quite acidic, a chain extension was
needed to shift the deuterium label to the β- or γ-position of the carbonyl and avoid deu-
terium loss due to a deuterium-hydrogen exchange. At first, two different routes were evaluated
(Scheme 3.6).
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Scheme 3.6. Proposed routes to synthesize β,β- and γ,γ-dideuterated fatty acids starting from deuterated
aldehydes 66.
Although the one-pot condensation reaction of the labelled aldehyde 66 with Meldrum’s acid
in triethylammonium formate (TEAF) led to the fatty acid in high yields,234 a complete loss of
the isotope label was observed. Lowering the reaction temperature from 100 ◦C to 50 ◦C failed
to retain the deuterium-label in the final product. For the other route, diketopiperazine 67 was
efficiently acylated via reaction with acetic anhydride. To test this route without wasting the
deuterated aldehyde, the synthesis was first performed with unlabelled decanal 56g (Scheme
3.7). The acylated precursor 68 was reacted with decanal 56g in the presence of KOtBu as a
base to give compound 69 in excellent yield. Hydrolysis of 69 with 6M HCl at reflux yielded
α-oxododecanoic acid 70a. However, when the Ca(OCl)2-mediated oxidative cleavage was at-
tempted,235 no conversion at all was observed. Therefore, this route was abandoned as well.
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Scheme 3.7. Attempt to transform decanal 56g into undecanoic acid 71a.
In another attempt, the labelled aldehydes 66b–d were reduced to the alcohols after reaction
with two equivalents of sodium borohydride in ethereal methanol (1:1). Mesylation,236 followed
by substitution with potassium cyanide and alkaline hydrolysis yielded the [3,3-di-2H]-fatty
acids 73a–c (Scheme 3.8).237
Alteratively, these α,α-dideuterated aldehydes 66a–d were transformed to the corresponding
β-hydroxy esters 74a–d via a Reformatsky reaction with ethyl bromoacetate 57 (Scheme 3.8).
Hydrolysis of β-hydroxy esters 74a–d gave the [4,4-di-2H]-β-hydroxy fatty acids 75a–d in
excellent yields.225
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Scheme 3.8. Transformation of α,α-dideuterated aldehydes 66a–d into deuterated fatty acid derivatives 75a–d,
73a–c and 76a–c.
These labelled fatty acids 73a–c were coupled with L-homoserine lactone hydrobromide 53 to
give N-(acyl-[3,3-di-2H])-L-homoserine lactones 78a–c (Scheme 3.9). A similar reaction with
[4,4-di-2H]-β-hydroxy fatty acids 75a–d gave N-(3-hydroxyacyl-[4,4-di-2H])-L-homoserine lac-
tones 77a–d, as a mixture of diastereomers. As expected, no separation of both diastereo-
mers was observed during both HPLC and GC-analysis, allowing this mixture to be used
as such as labelled spike for IDMS, utilizing a common analytical equipment. For the N-(3-
oxoacyl-[5,5-di-2H])-L-homoserine lactones 79a–c, [3,3-di-2H]-fatty acids 73a–c were reacted
with Meldrum’s acid to introduce the oxo function (Scheme 3.8), followed by amidation with
L-homoserine lactone hydrobromide 53 (Scheme 3.9).238 No significant loss of deuterium was
observed during this synthetic route.
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Scheme 3.9. Synthesis of N-(3-hydroxyacyl-[4,4-di-2H])-L-homoserine lactones 77a–d, N-(acyl-[3,3-di-2H])-L-
homoserine lactones 78a–c and N-(3-oxoacyl-[5,5-di-2H])-L-homoserine lactones 79a–c starting from deuterated
precursors 75a–d, 73a–c and 76a–c. The deuterium content was determined by ESI-MS.
This methodology allows the convenient and straightforward synthesis of AHLs with differ-
ent functionalities, starting from one easily available deuterated building block without the use
of deuterium gas or expensive catalysts. The presence of two deuterium atoms causes a mass
shift of two units, making these isotope-labelled analogues easily distinguishable from the nat-
urally occurring 13C-containing AHLs, with a mass one unit higher than the regular AHLs. All
deuterated AHLs 77a–d, 78a–c and 79a–c were fully characterized.
The degree of deuterium incorporation in the synthesized AHLs 65, 77a–d, 78a–c and 79a–c
was determined via HPLC-MS. To confirm the position of the isotope label, 1H and 13C NMR
spectra were recorded and compared with those of the unlabelled AHLs. The presence of deu-
terium atoms at the β-position of the acyl chain in N-(acyl-[3,3-di-2H])-L-homoserine lactones
78a–c was confirmed by the transformation of the signal of the α-protons of the acyl chain
from a triplet to a singlet and the disappearance of the quintet at δ 1.64 ppm (in CDCl3). A sim-
ilar alteration was observed in the spectra of N-(3-oxoacyl-[5,5-di-2H])-L-homoserine lactones
79a–c. For N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine lactone 65, the signal at δ 4.0 ppm
(CDCl3), linked with the CHOH-unit logically disappeared, whereas for N-(3-hydroxyacyl-
[4,4-di-2H])-L-homoserine lactones 77a–d the signal at δ 1.45 ppm (CDCl3) was absent. The
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expected quintet, associated with a dideuterated carbon atom, was not always clearly visible in
the 13C NMR spectrum due to excessive signal splitting and increased relaxation times.239 A
small isotope effect, resulting in an upfield shift of 0.1 to 0.2 ppm, was observed for the flanking
carbons, whereas this was negligible for the other carbon atoms.
The presence of deuterium atoms is also obvious from the infrared spectrum by the occurrence
of CD-vibrations in the CD2 moiety. The small peaks around 2200 and 2100 cm−1 correspond to
antisymmetric and symmetric CD2-vibrations. These signals can be used to study the integration
of deuterated AHLs in supported bilayers.216,240
3.1.5 GC-MS analysis of deuterated AHLs
Several methods have been developed to analyze AHLs with GC-MS.34,241,242 Therefore, the
suitability of the synthesized AHLs for this type of analysis was evaluated by studying the
electron impact (EI) mass fragmentation pattern (Table 3.2). The retention times of labelled and
unlabelled AHL were identical.
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Table 3.2: GC-MS data of discussed AHL-molecules.
AHL EI-MS m/z (rel. int.)
N-Dodecanoyl-L-homoserine lactone 1i 283 [M] (4), 156 (21), 143 (100), 125 (17), 102 (18), 83
(15), 57 (41), 55 (19), 43 (21), 41 (17)
N-(Dodecanoyl-[3,3-di-2H])-L-homoserine lactone 78c 285 [M] (4), 158 (15), 143 (100), 125 (17), 102 (14), 83
(13), 57 (44), 55 (11), 43 (21), 41 (14)
N-(3-Hydroxydodecanoyl)-L-homoserine lactone 2i 299 [M] (2), 281 (3), 214 (11), 197 (19), 172 (100), 144
(18), 143 (40), 125 (11), 102 (85), 83 (18), 69 (12), 57
(51), 56 (19), 55 (21), 43 (36), 41 (21)
N-(3-Hydroxydodecanoyl-[3-2H])-L-homoserine lactone 65 300 [M] (2), 282 (3), 215 (8), 197 (16), 173 (100), 145
(15), 143 (46), 125 (13), 102 (86), 83 (16), 69 (12), 57
(55), 56 (28), 55 (19), 43 (37), 41 (22)
N-(3-Hydroxydodecanoyl-[4,4-di-2H])-L-homoserine lactone 77c 301 [M] (2), 283 (2), 216 (11), 199 (17), 172 (100), 144
(24), 143 (28), 125 (9), 102 (79), 83 (12), 69 (9), 57 (48),
56 (22), 55 (14), 43 (33), 41 (17)
N-(3-Hydroxydodecanoyl)-L-homoserine lactone 2i + BSTFA-TMCS 371 [M+TMS] (1), 356 (100), 244 (40), 228 (10), 215
(5), 200 (14), 186 (8), 174 (8), 160 (6), 143 (23), 130
(11), 103 (6), 83 (9), 73 (27), 57 (5), 55 (5), 43 (7), 41 (6)
N-(3-Hydroxydodecanoyl-[3-2H])-L-homoserine lactone 65 + BSTFA-TMCS 372 [M+TMS] (1), 357 (100), 245 (42), 229 (10), 215
(6), 200 (14), 187 (7), 175 (6), 160 (7), 144 (18), 130
(13), 103 (6), 84 (6), 75 (16), 73 (33), 57 (5), 55 (5), 43
(8), 41 (6)
N-(3-Hydroxydodecanoyl-[4,4-di-2H])-L-homoserine lactone 77c + BSTFA-TMCS 373 [M+TMS] (1), 358 (100), 244 (40), 228 (11), 215 (5),
200 (14), 186 (8), 174 (8), 160 (6), 143 (18), 130 (9), 103
(6), 85 (6), 73 (31), 57 (5), 55 (4), 43 (7), 41 (6)
N-(3-Oxodecanoyl)-L-homoserine lactone 3g + BSTFA-TMCS 341 [M+TMS] (11), 326 (72), 270 (21), 257 (49), 241
(94), 215 (17), 169 (65), 150 (25), 125 (15), 73 (100), 57
(11), 43 (12)
N-(3-Oxodecanoyl-[5,5-di-2H])-L-homoserine lactone 79a + BSTFA-TMCS 343 [M+TMS] (9), 328 (60), 272 (16), 257 (44), 243 (81),
215 (16), 171 (57), 152 (24), 125 (12), 73 (100), 57 (11),
43 (15)
The characteristic mass fragment of N-acyl-L-homoserine lactones is situated at m/z 143, corre-
sponding to a McLafferty rearrangement. Since the synthesized deuterium-labelled derivatives
78a–c have the deuterium atoms located at the β-carbon, the label is lost and the ion with m/z
143 is formed as well (Scheme 3.10). To distinguish between the native and labelled AHLs, the
higher mass fragments, corresponding to different alkyl chain losses, but retaining the isotope
label should be targeted. The ion with m/z 158 (corresponding to m/z 156 in unlabelled AHLs)
was detected with sufficient intensity in all N-(acyl-[3,3-di-2H])-L-homoserine lactones 78a–c
and can be used in a SIM-method to detect only labelled analogues. In all compounds analyzed,
the molecular ion was detected, albeit with low intensities.
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Scheme 3.10. Main mass fragment formed via a McLafferty rearrangement during EI-ionization induced fragmen-
tation of N-(acyl-[3,3-di-2H])-L-homoserine lactones 78a–c.
The characteristic ion formed during fragmentation of N-(3-hydroxyacyl)-L-homoserine lac-
tones 2 is located at m/z 172. This fragment arises from an α-cleavage next to the hydroxy group.
Not surprisingly, this fragment can be observed in both unlabelled 2 and γ,γ-dilabelled N-
(3-hydroxyacyl)-L-homoserine lactones 77a–d (Scheme 3.11). However, in case of the mono-
labelled analogue 65, with the deuterium label at the β-position, a fragment with one mass
unit higher (m/z 173) results. Another characteristic ion is formed by the McLafferty rear-
rangement. Whereas the mass fragment of m/z 143 is observed in all N-(3-hydroxyacyl)-L-
homoserine lactones, the ion with m/z 144 is observed with an elevated intensity in case of the
N-(3-hydroxyacyl-[4,4-di-2H])-L-homoserine lactones 77a–d. This can be explained via an al-
ternative McLafferty rearrangement, in which not the proton of the hydroxy group is abstracted,
but rather the γ-proton (or deuterium in case of analogues 77a–d) of the alkyl chain, causing a
mass shift of one unit for analogues 77a–d. As only a minor (37-43%) increase in abundance of
m/z 144 is observed, a preference toward abstraction of the hydroxy proton can be concluded.
Unfortunately, an alternative fragmentation, a hydrogen rearrangement followed by a McLaf-
ferty rearrangement, also leads to m/z 144 in both the unlabelled and dilabelled analogues,
rendering this mass fragment not very useful to be targeted in a SIM-method. In the case of
the monolabelled analogue 65 this fragmentation leads to a fragment with m/z 145, indicating
that mainly the β-hydrogen (or deuterium) atom is abstracted (Scheme 3.11). Once again, the
molecular ion itself was detected, albeit with low intensities.
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Scheme 3.11. Main mass fragments formed during the fragmentation of isotope-labelled N-(3-hydroxyacyl)-L-
homoserine lactones 65 and 77c.
Due to the lability of N-(3-oxoacyl)-L-homoserine lactones 3 during chromatographic analy-
sis, a derivatization step is required. When N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA)
is used as silylation agent, detection via GC-MS becomes possible. The molecular ion and
the mass fragment resulting from the loss of one methyl group are detected with satisfying
intensities. The ion at m/z 257 is formed via a McLafferty rearrangement (Scheme 3.12). α-
Cleavage, with loss of the lactone unit, results in an alkyl chain fragment with m/z 243 for
N-(3-oxodecanoyl)-L-homoserine lactone 79a. A possible marker fragment with m/z 171, com-
mon to all N-(3-oxoacyl-[5,5-di-2H])-L-homoserine lactones 79a–c and with full retention of
the isotope label, is obtained after a H-rearrangement, followed by the expulsion of a neutral
homoserine lactone molecule (Scheme 3.12).
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Scheme 3.12. Formalisms for the main mass fragments formed during the fragmentation of isotope-labelled N-(3-
oxodecanoyl)-L-homoserine lactone 79a after derivatization with BSTFA.
When labelled N-(3-hydroxyacyl)-L-homoserine lactones 65 and 77a–d are treated with BSTFA,
the fragment with the highest intensity observed is the silylated compound minus a methyl group
(Scheme 3.13). Due to the high intensity and full retention of the isotope label, this fragment
can be used to detect specific labelled N-(3-hydroxyacyl)-L-homoserine lactones 65 and 77a–d
in a reliable manner.
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Scheme 3.13. Main mass fragments formed during the fragmentation of isotope-labelled N-(3-hydroxyacyl)-L-
homoserine lactones 65 and 77c after derivatization with BSTFA.
3.1.6 Synthesis of deuterated AHL-degradation products
To demonstrate and further extend the possible applications of these deuterated compounds,
two AHL-degradation products which occur in nature, were synthesized. The hydrolysis of
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the lactone ring of AHLs toward N-acyl homoserines, occurs in a temperature, pH and chain
length dependent way and results in a loss of QS-activity.36,243 N-(3-Oxoacyl)-L-homoserine
lactones 3 can form another type of degradation product. Via an intramolecular Claisen-type
rearrangement, a tetramic acid 11 can be formed (Scheme 1.1). Fascinating biological properties
such as antibacterial activity and iron chelation are associated with this type of compounds.9
Methods have been developed to detect both degradation products as well.42,244 However, no
deuterium-labelled N-acyl homoserines nor deuterated tetramic acids have been reported yet,
although these compounds could be used as internal standards for IDMS.
The corresponding tetramic acid 80 and the ring-opened product 81 were synthesized in good
yield, and a full retention of the deuterium label was observed during these transformations
(Scheme 3.14).
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Scheme 3.14. Synthesis of deuterated analogues tetramic acid 80 and ring-opened AHL 81. The deuterium content
was determined by ESI-MS.
3.1.7 Conclusion
In this part, an easy and reliable method to make suitable, deuterated standards of AHL-mole-
cules belonging to all three important classes of AHLs was described, starting from a cheap and
commercially available deuterium source. Deuterium loss via D/H-exchange is avoided by the
introduction of the isotope label at a non-enolizable position. All synthesized analogues were
fully characterized. These deuterated analogues of the major classes of AHLs can also be used
to synthesize the labelled analogues of the naturally occurring degradation products, without
a significant loss of deuterium. These labelled AHLs and degradation products can be used to
study the metabolization of AHLs in nature.
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3.2 Evaluation of the chemical reactivity ofN-(3-hydroxyacyl)-L-homoserine
lactones and derivatives
Abstract
It is known that N-(3-oxoacyl)-L-homoserine lactones can rearrange to tetramic acids with in-
teresting biological properties. In this part, it was evaluated if N-(3-hydroxyacyl)-L-homoserine
lactones can participate in such a similar rearrangement toward 1,4-oxazepane-2,5-diones. How-
ever, due to the preference of an amide for a trans-conformation, such a spontaneous rearrange-
ment proved to be very unlikely. It was shown for such a reaction to occur that a third substituent
at the amide nitrogen atom is required. Several N-protecting groups were evaluated for this
challenging cyclization reaction. With the use of the removable PMB-group, a N-unsubstituted
1,4-oxazepane-2,5-dione was synthesized. Via the application of pseudo-prolines, i.e. serine-
derived oxazolidines as another type of protecting group, a compound with the presumed struc-
ture of the natural product serratin was obtained. Due to the differences in spectral data, the
incorrect structural assignment of the natural product serratin was identified. Instead of the pre-
dicted seven-membered heterocycle, a symmetrical serratamolide analogue is proposed to be
the correct structure of serratin.
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3.2.1 Introduction
AHLs 17 can be degraded in many ways in nature. Bacteria produce several classes of quo-
rum quenching enzymes. Acylases cleave the fatty acid from the homoserine lactone unit,50,51
whereas lactonases hydrolyze the ester bond of the lactone ring (See Literature overview).5,7,10
Alternatively, lactonolysis can also occur non-enzymatically (See Literature overview).7,36 Many
bacterial secondary metabolites perform more than one function for the producing organism.
This is also the case for the N-(3-oxoacyl)-L-homoserine lactones 3. The tetramic acid type
degradation product 11 of this class of quorum sensing signals, formed by an intramolecu-
lar Claisen-type condensation (Scheme 1.1), has not only a bactericidal effect against Gram-
positive bacteria, but can also bind iron and serve as a primordial siderophore.9
One could wonder if a similar rearrangement could happen to the N-(3-hydroxyacyl)-L-homo-
serine lactones 2, where the hydroxy group could act as a nucleophile and open the lactone ring
to form a new, seven-membered ring-containing compound 82 (Scheme 3.15).245 This type of
behavior is suggested by the difference in heat stability of the autoinducers of Aliivibrio fisheri
(previously designated as Vibrio fisheri), oxo6 3c, and the autoinducer of Vibrio harveyi, HO4
2a. Heating a medium containing the autoinducer 3c of A. fisheri at 100 ◦C for 5 minutes did not
have an effect on the bioluminescence-inducing activity of this quorum sensing signal molecule
3c. Applying the same treatment to a medium containing the autoinducer 2a of V. harveyi,
caused a complete deactivation of the bioluminescence inducing activity.246 Not surprisingly,
both autoinducers lost their QS stimulating properties at high pH.
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Scheme 3.15. A) Possible rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones 2 toward seven-membered
ring 82. B) Reported structure of bacterial metabolite serratin (83).247
This type of rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones 2 has not been re-
ported in literature. However, the reported compound serratin (83) (Scheme 3.15), isolated from
the bacteria Serratia marcescens, resembles this type of rearrangement product quite well.247
The main difference is the presence of a hydroxymethyl substituent rather than a hydroxyethyl
substituent.247 Bacteria belonging to the Serratia genus are known to produce the cyclodep-
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sipeptides serratamolide A-F (42a–f) (Figure 3.2) which are composed out of similar building
blocks as serratin (83).248,249 These macrocyclic compounds do not only possess antimycobac-
terial activity, but can induce cell cycle arrest and proapoptotic effects in breast cancer cells.250
Also the lipoamino acid serratamic acid (84) has been isolated from alkaline extracts of S.
marcescens cultures (Figure 3.2),251,252 presumably formed by the hydrolysis of serratamolides
(42).248,249
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Figure 3.2. Serratamolides A-F (42a–f),248 and serratamic acid (84),251,252 produced by Serratia sp.
The most common AHLs occuring in Serratia sp. cultures are the rather short chain AHLs C4 1a
and C6 1c.167 However, also HO6 2c and HO8 2e have been detected in a Serratia strain, albeit
in limited amounts.253 Therefore, it could be tempting to speculate that an incorrect structure
was assigned to serratin (83) and that it results from the rearrangement of HO8 2e.
3.2.2 Rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones
As the exact biosynthetic origin of serratin (83) is unknown, the possibility was evaluated that
the seven-membered ring indeed arises from a spontaneous rearrangement of a bacterial HO-
AHL 2. Eberhard observed that the autoinducer of V. harveyi, HO4 2a lost its activity after
heating it for five minutes at 100 ◦C in minimal medium.246 Later on, it was hypothesized
that this was caused by the nucleophilic attack of the β-hydroxy group of this AHL.245 By
mimicking the described reaction conditions (heating at 100 ◦C for 5 min),246 followed by
attempts with other solvents and longer reaction times, this route was evaluated. However, the
formation of the desired seven-membered ring 82a was never observed (Scheme 3.16). The
starting material 2c was fully recovered. When the reaction time was prolonged, elimination
and hydrolysis products were observed as well.
Reaction conditions suited for the nucleophilic attack of the β-hydroxy group might give rise to
cyclic compound 82a, but then the resulting primary hydroxy group could reattack the seven-
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Scheme 3.16. Attempt to form serratin-like compound 82a via a heat-induced rearrangement of HO6 2c.
membered lactone, forming the more stable five-membered lactone ring, and once again yield-
ing starting material 2c. This difference in stability results from a combination of entropy and
energy terms and was studied by the group of Mandolini (Figure 3.3).254–256 The energy term
represents the increase in ring strain and unfavorable interactions needed to be overcome when
the open-chain form approaches the ring-shaped transition state. The entropy term is linked
with the probability of the two chain terminals coming close enough to interact.257 Therefore,
it is very unlikely that a significant amount of serratin-like structures 82 will result from the
spontaneous rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones 2.
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85 86 87
Figure 3.3. Reactivity plot for the cyclization of sodium ω-bromo carboxylates 85 in 99% aqueous DMSO at
50 ◦C.254–256
3.2.3 Rearrangement of N-(3-hydroxynonanoyl)-L-serine
In a next step, it was evaluated if a serratamic acid-like compound, N-(3-hydroxynonanoyl)-L-
serine (90) could lie at the origin of serratin (83). This compound 90 was synthesized via an
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EDC-mediated coupling reaction of β-hydroxynonanoic acid 58d with serine ester 88, followed
by alkaline hydrolysis (Scheme 3.17). When the free hydroxy group of serratin would attack the
seven-membered lactone, a four-membered lactone would be formed. As this type of lactone is
less stable than a five-membered lactone, it can be expected that at least some of the seven-
membered lactone ring should remain or can be reformed.254–256
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Scheme 3.17. Synthesis of N-(3-hydroxynonanoyl)-L-serine 90.
For the ring-closure, reaction of amino acid derivative 90 with 1 equiv of EDC and 1 equiv
of Et3N in water was tested but no reaction was observed. Repeating this reaction with EDC
with a catalytic amount of DMAP in dichloromethane yielded a complex reaction mixture.258
Stirring the reaction mixture overnight in acetic anhydride also failed to yield any of the desired
ring-closed product 83 (Table 3.3).258
Table 3.3: Attempts to cyclize N-(3-hydroxynonanoyl)-L-serine 90.
OOH
N
H
OH
O
HO HN
O O
O
OH
 reaction 
conditions
90 83
Entry Reaction conditions Result
1 1 equiv EDC.HCl, 1 equiv Et3N, H2O, r.t., o.n. No reaction
2 1 equiv EDC.HCl, cat. DMAP, dry CH2Cl2, r.t., o.n. Complex reaction mixture
3 Ac2O, r.t., o.n. Complex reaction mixture
As both HO-AHLs 2 as serratamic acid analogue 90 failed to yield serratin (83), another expla-
nation for the origin of this cyclic compound 83 was sought. Serratamolide A (42a) is synthe-
sized by the action of non-ribosomal peptide synthetases (NRPS) (Scheme 3.18), which explains
the fact that the most likely precursor, serratamic acid (84), was not found in serratamolide-
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deficient mutants. Alkaline extracts of the wild type do contain serratamic acid (84), but this
should be considered as a hydrolytic product of serratamolide 42. The NRPS SwrW, responsi-
ble for the synthesis of serratamolide A (42a), is the simplest unimodular NRPS and consists of
a condensation (C), adenylation (A), thiolation (T) and thioesterase (TE) domain, responsible
for the activation and coupling of serine and a β-hydroxydecanoic acid derivative.259 If however,
the serratamic acid linked to the TE-domain, is not transferred to the T-domain linked serratamic
acid, but undergoes a cyclization instead, cyclic compound 91 could be formed (Scheme 3.19).
So far, only serratin (83) has been reported in the literature, which points out the unlikeliness
of this type of cyclization. Perhaps the presence of the unusual β-hydroxynonanoic acid 58d
causes a disruption in the normal course of this biosynthetic route.
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Scheme 3.18. Biosynthesis of serratamolide A (42a) via the NRPS SwrW, consisting of a condensation (C), adeny-
lation (A), thiolation (T) and thioesterase (TE) domain. First, serine is adenylated by the A domain (1), then the
activated serine binds as a thioester to the T domain (2). The amine group of the bounded serine will react with an
ACP-linked β-hydroxydecanoyl moiety (3), followed by a transfer to the TE domain (4). Subsequently, a second
serine molecule passes through the same steps (5-7), resulting in two differently linked serratamic acids. Then
the hydroxy group of the β-hydroxydecanoyl moiety of the molecule linked to the T domain, will attack the TE
domain ester bond (8). A final transfer to the TE domain (9), followed by a cyclization, releases serratamolide A
(42a) (10).259,260
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Scheme 3.19. Possible explanation for the formation of serratin-like compound 91 via a deviation from the standard
biosynthetic route.
3.2.4 Cyclization of N-(3-hydroxyacyl)amino acids
Although several methods are available for the synthesis of 1,4-diazepane-2,5-diones,261–265, no
general method is known for the synthesis of 1,4-oxazepane-2,5-diones. Besides serratin (83),
several natural products have been isolated containing this seven-membered core. One exam-
ple is callipeltin L (92) (Figure 3.4), belonging to a group of antifungal peptides, produced
by the marine sponge Latrunculia sp.266 Compound 93 with a similar lactone core was iso-
lated from the methanolysis mixture of the marine immunosuppressant lipopeptide microcolin
A and shows relatively potent immunosuppressive activity as well.267 Also inducamide C (94),
isolated from a chemically induced mutant strain of Streptomyces sp. and exhibiting modest
cytotoxicity, contains the same 1,4-oxazepane-2,5-dione core.268 Because of the instability of
the lactone bond, it is often difficult to isolate sufficient amounts of these natural products to
fully assess their biological activities. However, the same lactone bond offers the distinct ad-
vantage of rendering the compound neutral by masking the carboxylic acid unit, allowing better
membrane permeability whereafter degradation or nucleophilic attack within the cell releases
the active compound.269,270 It was therefore decided to continue the synthetic efforts toward
serratin (83) in this work.
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Figure 3.4. 1,4-Oxazepane-2,5-dione core-containing natural products 92,266 93,267 and 94.268
However, the synthesis of medium-sized heterocycles still represents a synthetic challenge. A
head-to-tail cyclization often fails to yield the desired seven- or eight-membered heterocycles
because of a combination of energy and entropy terms (vide supra).257 The resistance toward
cyclization is even more prevalent when a carboxylic amide bond is present. The preference
of an amide for a trans-conformation removes both termini of the linear precursor from each
other’s proximity, impeding cyclization.271,272 As medium-sized lactams constitute a class with
a great potential for drug applications, many synthetic efforts have been devoted to this type of
medium-sized heterocycles. N-Substitution of the amide and dilute reaction conditions are often
applied,261 but methods using solid support,273,274 or those that rely on a Staudinger ligation for
ring closure,262,263 are described as well. Another possibility is the use of pincer auxiliaries,
fulfilling both a tethering and templating role.264
The apparent lack of cyclization that was observed for serine derivative 90 (Table 3.3), can be
explained by the fact that the amide bond strongly prefers a trans-conformation, whereas for the
desired cyclization to occur, a cis-amide bond is needed (Figure 3.5). The 2D-NOESY analysis
of methyl ester 89 revealed that indeed only the trans-conformer was present (Figure 3.6).275
OOH
N
H
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O
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HO
NH
OH
O
OH
O
trans-amide
Figure 3.5. Trans and cis-conformation of N-(3-hydroxynonanoyl)-L-serine 90.
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Figure 3.6. Zoom in of the 2D-NOESY spectrum of 89. In this spectrum, a clear interaction between NH (a) and
CH2CON (e) was observed. No such interaction was present between CHN (b) and CH2CON (e), indicating that
the amide exists as the trans-conformer.
The partial double bond character of the amide C-N bond, caused by the delocalization of the
lone pair on nitrogen, only allows slow internal rotation.271,272,276 In the case of larger hetero-
cycles, such as fourteen-membered rings, trans-amides can be included. This was used for the
synthesis of a serratamolide analogue. Noteworthy, during this synthesis seven-membered rings
were never observed.277
However, it is known that proline-containing peptides typically contain an elevated amount
of cis-amide bonds.278,279 Therefore, the proline-containing analogue 97 was synthesized and
three different conditions for cyclization were evaluated (Scheme 3.20).258 As intramolecular
cyclization is a first order reaction and dimerization is second order, dilute conditions were
applied to avoid the latter, unwanted, reaction. The bicyclic structure 98 was observed in all
cases, albeit in different amounts.
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Scheme 3.20. Synthesis and cyclization of N-(3-hydroxynonanoyl)-L-proline 97.
That the application of N,N-disubstituted amides could be useful to obtain cyclic products, was
also hinted by the appearance of a seven-membered ring containing side product 101 during
the bis-cyclization of acid 99 (Scheme 3.21).280,281 Bicyclic compound 100 is a precursor in
the synthesis of salinosporamide A (103), a secondary metabolite of the marine actinomycete
Salinispora tropica and a highly potent and selective inhibitor of the 20S proteasome which has
received a lot of attention for the treatment of cancer.282
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Scheme 3.21. Formation of the seven-membered ring containing side product 101 during the bis-cyclization of
99.280,281
To decide if the imposed rigidity, caused by the cyclic side chain of proline, was really neces-
sary for the cyclization, the highest yielding cyclization conditions were applied to sarcosine
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derivative 108 (Scheme 3.22). The existence of both cis and trans-isomers of this compound in
solution was apparent by the presence of both conformers being observed in 1H NMR and 13C
NMR (in CDCl3, Figure 3.7 A and 3.8 A).283 No such conformers were observed in the 1H NMR
and 13C NMR spectra of derivative 90. The cis/trans-ratio of isomers of 108 in a CDCl3 solution
is 1:3. A similar ratio is observed for N-dodecanoylsarcosine, although solvent and concentra-
tion can play an important role.284–286 The cyclic product 110, with a similar seven-membered
core as callipeltin L (92), was obtained in 62% yield. In the 1H and 13C NMR spectrum, differ-
ent isomers were not observed (CDCl3, Figure 3.7 B and 3.8 B), which is consistent with the
formation of a more rigid, cyclic structure lacking the possibility of cis/trans-isomerization. As
a proof of concept, the reaction was repeated with the glycine derivative 109 under identical
conditions, but no cyclization was observed (Scheme 3.22). As the ring-closing reaction only
proceeds with great difficulty, a spontaneous, non-enzymatical rearrangement can be excluded
for the origin of serratin (83).
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Scheme 3.22. Synthesis of N-(3-hydroxyacyl)amino acids 108 and 109 and ring closure toward 1,4-oxazepane-
2,5-dione 110.
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Figure 3.7. Zoom in of the 1H NMR spectrum of N-(3-hydroxydodecanoyl)sarcosine (108) (spectrum A) and the
cyclic derivative 110 (spectrum B). The existence of two rotamers in spectrum A is indicated by the presence of
two singlets around 3 ppm, corresponding to the N-methyl group. In spectrum B, only one signal is present for the
N-methyl group.
Figure 3.8. Zoom in of the 13C NMR spectrum of N-(3-hydroxydodecanoyl)sarcosine (108) (spectrum A) and
cyclic derivative 110 (spectrum B). The existence of two rotamers can clearly be observed in spectrum A whereas
only one conformer exists in spectrum B.
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3.2.5 Cyclization of N-(3-hydroxyacyl)amino acids with a deprotectable group at nitro-
gen
From the above-mentioned results, it is obvious that the N-(3-hydroxyacyl)amino acid deriva-
tive needs to be forced in the correct conformation for cyclization to occur. This necessity was
also observed during the synthesis of 1,4-oxazepan-5-ones.275 The introduction of a third sub-
stituent at nitrogen, as is the case for the proline and sarcosine derivatives 97 and 108, altered
the cis/trans-ratio, and resulted in cyclization. To obtain the natural product serratin (83), this
additional group at nitrogen should be a removable one. Because of the lability of the desired
lactone, many protecting groups, that can be applied for the synthesis of seven-membered lac-
tams, cannot be used for this cyclization as the reaction conditions needed for their removal
after the cyclization step, will destroy the lactone bond.
As a benzyl group can be removed via hydrogenolysis, this N-protecting group was evaluated as
a possible solution. Reductive amination of benzaldehyde 112 with methyl glycinate 105, used
as hydrochloride and released with the aid of triethylamine, yielded the N-benzyl-protected
methyl ester of glycine 113, which was coupled to β-hydroxynonanoic acid 58d. Alkaline hy-
drolysis in aqueous methanol, followed by cyclization in dilute reaction conditions gave the
desired N-benzyl-protected seven-membered ring-containing compound 116 (Scheme 3.23).
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Scheme 3.23. Synthesis of N-benzyl and N-PMB-protected seven-membered lactones 116 and 121 and CAN-
mediated deprotection of 121 to 7-hexyl-1,4-oxazepane-2,5-dione (122).
To remove the N-protecting group, several reaction conditions were tested but none was able
to deliver the desired deprotected compound 122 (Table 3.4).287–291 Either there was no reac-
tion at all (except for solvolysis of the lactone ring, Table 3.4, entries 1, 2 and 6) or a complex
reaction mixture was obtained (Table 3.4, entry 5). The only condition giving debenzylation,
albeit in moderate yield, was accompanied by ethanolysis of the lactone ring (Table 3.4, entry
3). Replacement of ethanol by ethyl acetate as a solvent, halted the deprotection, even when the
reaction time was significantly prolonged (Table 3.4, entry 4). Similar difficulties to remove a
benzyl group from a carboxamide were also encountered by Williams et al. during the deben-
zylation of a diketopiperazine.292
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Table 3.4: Reaction conditions evaluated for the N-deprotection of compound 116.287–291
N
O
O
O
C6H13
HN
O
O
O
C6H13
reaction
conditions
116 122
Entry Reaction conditions Result
1 3 bar H2, 1 wt. equiv 10% Pd/C, MeOAc, r.t., 48 h287 -[a]
2 3 bar H2, 0.5 wt. equiv 10% Pd/C, EtOH, r.t., 16 h288 -[b]
3 3 bar H2, 0.5 wt. equiv 20% Pd(OH)2/C, EtOH, r.t., 4 h289 -[c]
4 3 bar H2, 0.5 wt. equiv 20% Pd(OH)2/C, EtOAc, r.t., 24 h -[a]
5 1 equiv NBS, 0.2 equiv AIBN, EtOAc, ∆, 4 h290 -[d]
6 2.5 equiv NBS, 0.1 equiv NMA, dry CH2Cl2, r.t., o.n.291 -[a]
[a] No reaction. [b] No deprotection, degradation of starting material 116. [c] Deprotection followed
by solvolysis or solvolysis followed by deprotection. [d] Complex reaction mixture.
As the synthesis of the N-benzyl-protected seven-membered core-containing compound 116
was successful, whereas the N-deprotection proved to be problematic, the p-methoxybenzyl
(PMB) protecting group was evaluated as a more labile protecting group. Reductive amina-
tion of glycine methyl ester hydrochloride 105 with anisaldehyde 117 gave N-PMB-protected
methyl glycinate 118 in a good yield (Scheme 3.23).293 The same N-acylation and cycliza-
tion conditions used for the synthesis of the N-benzyl derivative 116 were applied to yield the
N-PMB-protected seven-membered ring-containing compound 121 (Scheme 3.23).
For the removal of the PMB-protecting group, several conditions were tested (Table 3.5). Both
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and ceric ammonium nitrate (CAN), the
reagents commonly used for PMB-deprotection, were evaluated under different reaction condi-
tions, alongside other reagents.281,294–298
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Table 3.5: Reaction conditions evaluated to remove the PMB-protecting group of N-PMB-1,4-oxazepane-2,5-
dione 121.281,294–298
C6H13
NO
OO
MeO
reaction conditions
C6H13
N
HO
OO
O
H
OMe
121
122 117
Entry Reaction conditions Result
1 2 equiv DDQ, CH2Cl2:H2O 9:1, r.t., 8 h -[a]
2 5 equiv CAN, CH3CN:H2O 4:1, 0 ◦C to r.t.,
2 h
122 (15%)[b]
3 5 equiv CAN, CH3CN:H2O (NaOAc/HOAc
buffer, pH 5.2), 0 ◦C, 2 h
122 (18%)[b] and 121 (41%)[b]
4 10 equiv CAN, CH3CN:H2O 4:1, 0 ◦C, 1 h 122 (30%)[b] and 121 (6%)[b]
5 5 equiv CAN, EtOAc:H2O 4:1, 0 ◦C, 2 h 122 (36%)[b] and 121 (28%)[b]
6 10 equiv CAN, EtOAc:H2O 4:1, 0 ◦C, 2 h 122 (32%)[b] and 121 (33%)[b]
7 5 equiv CAN, tBuOH:CH2Cl2 4:1, r.t., 2 h -[c]
8 5 equiv CAN, CH3CN:H2O 99:1, r.t., o.n. 122 (10%)[b] and 121 (70%)[b]
9 4 equiv PhI(OAc)2, MeOH, r.t., o.n. -[a]
10 BF3.OEt2, r.t., o.n. -[d]
11 BF3.OEt2, 128 ◦C, 6 h -[e]
[a] Solvolysis of 121. [b] Quantitative data were obtained after the extraction of the reaction mixture
with ethyl acetate, followed by a washing step with a saturated aq. sodium bicarbonate solution to
remove ring-opened degradation products. The crude yield of the different products was determined via
integration of the 1H NMR spectrum. [c] Deprotection followed by solvolysis or solvolysis followed
by deprotection. [d] No reaction. [e] Complex reaction mixture.
As the deprotection with 5 equivalents of CAN in a solvent mixture of ethyl acetate and water in
a 4:1-ratio gave the best result (Table 3.5, entry 5), this reaction was repeated on a larger scale
to give the pure, fully deprotected, seven-membered lactone 122 in 14% yield after purification
via column chromatography. This rather low yield can be attributed to several factors. First, the
reaction duration is too short to allow complete conversion, which is obvious from the recovery
of the N-PMB-protected lactone 121. Second, when the product 122 is formed, lactonolysis
can occur by the water present as a co-solvent, which is needed for the deprotection. This
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lactonolysis also can open the starting material 121, but this route seems to be slower. Third,
reactions with CAN often give rise to a laborious work-up because of the difficult separation of
the turbid aquatic phase and the organic phase.
The synthesis of the deprotected seven-membered core 122 was successfully completed, so the
focus was put on the synthesis of serratin (83), which differs from lactone 122 only by the pres-
ence of a hydroxymethyl group. However, when the N-acylation reaction was repeated with
methyl N-PMB-serinate, O-acylation instead of N-acylation was observed. To avoid this unde-
sired reaction, the reaction sequence was repeated with O-benzylserine, but when the cyclization
was attempted in the final step, a complex reaction mixture was obtained, instead of the desired
heterocycle. This lack of cyclization could be caused by steric factors. A similar observation
was made by Imramovský et al. during a coupling reaction of N-benzyloxycarbonyl-protected
amino acids with a salicylanilide.299 When N-Cbz-glycine and N-Cbz-alanine were used, a
seven-membered ring was formed. This type of cyclization was not observed when valine or
phenylalanine were used (Scheme 3.24).
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Scheme 3.24. Difference in cyclization behavior observed by Imramovský et al. during a salicylanilide esterifica-
tion.299
3.2.6 Application of photoremovable protecting groups (PPGs)
In an attempt to improve the low yield of the PMB-deprotection step, photolabile or photore-
movable protecting groups (PPGs) were tested. Their removal is solely based upon irradiation
with light, so the presence of water, which can cause lactonolysis, can be avoided. The effi-
ciency of photoconversion is determined by the quantum yield φ (proportion of molecules that
undergoes photolysis after absorption of a photon) and the absorption coefficient  (proportion
of incident light absorbed).300–302 PPGs are commonly applied in biochemistry to control the
release of certain bioactive compounds in living tissues. A caged compound is administered and
irradiated to release the bioagent at certain target sites. A PPG should have a strong absorption
at wavelengths above 300 nm to avoid absorption by and to minimize damage to the biological
system.300 PPGs have been used to force the cyclization of peptides via a ring contraction as
85
Results and discussion
well. In this case a 2-hydroxy-6-nitrobenzyl group is typically used. This PPG is introduced at
the N-terminus of the peptide and then the hydroxy group of this PPG forms a (macro)cyclic
ester with the C-terminus of the peptide. A subsequent O- to N-acyl transfer delivers the de-
sired cyclic compound, whereafter the PPG is removed via photolysis.303 To synthesize highly
strained cyclic peptides, it can be necessary to introduce two PPGs: one at the N-terminus to
fulfill a ring closure/contraction role and one in the middle of the peptide sequence to promote
a cis-amide bond to facilitate the cyclization.304
One of the most commonly used PPGs are the 2-nitrobenzyl derivatives 123. Some disadvan-
tages of this class are the slow rate of release after excitation and the toxic and strongly absorb-
ing by-products.300 Sometimes a protective thiol group is added to cope with this, or reduced
glutathione present within cells can give the same protection.301 Other commonly used groups
are the benzoin group 124, the p-hydroxyphenacyl group 125 and the coumarinyl group 126
(Figure 3.9).300,302
NO2
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X
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123 124 125 126
Figure 3.9. General structure of some PPGs, with X representing the caged compound.
Electronic excitation of 2-nitrobenzyl compounds 123 generates very quickly their aci-nitrotau-
tomers 127 (Scheme 3.25). The Z-nitronic acid 127 is formed via transfer of a benzylic hydro-
gen to an oxygen of the nitro group. Deprotonation followed by reprotonation gives the E-
nitronic acid 129 and allows cyclization to N-hydroxybenzisoxazoline 130, which then decays
to compound 131, hereby releasing the caged compound X.300,301 The quantum yield φ is not
readily manipulated but the absorption coefficient  can be varied, e.g. in case of the aromatic
nitro compounds by adding electron-donating groups to the aromatic ring, causing an increase
of absorbance at longer wavelengths (bathochromic shift). Substituents on the benzylic carbon
also have a profound effect, with a higher photolytic cleavage rate linked to a more electron
rich benzylic carbon atom.301,302,305,306 However, it is very difficult to predict the reaction rate or
efficiency. Solvent plays an important role in determining the half life of the PPGs as well.305
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Scheme 3.25. Mechanism of photolysis of 2-nitrobenzyl derivatives 123, with X representing the caged com-
pound.301
The first PPG that was evaluated was the 2-nitrobenzyl group.307,308 Commercially available 2-
nitrobenzaldehyde 132 was reacted with glycine methyl ester hydrochloride 105 (Scheme 3.26).
The obtained PPG-protected amino acid methyl ester 133 was coupled to β-hydroxynonanoic
acid 58d. Hydrolysis and cyclization yielded seven-membered ring 136. To avoid premature
photolysis, all reactions were shielded from light and purification via column chromatography
was only performed on the final product.
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Scheme 3.26. Synthesis of N-2-nitrobenzyl-protected seven-membered ring 136.
For the photolysis, two UV-light sources were evaluated: the OSRAM Ultra-Vitalux 300W -
230V E27 lamp (radiated power 315-400 nm (UVA) 13.6 W/m2 - radiated power 280-315 nm
(UVB) 3.0 W/m2) fitted with a UV-light transmitting, visible light absorbing Hoya U-360 filter,
and the UVLS-28 EL Series UV Lamp 8W - 230V (wavelength 366 nm), commonly used in
laboratories to visualize TLC-plates. Although several reaction conditions and times were eval-
uated, N-deprotection was never observed (Table 3.6). It seems that both lamps were unable to
deliver the needed intensity unlike the pulsed laser (pulse width 8 ns, energy 38 mJ, wavelength
355 nm) which was reported in literature to promote the photodeprotection of a 2-nitrobenzyl
group from a peptide chain.307 However, a hand-held UV lamp used for TLC visualization was
successfully employed to deprotect N-2-nitrobenzylglycine,308 showing the difference in ease
of photodeprotection between an amine and an amide.
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Table 3.6: Reaction conditions evaluated to remove the 2-nitrobenzyl group of 136.303–305,307
C6H13
NO
OO
NO2
reaction conditions
C6H13
N
HO
OO
hν
C6H13 N
O
O
OH NO2
OR
C6H13
H
N
O
O
OH
OR
R = H
R = Me
R = H
R = Me
136
122
137
138
135
134
Entry Reaction conditions UV-Source Result
1 1% DMSO in MeOH, r.t., 40 min OSRAM Ultra-Vitalux 300W -
230V
-[a]
2 1% AcOH in MeOH, r.t., 40 min OSRAM Ultra-Vitalux 300W -
230V
-[a]
3 CH2Cl2:CF3CH2OH 4:1, r.t., 6 h UVLS-28 EL Series UV Lamp 8W
- 230V, long wavelength, 366 nm
-[b]
4 1% DMSO in MeOH, r.t., 6 h UVLS-28 EL Series UV Lamp 8W
- 230V, long wavelength, 366 nm
-[a]
5 1% DMSO in p-dioxane, r.t., 6 h UVLS-28 EL Series UV Lamp 8W
- 230V, long wavelength, 366 nm
-[b]
6 1% AcOH in MeOH, r.t., 6 h UVLS-28 EL Series UV Lamp 8W
- 230V, long wavelength, 366 nm
-[a]
7 2.5 mM TES (N-[tris-
(hydroxymethyl)methyl]-2-
aminoethanesulfonic acid) in
H2O:CH3CN 3:2, r.t., 6 h
UVLS-28 EL Series UV Lamp 8W
- 230V, long wavelength, 366 nm
-[b]
8 0.1% TFA in H2O:CH3CN: 1:1,
r.t., 6 h
UVLS-28 EL Series UV Lamp 8W
- 230 V, long wavelength, 366 nm
-[a]
[a] Complete solvolysis of 136 without photodeprotection. [b] No reaction.
As the introduction of electron-donating groups causes an increase of absorbance at longer
wavelengths,305 2-methoxy-6-nitrobenzyl was evaluated as a PPG. 2-Hydroxy-6-nitrobenzal-
dehyde 141 was synthesized via a Duff reaction with m-nitrophenol 139 and hexamethylenete-
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tramine 140 (Scheme 3.27).309,310 The crude mixture was methylated with iodomethane. Purifi-
cation via column chromatography yielded the desired 2-methoxy-6-nitrobenzaldehyde 142 in
19% yield. The main side products that were isolated were 2-methoxy-4-nitrobenzaldehyde 143
and the methylated starting material 3-nitroanisole 144 in 10% and 5% yield, respectively.
NO2HO
N
N
N
N NO2HO
TFA, N2, 130 °C, 27 h
NO2MeO
O H
NO2MeO
1.2 equiv
1.1 equiv MeI
1.1 equiv K2CO3
DMF, 0 °C to r.t., 3 h
NO2MeO
O
H
(19%)(10%) (5%)
+
CHO
139 140 141
143 142 144
Scheme 3.27. Synthesis of the PPG-precursor 2-methoxy-6-nitrobenzaldehyde 142.
The reductive amination procedure used for the synthesis of methyl N-(2-nitrobenzyl)glycinate
133 (Scheme 3.26) did not yield the desired compound 145 when using 2-methoxy-6-nitrobenzal-
dehyde 142, so a slightly modified procedure was used and the target compound 145 was ob-
tained (Scheme 3.28).311 This compound was reacted with octanoyl chloride 54e under Schotten-
Baumann conditions to obtain N-protected compound 146.
NO2 O
HH2N
OMe
O
HCl. HN OMe
O
NO2
+ 1.1 equiv
1) 2 equiv Et3N, 
    DMF:MeOH 1:1, r.t., 1 h
2) 2 equiv NaBH4, 0 °C to r.t., o.n.
OMe OMe
N
OMe
O
NO2
2 equiv K2CO3
OMe
(30% yield over two steps)
THF:H2O 1:1, 
r.t., 2 h
O
Cl C7H15
O
C7H15
1 equiv
105 142 145
54e
146
Scheme 3.28. Synthesis of PPG-protected N-octanoyl glycine methyl ester 146.
The PPG-protected N-octanoyl glycine methyl ester 146 was synthesized as a model compound
to evaluate several photolysis conditions (Table 3.7). A blacklight bulb - E27 - 20W/230V was
used as a light source and both flow (reactor volume: 24 mL, flow rate: 0.3 mL/min) and batch
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set-ups were evaluated. This time, photolysis was observed in all cases. Performing the reaction
in flow gave a better conversion and required a shorter reaction time compared to the same re-
action conditions in batch (Table 3.7, entries 2 and 5). The reaction conditions which gave the
best result (Table 3.7, entry 3) were also applied on 2-nitrobenzyl protected substrate 136, but
once again no photolysis was observed.
Table 3.7: Reaction conditions evaluated to remove the 2-methoxy-6-nitrobenzyl group of 146 with a blacklight
bulb - E27 - 20W - 230V as a source of UV-light.303,305,309,311
N
OMe
O
NO2
OMe
O
C7H15 N
H
MeO
O
C7H15
O
hν
Reaction 
conditions
146 147
Entry Batch/Flow Solvent Reaction time (min) Result
1 Flow MeOH 80 42% conversion
2 Flow 1% AcOH in MeOH 80 57% conversion
3 Flow 1% DMSO in MeOH 80 67% conversion
4 Batch 1% DMSO in p-dioxane 480 27% conversion
5 Batch 1% AcOH in MeOH 480 35% conversion
Previous tests had shown that the seven-membered lactone 136 was stable in 1% DMSO in p-
dioxane (Table 3.6, entry 5) and these conditions were able to bring about the photolysis of the
2-methoxy-6-nitrobenzyl group of an amide nitrogen (Table 3.7, entry 4). Therefore, to obtain a
high yielding deprotection procedure for the desired 1,4-oxazepane-2,5-dione core, an attempt
was made to synthesize the N-(2-methoxy-6-nitrobenzyl)-protected lactone (Scheme 3.29).
Unlike previous N-acylation reactions that were performed using the same reaction conditions,
the N-acylation product 148 of the PPG-protected amino acid derivative 145 was only obtained
as the minor product (Scheme 3.29). The main isolated product 149 was the adduct of the
PPG-protected amino acid derivative 145 and isobutyl chloroformate. Alkaline hydrolysis of
the minor product 148, followed by a cyclization reaction, failed to yield the N-(2-methoxy-6-
nitrobenzyl)-protected seven-membered ring.
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OH
OOH
NO
HO
O
OMe
NO2
NH
O
OMe
NO2
1) 1 equiv NMM
    1 equiv
    20 min 0 °C
2) 1.05 equiv
EtOAc, 0 °C 2 h, then r.t., o.n.
Cl
O
O
NO Me
O
N
O
O
OMe
NO2OMe
OMe
OMe
(4%) (35%)
58d
145
148 149
Scheme 3.29. Attempt to N-acylate methyl N-(2-methoxy-6-nitrobenzyl)glycinate 145.
3.2.7 PPG-protected N-(3-hydroxyacyl)-L-homoserine lactones
As the UV-light driven removal of the 2-methoxy-6-nitrobenzyl PPG proved to be successful
(Table 3.7), it was decided to employ this group to synthesize a PPG-protected N-(3-hydroxy-
acyl)-L-homoserine lactone. This type of compounds allows the non-invasive, external interfer-
ence with the bacterial communication system by using light. In a previous study by Van der
Berg et al., researchers were able to temporarily modulate QS-regulated traits via photoswitch-
able compounds 150, which relied on the trans to cis-isomerization of the azobenzene pho-
tochromic unit upon UV-light irradiation. Exposure to visible light changes the conformation
back to mainly the trans-isomer (Scheme 3.30).312 Both compounds 150 had a QS-activating
effect but upon UV-light irradiation, compound 150a showed a drop in efficacy whereas com-
pound 150b had a fivefold increase in activity.
O
O
NH
O
N
N
n
O
O
NH
O
N
N
n
UV
Visible
light
n = 0
n = 1
trans-
trans-
cis-
cis-
n = 0
n = 1
150a150a
150b150b
Scheme 3.30. Photoswitchable QS-molecules 150.312
To obtain the PPG-protected hydroxy-AHL 154a, ethyl 3-hydroxynonanoate 55d was benzy-
lated via a reductive etherification,313,314 based upon Noyori’s TMSOTf-catalyzed acetaliza-
tion,315 followed by a triethylsilane-reduction of the acetal (Scheme 3.31).316 Alkaline hydro-
lysis of the O-PPG-protected ester 152a to the acid 153a, followed by EDC-mediated coupling
with L-homoserine lactone 53 yielded O-PPG-protected hydroxy-AHL 154a.
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O
O OH
NO2
O
OO2 equiv TMSCl
2.2 equiv Et3N
dry THF, r.t., 17 h
O
O
NO2
O
TMS
1) 1 equiv
0.1 equiv TMSOTf
2) 1 equiv Et3SiH
dry CH2Cl2, 
0 °C to r.t., o.n.
HO
O
NO2
O THF:MeOH:H2O 2:1:1, r.t., o.n.
5 equiv NaOH
OMe
O
H
MeOMeO
1 equiv Et3N
1 equiv EDC.HCl
1 equiv
OBrH.H2N
O
O
N
H O
O
NO2
O
H2O, r.t., o.n.
MeO
(24% yield over 4 steps, d.r.: 1:1)
55d 151a
142
152a153a
53
154a
Scheme 3.31. Synthesis of N-(3-((2-methoxy-6-nitrobenzyl)oxy)nonanoyl)-L-homoserine lactone 154a.
For the removal of the PPG-group, a solution of AHL 154a dissolved in 1% acetic acid in
methanol in an open beaker was irradiated with a blacklight bulb (E27 - 20W/230V) and sam-
ples were analyzed at regular time intervals via LC-MS (Figure 3.10). After 3 h, already more
than half of the caged AHL was released. When the experiment was repeated with 1% ethanol
in water as solvent mixture, to mimic biotesting conditions, photolysis was already complete
within 2 h. Remarkably, in both conditions tested, no solvolysis of the lactone ring was ob-
served during the monitoring via LC-MS.
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Figure 3.10. Photolysis of N-(3-((2-methoxy-6-nitrobenzyl)oxy)nonanoyl)-L-homoserine lactone 154a with a
blacklight bulb (E27 - 20W/230V) in 1% AcOH in MeOH.
A disadvantage of photolysis is the need for UV-radiation to release the caged compound. Al-
though peptides are relatively stable toward >350 nm UV light, this may not be the case for
complex heterocycles. Also methionine is sensitive toward photooxidation.305 However, the
two-photon irradiation technique can help to overcome the toxicity linked with UV-light irra-
diation. Because at high light intensity, chromophores may simultaneously absorb two red/NIR
photons, producing higher-energy excited states, similar to those accessible by direct excitation
with UV photons of about twice the frequency.302 As this requires very high light intensities,
only ultrafast pulsed lasers are suitable for this application. Using this approach, Neveu et al.
studied the effect of retinoic acid on zebrafish embryogenesis via the o-nitrobenzyl moiety pro-
tected derivative, which was photolysed via one- or two-photon excitation.317
3.2.8 Post-cyclization modification
As the route which led to the N-PMB-protected seven-membered ring 121 failed when ser-
ine was used instead of glycine, the introduction of a hydroxymethyl group on the N-PMB-
protected seven-membered ring 121 was evaluated.
Both reactions with paraformaldehyde as such and with paraformaldehyde as a source of formal-
dehyde via thermal cracking, were unable to introduce the desired hydroxymethyl group on the
N-methyl derivative 110, which was used as a test substrate (Table 3.8).318–320
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Table 3.8: Reaction conditions evaluated to introduce a hydroxymethyl group in cyclic compound 110.318–320
reaction
conditionsMe N
O
C9H19O
O Me N
O
C9H19O
O
HO
110 155
Entry Reaction conditions Result
1 15 equiv KHCO3, 11 equiv paraformalde-
hyde, DMF, r.t., 1 h to o.n.
-[a]
2 1) 1 equiv LDA, dry THF, N2, -78 ◦C, 1 h
2) 6 equiv paraformaldehyde, dry THF, N2,
-78 ◦C, 3 h to r.t., o.n.
After 3 h at -78 ◦C: -[a]
After o.n. at r.t.: -[b]
3 1) 2 equiv LDA, dry THF, N2, -78 ◦C, 1 h
2) 6 equiv paraformaldehyde, dry THF, N2,
-78 ◦C, 3 h to r.t., o.n.
After 3 h at -78 ◦C: -[a]
After o.n. at r.t.: -[b]
4 1) 1 equiv LDA, dry THF, N2, -78 ◦C, 1 h
2) formaldehyde (g) (formed by dry heat-
ing 10 equiv paraformaldehyde at 170 ◦C),
dry THF, N2, -78 ◦C, 3 h to r.t., o.n.
After 3 h at -78 ◦C: -[a]
After o.n. at r.t.: -[b]
[a] No reaction. [b] Complex reaction mixture.
3.2.9 Pseudo-prolines (ΨPro)
As the synthesis of the deprotected seven-membered ring 122 was performed well, but its appli-
cation using the same reaction conditions to the serine derivative in order to synthesize serratin
(83) failed, an alternative synthetic route was sought. Serine (and threonine) can react with
aldehydes or ketones to form oxazolidines (Scheme 3.32). These cyclic structures are unstable
in acidic environment, but can be acylated in an alkaline environment and isolated as such.321
Pseudo-prolines are commonly used to alter the solubility of peptides by disrupting secondary
structure formation or to facilitate the cyclization of small peptides.322,323 There are two ways
to introduce such a pseudo-proline moiety: either the pseudo-proline is synthesized separately
by reacting serine, threonine or cysteine with an aldehyde or ketone, and then included into the
peptide chain (Figure 3.32, route A), or the peptide chain is synthesized and then the pseudo-
proline is formed afterwards (post-insertion method, Figure 3.32, route B).322,324,325
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N
H
OH
O
X
Ser, Thr, Cys
     = AA
R'
O
R"
H+
R'
O
R"
H+
R'
R''
O
ClpeptideFmocHN
AA(ΨR',R"Pro), X = O or S
                        Y = H or Me
peptideFmocHN AA(ΨR',R"Pro)-OH
O
OPGpeptideFmocHN
peptideFmocHN AA-OH
Route A Route B
further incorporation into peptides
Y
Scheme 3.32. The two different routes to introduce a pseudo-proline moiety in a peptide chain.325
Variation of the C-2 ring substituents of a pseudo-proline has a profound effect on the ring stabil-
ity. Whereas dilute TFA affected ring opening of a 2,2-dimethyloxazolidine-peptide (Ser(ΨMe, Me
Pro)) within minutes, a treatment with trifluoromethanesulfonic acid for several hours was
needed to deprotect the rather stable C-2-unsubstituted oxazolidine (Ser(ΨH, HPro)).325 The
C-2 substitution pattern also has an influence on the conformational properties (Figure 3.11).
Whereas for peptides containing the unsubstituted serine-derived oxazolidines (Ser(ΨH, HPro))
the trans-isomer is the dominant one (66% trans in DMSO, determined via 1H NMR at 17
◦C), peptides containing the 2,2-dimethyl derivative (Ser(ΨMe, MePro)) have a clear preference
for the cis-conformer (less than 5% trans in DMSO, determined via 1H NMR at 17 ◦C). The
cis/trans-ratio of the C-2 monosubstituted oxazolidines lies somewhere in between.326–328
N R'''
O
OR
R'' O
N R'''
O
OR
O R''
cis trans
R' R'
Figure 3.11. Cis and trans-conformers of a pseudo-proline.326
Oxazolidine 157b was synthesized by heating the hydrochloride of the methyl ester of L-serine
88 with pivaldehyde 156 and triethylamine with continuous removal of water (Scheme 3.33).
This crude oxazolidine 157b was obtained as a 3:2-mixture of diastereomers in 71% yield.322,329
Several procedures were evaluated for the N-acylation of oxazolidine 157b (Table 3.9). The
formation of the mixed anhydride of β-hydroxynonanoic acid 58d via reaction with isobutyl
chloroformate, followed by reaction with the methyl ester of oxazolidine 157b proved to be
the best procedure to obtain compound 158b (Table 3.9, entry 4).330 The N-acylated 2-tBu-
oxazolidine 158b possessed a C2,C4-cis-relation, although the starting oxazolidine 157b was
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obtained as a 3:2 diastereomeric mixture. Ring-chain tautomerism allows equilibration to the
more stable product with the tBu-group on a quasi-axial position. The amide nitrogen in the
five-membered-ring is considerably pyramidalized, allowing some overlap of the nitrogen lone
pair with the amide carbonyl group.331–333 Subsequent alkaline hydrolysis of the N-acylated 2-
tBu-oxazolidine 158b, followed by cyclization in dilute reaction conditions yielded the bicyclic
structure 160b (Scheme 3.33).
H2N
OMe
O
OH
HCl.
H
O
R1
N
H
OMe
O
O
R1
N
H
OMe
O
O
C6H13 OH
OOH N
OMe
O
O
O
1) 1 equiv NMM
    1 equiv
    20 min, 0 °C
2) 1.05 equiv
EtOAc, 0 °C, 2 h, then r.t., o.n.
Cl
O
O
NO Me
HO C6H13
5 equiv NaOH MeOH:H2O 3:1, 
r.t., o.n.
N
OH
O
O
O
HO C6H13
N O
OO
O
C6H13
0.2 equiv DMAP
1.1 equiv EDC.HCl
dry CH2Cl2, r.t., o.n. 
   (dilute, 20 mM)
R1 = Ph
R1 = tBu
(R1 = Ph, R2 = H, not isolated) 
(R1 = tBu, R2 = H, 71%, d.r.: 57:43)
or
         (not isolated)
H
(R1 = Ph, R2 = H, 53% over 3 steps, d.r. 1:1)
(R1 = tBu, R2 = H, 63% over 3 steps, d.r. 1:1)
(R1 = R2 = Me, 18% over 3 steps, d.r. 1:1.3)
For R1 = Ph: 2 equiv MgSO4,
dry CH2Cl2:Et3N 4:1, r.t., o.n.
For R1 = tBu: 1.1 equiv Et3N,
hexane, ∆, 48 h, Dean-Stark
1.1-1.5 equiv
R1
N
H
OMe
O
OH
0.1 equiv PTSA.H2O
5 equiv DMP 
(2,2-dimethoxypropane)
dry toluene, ∆, 3 h,
    Dean-Stark
C6H13
OOH
R1
R2
R1
R2
R1
R2
For R1 = R2 = MeFor R
1
 = Ph or tBu and R2 = H
R2
R2
         (not isolated)
112
156
88
157a
157a
157b
157b
58d
158a–c
89
159a–c160a
160b
160c
Scheme 3.33. Synthesis of oxazolidine-containing bicyclic structures 160a–c.
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Table 3.9: Reaction conditions evaluated for the N-acylation of 2-tbutyloxazolidine 157b.
N
H
OMe
O
O N
OMe
O
O
O
HO
HO
O OH
+
reaction
conditions
1.05 equiv
157b 58d 158b
Entry Reaction conditions Result
1 1 equiv EDC.HCl, 1 equiv Et3N, CH2Cl2, r.t., 2 d -[a]
2 0.1 equiv DMAP, 1 equiv DCC, r.t., o.n. -[a]
3 1 equiv DMAP, 1 equiv DCC, r.t., 2 d -[b]
4 1 equiv N-methylmorpholine (NMM), 1 equiv isobutyl
chloroformate, EtOAc, 2 h at 0 ◦C, r.t., o.n.
158b (63%)[c]
5 1 equiv N-methylmorpholine (NMM), 1 equiv isobutyl
chloroformate, dry THF, 2 h at 0 ◦C, r.t., o.n.
158b (42%)[c]
[a] No reaction. [b] Complex reaction mixture [c] Crude yield after work-up determined via integration of the 1H
NMR spectrum.
Bicyclic compound 160b was obtained as a 1:1 mixture of diastereomers. The diastereomers
(RSS)-160b and (RRS)-160b were separated via column chromatography followed by recrys-
tallization. One of the two diastereomers remained an amorphous powder, whereas the other
one formed needle-like crystals, allowing structure confirmation and stereochemistry determi-
nation via X-ray diffraction analysis (Figure 3.12). The crystals belong to the orthorhombic
Sohnke space group P212121 and hence contain only one enantiomer, being (RSS)-160b with a
cis-relationship of the substituents. The C6H13-alkyl chain was disordered over two positions in
the crystal due to its flexibility.
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N
(S)O
(R)
(S)
O
O
O
HA)
(RSS)-160b
HN
(S)HO (S)
O
O
OB)
(SS)-160b83
Figure 3.12. A) Molecular structure of (RSS)-160b, showing thermal displacement ellipsoids, drawn at the 30%
probability level. The positional disorder of the C6H13-alkyl chain is shown in yellow. B) Stereochemistry of
serratin ((SS)-83) based upon comparison with theoretical calculations of the 13C NMR chemical shift.247
Both diastereomers showed quite different chemical shifts. The crystalline diastereomer (RSS)-
160b has both its substituents in a cis-relationship. This RSS-diastereomer showed a signal for
CH-O at 75.2 ppm (CDCl3) in the 13C NMR spectrum and the attached hydrogen atom CH-O
showed a multiplet at 4.71-4.83 ppm (CDCl3) in the 1H NMR spectrum. For the other diaste-
reomer (RRS)-160b, with a RRS-stereochemistry, the corresponding signals were at 79.7 ppm
(CDCl3, 13C NMR) and 4.68-4.79 ppm (CDCl3, 1H NMR). The signal around 70 ppm in the
13C NMR spectrum is quite characteristic and is present in all 1,4-oxazepane-2,5-diones de-
scribed in literature (Figure 3.13 and Table 3.10).247,258,266–268,299,334,335 Another difference was
the shift of the CH2 adjacent to the CH-O moiety. For diastereomer (RSS)-160b the correspond-
ing signals were a dd at 2.85 ppm (CDCl3) and a dd at 2.97 ppm (CDCl3), whereas for the
other diastereomer (RRS)-160b a d at 2.72 ppm (CDCl3) and a dd at 3.14 ppm (CDCl3) were
observed. For serratin (83), Luna et al. noticed signals for the CH2 at 2.42 ppm (dd, CDCl3) and
2.62 ppm (dd, CDCl3) and a signal for CH-O at 72.4 ppm (CDCl3) in the 13C NMR spectrum.247
These values seem to be consistent with our observations for diastereomer (RSS)-160b.
99
Results and discussion
N
O
O
S
O
N
O
O
O
O
N
O
O
MeO
HN
HO
N
O
NH2O
Me
NH
O
O
O
Cl
N
H
OH
ClPeptide chain
N
O
O
O
N
O
O
O
Br
N
O
O
O
N
H
Cl
HN
O
Me
N
OMe
O
(S) NH
(S)O
O
O
OH
N
O O
O
NH
Fmoc
(SS)-
N
O
O
O
(R) NH
(S)O
O
O
OH
(SR)-
92 93 94
83 83 161 162 163
164 165 166
Figure 3.13. 1,4-Oxazepane-2,5-diones described in literature.247,258,266–268,299,334,335
Table 3.10: Spectral data of 1,4-oxazepane-2,5-diones described in literature. NA: not applicable, NM: not men-
tioned.247,258,266–268,299,334,335
N
O
O
O
A B
C
DE
F
G
B C E F G
Structure (NMR solvent) δC δH δC δC δH δC δH δC
Callipeltin L (92) (CD3OD) 266 169.4 3.92 56.6 164.8 4.35 60.3 6.17 77.7
93 (CDCl3) 267 166.2 3.59 68.4 163.2 3.87 59.7 5.25 72.6
Inducamide C (94) ((CD3)2SO) 268 170.8 4.3 59.2 164.1 NA NA NA NA
Serratin 83 (CDCl3) 247 169.4 4.65 54.4 169.2 2.42 and 2.62 40.5 5.3 72.4
Serratin 83 (SR Theoretical) 247 165.7 NM 57.3 174.5 NM 45.4 NM 79.1
Serratin 83 (SS Theoretical) 247 167.7 NM 53.5 167.8 NM 44.9 NM 73.8
161 (CDCl3) 334 NM 4.47 NM NM 4.98 NM NA NM
162 (CDCl3) 334 NM 4.46 NM NM 2.56 and 3.20 NM NA NM
163 ((CD3)2CO) 299 167.8 5.57 53.4 160.4 NA NA NA NA
164 (CDCl3) 258 NM 4.82 NM NM NA NM NA NM
165 (CDCl3) 258 NM 4.46 NM NM NA NM NA NM
166 (CDCl3) 335 162.7 4.19 58.8 170.0 4.28 54.8 4.38 and 4.8 70.5
As the 2-tBu-oxazolidine is a rather stable type of oxazolidine, it was decided to synthesize two
different types of oxazolidines as well. The first type was the more labile 2,2-dimethyloxazoli-
dine (Ser(ΨMe,MePro)), which undergoes rapid deprotection in dilute TFA.325 Unlike the Ser-
(ΨtBuPro) 157b, this type of oxazolidine cannot be isolated as such and is commonly introduced
via the post-insertion route (Scheme 3.32, route B). Therefore, methyl N-(3-hydroxynonanoyl)-
serinate 89 was reacted with 2,2-dimethoxypropane (DMP) with continuous removal of water
to yield compound 158c (Scheme 3.33).336 As 1H NMR analysis revealed that this N-acylated
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oxazolidine 158c, obtained after column chromatography, was less pure than the crude com-
pound after work-up because of degradation during purification, it was decided to proceed with
the reaction sequence without further purification. Hydrolysis of compound 158c with NaOH
in a water:methanol (ratio 1:3) mixture, followed by cyclization gave 2,2-dimethyloxazolidine
protected oxazepane-2,5-dione 160c in a total yield of 18% after purification. Once again, the
CH-O and CH2 of both diastereomers gave distinct signals in NMR spectroscopy.
For the 2-phenyloxazolidine derivative, L-serine methyl ester hydrochloride 88 was neutralized
with Et3N and allowed to react with benzaldehyde 112 to produce oxazolidine derivative 157a
(Scheme 3.33).337 This compound was N-acylated with β-hydroxynonanoic acid 58d and the
ester functionality was hydrolyzed under alkaline conditions to furnish compound 159a. The
2-phenyloxazolidine protected oxazepane-2,5-dione 160a was obtained in 53% total isolated
yield after the DMAP-catalyzed cyclization under dilute reaction conditions (Scheme 3.33).
Several reaction conditions were evaluated to deprotect the oxazolidine unit without opening
the seven-membered lactone (Table 3.12). A catalytic amount of bismuth(III) bromide was suc-
cessfully employed by Cong et al. to deprotect a cyclic N,O-aminal under mild reaction condi-
tions.338 However for substrates 160a–c, no reaction was observed (Table 3.12, entries 1A-C).
This could be explained by the fact that the reactivity of the oxazolidine ring is dramatically
reduced upon amidation.339 When a catalytic amount of water was added to the reaction mix-
ture, the 2-phenyloxazolidine moiety of the trans-diastereomer (RRS)-160a was deprotected to
the ring-opened structure 90 (Table 3.12, entry 2B). As traces of the ring-opened, oxazolidine-
containing, product 159a were detected during the course of the reaction, unlike the deprotected
compound 83, hydrolysis probably preceded deprotection. The other diastereomer (RSS)-160a
could be recovered from the crude reaction mixture, albeit in a severely reduced amount. For the
two other types of oxazolidines, all stereoisomers seemed to react at a similar rate and only the
deprotected and hydrolyzed product 90 was isolated (Table 3.12, entries 2A and C). In an alter-
native procedure, mild acidic conditions for deprotection were used by employing formic acid in
a THF:H2O-mixture (Table 3.12, entries 3A and B).340 In the case of the tBu-containing oxazoli-
dine 160b, a quick hydrolysis of both diastereomers to 159b was observed. Interestingly, for the
2-phenyloxazolidine 160a the trans-diastereomer (RRS)-160a hydrolyzed significantly faster
than the cis-diastereomer (RSS)-160a: whereas the starting compound had a d.r. of 1:1, this
changed to 1:2.7 for the recovered starting material. Treatment with an acidic resin also failed
to deliver the desired compound (Table 3.12, entries 4A and B).341 5% TFA in dichloromethane
left the 2-tBu-oxazolidine 160b intact, even after a reaction time of 48 h (Table 3.12, entry
5A).323 Under the same conditions, the trans-diastereomer of the 2,2-dimethyloxazolidine 160c
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was successfully deprotected (Table 3.12, entry 5C). The 1H NMR of the crude reaction mix-
ture, obtained after washing with a saturated aqueous NaHCO3-solution to remove the TFA and
the ring-opened product, revealed the presence of only the cis-diastereomer. The deprotected
trans-isomer (SR)-83 however was not detected. When the same treatment was applied on the
2-phenyloxazolidine-protected seven-membered ring 160a a similar observation was made: the
trans-diastereomer (RRS)-160a seemed to react faster, but none of the deprotected serratin (83)
could be isolated (Table 3.12, entry 5B and Figure 3.14). When 4M of HCl (g) in dioxane was
evaluated for the removal of the oxazolidine moiety,323 a difference in reactivity was observed
between the 2-tBu- and the 2-phenyloxazolidine moiety: in the case of the tBu-compound 160b,
the cis-diastereomer (RSS)-160b was deprotected faster whereas for the latter compound 160a,
the trans-diastereomer (RRS)-160a was deprotected faster. In both cases none of the deprotected
seven-membered ring 83 could be isolated (Table 3.12, entries 6A and B). When the reaction
time was prolonged, all of the starting material was converted to the deprotected, hydrolyzed
compound 90. The protocol with 1,3-propanedithiol in acidic trifluoroethanol, i.e. containing
2% HCl, developed by Corey,342 also caused a faster deprotection of the trans-diastereomer of
both the tBu- and the 2-phenyloxazolidine compared to the cis-isomers. Once again, no depro-
tected serratin (83) could be isolated.
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Table 3.12: Reaction conditions evaluated to achieve the deprotection of the different oxazolidine moieties of
seven-membered rings 160a, 160b and 160c.328,338,340–342
HN (S)
HO
(S) O
O
O
C6H13
N
O
R1
O
O
O
C6H13
H
deprotection
(R1 = Ph, R2 = H)
(R1 = tBu, R2 = H)
(R1 = R2 = Me)
(SS)-
HN
HO
O
O
C6H13
OH
OH
N
O
O
C6H13HO
O
OH
R2
R1
R2
(R1 = Ph, R2 = H)
(R1 = tBu, R2 = H)
(R1 = R2 = Me)
HN (S)
HO
(R) O
O
O
C6H13
+
(SR)-160a
160b
160c
8383 90
159a
159b
159c
Entry Reaction conditions ΨPro Result[a]
derivative
1A 0.1 equiv BiBr3, CH3CN, r.t., 1 h to o.n.338 tBu -[b]
1B Idem Ph -[b]
1C Idem DiMe -[b]
2A 1 equiv BiBr3, cat. H2O, CH3CN, r.t., 1 h to
48 h
tBu -[c]
2B Idem Ph Conversion of trans-diastereomer (RRS)-
160a to 90. No isolation of (SR)-
83. Slower reaction of cis-diastereomer
(RSS)-160a.
2C Idem DiMe -[c]
3A THF:H2O:HCOOH 3:1:1, r.t., 1 h to 48 h340 tBu Ring-opening to 159b
3B Idem Ph Ring-opening to 159a; trans-diastereomer
(RRS)-160a reacts faster than (RSS)-160a
4A Amberlyst 15, acetone:H2O 9:1, r.t., 1 h to
24 h341
tBu -[b]
4B Idem Ph -[b]
5A 5% TFA in dry CH2Cl2, 0 ◦C, 3 h, then r.t.,
48 h328
tBu -[b]
5B Idem Ph No reaction of cis-diastereomer (RSS)-
160a; deprotection of trans-diastereomer
(RRS)-160a to 90
5C Idem DiMe No reaction of cis-diastereomer (SS)-
160c; deprotection of trans-diastereomer
(RS)-160c to 90
6A 4M HCl in dioxane, 0 ◦C to r.t., 1 h to 24 h328 tBu Formation of 90; faster reaction of the cis-
diastereomer (RSS)-160b
6B Idem Ph Formation of 90; faster reaction of the
trans-diastereomer (RRS)-160a
7A 3 equiv 1,3-propanedithiol, 2% HCl in 2,2,2-
trifluoroethanol, r.t., 1 h to 24 h342
tBu Formation of 90; faster reaction of the
trans-diastereomer (RRS)-160b
7B Idem Ph Formation of 90; faster reaction of the
trans-diastereomer (RRS)-160a
[a] Based on LC-MS analysis during the course of the reaction and 1H NMR analysis of the crude reaction mixture
after work-up. [b] No reaction. [c] Deprotection and ring-opening or ring-opening and deprotection. Only recovery
of 90.
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As deprotection was observed but isolation of serratin (83) failed, either because of depro-
tection followed by immediate ring-opening or by first ring-opening and then deprotection,
another route for the 2-phenyloxazolidine 160a was evaluated. In a first attempt to remove the
2-phenyloxazolidine unit from 160a, hydrogenolysis with Pd/C in ethyl acetate and in methanol
was evaluated, but no reaction (Table 3.13, entry 1) or only a limited conversion, combined with
degradation (Table 3.13, entry 2), were obtained. When Pd(OH)2/C was employed in ethanol,
a complete debenzylation was observed, unfortunately combined with ethanolysis of the de-
protected product (Table 3.13, entry 3). When the reaction was repeated in ethyl acetate, de-
protection without solvolysis was observed (Table 3.13, entry 4). Remarkably, both diastereo-
mers behaved differently: only the seven-membered ring (SS)-83 with both substituents in a
cis-relationship was obtained and isolated in 22% yield (based on the total amount of starting
material). The diastereomeric ratio of the recovered, oxazolidine-containing starting material
160a had consequently changed from 1:1 to 1:3, favoring the (RRS)-diastereomer (Figure 3.14).
This observed selectivity for (RSS)-160a could be explained by steric factors. The (RSS)-isomer
of 160a has the phenyl and alkyl substituent on the same side of the bicyclic ring system (see
Figure 3.12 for (RSS)-160b), allowing a relatively unhindered interaction of the opposed side
with the palladium catalyst. As the (RRS)-isomer has the bulky phenyl substituent on one side
and the alkyl substituent on the other side, it is expected that such an interaction with the cata-
lyst proceeds with more difficulty.
Table 3.13: Reaction conditions evaluated for the removal of the 2-phenyloxazolidine moiety of 160a.
N (S) O
OO
(R)
O
C6H13
HN (S) O
OHO
(S)
O
C6H13
Reaction conditions
HN (S) O
OHO
(R)
O
C6H13
+
(SS)- (SR)-(d.r.: 1:1)
H
160a 8383
Entry Reaction conditions Result
1 4 atm H2, 25 wt% Pd/C, EtOAc, r.t., o.n. -[a]
2 4 atm H2, 25 wt% Pd/C, MeOH, r.t., o.n. -[b]
3 4 atm H2, 25 wt% Pd(OH)2/C, EtOH, r.t., o.n. -[c]
4 1 atm H2, 50 wt% Pd(OH)2/C, EtOAc, r.t., 6 h (SS)-83 (22%). No reaction of the
other diastereomer; recovery of
starting material 160a (67%) with
a d.r. of 1:3
[a] No reaction. [b] Solvolysis of starting material 160a. [c] Deprotection and solvolysis or solvolysis and
deprotection.
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Figure 3.14. Overlay of the 1H NMR spectra of 2-phenyloxazolidine protected compound 160a (in CDCl3) and
the crude 1H NMR spectra (in CDCl3) of the same compound 160a recovered after treatment with 5% TFA in
CH2Cl2 or H2 gas and Pd(OH)2/C in EtOAc.
The (RSS)-diastereomer that was deprotected, however, had the correct stereochemistry to de-
liver serratin (SS)-83. In the 1H NMR spectrum (CDCl3), a signal for NH became visible, which
is consistent with a successful deprotection. The CH-O-signal at 73.7 ppm (CDCl3) was also
present, indicating that the seven-membered heterocycle was still intact. However, unlike the
value around 5.30 ppm (CDCl3) reported by Luna et al. for CH-O, a multiplet around 4.73-4.81
ppm (CDCl3) was observed. A big difference for the adjacent CH2 was also apparent: whereas
Luna et al. reported two dd at 2.42 and 2.62 ppm (CDCl3), we detected the corresponding
signals at 2.79 and 2.87 ppm (CDCl3).
The values reported by Luna et al. show a lot of similarities with the spectral data of the com-
pound serratamolide A (42a) (Table 3.14). This antimycobacterial cyclodepsipeptide is pro-
duced by Serratia sp. and has the CH-O signal at 5.33 ppm (1H NMR, CD3OD), the CH-O
signal at 73.2 ppm (13C NMR, CD3OD) and the adjacent CH2 at 2.39 and 2.72 ppm (1H NMR,
CD3OD).248 That the actual structure of serratin (83) could be a serratamolide analogue is also
suggested by the observed vicinal coupling constants of the O-CHCH2C(=O) moiety. Whereas
for the compound synthesized in this study vicinal coupling constants of 11.3 Hz and 3.0 Hz
were observed, which corresponds to a conformation as depicted in figure 3.12 with one large
and one small dihedral angle of the coupling protons, values of 4.9 Hz and 2.0 Hz were reported
by Luna et al.247 These small vicinal coupling constants were also reported for serratamolide
A (42a) (5.0 Hz and 2.6 Hz), which correspond with a more flexible structure and smaller di-
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hedral angles (Table 3.14).343 Serratamolide A (42a) is a symmetrical molecule composed of
two serine units and two times β-hydroxydecanoic acid as the fatty acid moiety. However, the
asymmetrical analogue serratamolide F (42f) has a β-hydroxydecanoic acid moiety but also
a β-hydroxynonanoic acid moiety in its structure.248 It is known that during the biosynthesis
of cyclic lipopeptides, a relaxed substrate specificity can give rise to the production of several
analogues of one main cyclic lipopeptide compound.134,248 Therefore, if a symmetrical serrata-
molide exists with two β-hydroxynonanoic acid tails, the corresponding NMR spectra would
contain only a limited number of signals with values nearly identical to those reported by Luna
et al. for serratin (83) (Table 3.14).
Table 3.14: Comparison of the spectral data of serratamolide (42) and serratin (83).247,248,250,343,344
NH
O HN
O
O
O
O
O
R1
R2
OH
HO
A: R1 = (CH2)6CH3, R2 = (CH2)6CH3
B: R1 = CH2CH=CH(CH2)5CH3, R2 = (CH2)6CH3
C: R1 = (CH2)8CH3, R2 = (CH2)6CH3
D: R1 = (CH2)7CH3, R2 = (CH2)6CH3
E: R1 = (CH2)4CH3, R2 = (CH2)6CH3
F: R1 = (CH2)5CH3, R2 = (CH2)6CH3
C
B
E
F
G
Serratamolide
NHO
O
O
OH
(SS)-
B C
EF
G
H
H
42a
42b
42c
42d
42e
42f
83
B C E F G H
Structure (NMR sol-
vent)
δC δH δC δC δH δC δH δC δH δC
Serratamolide A (42a)
(CD3OD) 343
NM 4.49 (t, J = 3.6
Hz)
NM NM 2.34 (dd, J = 13.6 Hz, 2.6 Hz)
and 2.68 (dd, J = 13.6 Hz, 5.0
Hz)
NM 5.39
(m)
NM 3.82 (dd, J =
10.8 Hz, 3.3
Hz) and 4.08
(dd, J = 10.8
Hz, 3.8 Hz)
NM
Serratamolide A (42a)
(CD3OD) 250
NM 4.47 (m) NM NM 2.33 (dd) and 2.67 (dd) NM 5.28
(m)
NM 3.82 (dd) and
4.07 (dd)
NM
Serratamolide A (42a)
(CD3OD) 248
171.3 4.53 (dd, J =
3.8 Hz, 3.2
Hz)
56.3 172.0 2.39 (dd, J = 13.5 Hz, 2.7 Hz)
and 2.72 (dd, J = 13.5 Hz, 4.9
Hz)
41.2 5.33
(m)
73.2 3.87 (dd, J =
10.8 Hz, 3.2
Hz) and 4.11
(dd, J = 10.8
Hz, 3.8 Hz)
63.2
Serratamolide B
(42b), C10:0 alkyl
chain (CD3OD) 248
171.3 4.52 (dd, J =
3.9 Hz, 3.4
Hz)
56.4 171.8 2.40 (dd, J = 13.6 Hz, 2.9 Hz)
and 2.73 (dd, J = 13.6 Hz, 4.8
Hz)
41.2 5.33
(m)
73.2 3.87 (dd, J =
10.8 Hz, 3.4
Hz) and 4.11
(dd, J = 10.8
Hz, 3.9 Hz)
63.1
Serratamolide B
(42b), C12:1 alkyl
chain (CD3OD) 248
171.0 4.53 (dd, J =
4.1 Hz, 3.4
Hz)
56.4 172.0 2.44 (dd, J = 13.6 Hz, 2.9 Hz)
and 2.70 (dd, J = 13.6 Hz, 4.8
Hz)
40.4 5.24
(m)
73.1 3.87 (dd, J =
10.8 Hz, 3.4
Hz) and 4.08
(dd, J = 10.8
Hz, 4.1 Hz)
63.1
Serratamolide A (42a)
(CDCl3) 344
169.6 4.40 (m) 54.6 169.4 2.30 (d) and 2.55 (d) 40.4 5.20
(m)
72.4 3.70 (m) and
4.05 (m)
63.0
Serratin (83) (CDCl3)
reported by Luna et
al. 247
169.4 4.65 (dt, J =
8.1 Hz, 2.8
Hz)
54.4 169.2 2.42 (dd, J = 14.1 Hz, 2.0 Hz)
and 2.62 (dd, J = 14.1 Hz, 4.9
Hz)
40.5 5.30
(m)
72.4 3.85 (d, J = 8.8
Hz) and 4.22
(d, J = 8.8 Hz)
63.4
Serratin (83) (CDCl3)
reported in this study
171.6 4.49 (m) 52.8 169.5 2.79 (dd, J = 18.7 Hz, 3.0 Hz)
and 2.87 (dd, J = 18.6 Hz, 11.3
Hz)
41.7 4.77
(m)
73.7 3.89 (ddd, J =
12.3 Hz, 8.3
Hz, 4.3 Hz)
and 4.06 (ddd,
J = 12.0 Hz,
5.0 Hz, 5.0
Hz)
61.1
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3.2.10 Conclusion
In this chapter, the evaluation of HO-AHLs 2 in an intramolecular rearrangement leading to 1,4-
oxazepane-2,5-diones, resembling the rearrangement of oxo-AHLs 3 to tetramic acids 11, was
performed. One compound, serratin (83), with such a structure, has been isolated from a bacte-
rial culture broth, hinting the possibility of such a rearrangement. However, both HO-AHLs 2 as
N-(3-hydroxynonanoyl)-L-serine (90) refused to participate in such a cyclization. As analogues
with a third N-substituent cyclized readily, it was concluded that the preference of a secondary
carboxylic amide for a trans-conformation hinders such reactivity for HO-AHLs 2, pointing out
the unlikeliness that such a spontaneous rearrangement of a N-mono- or disubstituted compound
could lie at the origin of serratin (83).
As several natural products containing a 1,4-oxazepane-2,5-dione-core are known, and few
methods have been described to synthesize this type of compounds, a method for the synthesis
of such 1,4-oxazepane-2,5-diones was developed. Because of the presence of an amide, which
has a preference for a trans-conformation, and the presence of a labile lactone moiety in this
core, many synthetic methodologies commonly used for the cyclization toward medium-sized
heterocycles cannot be applied. Therefore, several N-protecting groups were tested and PMB
was applied as a protecting group to force the linear amino acid precursor in a correct con-
formation for cyclization to occur. Via the application of pseudo-prolines as another type of
protecting group for serine derivatives, a compound with the presumed structure of the natural
product serratin (83) was obtained. As a result of the differences in spectral data, the incorrect
structural assignment of the natural product serratin (83) was identified. Instead of the alleged
seven-membered heterocycle, a symmetrical serratamolide 42 analogue is proposed to be the
correct structure of serratin.
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3.3 The influence of quorum sensing signal molecules on plants and fungi
Abstract
Pseudomonas sp. CMR12a is a strain which could potentially be applied as a biocontrol agent
against the cocoyam root rot disease caused by Pythium myriotylum. To better understand the
role of QS in the biocontrol activity of this strain, the influence of one of its QS signal molecules,
HO12, on plant growth was studied. The influence of this compound on two plant species,
lettuce (Lactuca sativa) and Arabidopsis thaliana, was evaluated but no direct effects were
observed. The bioactivity of a degradation product of oxo-AHLs, a tetramic acid, was evaluated
as well. Neither plant growth stimulating nor inhibiting effects were observed, but a significant
growth reduction of the agriculturally relevant plant pathogen Rhizoctonia solani was observed.
As tetramic acids display algicidal effects as well, these compounds might have the potential to
be used as an algicide or fungicide or a combination of both in hydroponics.
Graphical abstract
Keywords
AHL, quorum sensing, AHL-plant interactions, biocontrol, tetramic acid, fungi
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3.3.1 Introduction
The production of bioactive metabolites has attracted scientific interest in order to use microor-
ganisms as biocontrol agents. In this approach an organism is applied that exerts an antagonistic
effect on an agricultural plague. As fungicides are often not sufficiently effective anymore due
to resistance development and both an economically non-viable and environmentally unfriendly
option, the use of a biocontrol agent could often form a sustainable alternative.345 The produc-
tion of many secondary metabolites is regulated by QS. Some of these metabolites are required
for biofilm formation whereas other exert antimicrobial effects. Not surprisingly, a mutation of
the QS system often gives rise to mutants which are impaired in bioactivity and habitat colo-
nization.346 Therefore, if one wants to apply a microorganism as a biocontrol agent, a thorough
understanding of the (QS) regulation of its secondary metabolite production is required.
In an attempt to find a biocontrol agent against the cocoyam root rot disease, several fluorescent
Pseudomonas ssp., characterized by the production of fluorescent green-yellow siderophores
called pyoverdins, were isolated from the rhizospheres of healthy cocoyam plants (Xanthosoma
sagittifolium) (Figure 3.15) in Cameroon and evaluated as biocontrol agents.347 This tropical
tuber crop is an important constituent of the human diet in (sub)tropical regions as the tubers
are rich in carbohydrates and contain a substantial amount of essential amino acids, fats and
vitamins.348 Of all existing cocoyam varieties, white cocoyam is the highest yielding and most
tasteful, and therefore the preferred variety. However, this variety is also the most susceptible
to the cocoyam root rot disease.347 This disease is caused by the oomycete Pythium myriotylum
and can reduce the harvested tuber yield with more than 90%.349
Figure 3.15. Left: cocoyam (Xanthosoma sagittifolium) plant; right: harvested cocoyam tubers.348
Out of all the isolates, Pseudomonas sp. CMR12a proved to be an efficient Py. myriotylum an-
tagonist. It was found that the biological activity of this strain was linked with the production of
antifungal phenazines 167 and cyclic lipopeptide (CLP)-type biosurfactants 168 and 169 (Fig-
ure 3.16).347 Besides Py. myriotylum, Pseudomonas sp. CMR12a also succeeded in suppressing
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root rot disease on bean (Phaseolus vulgaris) caused by Rhizoctonia solani AG 2-2 and AG
4-HGI as well as the damping-off disease caused by R. solani AG 2-1 on Chinese cabbage
(Brassica chinensis).201,202
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Figure 3.16. Secondary metabolites and QS signal molecules produced by Pseudomonas sp. CMR12a:
phenazine-1-carboxamide (PCN) 167, the CLPs orfamide B, D, E (168a–c) and sessilin A (169a), and the
AHLs N-(3-hydroxyhexanoyl)-L-homoserine lactone (HO6) 2c, N-hexanoyl-L-homoserine lactone (C6) 1c, N-
(3-hydroxyoctanoyl)-L-homoserine lactone (HO8) 2e, N-octanoyl-L-homoserine lactone (C8) 1e and N-(3-
hydroxydodecanoyl)-L-homoserine lactone (HO12) 2i.350
In previous research the antagonistic effect of Pseudomonas sp. CMR12a against the cocoyam
root rot pathogen was ascribed to the phenazine and CLP-production of this strain.347 It was
shown that phenazine production was QS regulated and a role of QS in CLP-production could
not be excluded as well.350 A thorough understanding of the QS pathways could help to fine-
tune the secondary metabolite production and strongly enhance the efficacy of Pseudomonas
sp. CMR12a as a biocontrol agent. However, there was also a plant growth stimulatory effect of
QS signal molecule HO12 2i observed. The two other HO-AHLs, HO6 2c and HO8 2e did not
display such activity.351,352 Therefore, to fully assess the role of QS on the biocontrol activity of
strain CMR12a, the effect of compound 2i on plant growth was studied further.
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3.3.2 Evaluating the effect of AHLs on the growth of lettuce
A lot of research has been carried out on the influence of AHLs on plants (see Literature
overview). In most cases these studies are limited to the economically non-important plants
Arabidopsis thaliana and Medicago truncatula. Most of these studies apply 10 µM of the AHL
to evaluate the effects (Appendix, Table 8.1).54,68,70,73,74,79,83 In the supernatant of planktonic P.
aeruginosa cultures, concentrations of 5-15 µM of oxo12 3i are detected.34,35 However, concen-
trations higher than 600 µM of oxo12 3i have been detected in P. aeruginosa biofilms, whereas
outside the biofilm only nM concentration of AHLs were found.34 In a 6 days old subtidal
biofilm, concentrations exceeding 3000 µM of C12 1i were detected.353 These observations
point out the strong spatial heterogeneity regarding AHL concentrations but as well the exis-
tence of AHL hotspots with local concentrations exceeding the micromolar range, making 10
µM a biologically relevant concentration. It was therefore decided to use a concentration of 10
µM as well.
In previous research, a root growth stimulating effect of 10 µM HO12 2i on lettuce (Lactuca
sativa) was observed, whereas shorter-chain analogues HO6 2c and HO8 2e were inactive.351,352
Unsubstituted AHL C14 1k was added as well as the strongest growth influencing effect are
associated with long-chain AHLs.55 However, in an exploratory experiment, a huge growth dif-
ference between the control plates (MS plant agar medium with 0.01% ethanol) was observed,
depending on the position in the growth chamber (Figure 3.17).
Figure 3.17. Two control plates with lettuce seedlings.
A second attempt with a more randomized distribution of the plates in the growth chamber re-
vealed again a clear effect of the position in the growth chamber but no clear effect of the added
compounds on root growth could be observed, even when comparing within the same line of
the growth chamber (Figure 3.18 and 3.19).
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Figure 3.18. Effect of HO12 2i and C14 1k on the growth of lettuce seedlings.
Figure 3.19. Measured primary root length of lettuce seedlings after exposure to C14 1k and HO12 2i. Represented
values are the mean of twelve plants. Bars with a different letter are statistically different according to Tukey’s post-
hoc test (p = 0.05).
To exclude possible concentration effects, several concentrations of HO12 2i were tested but no
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growth stimulating effect could be observed for the concentrations under study (Figure 3.20).
Figure 3.20. Effect of different HO12 2i concentrations on the growth of lettuce seedlings.
Due to the difficulties to control the interplate variability linked with the light incidence in
the growth chamber and the apparent absence of growth influencing effects, this experimental
set-up was abandoned and a switch to A. thaliana, which displays less variability, was made.
3.3.3 Evaluating the effect of AHLs and TA on the growth of Arabidopsis thaliana
As it is known that C10 1g inhibits root growth in A. thaliana,54 this AHL 1g was included
as a negative control. Several plant-associated bacteria use oxo-AHLs 3 (e.g. Pseudomonas
syringae pv. syringae produces oxo6 3c and oxo8 3e, Agrobacterium tumefaciens produces
oxo8 3e, Sinorhizobium meliloti produces oxo14 3k and oxo16 3m).62,63 These oxo-AHLs 3
can rearrange to tetramic acids 11 (see Literature overview),9,42 suggesting these TA can occur
in the rhizosphere. It is known that TA12 11a exhibits strong algicidal effects (Michail Syrpas,
PhD thesis).354 Therefore, the tetramic acid 11a, derived from the intramolecular rearrangement
of oxo12 3i was tested as well (Figure 3.21).
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Figure 3.21. Effect of C10 1g, HO12 2i and TA12 11a on the growth of A. thaliana seedlings.
In this assay, no clear effect of the position in the growth chamber was observed. The primary
root growth inhibitory effect of C10 1g on A. thaliana was confirmed.54 However, no such
inhibitory (or stimulatory) effect was observed for HO12 2i. Also TA12 11a did not display a
growth inhibitory effect. As it is known that TA12 11a exhibits strong algicidal effects (Michail
Syrpas, PhD thesis),354 this compound could be used in hydroponics.
However, when tetramic acid-containing fungal metabolite trichosetin (170) (Figure 3.22) was
added to seedlings (3-27 µM), it inhibited root and shoot growth of the five plant species
(Vigna radiata, Lycopersicon esculentum, Oryza sativa, Medicago sativa and Capsicum fru-
tescens) evaluated.355 This inhibition was caused by damaging the cell membrane.355 On the
other hand, 1-10 µM harzianic acid (171) (Figure 3.22), a secondary metabolite produced by
Trichoderma, promotes the growth of tomato seedlings (Solanum lycopersicum cv. Roma) pre-
sumably due to its iron-binding activity.356,357 No such growth promotion of tomato seedlings
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was observed using a concentration of 100 µM harzianic acid (171), although a higher germina-
tion percentage was observed for the treated tomato seeds.356,357 The growth of canola (Brassica
napus) seedlings was inhibited by high (10-100 µg per seed) harzianic acid (171) concentrations
whereas low (1, 10 and 100 ng harzianic acid (171) per seed) doses stimulated the growth of the
seedlings, stressing the importance of the applied concentration of a compound.358 Therefore,
to fully understand the bioactivity of TA12 11a a dose-response study should be performed.
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Figure 3.22. Chemical structure of bacterial TA12 11a, used in this study, and fungal tetramic acids trichosetin
(170) and harzianic acid (171).
3.3.4 Evaluating the effect of AHLs and TA on the growth of fungi
Several natural products containing a tetramic acid core display antifungal activity.359 It was
also shown by Hogan et al. that oxo12 3i influences the morphology of the yeast Candida
albicans at concentrations of 200 µM. This could be caused by the formation of TA12 11a
but is less likely as the unsubstituted AHL C12 1i had a similar effect.360 Therefore, to further
explore the potential of TA12 11a, the effect of this compound on two agriculturally relevant
plant pathogenic fungi, Botrytis cinerea and Rhizoctonia solani, was tested. As the minimum
inhibitory concentration of TA12 11a on the diatom Phaeodactylum tricornutum was between
20 and 50 µM (Michail Syrpas, PhD thesis),354 50 µM was selected to test the effect of TA12
11a on these economically relevant fungi. Whereas no significant effect was observed on B.
cinerea, up to 13% growth reduction was observed when tested on the soil-borne pathogen R.
solani (Figure 3.23). Previously, bactericidal activity was already reported for this compound
11a.9,41
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Figure 3.23. Top: Effect of TA12 11a and C10 1g on the growth of fungi B. cinerea and R. solani. Represented
values are the mean of eight repetitions. Bars with a different letter are statistically different according to Tukey’s
post-hoc test (p = 0.05). Bottom: Photographs of the mycelium of R. solani obtained after the different treatments.
3.3.5 Conclusions
In this part, the effect of QS molecules and a TA on the growth of plants and fungi was assessed.
Because of the high variability associated with the assay utilizing lettuce, no reliable conclu-
sions could be obtained for this plant. For A. thaliana the root growth inhibiting effect of C10
1g was confirmed, but no effect of HO12 2i nor TA12 11a was observed under the conditions
tested. However to fully disclose the effect of the QS signal molecules as such in the biocontrol
capacity of Pseudomonas sp. CMR12a, contact studies with a pathogen after AHL-treatment
should be evaluated, as it is known that several AHLs are able to induce systemic resistance to
plants.
Although algicidal effects are associated with TA12 11a, this compound did not inhibit the
growth of A. thaliana. On the other hand, in a preliminary experiment TA12 11a was able to
significantly reduce the growth of the agriculturally relevant pathogen R. solani but showed only
limited activity against B. cinerea. Therefore, further research should be carried out to evaluate
the potential of this tetramic acid 11a to be used as an algicide or fungicide in hydroponics. Dif-
ferent concentrations, different pathogens and the effect on different plants should be carefully
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evaluated to fully assess the potential of this compound.
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3.4 The influence of the quorum sensing signal molecule N-(3-hydroxy-
octanoyl)-L-homoserine lactone on the regulation of cyclic lipopeptide
production by Pseudomonas sp. CMR12a
Abstract
In this part the influence of a QS signal molecule, HO8 2e, on the swarming behavior of Pseu-
domonas species CMR12a was studied. It was shown that this QS signal could stimulate or-
famide production via activation of the PhzI/PhzR-operon. No effect on sessilin production was
observed. After a comparison of the effect of this compound 2e with the swarming phenotype
on agar plates, it was hypothesized that both CLPs, orfamide and sessilin, which are produced
by this bacterium fulfill a crucial role in its swarming behavior. It is believed that QS controls
the final swarming phenotype. This control depends on an elegant fine-tuning of the ratio of the
two produced CLPs, orfamide and sessilin, via the control of the orfamide production. When
the cell density and thus the concentration of HO8 2e increases, more orfamide is produced.
It is hypothesized that the decrease of the sessilin/orfamide ratio causes a sessile behavior in
a structured biofilm. On the other hand, when the sessilin/orfamide ratio increases, a switch to
swarming behavior might be made once more.
Graphical abstract
Keywords
AHL, quorum sensing, CLP, swarming, metabolite regulation
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3.4.1 Introduction
In previous research, it was shown that Pseudomonas sp. CMR12a needs to produce either
phenazines 167, or CLPs 168 and 169 to exert its biocontrol activity (Figure 3.16).201,202,347
However, the regulatory mechanisms controlling CLP-production and the possible influence of
QS are far from being understood in this promising biocontrol strain.
Pseudomonas sp. CMR12a produces two types of CLPs: orfamides and sessilins (Figure 3.16).
Orfamides B, D and E (168a–c) are produced in similar amounts and consist of a peptide
containing 10 amino acids coupled to a β-hydroxytetradecanoyl, β-hydroxydodecanoyl or β-
hydroxytetradecenoyl fatty acid tail. Sessilins are made up out of an 18 amino acid peptide core,
linked to a β-hydroxyoctanoyl fatty acid moiety and differ only one amino acid from the toxic
tolaasins, produced by mushroom pathogen P. tolaasii. Sessilin A (169a) is the main compound
produced, but sessilin B and C are detected in minor amounts as well.350 The two types of CLP
seem to fulfill a different role: whereas orfamide is indispensable for swarming, sessilin seems
to oppose swarming and stimulate biofilm formation.117,350
Quorum sensing (QS) regulates different bacterial phenotypes such as swarming, virulence
expression, biofilm formation, bioluminescence, etc. in a population density-dependent man-
ner (see Literature overview).2,3 Strain Pseudomonas sp. CMR12a possesses two QS systems,
both controlled by the GacS/GacA two-component regulatory system. The first, designated
PhzI/PhzR, uses N-(3-hydroxyhexanoyl)-L-homoserine lactone (HO6) 2c, N-hexanoyl-L-homo-
serine lactone (C6) 1c, N-(3-hydroxyoctanoyl)-L-homoserine lactone (HO8) 2e and N-octanoyl-
L-homoserine lactone (C8) 1e as signal molecules (Figure 3.16) and regulates phenazine pro-
duction. The second system, CmrI/CmrR, uses the uncommon N-(3-hydroxydodecanoyl)-L-
homoserine lactone (HO12) 2i but its function is yet unknown.361
The production of CLPs is subjected to complex regulatory circuits. The GacS/GacA two-
component system is often a crucial element (see Literature overview).153–156,158,159 The biosyn-
thesis gene clusters of sessilin and orfamide of Pseudomonas sp. CMR12a were only recently
fully characterized (Figure 3.24).362 As in many other NRPS genes, LuxR-type regulators are
present in the flanking regions.114,162 Whereas LuxR-type regulators OfaR1 and OfaR2 control
both sessilin and orfamide production in Pseudomonas sp. CMR12a, no apparent function was
found for SesR.362
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Figure 3.24. Schematic representation of A) sessilin and B) orfamide gene clusters of Pseudomonas sp. CMR12a.
SesR, OfaR1 and OfaR2: LuxR-type transcriptional regulators. SesT: NodT-like outer membrane lipoprotein.
SesD: SyrD-like ABC transporter protein. MacA: periplasmatic membrane protein. MacB: inner membrane pro-
tein. Figure from Olorunleke et al.362
In only a limited number of cases AHLs play an important regulating role in CLP production
(see Literature overview).21–25,126,167,363 However, previous research hinted the involvement of
QS in the CLP production of Pseudomonas sp. CMR12a. The aim of this study was therefore
to obtain a better understanding of the complex regulation of CLP-production in the promising
biocontrol strain Pseudomonas sp. CMR12a.
3.4.2 Recycling of the fatty acid tail of HO-AHLs into CLPs
It is an intriguing observation that Pseudomonas sp. CMR12a uses only a limited number of
different β-hydroxy fatty acid moieties for its secondary metabolite production. Whereas one
of the AHLs of the PhzI/PhzR QS system, HO8 2e, shares the same fatty acid moiety with
sessilin A (169a), this overlap is also present between orfamide D (168b) and the AHL HO12
2i used by the CmrI/CmrR system. Therefore, a first goal of this study was to investigate if
the fatty acid tails of AHLs are recycled into the CLPs. This hypothesis was based on several
observations. First, it is known that several pseudomonads contain an AHL-acylase, enabling
them to metabolize AHLs and use the acyl chain.5,52,53 Second, when decanoic acid is added to
the fermentation medium of Streptomyces roseosporus, this fatty acid is incorporated, leading
to the production of daptomycin (12) instead of the natural analogues with a branched fatty
acid side chain.125 This experimental result shows the possibility to influence the fatty acid
incorporation of the NRPS. Third, in previous research it was observed that a sessilin mutant
of Pseudomonas sp. CMR12a displayed a remarkably higher phenazine production than the
wild type.201 Phenazine production is influenced by the QS signal HO8 2e. As sessilin has
the same β-hydroxyoctanoyl fatty acid side chain, abolishment of sessilin production could
give rise to a higher HO8 2e concentration and hence more phenazine production. Finally, as
long-chain AHLs rely on active transport to be secreted,33 these compounds can accumulate in
starving cells. Pseudomonas sp. CMR12a produces such a long-chain AHL, HO12 2i. Using
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this β-hydroxydodecanoyl chain from this AHL 2i to produce orfamide D (168b), which has
the same β-hydroxy fatty acid chain, could enable Pseudomonas sp. CMR12a to start swarming
and escape the nutrient-depleted environment. As orfamide and sessilin production only starts
in the late exponential phase,362 AHLs are expected to be present in abundant concentrations.
To evaluate the effect of QS on the swarming behavior, three AHLs with a different chain
length were synthesized (see section 3.1) and added to the wild type and to two QS mutants
(for a list of mutants used in this study, see Experimental part, section 5.5).225 The first mutant,
∆phzI∆cmrI, lacks active LuxI-analogues and therefore displays no AHL-production at all. The
other mutant, ∆phzR∆cmrR, has no active LuxR-type proteins and as a consequence is unable
to detect AHLs. One of the added compounds was a native AHL of PhzI, HO8 2e. This AHL is
the major AHL produced by this strain. The production of the CLP viscosin by P. fluorescens
5064 is regulated via this QS signal molecule HO8 2e as well.21 The other two added AHLs had
an acyl chain containing one carbon atom less (HO7 2d) or more (HO9 2f). These unnatural
AHLs were tested to monitor the specificity of the LuxR-analogue.
The typical swarming phenotype observed for the wild type consisted of the formation of a thick
central structure with swarming at the edges (Figure 3.25). This type of swarming was present
without the addition of AHLs and with addition of HO7 2d and HO8 2e. The ∆phzR∆cmrR-
mutant covered the entire plate in all conditions tested. As this mutant does not possess active
LuxR-type proteins it cannot respond to the added AHL molecules. Interestingly, a distinct
difference was observed after addition of HO7 2d and HO8 2e to the ∆phzI∆cmrI-mutant.
While in the absence of AHLs, swarming similar to the ∆phzR∆cmrR-mutant was observed,
the addition of 10 µM HO7 2d or HO8 2e halted the swarming, and a similar phenotype as
the wild type was observed. The application of HO9 2f on the other hand was unable to stop
swarming, and caused a full coverage of the plates, as observed for the other strains. This type
of AHL-controlled behavior seems to suggest that an activated LuxR-type protein can act as a
brake for swarming.
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Figure 3.25. Observed swarming behavior of Pseudomonas sp. CMR12a and its QS mutants on 0.6% LB agar with
and without the exogenously added AHLs HO7 2d, HO8 2e and HO9 2f. Cell density of inoculum: 105 CFU/mL.
Pictures taken after 41 h of incubation at 28 ◦C.
As sessilin, the CLP linked with biofilm formation and swarming inhibition, also contains the
same β-hydroxyoctanoyl fatty acid moiety, it is tempting to speculate that at least a part of the
HO8 AHLs 2e is recycled for the biosynthesis of sessilin. However, analysis of the produced
CLPs after addition of HO7 2d to the ∆phzI∆cmrI-mutant, did not reveal the presence of a
sessilin analogue with a β-hydroxyheptanoyl fatty acid tail. This experiment was also repeated
with isotope-labelled HO8 77a (see section 3.1.4),364 but once again no recycling of the la-
belled fatty acid part into sessilin could be observed. Scraping off the cells and quantification
of the produced CLPs after extraction did not reveal an increase in sessilin after the addition of
HO8 2e. Unexpectedly, the amount of orfamide did increase (Figure 3.26). These results led to
abandoning the recyclation hypothesis. The origin of the β-hydroxy fatty acid side chain could
be sought in the poly-β-hydroxyalkanoates (PHA), which are typically composed of β-hydroxy
fatty acids with 4 to 12 carbon atoms and which are accumulated in several pseudomonads.365
Alternatively, the β-hydroxy fatty acid tail could also originate from the primary metabolism.117
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Figure 3.26. Sessilin and orfamide levels of the Pseudomonas sp. CMR12a ∆phzI∆cmrI-mutant, without and
with the addition of 10 µM of HO8 2e. Cell density of inoculum: 105 CFU/mL. Cultures were inoculated on 0.6%
LB agar plates and after 41 h of incubation at 28 ◦C, all cells were scraped off and ultrasonicated. Represented
values are the mean of three repetitions. Bars with a different letter are statistically different according to a two
sample t-test (p = 0.05).
The fact that the shorter-chain AHLs HO7 2d and HO8 2e, unlike the slightly longer HO9 2f,
had a clear phenotypic effect, suggests mainly involvement of the PhzI/PhzR operon, which
produces and detects the shorter-chain AHLs HO6 2c, HO8 2e, C6 1c and C8 1e. To evaluate if
the PhzI/PhzR QS system was activated differently by the applied HO-AHLs 2d–f, phenazine
production which is controlled by the PhzI/PhzR operon,18,366 was monitored spectrophotomet-
rically after the addition of the AHLs (Figure 3.27). As expected, phenazine production was
observed in all cases for the wild type. Because of the absence of active LuxR-type proteins
in the ∆phzR∆cmrR-mutant, no phenazine production was observed in all conditions evalu-
ated for this mutant. For the ∆phzI∆cmrI-mutant on the other hand, the absence of phenazine
production could be restored to wild type levels by the addition of HO7 2d or HO8 2e. The
longer-chain analogue HO9 2f failed to evoke phenazine production. As the CmrI/CmrR sys-
tem does not lead to a distinct phenotype upon (de)activation,361 it was not possible to perform
a similar assay to evaluate the activation of this QS operon by the different AHLs.
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Figure 3.27. Observed phenazine production of Pseudomonas sp. CMR12a and its QS mutants ∆phzI∆cmrI
and ∆phzR∆cmrR with and without the exogenously added AHLs HO7 2d, HO8 2e and HO9 2f after 24 h of
incubation on a shaker at 28 ◦C. Represented values are the mean of two repetitions. Bars with a different letter
are statistically different according to Tukey’s post-hoc test (p = 0.05).
3.4.3 Effect of HO8 on the swarming phenotype of Pseudomonas sp. CMR12a and its QS
mutants
To further assess the effect of HO8 2e and the role of the two different QS systems, the swarm-
ing assay was repeated with the wild type, the ∆phzR∆cmrR-mutant (unable to detect AHLs),
the ∆phzI∆cmrIR-mutant (with only phzR active) and the ∆phzIR∆cmrI-mutant (with only
cmrR active) (Figure 3.28). One striking observation is the difference in colony morphology
between the ∆phzR∆cmrR-mutant (without active LuxR-analogues) and the other strains with
at least one active LuxR-analogue. Whereas the latter strains formed a central sun-like structure
and started swarming via the edges, the ∆phzR∆cmrR-mutant immediately started to swarm
in a disorganized manner. For the wild type and the ∆phzI∆cmrIR-mutant, the addition of
HO8 2e intensified the formation of the central structure. Elevated amounts of HO8 2e de-
layed the swarming out of the edges. The central, sun-shaped structure was also present in the
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∆phzIR∆cmrI-mutant albeit less pronounced. The influence of the addition of HO8 2e seemed
to be negligible as well.
Figure 3.28. Observed swarming behavior of Pseudomonas sp. CMR12a and its QS mutants on 0.6% LB agar
with and without exogenously added HO8 2e. Cell density of inoculum: 105 CFU/mL. Pictures taken after 41 h of
incubation at 28 ◦C.
As for a given strain, several distinct swarming patterns were observed varying from one assay
to the other, the influence of the number of viable bacterial cells was evaluated by performing
a swarming assay employing an inoculum with a different cell density (Figure 3.29). At high
cell densities, swarming behavior was observed for all strains tested. However, both the wildtype
and the ∆cmrIR-mutant showed only limited swarming behavior at an inoculum of less than 107
CFU/mL, but deletion of the PhzI/PhzR-operon (mutants ∆phzIR and ∆phzIR∆cmrIR) led to
a swarming phenotype, even at low starting cell densities. These results stress the importance
of the PhzI/PhzR-operon for controlling the swarming behavior and show that cell density can
play a crucial role. Alternatively, different factors could also play a role. Swarming is flagellum-
dependent and typically strictly regulated. On the other hand, the presence of CLPs could also
give rise to flagellum-independent sliding by wetting the surface. These two types of motility
might be impacted differently by QS, hence complicating the interpretation of these swarming
assays.
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Figure 3.29. Observed swarming behavior of Pseudomonas sp. CMR12a and its QS mutants on 0.6% LB agar
starting from an inoculum with a different cell density. Pictures taken after 41 h of incubation at 28 ◦C.
3.4.4 Possible QS-regulated secretion of CLPs
CLPs are secreted by ABC transporters. These are similar to the macrolide efflux transporter
MacA-MacB-TolC found in E. coli. The corresponding MacA-MacB genes are found down-
stream of the orfamide and sessilin biosynthetic genes (Figure 3.24). SesT is annotated as a
NodT family efflux transporter. As the orfamide gene cluster is not preceded by a NodT family
efflux transporter it was previously hypothesized that the MacA-MacB transporters of sessilin
and orfamide both use the same outer membrane efflux transporter upstream of the sessilin
biosynthetic cluster.350,362
To evaluate if QS could stimulate the secretion of CLPs via the activation of an alternative
efflux transporter, the different native AHLs of Pseudomonas sp. CMR12a were added to a
NodT2-mutant. This mutant lacks an active NodT2-transport protein and as a consequence fails
to secrete sessilin efficiently. The cytotoxic properties of this CLP cause a significant growth
impairment. However, no significant increase in growth, measured as optical density (OD),
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was observed after the addition of the AHLs to the strains in liquid LB medium (Figure 3.30).
Compared to the wild type, no growth differences were observed for the ∆phzI∆cmrI-mutant
(Figure 3.30).
Figure 3.30. Optical densities observed for Pseudomonas sp. CMR12a wt. and its mutants NodT2 and
∆phzI∆cmrI with and without added AHLs HO6 2c, HO8 2e and HO12 2i. Cultures were inoculated (inocu-
lum: 104 CFU/mL) in liquid LB medium and incubated for 24 h on a shaker at 28 ◦C. Represented values are the
mean of three repetitions. Bars with a different letter are statistically different according to Tukey’s post-hoc test
(p = 0.05).
3.4.5 Quantification of CLPs
To enhance the standardization and quantification of the CLP production, it was decided to con-
tinue using liquid medium instead of agar plates. Via this approach it was possible to compare
the CLP production between different strains with or without the addition of AHLs in a quantita-
tive way via HPLC analysis. However, CLP production also strongly depends on the incubation
conditions, for example in agitated cultures Pseudomonas sp. CMR12a produces more biomass
but the cells remain planktonic and have strongly reduced intracellular sessilin levels compared
to still cultures in the same medium.350,362 Therefore, a comparison of results obtained on agar
plates with those obtained in still, liquid cultures should always be made with great caution. Im-
portantly, insufficient amounts of pure sessilin have been isolated to develop a calibration curve
to convert chromatographic peak areas to molar concentrations. As several factors influence the
detection of a compound, a larger peak area on a chromatogram for a certain compound does
not necessarily corresponds to a higher concentration of that compound compared to another
compound. Therefore, the data represented below can only be used for relative comparisons
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between the different strains.
To evaluate the effect of the two different QS systems, mutants lacking either the PhzI/PhzR
(∆phzIR) or the CmrI/CmrR (∆cmrIR) QS system were employed. There were no differences
in growth observed between the different strains under study, except a slower initial growth for
the ∆phzIR-mutant (data not shown). Orfamide and sessilin are coproduced starting in the late
exponential phase.362 One important observation was that the relative extracellular orfamide
concentration was tenfold lower than the relative sessilin concentration (Figure 3.31). On the
other hand, inside the cells orfamide was the dominant CLP, indicating a preferential secretion
of the cytotoxic sessilin. The amount of sessilin secreted by the ∆phzIR-mutant was slightly
lower than the wild type and this reduction was also visible inside the bacterial cells. This slight
reduction of intracellular sessilin levels was also observed in the ∆cmrIR-mutant, but was less
clear extracellular (Figure 3.31). For orfamide, a significantly reduced production was observed
for the ∆phzIR-mutant (Figure 3.31). The intracellular orfamide concentration was on average
two times higher in the wild type, and the extracellular concentration seven times higher. The
fact that the extracellular concentration is more strongly reduced than the intracellular concen-
tration points to a certain intracellular accumulation. However, as the intracellular concentration
was significantly reduced as well, it is clear that rather the orfamide production than the secre-
tion is affected. This trend was not observed for the ∆cmrIR-mutant.
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Figure 3.31. Observed CLP levels in Pseudomonas sp. CMR12a and its QS mutants in LB-medium under still
growth conditions at 28 ◦C. Cell density of inoculum: 105 CFU/mL. A) Intracellular sessilin. B) Extracellular
sessilin. C) Intracellular orfamide. D) Extracellular orfamide. Data expressed as the peak area of total extracted
ions of the LC-MS spectrum and corrected for cell density (measured as OD620). Represented values are the mean
of three repetitions. Bars with a different letter are statistically different according to Tukey’s post-hoc test (p =
0.05).
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As a confirmation, this assay was repeated with the wild type and the ∆phzIR-mutant, and the
∆phzI-mutant was included as well (Figure 3.32). This mutant does not contain active PhzI-
proteins, and as a consequence cannot produce C6 1c, C8 1e, HO6 2c and HO8 2e. The PhzR-
proteins on the other hand are present so this strain can respond to added AHLs. Therefore is it
possible to complement this ∆phzI-mutant with HO8 2e to assess the effect of this QS signal
molecule. Once again the ∆phzIR-mutant had significantly reduced orfamide levels, both intra-
and extracellularly. The orfamide levels for the ∆phzI-mutant are lower than the wild type
but higher than the ∆phzIR-mutant. This increased production level compared to the ∆phzIR-
mutant suggests a residual effect of the present PhzR-proteins, possibly by binding with AHLs
produced by the CmrI/CmrR-operon. Alternatively, the PhzR proteins could also act AHL-
independently. As in the case of the PcoI/PcoR QS operon of P. corrugata, where the absence
of AHLs causes the PcoR-protein to act as an activator of different virulence genes, while in the
presence of AHLs, this activation goes via co-transcription of rfiA.24
Interestingly, the reduction in orfamide could be fully restored to wild type levels via the ad-
dition of 10 µM of the native AHL HO8 2e (Figure 3.32). This clearly indicates an important
regulatory effect of this QS signal molecule. In previous research, it was shown that a mutation
in LuxR-type regulator genes ofaR1 or ofaR2 led to a weaker transcript of the genes sesABC,
MacA1B1, and ofaBC. On the other hand, the transcription of ofaA and macA2B2 was only
marginally affected.362 Therefore, another promoter which enables transcription of ofaA and
macA2B2 might form a target of the QS regulation of the orfamide production. The reactivation
of the Phz-operon upon addition of HO8 AHL 2e was also obvious by the reappearance of the
yellow-colored phenazines in the cell pellet obtained after centrifugation of the culture broth
(Figure 3.33), which can be used as a quick visual check to evaluate if the PhzI/PhzR-operon is
active.
The fact that orfamide production and not sessilin production can be influenced by the addition
of HO8 2e, confirms the analysis of the swarming assay on the agar plates where an increase
of orfamide was observed but not of sessilin (see section 3.4.2). As orfamide is associated
with swarming and sessilin inhibits swarming and stimulates biofilm formation,350 these results
seem to contradict the observed swarming behavior on agar plates, where the addition of HO8
2e seemed to oppose swarming (Figure 3.25 and 3.28).
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Figure 3.32. Observed CLP levels in Pseudomonas sp. CMR12a and its QS mutants in LB-medium under still
growth conditions at 28 ◦C. Cell density of inoculum: 105 CFU/mL. A) Intracellular sessilin. B) Extracellular
sessilin. C) Intracellular orfamide. D) Extracellular orfamide. Data expressed as the peak area of total extracted
ions of the LC-MS spectrum and corrected for cell density (measured as OD620). Represented values are the mean
of three repetitions. Bars with a different letter are statistically different according to Tukey’s post-hoc test (p =
0.05).
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Figure 3.33. Cell pellet obtained after 24 h incubation in LB medium under still growth conditions at 28 ◦C,
followed by centrifugation and removal of the supernatant. Cell density of inoculum: 105 CFU/mL. From left to
right: 12a wt., ∆phzIR-mutant, ∆phzI-mutant, ∆phzI-mutant + 10 µM HO8 2e.
In a subsequent assay the ∆phzR∆cmrR-mutant was included, lacking any active LuxR-type
proteins, and 10 µM HO8 2e was added to all the strains under investigation. Surprisingly, a
small reduction in orfamide production was observed for the wild type when HO8 2e was added,
perhaps by disturbing the normal regulatory circuit due to the addition of the AHL (Figure
3.34). As expected, the exogenously added HO8 2e failed to increase the orfamide production
in the ∆phzIR-mutant, because of the absence of the corresponding PhzR receptor proteins.
Therefore it can be concluded that the added HO8 2e should interact with the PhzR receptor
and not any alternative receptor to influence orfamide production. The ∆phzR∆cmrR-mutant
showed a reduced production of orfamide similar to the ∆phzIR-mutant after 24 h although
after 41 h near wild type levels were observed (Figure 3.34). As this strain displays a slower
growth, it could be that its orfamide production peaks at a different time as compared to the
wild type.
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Figure 3.34. Observed CLP levels in Pseudomonas sp. CMR12a and its QS mutants in LB-medium under still
growth conditions at 28 ◦C. Cell density of inoculum: 105 CFU/mL. A) Intracellular orfamide. B) Extracellular
orfamide. Data expressed as the peak area of total extracted ions of the LC-MS spectrum and corrected for cell
density (measured as OD620). Represented values are the mean of three repetitions. Bars with a different letter are
statistically different according to Tukey’s post-hoc test (p = 0.05).
For the sessilin production no clear effect of the addition of 10 µM HO8 2e could be observed in
any strain (Figure 3.34). The ∆phzR∆cmrR-mutant however showed a distinct higher sessilin
production than the wild type and the other QS mutants. The cause of this increase is not clear
yet. Although sessilin is linked with biofilm formation, these results indicate that a higher ses-
silin versus orfamide ratio might shift the bacterial motility toward swarming in an unstructured
manner as observed in the ∆phzR∆cmrR-mutant (Figure 3.35) and stimulation of orfamide
production via the addition of HO8 2e to the ∆phzI-mutant might cause the formation of the
central round structure and swarming from the edges.
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Figure 3.35. Left: typical swarming phenotype observed on 0.6% LB agar with an active Phz-operon. Right:
typical swarming phenotype observed on 0.6% LB agar with an inactive Phz-operon. Cell density of inoculum:
105 CFU/mL. Pictures taken after 41 h of incubation at 28 ◦C.
3.4.6 Interaction orfamide-sessilin
It is known that different CLPs can interact with each other. One well-described example is the
white line-inducing principle (WLIP), which causes the production of a white precipitate when
confronted with a CLP of the tolaasin group.114 The same reaction has also been observed for
sessilin and orfamide: when they are both secreted they interact to form a white precipitate.350
As a sessilin mutant shows a clear swarming behavior, and as an orfamide mutant is unable to
swarm it was believed that orfamide is required for swarming and sessilin opposes swarming.350
Therefore, sessilin can hinder swarming by co-precipitating with orfamide. In the Pseudomonas
sp. CMR12a wt. only sessilin is secreted in high amounts and orfamide is retained close to or
inside the bacterial cells, avoiding such a precipitation reaction under normal circumstances.
Alternatively, sessilin can also block orfamide secretion as they both rely on the same outer
membrane protein, SesT, to be secreted.362
However, in this study it was observed that a decrease in orfamide production, as is the case for
mutants lacking an active Phz-operon, stimulates swarming. A restoration of orfamide produc-
tion to wild type level, for example by the addition of HO8 2e, halted swarming (Figure 3.25
and 3.28). It was therefore hypothesized that both sessilin and orfamide can be responsible for
swarming and that the interaction between those two CLPs determines the final phenotype. Or-
famide alone is sufficient to swarm but sessilin requires a minimal amount of orfamide to evoke
swarming. The reason for this dependence of sessilin on orfamide to swarm is yet unknown.
When sessilin is the major CLP present and orfamide only as a minor component, sessilin is the
putative causal agent of the swarming. This swarming has a rather unstructured appearance (for
example figure 3.28, strain ∆phzR∆cmrR). Remarkably, the amount of extracellular sessilin
significantly increases in time, whereas the amount of extracellular orfamide peaks and then
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decreases. This increase of the sessilin/orfamide ratio could shift the cells to swarming when
nutrients are exhausted. When besides sessilin, also an increased amount of orfamide is present,
they might impede each other’s swarming inducing activity and it is hypothesized that then the
characteristic sun-shaped structure is formed and no swarming is observed (Figure 3.28, strain
∆phzI∆cmrIR + HO8 2e). When only orfamide is present, as is the case in a sessilin mutant,
orfamide is the driving force for the swarming phenotype.
To confirm this hypothesis, a strain that secretes orfamide in the culture medium and a strain
that has a high sessilin to orfamide ratio and secretes sessilin in the culture medium were mixed.
Sessilin mutant ∆CLP1 does not produce sessilin and releases orfamide in the medium. This
strain shows a strong swarming phenotype.350 Mutant ∆PhzIR has a strongly reduced orfamide
production but produces sessilin at wild type levels (Figure 3.31, 3.32 and 3.34). This strain also
has a strong swarming behavior. When cultured separately both ∆CLP1 and ∆PhzIR display
a swarming phenotype (Figure 3.36). ∆CLP1 swarms due to the high levels of extracellular
orfamide, whereas ∆PhzIR relies on sessilin for swarming. When cultured together, resulting
in high levels of both sessilin and orfamide in the extracellular environment which then interact,
a more sessile phenotype is observed (Figure 3.36). However when one of the CLPs takes the
upper hand, as is the case for sessilin in the ∆CLP1:∆PhzIR 1:2 mix, swarming is reactivated.
This effect is less clear for orfamide in the ∆CLP1:∆PhzIR 2:1 mix as sessilin has a stronger
deactivating effect on orfamide. The small difference in swarming phenotype observed between
the co-culture of ∆CLP1 and ∆PhzIR (∆CLP1 + ∆PhzIR) versus the 1:1 mixture of both
strains (∆CLP1-∆PhzIR 1:1) could be explained by a different ratio of both CLPs as both
mutants might have a different growth pattern.
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Figure 3.36. Swarming phenotypes obtained for strains Pseudomonas sp. CMR12a wt., ∆CLP1, ∆PhzIR and
mixtures of these strains on 0.6% LB agar. Cell density of inoculum: 105 CFU/mL. Pictures taken after 21 and
27 h incubation at 28 ◦C. For the ∆CLP1+∆PhzIR treatment, the bacteria were co-cultivated in liquid LB culture
medium and plated as such. For the ∆CLP1-∆PhzIR 1:1, 2:1 and 1:2 swarming plates, separate cultures of both
bacteria were added together in the specified ratio/concentration and then plated. Experiment performed by Dr.
Feyisara Olorunleke (Department of Crop protection, Faculty of Bioscience Engineering, Ghent University).
3.4.7 Conclusions
In this work the influence of a QS signal molecule, HO8 2e, on the swarming behavior of Pseu-
domonas sp. CMR12a was studied. Via studies with several QS-mutants in liquid LB medium,
it was shown that this QS signal could stimulate orfamide production via activation of the
PhzI/PhzR-operon. Orfamide is associated with a swarming phenotype. However, in swarm-
ing assays on agar plates, a more sessile phenotype was observed after application of this QS
signal 2e. It is therefore hypothesized that the other CLP sessilin, which was associated with
biofilm formation and the inhibition of swarming, also plays a role in swarming and that the
final phenotype depends on the ratio of both CLPs. It is believed that QS can fine-tune the ratio
of the two produced CLPs, orfamide and sessilin, via the control of orfamide production (Fig-
ure 3.37). The swarming pattern of Pseudomonas sp. CMR12a is hypothesized to proceed as
follows. At first, when only sessilin is secreted no swarming is observed and the colony is es-
tablished via the formation of a biofilm. Subsequently, a minute amount of orfamide is secreted,
causing a swarming phenotype which expands the colony size. When the quorum and thus the
concentration of HO8 2e increases, orfamide production goes up and swarming is inhibited.
When the orfamide production starts to decrease, and as a consequence the sessilin/orfamide
ratio increases, a switch to swarming behavior is made once more to anticipate nutrient deple-
tion.
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Figure 3.37. Hypothetical influence of different extracellular orfamide and sessilin ratios on the swarming behavior
of Pseudomonas sp. CMR12a.
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Chapter 4
Perspectives
The deuterated fatty acids 64, 73 and 75 (Figure 4.1), which were synthesized in the first part of
this PhD research in good yields, or more generally the application of the developed method-
ology allowing the design and synthesis of tailor-made deuterated fatty acids, can be used as a
powerful tool to elucidate the biosynthetic origin of several metabolites containing a fatty acid
tail by feeding these compounds to bacterial cultures and evaluating if the isotope-label appears
in the compound of interest. Besides their application as internal standard in isotope-dilution
mass spectrometry to quantify AHLs, the isotope-labelled AHLs 65, 77, 78 and 79 and AHL-
degradation products 80 and 81 (Figure 4.1) can be employed to study the metabolization (and
perhaps recyclation) of the AHL acyl chain.
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Figure 4.1. General structure (R = alkyl chain) of the synthesized deuterated fatty acids 64, 73, and 75, AHLs 65,
77, 78 and 79 and AHL-degradation products 80 and 81.
In the second part, the spontaneous rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones
2 toward 1,4-oxazepane-2,5-diones 82 was excluded because of the absence of the correct con-
formation for cyclization to proceed. However, it was shown that the introduction of a third
substituent at the amide nitrogen atom gave rise to an elevated amount of the amide in the
cis-conformation, allowing cyclization. Therefore, it could be of interest to synthesize N-(3-
hydroxyacyl)-L-homoserine lactones with a third substituent at nitrogen (e.g. PMB for 173) and
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to re-evaluate the cyclization. These compounds could be accessed via a reductive amination of
L-homoserine lactone hydrobromide 53, followed by the developed coupling protocol with a β-
hydroxy fatty acid 58 (Scheme 4.1). As no such N-protected N-(3-hydroxyacyl)-L-homoserine
lactones have been reported yet, it would also be interesting to evaluate their bioactivity, al-
though the introduction of a bulky substituent often leads to a loss of QS activity.
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Scheme 4.1. Proposed synthetic route toward N-PMB-protected N-(3-hydroxyacyl)-L-homoserine lactones 173,
followed by a heat- or acid-induced rearrangement to 1,4-oxazepane-2,5-dione 174.
As no synthetic route toward the 1,4-oxazepane-2,5-diones 175 existed, the biological activities
of this class compounds has not been studied yet. A first interesting area to test these seven-
membered ring structures 175 is as QS modulators. Several AHL-analogues with an alteration of
the lactone ring have been tested, with differing activities (Figure 4.2).12 Some AHL-analogues
mimic the AHL-structure very closely, whereas others only show distant (or no) similarities.
Typically, modifications of the AHL lactone ring are tolerated but result in compounds with
a reduced QS activity. The retainment of hydrogen bond acceptors seems to be important.13
The 1,4-oxazepane-2,5-diones 175 would not be susceptible to degradation by specific AHL-
degrading enzymes. However, these compounds 175 can be broken down by abiotic degradation
as they still contain the lactone moiety.
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Figure 4.2. A small selection of QS modulators 176-180 with an alteration of the lactone ring,12 and the general
structure of the synthesized 1,4-oxazepane-2,5-diones 175.
Small cyclic peptides have interesting biological properties and are a promising class of drug
candidates.367 The comparison of the seven-membered bislactams with the 1,4-oxazepane-2,5-
dione-analogues 175, which have one lactam and one lactone bond instead of two lactam bonds,
could therefore help developing interesting structure-activity relationships. One important as-
pect of cyclic peptides is their resistance toward enzymatic degradation. It is expected that
1,4-oxazepane-2,5-dione-analogues 175 also possess this resistance as the enzyme-catalyzed
hydrolytic breakdown of peptides usually starts at the C- or N-terminus. The 1,4-oxazepane-
2,5-dione-analogues 175 contain a lactone moiety, so these compounds are sensitive to alkaline
hydrolysis. These compounds 175 could therefore be used to study the temporary activation of
a target receptor.
Also bicyclic structures 98 (Scheme 3.20) and 160a–c (Scheme 3.33) could be interesting scaf-
folds to test for bioactivity. For example, bicyclic compounds 181 and 182 (Figure 4.3) can bind
to X-linked inhibitors of apoptosis proteins (XIAPs), which are central regulators of both death-
receptor-mediated and mitochondria-mediated apoptosis pathways and have potential applica-
tion in cancer treatment.368 Also analogues 183 and 184 (Figure 4.3) are able to inhibit human
immunodeficiency virus type-1 integrase (HIV-1 IN), albeit with relatively low potency.258,369
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Figure 4.3. Bioactive bicyclic compounds 181, 182, 183 and 184.258,368
As mentioned before, the lability of the lactone moiety might seem a disadvantage at first, but
can be used to temporarily influence certain receptors without the risk of accumulation of the
cyclic compound. A second distinct advantage is that the cyclization renders the compound neu-
tral by masking the carboxylic acid unit, allowing a better membrane permeability whereafter
hydrolysis releases the charged N-(3-hydroxyacyl)amino acid derivative. As a lot of interest
exists in N-acyl amino acids, for example as biosurfactants or feed additives, the cyclic ana-
logues could be used to temporary inactivate these N-(3-hydroxyacyl)amino acids, followed by
a release after hydrolysis. However for such application, a stability study of the synthesized
1,4-oxazepane-2,5-diones 175 at different pH-ranges is required.
During the hydrogenolytic deprotection of serratin precursor 160a, it was observed that only
the (RSS)-diastereomer got deprotected (Table 3.13). Because of this selectivity, the maximum
yield that can be obtained after the deprotection step when starting from oxazolidine-containing
bicyclic structure 160a with a d.r. of 1:1 is 50% of compound 83, combined with the recovery
of the unreacted (RRS)-isomer of 160a. Therefore, to ameliorate this yield, the (S)-enantiomer
of β-hydroxynonanoic acid 58d should be used for the synthesis to obtain only (RSS)-160a.
Several methods have been described for the enantioselective synthesis of β-hydroxy fatty acids.
Typically, the corresponding β-keto methyl esters 185 are stereoselectively reduced via the use
of a chiral catalyst (Scheme 4.2).370–372
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Scheme 4.2. Stereoselective reduction of β-keto esters 185 to β-hydroxy esters 186, followed by a hydrolysis step
to yield enantiomerically pure β-hydroxy fatty acids 58.
To enantioselectively synthesize the (RRS)-isomer of 160a, for example for biotesting or to fur-
ther evaluate deprotection conditions for this compound, the (R)-enantiomer of β-hydroxynona-
noic acid 58d is required. This (R)-enantiomer of β-hydroxynonanoic acid 58d could also be
obtained from castor oil (Figure 4.4). Because of the presence of ricin, a water-soluble toxin,
castor oil is inedible. Because of its unique, high ricinoleic acid (187) level (up to 90% of the
fatty acid content in castor oil), it has received a lot of attention from the chemical industry.373,374
Figure 4.4. Mature castor oil plant (Ricinus communis) (left) and the oil-containing castor beans (right). Image
source: www.arkive.org/castor-oil-plant/ricinus-communis/.
Ricinoleic acid (187) can be transformed into (R)-3-hydroxynonanoic acid 58d via ozonoly-
sis,375 or via reaction with hydrogen peroxide over a tungsten catalyst (Scheme 4.3).376,377
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Scheme 4.3. Proposed application of castor oil-derived (R)-3-hydroxynonanoic acid 58d for the enantioselective
synthesis of (RRS)-160a.
During the search for a suitable N-protecting group to force the linear precursors in the correct
conformation for cyclization to proceed, 2-methoxy-6-nitrobenzyl was evaluated. Although un-
successful for the synthesis of the desired 1,4-oxazepane-2,5-dione, this photoremovable group
was used for the synthesis of photolabile AHL 154a. The photolysis was complete within 2 h in
1% ethanol in water. However, to allow the application of this compound in biological experi-
ments, the harmfulness of the UV-radiation (360 nm) on the microorganisms should be studied.
Alternatively, the possibility of two-photon excitation could be evaluated, as this process can
proceed with red or NIR light (720 nm), but this requires high light intensities.
During biotesting, no direct effect of the QS signal HO12 2i on the growth of lettuce and A.
thaliana was observed. However, to fully understand the role of HO12 2i in the biocontrol
activity of Pseudomonas sp. CMR12a, the effect of this compound in pathogen contact studies
should be evaluated as it might lead to induced systemic resistance of the plants. For tetramic
acid 11a, a degradation product of oxo-AHL 3i, no negative effects on the growth of A. thaliana
were observed a well. However, this lack of growth inhibiting effect could be an advantage as
this compound has known algicidal properties. In a preliminary screening, an antifungal effect
against the pathogenic fungus Rhizoctonia solania was observed. To fully grasp the antifungal
potential of this tetramic acid, several concentrations should be tested and the effect on several
fungal pathogens should be evaluated. Because of the algicidal and antifungal effects, it was
suggested that this compound could be used in hydroponics. To test this hypothesis, such an
experimental hydroponics set-up should be developed and the effect of tetramic acid 11a on
several plants with and without the addition of algae and fungi should be assessed.
In this thesis, the effect of QS signal molecule HO8 2e on the swarming behavior of promis-
ing biocontrol strain Pseudomonas sp. CMR12a was clarified. The hypothesis that the fatty
acid tail of this QS signal might be reused for the synthesis of CLPs was refuted. However, it
could be interesting to add labelled β-hydroxy fatty acids 75 to evaluate if these compounds
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get incorporated in the CLPs. One could also add β-hydroxy fatty acids with a slightly differ-
ent chain length or substitution pattern in an attempt to obtain several CLP-analogues with a
modified fatty acid tail. Our results led to the hypothesis that HO8 2e controls the swarming
by stimulating the orfamide production and hence controlling the sessilin/orfamide ratio. The
typical course of the extracellular orfamide and sessilin levels in liquid LB medium is repre-
sented in figure 4.5. The orfamide level peaks at the beginning of the stationary phase and then
drops whereas the extracellular sessilin levels keep increasing. Based on the CLP-quantification
in liquid medium and comparison with swarming phenotypes on agar plates, a hypothesis for
the typical course of the swarming was developed. However, orfamide and sessilin levels were
quantified in only a limited number of swarming plates. To confirm the proposed effect of the
ratio of these CLPs on the swarming behavior, CLP quantification on swarming plates is re-
quired, preferably at different stages of the swarming. It would also be interesting to monitor
the HO8 2e concentration to see if it follows a similar pattern as orfamide (Figure 4.5, dashed
line HO8-1). Alternatively, it could be that the amount of HO8 2e keeps increasing (Figure 4.5,
dashed line HO8-2) and that a high concentration of HO8 2e exerts a different effect on the
orfamide production compared to low concentrations.
Figure 4.5. Observed course of extracellular orfamide and sessilin (bars not on scale) and OD620 of Pseudomonas
sp. CMR12a. The dashed lines gives two hypothetical courses (HO8-1 and HO8-2) of the QS signal molecule HO8
2e.
Also the dependence of sessilin on orfamide to cause a swarming behavior rises many ques-
tions. As an orfamide mutant is unable to swarm it was first thought that sessilin only inhibited
swarming. However, the present results have shown that sessilin is mostly the causal agent for
swarming but requires at least some orfamide to exert its effect. This phenomenon could be fur-
ther studied in depth by mixing an orfamide mutant with different concentrations of orfamide
to see at which concentration swarming reappears.
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In this work the focus was on the effect of HO8 2e on swarming as this is the main AHL
produced by this strain. However, it would be interesting to evaluate the effect of the other
produced AHLs. It is expected that the short-chain AHL HO6 2c will display a similar effect as
HO8 2e. This might also be the case for unfunctionalized AHLs C6 1c and C8 1e, although a
drop in activity might be present. The role of longer-chain AHL HO12 2i can only be guessed
for so far, as the role of the second QS operon Cmr which produces this AHL is not clear
yet. In general, a better understanding of the regulation of CLP-production in Pseudomonas sp.
CMR12a could tremendously aid the application of this strain as a biocontrol agent for tropical
regions, either by being able to stimulate metabolite production on desired moments, or by
targeted genetical engineering of this strain.
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Chapter 5
Experimental part
5.1 General methods
Flame-dried glassware was used for all non-aqueous reactions. Commercially available sol-
vents and reagents were purchased from common chemical suppliers and used without further
purification, unless stated otherwise. Sodium borodeuteride (98% D) and D2O (99.9% D) were
purchased form Sigma-Aldrich.
Solvents
Diethyl ether, tetrahydrofuran and toluene were dried by distillation over sodium/ benzophenone
ketyl. Methanol was reacted in the presence of magnesium and iodine, distilled and kept over
molecular sieves. Dichloromethane was distilled from calcium hydride prior to use. Petroleum
ether refers to the 40-60 ◦C boiling fraction. Acetonitrile was kept over molecular sieves at least
24 hours prior to use.
Column chromatography
The purification of the reaction mixtures was performed by column chromatography with sil-
ica gel (Acros, particle size 0.035-0.070 mm, pore diameter ca. 6 nm). Solvent systems were
determined via thin layer chromatography (TLC) on glass plates coated with silica gel (Merck,
Kieselgel 60 F254, precoated 0.25 mm) using standard visualization techniques or agents: UV
fluorescence (254 nm and 366 nm) and coloring with iodine vapors or with potassium perman-
ganate solution.
Liquid chromatography
Liquid chromatography analysis was performed by a reverse phase LC-column (Eclipse plus
C18 column). The LC column has dimensions of 50 x 4.6 mm and has a particle size of 3.5 µm.
Gradient elution was used (30% acetonitrile in water to 100% acetonitrile over 6 minutes).
Gas chromatography mass spectrometry
GC-MS Spectra were recorded on an Agilent HP 6890 series with a DB-5 MS fused-silica
capillary column (30 m; 0.25 mm, film thickness = 0.25 µm) connected to an Agilent HP 5973
series Mass Selective Detector mass spectrometer.
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Mass spectrometry
Low-resolution mass spectra were recorded using a direct inlet system with an Agilent 1100
series LC/MSD type SL with a UV detector and mass spectrometer with electrospray ionisation
geometry (ESI 70 eV) using a Mass Selective Detector (quadrupole). High-resolution mass
spectra were obtained using an Agilent 1100 series HPLC coupled to an Agilent 6210 TOF-
Mass Spectrometer, equipped with ESI/APCI-multimode source.
NMR spectroscopy
1H (300 or 400 MHz) and 13C (75 or 100.6 MHz) NMR spectra were recorded on a Jeol Eclipse
FT 300 NMR spectrometer or a Bruker Avance III Nanobay 400 MHz spectrometer at room
temperature. Peak assignments were obtained with the aid of DEPT, COSY, HSQC and/or
HMBC spectra. The compounds were diluted in deuterated solvents, quoted in parts per million
(ppm) with tetramethylsilane as internal standard.
Infrared spectroscopy
IR spectra were recorded with a Perkin-Elmer Spectrum One FTIR spectrometer with an ATR
(Attenuated Total Reflectance) accessory in neat form.
Melting point
Melting points were measured using a Kofler bench, type WME Heizbank of Wagner & Munz.
X-ray analysis
For the structure of (RSS)-160b, X-ray intensity data were collected at room temperature on
an Agilent Supernova Dual Source (Cu at zero) diffractometer equipped with an Atlas CCD
detector using ω scans and CuKα (λ = 1.54178 Å) radiation. The images were interpreted and
integrated with the program CrysAlisPro.378 Using Olex2,379 the structure was solved by direct
methods using the ShelXS structure solution program and refined by full-matrix least-squares
on F2 using the ShelXL program package.380,381 Non-hydrogen atoms were anisotropically re-
fined and the hydrogen atoms in the riding mode and isotropic temperature factors fixed at 1.2
times U(eq) of the parent atoms (1.5 times for methyl groups).
CCDC 1541166 contains the supplementary crystallographic data for compound (RSS)-160b
and can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or from the
Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44-
1223-336033; or deposit@ccdc.cam.ac.uk).
All X-ray diffraction analyzes were performed in collaboration with Prof. Dr. K. Van Hecke,
XStruct, Department of Inorganic and Physical Chemistry, Ghent University, Belgium.
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5.2 Synthesis of deuterated AHLs
Synthesis of [3-2H]-3-hydroxydodecanoic acid 64
Diethyl carbonate 61 (2.1 equiv, 22 mmol, 2.5 mL) and sodium hydride (60% dispersion in
mineral oil, 3 equiv, 30 mmol, 1.2 g) in 20 mL of dry THF were stirred at reflux under a
nitrogen atmosphere. 2-Undecanone 60 (1 equiv, 10 mmol, 2.1 mL) was added dropwise and
the resulting mixture was stirred at reflux overnight. After cooling down to r.t., the suspension
was poured into a mixture of saturated aq. NH4Cl, 5% aq. HCl and ice. Extraction (three times
50 mL of diethyl ether) and washing of the combined organic phases, followed by drying over
MgSO4 and removal of the solvent in vacuo, afforded 2.3 g of ethyl 3-oxododecanoate 62 (9.4
mmol) as a yellow oil in 94% yield. This crude β-ketoester 62 was used for the next step without
further purification.
To a stirred solution of ethyl 3-oxododecanoate 62 (1 equiv, 8.5 mmol, 2.0 g) in 25 mL of
methanol was added 22 mL of 2M aq. NaOH (5 equiv, 44 mmol, 1.7 g). The resulting mixture
was stirred overnight at room temperature, after which it was extracted with 50 mL of diethyl
ether. The organic phase was discarded and the aqueous phase was acidified to pH 2 by addition
of 2M aq. HCl, and extracted three times with 50 mL of diethyl ether. The combined organic
phases were dried over MgSO4 and the solvent was removed in vacuo. Recrystallization from
hexane afforded 3-oxododecanoic acid 63 as a colorless powder (1.37 g, 6.4 mmol, 75% yield).
Sodium borodeuteride (1.5 equiv, 7.5 mmol, 0.31 g) was added to a solution of 3-oxododecanoic
acid 63 (1 equiv, 5 mmol, 1.1 g) in diethyl ether:methanol 1:1 (10 mL) at 0 ◦C. The ice bath was
removed and the mixture was stirred at room temperature for 2 h. The mixture was diluted with
10 mL of 2M aq. HCl and 10 mL of diethyl ether. After phase separation, the aqueous phase
was extracted twice with 10 mL of diethyl ether. The combined extracts were washed with 20
mL of brine and dried over MgSO4. Filtration and evaporation of the solvent in vacuo yielded
pure [3-2H]-3-hydroxydodecanoic acid 64 (98%, 1.1 g, 4.95 mmol) as a colorless powder.
OH
ODHO
64
[3-2H]-3-Hydroxydodecanoic acid 64 (89% D). 1H NMR (400
MHz, CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz, CH3), 1.20-1.61
(16H, m, (CH2)8CH3), 2.47 (1H, d, J = 16.6 Hz, CHH’COOH),
2.58 (1H, d, J = 16.6 Hz, CHH’COOH), 4.00-4.11 (0.1H, m, CHOH) ppm. 13C NMR (100
MHz, CDCl3): δ = 14.1 (CH3), 22.7, 25.4, 29.3, 29.5, 29.6 (2C), 31.9, 36.3 ((CH2)8CH3),
41.0 (CH2COOH), 67.4-68.3 (m, CDOH), 68.2 (CHOH), 177.8 (COOH) ppm. MS (ESI): m/z
(%): 218 (M+H+, 7), 235 (M+NH+4 , 100). HRMS mass calcd.: C12H22DO
−
3 216.1715; found:
216.1721. IR (cm−1): νmax 913, 1226 (C-O), 1680 (C=O), 2130 (C-D), 2848, 2915, 2953, 3050
(COO-H), 3534 (O-H). Melting point: 72-74 ◦C. Colorless powder. Yield: 98%.
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General procedure for the synthesis of deuterated aldehydes 66a–d
As described by Ariza et al.,231 freshly distilled aldehyde 56c,d,g,h (1 equiv, 13 mmol), 4-
(N,N-dimethylamino)pyridine (0.1 equiv, 1.3 mmol, 0.16 g) and D2O (10 equiv, 130 mmol,
2.3 mL) were added to a septum sealed flask and heated at 100 ◦C for 1 h. Then 20 mL of
dichloromethane and 5 mL of 1M aq. HCl were added. The organic phase was washed with 15
mL of saturated aq. NaHCO3 and 15 mL of brine. Drying over MgSO4, filtration and removal of
the solvent in vacuo yielded the deuterated aldehyde 66a–d (71-97% yield). To obtain a higher
degree of deuterium incorporation, the obtained deuterated aldehyde was subjected to a second
iteration with fresh D2O.
General procedure for the synthesis of deuterated β-hydroxy fatty acids 75a–d
To a stirred suspension of activated zinc dust (acid-washed and dried) (1.3 equiv, 6.5 mmol, 0.43
g) in 20 mL of anhydrous diethyl ether in a flame-dried bulb, was added chlorotrimethylsilane
(0.1 equiv, 0.5 mmol, 65 µL). The mixture was stirred at room temperature for 15 min and then
heated at reflux for 10 min. The suspension was allowed to cool down to r.t. and a mixture of
ethyl bromoacetate 57 (1 equiv, 5 mmol, 0.57 mL) and deuterated aldehyde 66a–d (1 equiv,
5 mmol) was added dropwise in such a rate that a gentle reflux was obtained. The resulting
mixture was further heated at reflux for 1 h, after which it was cooled down and 20 mL of
2M aq. HCl was added. After stirring for 15 min, the layers were separated and the aqueous
phase was extracted two times with 20 mL of diethyl ether. The combined organic phases were
washed with 20 mL of saturated aq. NaHCO3 and 20 mL of brine. Drying over MgSO4 and
removal of the solvent in vacuo yielded the desired β-hydroxy ethyl ester 74a–d as a colorless
oil in 92-97% yield. The obtained ester 74a–d was dissolved in 30 mL of a 2:1 mixture of
tetrahydrofuran:methanol and placed in an ice bath. Then, 10 mL of 1M aq. LiOH (2 equiv, 10
mmol, 0.24 g) was added and the stirring was continued for 2 h at 0 ◦C. Subsequently, the ice
bath was removed and the hydrolysis continued at room temperature overnight. The mixture
was extracted once with 20 mL of diethyl ether to remove unreacted ester. The aqueous phase
was acidified with 2M aq. HCl to pH 2 and extracted three times with 20 mL of diethyl ether.
Drying over MgSO4, filtration and rotary evaporation in vacuo of the solvent yielded crude β-
hydroxy fatty acid 75a–d. Recrystallization from diethyl ether gave the pure fatty acid 75a–d
as a colorless powder (84-95% yield).
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[4,4-di-2H]-3-Hydroxyoctanoic acid 75a (86% D). 1H NMR (400 MHz,
CDCl3): δ = 0.89 (3H, t, J = 6.7 Hz, CH3), 1.22-1.48 (6H, m,
(CH2)3CH3), 2.46 (1H, dd, J = 16.4 Hz, 8.9 Hz, CHH’COOH), 2.58
(1H, dd, J = 16.6 Hz, 3.0 Hz, CHH’COOH), 4.04 (1H, dd, J = 8.7 Hz, 3.1 Hz, CHOH) ppm. 13C
NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.4, 25.1, 31.7 ((CH2)3CH3), 35.1-35.9 (m, CD2),
41.1 (CH2COOH), 68.1 (CHOH), 177.9 (COOH) ppm. MS (ESI): m/z (%): 163 (M+H+, 25),
180 (M+NH+4 , 100). HRMS mass calcd.: C8H14D2O
−
3 161.1152; found: 161.1154. IR (cm
−1):
νmax 911, 1218 (C-O), 1678 (C=O), 2105 (CD2), 2180 (CD2), 2858, 2918, 2952, 3025 (COO-
H), 3536 (O-H). Melting point: 48-50 ◦C. Colorless powder. Yield: 89%.
OH
OH O
D D
75b
[4,4-di-2H]-3-Hydroxynonanoic acid 75b (93% D). 1H NMR (400
MHz, CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz, CH3), 1.21-1.50 (8H, m,
(CH2)4CH3), 2.48 (1H, dd, J = 16.6 Hz, 8.8 Hz, CHH’COOH), 2.58
(1H, dd, J = 16.6 Hz, 3.1 Hz, CHH’COOH), 4.03 (1H, dd, J = 8.8 Hz, 3.1 Hz, CHOH) ppm.
13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.6, 25.2, 29.1, 31.8 ((CH2)4CH3), 35.7 (quin-
tet, JC−D = 19.4 Hz, CD2), 41.0 (CH2COOH), 68.0 (CHOH), 178.0 (COOH) ppm. MS (ESI):
m/z (%): 176 (M+H+, 26), 194 (M+NH+4 , 100). HRMS mass calcd.: C9H16D2O
−
3 175.1309;
found: 175.1311. IR (cm−1): νmax 913, 1218 (C-O), 1681 (C=O), 2103 (CD2), 2174 (CD2),
2856, 2916, 2952, 3050 (COO-H), 3536 (O-H). Melting point: 61-63 ◦C. Colorless powder.
Yield: 84%.
OH
OH O
D D
75c
[4,4-di-2H]-3-Hydroxydodecanoic acid 75c (95% D). 1H NMR
(400 MHz, CDCl3): δ = 0.87 (3H, t, J = 7.0 Hz, CH3), 1.21-
1.50 (14H, m, (CH2)7CH3), 2.48 (1H, dd, J = 16.5 Hz, 8.9 Hz,
CHH’COOH), 2.58 (1H, dd, J = 16.5 Hz, 3.2 Hz, CHH’COOH), 4.05 (1H, dd, J = 8.9 Hz,
3.2 Hz, CHOH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 25.3, 29.3, 29.4,
29.5, 29.6, 31.9 ((CH2)7CH3), 35.7 (quintet, JC−D = 19.8 Hz, CD2), 41.1 (CH2COOH), 68.0
(CHOH), 178.0 (COOH) ppm. MS (ESI): m/z (%): 201 (M-H2O, 80), 219 (M+H+, 6), 241
(M+Na+, 100). HRMS mass calcd.: C12H22D2O3NH+4 236.2189; found: 236.2181. IR (cm
−1):
νmax 914, 1228 (C-O), 1677 (C=O), 2102 (CD2), 2179 (CD2), 2848, 2915, 2953, 3063 (COO-
H), 3534 (O-H). Melting point: 73-74 ◦C. Colorless powder. Yield: 89%.
OH
OH O
D D
75d
[4,4-di-2H]-3-Hydroxytridecanoic acid 75d (93% D). 1H NMR
(400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz, CH3), 1.20-
1.48 (16H, m, (CH2)8CH3), 2.47 (1H, dd, J = 16.6 Hz, 8.9 Hz,
CHH’COOH), 2.58 (1H, dd, J = 16.5 Hz, 3.1 Hz, CHH’COOH), 4.02 (1H, dd, J = 8.9 Hz, 3.1
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Hz, CHOH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 25.2, 29.3, 29.4, 29.56,
29.58, 29.60, 31.9 ((CH2)8CH3), 35.4-36.2 (m, CD2), 41.0 (CH2COOH), 67.9 (CHOH), 178.0
(COOH) ppm. MS (ESI): m/z (%): 233 (M+H+, 7), 250 (M+NH+4 , 100). HRMS mass calcd.:
C13H24D2O3NH+4 250.2346; found: 250.2340. IR (cm
−1): νmax 915, 1219 (C-O), 1681 (C=O),
2100 (CD2), 2182 (CD2), 2847, 2914, 2952, 3031 (COO-H), 3534 (O-H). Melting point: 78-80
◦C. Colorless powder. Yield: 95%.
General procedure for the synthesis of deuterated fatty acids 73a–c
α,α-Dideuterated aldehyde 66b–d (1 equiv, 10 mmol) was dissolved in 20 mL of a 1:1 methanol:
diethyl ether mixture whereafter sodium borohydride (2 equiv, 20 mmol, 0.76 g) was added por-
tionwise. The reaction was stirred for 2 h at room temperature and quenched by the dropwise
addition of water. The mixture was acidified by the addition of 2M aq. HCl and the aqueous
layer was extracted three times with 20 mL of ethyl acetate. The combined organic phases were
washed with 30 mL of brine and dried over MgSO4. Removal of the drying agent by filtration
and evaporation of the solvent in vacuo gave the β,β-dideuterated alcohol (88-96% yield). The
obtained crude β,β-dideuterated alcohol (1 equiv, 10 mmol) was dissolved in 30 mL of dry
diethyl ether and triethylamine (1.4 equiv, 14 mmol, 2.0 mL) was added. The resulting solu-
tion was placed in an ice bath and methanesulfonyl chloride (1.15 equiv, 11.5 mmol, 1.1 mL)
was added dropwise. The stirring was continued for 2 h at room temperature, then 25 mL of
water was added to the resulting turbid suspension. The phases were separated and the organic
phase was washed with 15 mL of saturated aq. NaHCO3. Drying over MgSO4, filtration and
removal of the solvent in vacuo gave the desired alkyl methanesulfonate 72a–c (77-96% yield).
To obtain the alkyl nitrile, the mesylate 72a–c (1 equiv, 10 mmol) was dissolved in dimethyl
sulfoxide (30 mL), followed by the addition of potassium cyanide (2.5 equiv, 25 mmol, 1.63
g). Stirring overnight at 120 ◦C resulted in the formation of a thick precipitate. The reaction
mixture was cooled down and partitioned between water (20 mL) and diethyl ether (20 mL).
The aqueous layer was extracted three times with diethyl ether (3 x 20 mL) and the combined
organic phases were dried over MgSO4. Removal of the solvent in vacuo yielded the alkyl ni-
triles (86-95% yield). To a solution of the nitrile (1 equiv, 10 mmol) in 40 mL of methanol
was added 4 mL of 10M aq. NaOH (4 equiv, 40 mmol, 1.60 g) and the resulting mixture was
stirred at reflux overnight. After cooling down, methanol was removed under reduced pressure
and the remaining heterogeneous mixture was heated at reflux for a further 2 h. The suspension
was extracted with 20 mL of diethyl ether to remove impurities and unreacted nitrile, followed
by acidification with 2M aq. HCl and extraction with diethyl ether (3 x 50 mL). Drying over
MgSO4 and removal of the solvent in vacuo yielded the desired deuterium-labelled fatty acids
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73a–c (58-80% yield).
OH
OD D
73a
[3,3-di-2H]-Octanoic acid 73a (93% D). 1H NMR (400 MHz, CDCl3): δ
= 0.88 (3H, t, J = 6.9 Hz, CH3), 1.20-1.38 (8H, m, (CH2)4CH3), 2.33
(2H, s, CH2COOH), 11.56 (1H, br s, COOH) ppm. 13C NMR (100
MHz, CDCl3): δ = 14.1 (CH3), 22.6, 28.80, 28.84, 31.6 ((CH2)4CH3), 23.5-24.5 (m, CD2),
34.0 (CH2COOH), 180.6 (COOH) ppm. IR (cm−1): νmax 934, 1230, 1275 (C-O), 1412, 1705
(C=O), 2857, 2925. Colorless oil. Yield: 58%.
OH
OD D
73b
[3,3-di-2H]-Undecanoic acid 73b (95% D). 1H NMR (400 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz, CH3), 1.18-1.37 (14H, m,
(CH2)7CH3), 2.33 (2H, s, CH2COOH), 11.31 (1H, br s, COOH)
ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 28.9, 29.2, 29.3, 29.4, 29.6, 31.9
((CH2)7CH3), 23.5-24.7 (m, CD2), 33.9 (CH2COOH), 180.0 (COOH) ppm. IR (cm−1): νmax
927, 1252 (C-O), 1692 (C=O), 2111 (CD2), 2201 (CD2), 2850, 2918, 2955, 3019. Colorless oil.
Yield: 80%.
OH
OD D
73c
[3,3-di-2H]-Dodecanoic acid 73c (92% D). 1H NMR (400 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.6 Hz, CH3), 1.18-1.37 (16H, m,
(CH2)8CH3), 2.32 (2H, s, CH2COOH), 9.34 (1H, br s, COOH)
ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 28.9, 29.2, 29.3, 29.4, 29.6 (2C),
31.9 ((CH2)8CH3), 23.6-24.8 (m, CD2), 34.0 (CH2COOH), 179.9 (COOH) ppm. IR (cm−1):
νmax 931, 1275 (C-O), 1429, 1695 (C=O), 2848, 2912. Colorless powder. Melting point: 40-41
◦C. Yield: 70%.
General procedure for the synthesis of deuterated AHLs 65, 77a–d and 78a–c
The deuterated analogues of N-acyl-L-homoserine lactones 1 and N-(3-hydroxyacyl)-L-homo-
serine lactones 2 were synthesized following the procedure described by Chhabra et al.227 Tri-
ethylamine (1 equiv, 2 mmol, 0.28 mL) was added to a stirred solution of L-homoserine lactone
hydrobromide 53 (1 equiv, 2 mmol, 0.36 g) in 5 mL of water, followed by the addition of
the appropriate deuterated fatty acid (64, 73a–c or 75a–d, 1 equiv, 2 mmol) and 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (1 equiv, 2 mmol, 0.38 g). After stirring for
3 h or overnight at room temperature, 15 mL of water was added and the aqueous phase was
extracted three times with 20 mL of ethyl acetate. The combined organic phases were washed
with 30 mL of saturated aq. NaHCO3 and 30 mL of brine. Drying over MgSO4, followed by
filtration and evaporation of the solvent in vacuo gave the crude product. Purification via col-
umn chromatography on silica gel (ethyl acetate:petroleum ether 3:2 to 4:1) yielded the desired
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deuterated AHL 65, 77a–d and 78a–c as a colorless powder.
O
O
N
H
ODHO
65
N-(3-Hydroxydodecanoyl-[3-2H])-L-homoserine lactone 65
(89% D). Spectral data were obtained from a 1:1 mixture of
diastereomers. 1H NMR (400 MHz, CDCl3): δ = 0.88 (3H,
t, J = 6.9 Hz, CH3), 1.19-1.57 (16H, m, (CH2)8CH3), 2.13-2.26 (1H, m, OCH2CHH’), 2.33
(0.5H, d, J = 15.4 Hz, CHH’CDOH), 2.35 (0.5H, d, J = 15.4 Hz, CHH’CDOH), 2.44 (0.5H,
d, J = 15.4 Hz, CHH’CDOH), 2.46 (0.5H, d, J = 15.4 Hz, CHH’CDOH), 2.81 (1H, dddd, J
= 12.5 Hz, 8.6 Hz, 5.9 Hz, 1.2 Hz, OCH2CHH’), 3.13 (1H, br s, OH), 4.0 (0.1H, m, CHOH),
4.29 (1H, ddd, J = 11.2 Hz, 9.3 Hz, 6.0 Hz, OCHH’), 4.480 (0.5H, td, J = 9.1 Hz, 1.3 Hz,
OCHH’), 4.483 (0.5H, td, J = 9.1 Hz, 1.4 Hz, OCHH’), 4.56 (0.5H, ddd, J = 11.7 Hz, 8.6 Hz,
6.2 Hz, CHN), 4.59 (0.5H, ddd, J = 11.8 Hz, 8.7 Hz, 6.3 Hz, CHN), 6.60 (0.5H, d, J = 5.8 Hz,
NH), 6.65 (0.5H, d, J = 5.7 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7,
25.5, 29.3, 29.5, 29.56, 29.59, 31.9, 36.8, 36.9 ((CH2)8CH3), 29.9 (CH2CHN), 30.0 (CH2CHN),
42.5 (CH2CONH), 42.6 (CH2CONH), 49.0 (CHN), 49.2 (CHN), 66.1 (CH2O), 66.2 (CH2O),
68.2 (t, JC−D = 21.6 Hz, CDOH), 68.3 (t, JC−D = 21.7 Hz, CDOH), 68.6 (COHunlabelled), 68.7
(COHunlabelled), 173.0 (CONH), 173.1 (CONH), 175.70 (COO), 175.74 (COO) ppm. MS (ESI):
m/z (%): 301 (M+H+, 100). HRMS mass calcd.: C16H29DNO4H+ 301.2232; found: 301.2237.
IR (cm−1): νmax 951, 1008, 1178, 1548 (HN-C=O), 1627 (HN-C=O), 1768 (C=Olactone), 2850,
2919, 3315 (N-H or O-H), 3494 (N-H or O-H). Chromatography: EtOAc:petroleum ether 4:1
Rf = 0.16. Melting point: 107-108 ◦C. Colorless powder. Yield: 65%.
O
O
N
H
OOH
D D
77a
N-(3-Hydroxyoctanoyl-[4,4-di-2H])-L-homoserine lactone 77a (86%
D). Spectral data were obtained from a 3:2 mixture of diastereomers.
1H NMR (400 MHz, CDCl3): δ diastereomer 1 (major): 0.88 (3H, t, J
= 6.8 Hz, CH3), 1.19-1.43 (6H, m, (CH2)3CH3), 2.15-2.27 (1H, m, OCH2CHH’), 2.35 (1H, dd,
J = 15.6 Hz, 8.9 Hz, CHH’CHOH), 2.43 (1H, dd, J = 15.6 Hz, 2.8 Hz, CHH’CHOH), 2.82 (1H,
dddd, J = 12.8 Hz, 8.4 Hz, 5.9 Hz, 1.1 Hz, OCH2CHH’), 3.05 (1H, br s, OH), 4.00-4.06 (1H,
m, CHOH), 4.29 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 6.0 Hz, OCHH’), 4.43-4.50 (1H, m, OCHH’),
4.58 (1H, ddd, J = 11.6 Hz, 8.7 Hz, 6.2 Hz, CHN), 6.58 (1H, d, J = 5.6 Hz, NH) ppm; dia-
stereomer 2 (minor): 0.88 (3H, t, J = 6.8 Hz, CH3), 1.19-1.43 (6H, m, (CH2)3CH3), 2.15-2.27
(1H, m, OCH2CHH’), 2.33 (1H, dd, J = 15.6 Hz, 8.9 Hz, CHH’CHOH), 2.46 (1H, dd, J = 15.6
Hz, 2.8 Hz, CHH’CHOH), 2.82 (1H, dddd, J = 12.8 Hz, 8.4 Hz, 5.9 Hz, 1.1 Hz, OCH2CHH’),
3.05 (1H, br s, OH), 4.00-4.06 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 6.0 Hz,
OCHH’), 4.43-4.50 (1H, m, OCHH’), 4.56 (1H, ddd, J = 11.5 Hz, 8.7 Hz, 6.1 Hz, CHN), 6.50
(1H, d, J = 5.6 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ diastereomer 1 (major): 14.1
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(CH3), 22.4, 25.2, 31.8 ((CH2)3CH3), 29.8 (CH2CHN), 36.0-36.9 (m, CD2), 42.7 (CH2CONH),
49.2 (CHN), 66.20 (CH2O), 68.6 (COH), 173.1 (CONH), 175.9 (COO) ppm; diastereomer 2
(minor): 14.1 (CH3), 22.4, 25.2, 31.8 ((CH2)3CH3), 29.7 (CH2CHN), 36.0-36.9 (m, CD2), 42.6
(CH2CONH), 49.0 (CHN), 66.18 (CH2O), 68.5 (COH), 173.0 (CONH), 175.8 (COO) ppm.
MS (ESI): m/z (%): 246 (M+H+, 100). HRMS mass calcd.: C12H19D2NO4H+ 246.1669; found:
246.1672. IR (cm−1): νmax 948, 1018, 1177, 1382, 1541 (HN-C=O), 1644 (HN-C=O), 1771
(C=Olactone), 2101 (CD2), 2179 (CD2), 2849, 2940, 2957, 3342 (N-H or O-H). Chromatogra-
phy: EtOAc:petroleum ether 4:1 Rf = 0.15. Melting point: 85-87 ◦C. Colorless powder. Yield:
48%.
O
O
N
H
OOH
D D
77b
N-(3-Hydroxynonanoyl-[4,4-di-2H])-L-homoserine lactone 77b
(93% D). Spectral data were obtained from a 3:2 mixture of dia-
stereomers. 1H NMR (400 MHz, CDCl3): δ diastereomer 1 (ma-
jor): 0.88 (3H, t, J = 6.8 Hz, CH3), 1.20-1.45 (8H, m, (CH2)4CH3), 2.13-2.26 (1H, m,
OCH2CHH’), 2.35 (1H, dd, J = 15.5 Hz, 8.9 Hz, CHH’CHOH), 2.44 (1H, dd, J = 15.5 Hz,
2.8 Hz, CHH’CHOH), 2.82 (1H, dddd, J = 12.6 Hz, 8.6 Hz, 5.9 Hz, 1.1 Hz, OCH2CHH’), 3.10
(1H, br s, OH), 3.99-4.06 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 5.9 Hz, OCHH’),
4.45-4.51 (1H, m, OCHH’), 4.58 (1H, ddd, J = 11.6 Hz, 8.7 Hz, 6.2 Hz, CHN), 6.60 (1H, d, J
= 5.6 Hz, NH) ppm; diastereomer 2 (minor): 0.88 (3H, t, J = 6.8 Hz, CH3), 1.20-1.45 (8H, m,
(CH2)4CH3), 2.13-2.26 (1H, m, OCH2CHH’), 2.33 (1H, dd, J = 15.5 Hz, 8.9 Hz, CHH’CHOH),
2.46 (1H, dd, J = 15.5 Hz, 2.8 Hz, CHH’CHOH), 2.82 (1H, dddd, J = 12.6 Hz, 8.6 Hz, 5.9 Hz,
1.1 Hz, OCH2CHH’), 3.10 (1H, br s, OH), 3.99-4.06 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.3
Hz, 9.3 Hz, 5.9 Hz, OCHH’), 4.45-4.51 (1H, m, OCHH’), 4.56 (1H, ddd, J = 11.5 Hz, 8.7 Hz,
6.1 Hz, CHN), 6.55 (1H, d, J = 5.6 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ diaste-
reomer 1 (major): 14.1 (CH3), 22.6, 25.3, 29.1, 31.8 ((CH2)4CH3), 29.8 (CH2CHN), 35.8-36.7
(m, CD2), 42.7 (CH2CONH), 49.1 (CHN), 66.18 (CH2O), 68.6 (COH), 173.1 (CONH), 175.9
(COO) ppm; diastereomer 2 (minor): 14.1 (CH3), 22.6, 25.3, 29.1, 31.8 ((CH2)4CH3), 29.7
(CH2CHN), 35.8-36.7 (m, CD2), 42.6 (CH2CONH), 48.9 (CHN), 66.15 (CH2O), 68.5 (COH),
173.0 (CONH), 175.8 (COO) ppm. MS (ESI): m/z (%): 260 (M+H+, 100). HRMS mass calcd.:
C13H21D2NO4H+ 260.1831; found: 260.1832. IR (cm−1): νmax 950, 1012, 1174, 1382, 1543
(HN-C=O), 1645 (HN-C=O), 1768 (C=Olactone), 2103 (CD2), 2184 (CD2), 2855, 2920, 2956,
3302 (N-H or O-H). Chromatography: EtOAc:petroleum ether 4:1 Rf = 0.18. Melting point:
97-98 ◦C. Colorless powder. Yield: 58%.
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77c
N-(3-Hydroxydodecanoyl-[4,4-di-2H])-L-homoserine lac-
tone 77c (95% D). Spectral data were obtained from a 5:4
mixture of diastereomers. 1H NMR (400 MHz, CDCl3):
δ diastereomer 1 (major): 0.88 (3H, t, J = 6.9 Hz, CH3), 1.19-1.43 (14H, m, (CH2)7CH3), 2.13-
2.26 (1H, m, OCH2CHH’), 2.35 (1H, dd, J = 15.4 Hz, 8.9 Hz, CHH’CHOH), 2.43 (1H, dd, J
= 15.4 Hz, 2.8 Hz, CHH’CHOH), 2.77-2.86 (1H, m, OCH2CHH’), 3.11 (1H, br s, OH), 3.98-
4.05 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.2 Hz, 9.3 Hz, 5.9 Hz, OCHH’), 4.43-4.51 (1H,
m, OCHH’), 4.59 (1H, ddd, J = 11.6 Hz, 8.8 Hz, 6.1 Hz, CHN), 6.53-6.64 (1H, m, NH) ppm;
diastereomer 2 (minor): 0.88 (3H, t, J = 6.9 Hz, CH3), 1.19-1.43 (14H, m, (CH2)7CH3), 2.13-
2.26 (1H, m, OCH2CHH’), 2.33 (1H, dd, J = 15.3 Hz, 8.9 Hz, CHH’CHOH), 2.46 (1H, dd, J
= 15.4 Hz, 2.7 Hz, CHH’CHOH), 2.77-2.86 (1H, m, OCH2CHH’), 3.11 (1H, br s, OH), 3.98-
4.05 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.2 Hz, 9.3 Hz, 5.9 Hz, OCHH’), 4.43-4.51 (1H,
m, OCHH’), 4.56 (1H, ddd, J = 11.6 Hz, 8.7 Hz, 6.1 Hz, CHN), 6.53-6.64 (1H, m, NH) ppm.
13C NMR (100 MHz, CDCl3): δ diastereomer 1 (major): 14.1 (CH3), 22.7, 25.3, 29.3, 29.5,
29.56, 29.60, 31.9 ((CH2)7CH3), 30.04 (CH2CHN), 35.8-36.8 (m, CD2), 42.6 (CH2CONH),
49.2 (CHN), 66.2 (CH2O), 68.6 (COH), 173.05 (CONH), 175.67 (COO), 175.75 (COO) ppm;
diastereomer 2 (minor): 14.1 (CH3), 22.7, 25.3, 29.3, 29.5, 29.56, 29.60, 31.9 ((CH2)7CH3),
29.98 (CH2CHN), 35.8-36.8 (m, CD2), 42.5 (CH2CONH), 49.0 (CHN), 66.1 (CH2O), 68.5
(COH), 173.01 (CONH), 175.67 (COO) ppm. MS (ESI): m/z (%): 302 (M+H+, 100). HRMS
mass calcd.: C16H27D2NO4H+ 302.2300; found: 302.2300. IR (cm−1): νmax 952, 1014, 1177,
1382, 1549 (HN-C=O), 1625 (HN-C=O), 1766 (C=Olactone), 2082 (CD2), 2185 (CD2), 2851,
2919, 2956, 3326 (N-H or O-H), 3461 (N-H or O-H). Chromatography: EtOAc:petroleum ether
4:1 Rf = 0.15. Melting point: 107-108 ◦C. Colorless powder. Yield: 63%.
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N-(3-Hydroxytridecanoyl-[4,4-di-2H])-L-homoserine lac-
tone 77d (93% D). Spectral data were obtained from a 5:4
mixture of diastereomers. 1H NMR (400 MHz, CDCl3):
δ diastereomer 1 (major): 0.88 (3H, t, J = 6.9 Hz, CH3), 1.19-1.43 (16H, m, (CH2)8CH3), 2.13-
2.25 (1H, m, OCH2CHH’), 2.35 (1H, dd, J = 15.4 Hz, 8.7 Hz, CHH’CHOH), 2.43 (1H, dd, J
= 15.4 Hz, 2.8 Hz, CHH’CHOH), 2.79-2.87 (1H, m, OCH2CHH’), 3.04 (1H, br s, OH), 3.98-
4.04 (1H, m, CHOH), 4.29 (1H, ddd, J = 11.2 Hz, 9.3 Hz, 5.9 Hz, OCHH’), 4.45-4.51 (1H, m,
OCHH’), 4.57 (1H, ddd, J = 11.6 Hz, 8.6 Hz, 5.7 Hz, CHN), 6.46-6.57 (1H, m, NH) ppm; dia-
stereomer 2 (minor): 0.88 (3H, t, J = 6.9 Hz, CH3), 1.19-1.43 (16H, m, (CH2)8CH3), 2.13-2.25
(1H, m, OCH2CHH’), 2.33 (1H, dd, J = 15.5 Hz, 9.0 Hz, CHH’CHOH), 2.46 (1H, dd, J = 15.3
Hz, 2.8 Hz, CHH’CHOH), 2.79-2.87 (1H, m, OCH2CHH’), 3.04 (1H, br s, OH), 3.98-4.04 (1H,
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m, CHOH), 4.29 (1H, ddd, J = 11.2 Hz, 9.3 Hz, 5.9 Hz, OCHH’), 4.45-4.51 (1H, m, OCHH’),
4.56 (1H, ddd, J = 11.6 Hz, 8.6 Hz, 5.9 Hz, CHN), 6.46-6.57 (1H, m, NH) ppm. 13C NMR
(100 MHz, CDCl3): δ diastereomer 1 (major): 14.1 (CH3), 22.7, 25.3, 29.3, 29.5, 29.6 (3C),
31.9 ((CH2)8CH3), 30.0 (CH2CHN), 35.7-36.8 (m, CD2), 42.6 (CH2CONH), 49.1 (CHN), 66.2
(CH2O), 68.6 (COH), 173.05 (CONH), 175.7 (COO) ppm; diastereomer 2 (minor): 14.1 (CH3),
22.7, 25.3, 29.3, 29.5, 29.6 (3C), 31.9 ((CH2)8CH3), 29.9 (CH2CHN), 35.7-36.8 (m, CD2), 42.5
(CH2CONH), 49.0 (CHN), 66.1 (CH2O), 68.5 (COH), 173.02 (CONH), 175.7 (COO) ppm.
MS (ESI): m/z (%): 316 (M+H+, 100). HRMS mass calcd.: C17H29D2NO4H+ 316.2457; found:
316.2448. IR (cm−1): νmax 948, 1022, 1177, 1382, 1549 (HN-C=O), 1641 (HN-C=O), 1770
(C=Olactone), 2102 (CD2), 2177 (CD2), 2849, 2917, 2953, 3312 (N-H or O-H), 3490 (N-H or
O-H). Chromatography: EtOAc:petroleum ether 4:1 Rf = 0.16. Melting point: 110-112 ◦C.
Colorless powder. Yield: 42%.
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N-(Octanoyl-[3,3-di-2H])-L-homoserine lactone 78a (92% D).
1H NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz, CH3),
1.20-1.36 (8H, m, (CH2)4CH3), 2.12 (1H, dddd, J = 12.5 Hz,
11.5 Hz, 11.5 Hz, 8.8 Hz, OCH2CHH’), 2.23 (2H, s, CH2CONH), 2.88 (1H, dddd, J = 12.5 Hz,
8.5 Hz, 5.8 Hz, 1.2 Hz, OCH2CHH’), 4.28 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 5.8 Hz, OCHH’),
4.47 (1H, td, J = 9.1 Hz, 1.0 Hz, OCHH’), 4.54 (1H, ddd, J = 11.6 Hz, 8.5 Hz, 5.6 Hz,
CHN), 5.94 (1H, s, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.6, 28.9, 29.0,
31.6 ((CH2)4CH3), 24.4-25.4 (m, CD2), 30.6 (CH2CHN), 36.0 (CH2CONH), 49.2 (CHN), 66.1
(CH2O), 173.8 (CONH), 175.7 (COO) ppm. MS (ESI): m/z (%): 230 (M+H+, 100). HRMS
mass calcd.: C12H19D2NO3H+ 230.1725; found: 230.1709. IR (cm−1): νmax 1010, 1170, 1545
(HN-C=O), 1643 (HN-C=O), 1774 (C=Olactone), 2107 (CD2), 2194 (CD2), 2852, 2920, 3314
(N-H or O-H). Chromatography: EtOAc:petroleum ether 3:2 Rf = 0.19. Melting point: 130-132
◦C. Colorless powder. Yield: 55%.
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O
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N-(Undecanoyl-[3,3-di-2H])-L-homoserine lactone 78b (95%
D). 1H NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz,
CH3), 1.21-1.32 (14H, m, (CH2)7CH3), 2.12 (1H, dddd, J =
12.5 Hz, 11.5 Hz, 11.5 Hz, 8.8 Hz, OCH2CHH’), 2.23 (2H, s, CH2CONH), 2.88 (1H, dddd, J
= 12.6 Hz, 8.5 Hz, 5.8 Hz, 1.1 Hz, OCH2CHH’), 4.29 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 5.9 Hz,
OCHH’), 4.47 (1H, td, J = 9.1 Hz, 1.0 Hz, OCHH’), 4.54 (1H, ddd, J = 11.6 Hz, 8.5 Hz, 5.6 Hz,
CHN), 5.96 (1H, d, J = 5.6 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7,
29.0, 29.28, 29.30, 29.5, 29.6, 31.9 ((CH2)7CH3), 24.7 (quintet, JC−D = 19.2 Hz, CD2), 30.5
(CH2CHN), 36.0 (CH2CONH), 49.2 (CHN), 66.1 (CH2O), 173.8 (CONH), 175.7 (COO) ppm.
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MS (ESI): m/z (%): 272 (M+H+, 100). HRMS mass calcd.: C15H25D2NO3H+ 272.2195; found:
272.2182. IR (cm−1): νmax 1010, 1171, 1547 (HN-C=O), 1643 (HN-C=O), 1779 (C=Olactone),
2113 (CD2), 2205 (CD2), 2851, 2919, 3315 (N-H or O-H). Chromatography: EtOAc:petroleum
ether 3:2 Rf = 0.21. Melting point: 135-136 ◦C. Colorless powder. Yield: 69%.
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N-(Dodecanoyl-[3,3-di-2H])-L-homoserine lactone 78c (92%
D). 1H NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz,
CH3), 1.19-1.35 (16H, m, (CH2)8CH3), 2.12 (1H, dddd, J =
12.5 Hz, 11.5 Hz, 11.5 Hz, 8.8 Hz, OCH2CHH’), 2.23 (2H, s, CH2CONH), 2.88 (1H, dddd,
J = 12.6 Hz, 8.5 Hz, 5.8 Hz, 1.1 Hz, OCH2CHH’), 4.28 (1H, ddd, J = 11.3 Hz, 9.3 Hz, 5.8
Hz, OCHH’), 4.47 (1H, td, J = 9.1 Hz, 1.0 Hz, OCHH’), 4.53 (1H, ddd, J = 11.6 Hz, 8.5 Hz,
5.6 Hz, CHN), 5.93 (1H, d, J = 4.8 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1
(CH3), 22.7, 29.0, 29.27, 29.32, 29.5, 29.6 (2C), 31.9 ((CH2)8CH3), 24.3-25.4 (m, CD2), 30.4
(CH2CHN), 36.0 (CH2CONH), 49.1 (CHN), 66.1 (CH2O), 173.8 (CONH), 175.8 (COO) ppm.
MS (ESI): m/z (%): 286 (M+H+, 100). HRMS mass calcd.: C16H27D2NO3H+ 286.2351; found:
286.2335. IR (cm−1): νmax 1010, 1171, 1546 (HN-C=O), 1643 (HN-C=O), 1775 (C=Olactone),
2110 (CD2), 2194 (CD2), 2850, 2918, 3315 (N-H or O-H). Chromatography: EtOAc:petroleum
ether 3:2 Rf = 0.23. Melting point: 137-139 ◦C. Colorless powder. Yield: 52%.
General procedure for the synthesis of deuterated AHLs 79a–c
To a stirred solution of β,β-dideuterated fatty acid 73a–c (1 equiv, 2 mmol) in 20 mL of dry
dichloromethane, was added 4-(N,N-dimethylamino)pyridine (2.1 equiv, 4.2 mmol, 0.51 g), 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.1 equiv, 2.2 mmol, 0.42 g) and
Meldrum’s acid (1 equiv, 2 mmol, 0.29 g). The resulting clear yellow solution was stirred for
20 h at room temperature. The solvent was removed by rotary evaporation in vacuo, the residue
was redissolved in ethyl acetate (50 mL) and washed with 30 mL of 2M aq. HCl. Drying over
MgSO4, followed by filtration to remove the drying agent and evaporation of the solvent in
vacuo yielded acylated Meldrum’s acid 76a–c quantitatively, which was used without further
purification. The deuterium-labelled, acylated Meldrum’s acid 76a–c was dissolved in acetoni-
trile (30 mL), after which triethylamine (1.2 equiv, 2.4 mmol, 0.33 mL) and L-homoserine lac-
tone hydrobromide 53 (1 equiv, 2 mmol, 0.36 g) were added. The mixture was stirred at room
temperature for 2 h and then heated at reflux overnight. The solvent was removed in vacuo and
the resulting residue was dissolved in 30 mL of ethyl acetate and 30 mL of water. After sepa-
ration of both layers, the aqueous phase was extracted two times with 30 mL of ethyl acetate.
The combined organic phases were washed with 60 mL of saturated aq. NaHCO3 and 60 mL of
brine. Drying over MgSO4 and removal of the solvent in vacuo yielded crude deuterated AHL
158
Experimental part
79a–c. Purification via column chromatography on silica gel (ethyl acetate:petroleum ether 3:2
to 4:1) gave the pure product as a colorless powder.
O
N
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N-(3-Oxodecanoyl-[5,5-di-2H])-L-homoserine lactone 79a (93%
D). 1H NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz,
CH3), 1.20-1.32 (8H, m, (CH2)4CH3), 2.23 (1H, dddd, J = 12.5
Hz, 11.3 Hz, 11.3 Hz, 8.9 Hz, OCH2CHH’), 2.51 (2H, s, CH2CONH), 2.76 (1H, dddd, J = 12.6
Hz, 8.7 Hz, 6.0 Hz, 1.4 Hz, OCH2CHH’), 3.47 (2H, s, COCH2CO), 4.28 (1H, ddd, J = 11.0 Hz,
9.3 Hz, 6.1 Hz, OCHH’), 4.47 (1H, td, J = 9.1 Hz, 1.3 Hz, OCHH’), 4.59 (1H, ddd, J = 11.5
Hz, 8.7 Hz, 6.6 Hz, CHN), 7.66 (1H, d, J = 5.6 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ
= 14.1 (CH3), 22.6, 28.7, 28.9, 31.6 ((CH2)4CH3), 22.2-23.4 (m, CD2), 29.6 (CH2CHN), 43.6
(CD2CH2CO), 48.4 (COCH2CO), 49.0 (CHN), 65.9 (CH2O), 166.5 (CONH), 175.0 (COO),
206.5 (CH2COCH2) ppm. MS (ESI): m/z (%): 272 (M+H+, 100), 289 (M+NH+4 , 20). HRMS
mass calcd.: C14H21D2NO4H+ 272.1831; found: 272.1833. IR (cm−1): νmax 1010, 1023, 1165,
1356, 1548 (HN-C=O), 1646 (HN-C=O), 1712 (C=Oketone), 1776 (C=Olactone), 2112 (CD2),
2193 (CD2), 2851, 2918, 2957, 3081 (N-H or O-H), 3284 (N-H or O-H). Chromatography:
EtOAc:petroleum ether 3:2 Rf = 0.21. Melting point: 81-82 ◦C. Colorless powder. Yield: 49%.
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N-(3-Oxotridecanoyl-[5,5-di-2H])-L-homoserine lactone
79b (95% D). 1H NMR (400 MHz, CDCl3): δ = 0.88 (3H,
t, J = 6.8 Hz, CH3), 1.19-1.33 (14H, m, (CH2)7CH3),
2.24 (1H, dddd, J = 12.5 Hz, 11.3 Hz, 11.3 Hz, 9.0 Hz, OCH2CHH’), 2.51 (2H, s, CH2CONH),
2.76 (1H, dddd, J = 12.5 Hz, 8.7 Hz, 6.1 Hz, 1.4 Hz, OCH2CHH’), 3.47 (2H, s, COCH2CO),
4.28 (1H, ddd, J = 11.0 Hz, 9.3 Hz, 6.1 Hz, OCHH’), 4.48 (1H, td, J = 9.1 Hz, 1.3 Hz, OCHH’),
4.60 (1H, ddd, J = 11.5 Hz, 8.7 Hz, 6.6 Hz, CHN), 7.67 (1H, d, J = 5.7 Hz, NH) ppm. 13C
NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 28.8, 29.3, 29.4, 29.5, 29.6, 31.9 ((CH2)7CH3),
22.2-23.4 (m, CD2), 29.7 (CH2CHN), 43.7 (CD2CH2CO), 48.2 (COCH2CO), 49.0 (CHN),
65.9 (CH2O), 166.4 (CONH), 174.7 (COO), 206.6 (CH2COCH2) ppm. MS (ESI): m/z (%):
314 (M+H+, 100), 331 (M+NH+4 , 21). HRMS mass calcd.: C17H27D2NO4H
+ 314.2295; found:
314.2305. IR (cm−1): νmax 1006, 1016, 1176, 1356, 1544 (HN-C=O), 1642 (HN-C=O), 1716
(C=Oketone), 1776 (C=Olactone), 2092 (CD2), 2164 (CD2), 2850, 2919, 3071 (N-H or O-H), 3294
(N-H or O-H). Chromatography: EtOAc:petroleum ether 4:1 Rf = 0.37. Melting point: 86-88
◦C. Colorless powder. Yield: 66%.
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N-(3-Oxotetradecanoyl-[5,5-di-2H])-L-homoserine lac-
tone 79c (93% D). 1H NMR (400 MHz, CDCl3): δ
= 0.88 (3H, t, J = 6.9 Hz, CH3), 1.20-1.32 (16H, m,
(CH2)8CH3), 2.23 (1H, dddd, J = 12.5 Hz, 11.3 Hz, 11.3 Hz, 9.0 Hz, OCH2CHH’), 2.51
(2H, s, CH2CONH), 2.76 (1H, dddd, J = 12.6 Hz, 8.7 Hz, 6.1 Hz, 1.4 Hz, OCH2CHH’),
3.47 (2H, s, COCH2CO), 4.28 (1H, ddd, J = 11.1 Hz, 9.3 Hz, 6.1 Hz, OCHH’), 4.48 (1H,
td, J = 9.1 Hz, 1.3 Hz, OCHH’), 4.59 (1H, ddd, J = 11.5 Hz, 8.7 Hz, 6.6 Hz, CHN), 7.66
(1H, d, J = 5.4 Hz, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 22.7, 28.8,
29.30, 29.32, 29.4, 29.6, 29.8, 31.9 ((CH2)8CH3), 22.3-23.2 (m, CD2), 29.6 (CH2CHN), 43.7
(CD2CH2CO), 48.2 (COCH2CO), 49.0 (CHN), 65.9 (CH2O), 166.4 (CONH), 174.9 (COO),
206.6 (CH2COCH2) ppm. MS (ESI): m/z (%): 328 (M+H+, 100), 345 (M+NH+4 , 19). HRMS
mass calcd.: C18H29D2NO4H+ 328.2457; found: 328.2446. IR (cm−1): νmax 1007, 1016, 1176,
1356, 1544 (HN-C=O), 1641 (HN-C=O), 1716 (C=Oketone), 1775 (C=Olactone), 2101 (CD2),
2192 (CD2), 2850, 2918, 2954, 3073 (N-H or O-H), 3294 (N-H or O-H). Chromatography:
EtOAc:petroleum ether 3:2 Rf = 0.24. Melting point: 94-95 ◦C. Colorless powder. Yield: 54%.
Synthesis of tetramic acid 80
313 mg of N-(3-oxotridecanoyl-[5,5-di-2H])-L-homoserine lactone 79b (1 equiv, 1 mmol) was
dissolved in 3 mL of dry methanol under a nitrogen atmosphere. Then 1 equiv of NaOMe in
methanol (0.5M, 54 mg in 2 mL) was added and the mixture was stirred at reflux for 3 h.
Subsequently, the reaction mixture was poured into 10 mL of water and extracted with 10 mL
of diethyl ether. The organic phase was discarded and the aqueous phase was acidified with
2M aq. HCl and extracted three times with 10 mL of diethyl ether. Drying of the combined
organic phases over MgSO4, evaporation of the solvent in vacuo and recrystallization from
hexane yielded 250 mg of tetramic acid 80 as a colorless powder.
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3-(1-Hydroxyundecylidene-[5,5-di-2H])-5-(2-hydroxyethyl)-
pyrrolidine-2,4-dione 80 (95% D). 1H NMR (400 MHz,
CD3OD): δ = 0.88 (3H, t, J = 6.8 Hz, CH3), 1.20-1.37
(14H, m, (CH2)7CH3), 1.68-1.79 (1H, m, HOCH2CHH’),
1.96-2.05 (1H, m, HOCH2CHH’), 2.80 (2H, s, CH2CONH), 3.62-3.73 (2H, m, HOCH2), 3.96
(1H, m, CHN) ppm. 13C NMR (100 MHz, CD3OD): δ = 14.4 (CH3), 23.7, 30.1, 30.3, 30.4,
30.6, 30.7, 33.1 ((CH2)7CH3), 26.2 (quintet, JC−D = 19.1 Hz, CD2), 33.9 (CD2CH2CO), 35.7
(CH2CHN), 59.3 (CH2OH), 60.0-61.5 (m, CHN), 101.5-102.3 (m, COCCO), 175.5-177.1 (m,
CONH), 191.0-191.6 (m, CD2CH2CHOH), 197.8-198.5 (m, NHCHCO) ppm. MS (ESI): m/z
(%): 314 (M+H+, 100). HRMS mass calcd.: C17H27D2NO4H+ 314.2295; found: 314.2297.
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Melting point: 80-81 ◦C. Colorless powder. Yield: 80%.
Synthesis of ring-opened AHL 81
200 mg of N-(undecanoyl-[3,3-di-2H])-L-homoserine lactone 78b (1 equiv, 0.74 mmol) was
dissolved in 2 mL of acetonitrile at 0 ◦C. Then 2 mL of 2M aq. NaOH (5 equiv, 3.7 mmol,
0.15 g) was added and the mixture was stirred overnight at room temperature. The reaction
mixture was extracted with 5 mL of ethyl acetate. The organic phase was discarded and the
aqueous phase acidified to pH 2 with 2M aq. HCl. Extraction with ethyl acetate (3 x 5 mL),
followed by drying over MgSO4 and evaporation of the combined organic phases in vacuo and
recrystallization from acetone gave 188 mg of ring-opened AHL 81 as a colorless powder.
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N-(Undecanoyl-[3,3-di-2H])-L-homoserine 81 (95% D). 1H
NMR (400 MHz, CD3OD): δ = 0.91 (3H, t, J = 6.8 Hz,
CH3), 1.23-1.40 (14H, m, (CH2)7CH3), 1.81-1.91 (1H,
m, HOCH2CHH’), 2.05-2.15 (1H, m, HOCH2CHH’), 2.24
(2H, s, CH2CONH), 3.57-3.71 (2H, m, HOCH2), 4.52 (1H, dd, J = 9.3 Hz, 4.6 Hz, CHN)
ppm. 13C NMR (100 MHz, CD3OD): δ = 14.4 (CH3), 23.7, 30.1, 30.43, 30.46, 30.65, 30.71,
33.1 ((CH2)7CH3), 26.0-27.0 (m, CD2), 35.3 (CH2CHN), 36.7 (CH2CONH), 50.9 (CHN),
59.3 (CH2OH), 175.5 (CONH), 176.5 (COOH) ppm. MS (ESI): m/z (%): 290 (M+H+, 100),
312 (M+Na+, 38). HRMS mass calcd.: C15H27D2NO4H+ 290.2295; found: 290.2296. Melting
point: 114-115 ◦C. Colorless powder. Yield: 88%.
5.3 GC-MS conditions for the analysis of deuterated AHLs
GC-MS Analyses were carried out according to the procedure developed by Cataldi et al. with
minor modifications.241 Conditions applied were: inlet pressure 77.1 kPa; He: 23.3 mL/min;
injection volume: 1 µL; injector temperature: 250 ◦C; transfer line: 300 ◦C; electron energy:
70 eV. The oven temperature program was: initial temperature and hold for 5 min at 100 ◦C,
then increasing at a ramp of 10 ◦C per min to 300 ◦C. The injector was operated in splitless
mode (60 s valve time). The carrier gas used was helium with a constant flow of 1 mL/min.
AHLs were dissolved in dichloromethane. For the derivatization, 100 µL of 99:1 BSTFA-
TMCS [N,O-bis(trimethylsilyl)trifluoroacetamide - trimethylchlorosilane] was added to 100 µL
of dichloromethane containing the AHL and the mixture was allowed to stand for 10 min at
room temperature prior to injection in the GC.
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5.4 Synthesis of 1,4-oxazepane-2,5-diones
General procedure A: N-acylation of a primary amine
Triethylamine (1 equiv) was added to a stirred solution of the amino acid methyl ester hy-
drochloride (1 equiv) in water (5 mL/mmol methyl ester), followed by the addition of the
appropriate carboxylic acid (1 equiv) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hy-
drochloride (1 equiv). After stirring overnight at room temperature, water (15 mL/mmol methyl
ester) was added and the aqueous phase was extracted three times with ethyl acetate. The com-
bined organic phases were washed with saturated aq. NaHCO3 and brine. Drying over MgSO4,
followed by filtration and evaporation of the solvent in vacuo gave the crude product. If neces-
sary, a purification step via column chromatography was included.
General procedure B: N-acylation of a secondary amine
The N-acylation was executed according to the procedure of Falorni et al. with minor adapta-
tions.330 Briefly, the appropriate fatty acid (1 equiv) was dissolved in ethyl acetate (2 mL/mmol
fatty acid) and cooled to 0 ◦C whereafter N-methylmorpholine (1 equiv) was added, followed by
the dropwise addition of isobutyl chloroformate (1 equiv). The resulting turbid suspension was
stirred for 20 min at 0 ◦C. The secondary amine (1.05 equiv), dissolved in a minimal amount
of ethyl acetate, was added at the same temperature and after 2 h the reaction mixture was al-
lowed to warm to room temperature and stirred overnight. Water was added and the aqueous
phase was extracted twice with ethyl acetate. The combined organic phases were washed with
a saturated solution of aq. NaHCO3 and brine, dried (MgSO4) and the solvent was removed via
rotary evaporation to yield the N-acylated product.
General procedure C: hydrolysis
5 Equiv of 2M aq. NaOH were added to the methyl ester dissolved in methanol (ratio MeOH:
H2O 3:1). The reaction mixture was left to stir at room temperature for 3 h to overnight, followed
by an extraction step with hexane. The aqueous phase was acidified with 2M aq. HCl and
extracted three times with ethyl acetate. After washing with brine, followed by drying (MgSO4)
and removal of the drying agent by filtration, the solvent was removed by rotary evaporation
to yield the crude hydrolyzed product, which was purified, if applicable, via recrystallization in
diethyl ether:hexane.
General procedure D: cyclization
The free carboxylic acid was dissolved in dry CH2Cl2 to obtain a 20 mM solution whereafter
1.1 equiv of EDC.HCl and 0.2 equiv of DMAP were added. The resulting reaction mixture was
stirred overnight at room temperature, after which the solvent was removed in vacuo and the
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residue redissolved in ethyl acetate:water 1:1. The aqueous phase was extracted twice with ethyl
acetate, the organic phases were combined and subsequently washed with a saturated solution
of aq. NaHCO3 and brine. Drying with MgSO4, filtration and rotary evaporation of the solvent
yielded the crude seven-membered ring-containing product, which was purified via column
chromatography.
Synthesis of serine derivatives
Compound 89 was synthesized by reacting L-serine methyl ester hydrochloride 88 (1 equiv, 20
mmol, 3.1 g) with β-hydroxynonanoic acid 58d (1 equiv, 20 mmol, 3.48 g), following general
procedure A to yield 2.91 g (10.6 mmol, 53% yield) of compound 89. Diastereomers (ratio 1:1)
could not be separated via flash chromatography (ethyl acetate:petroleum ether 4:1).
OOH
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Methyl N-(3-hydroxynonanoyl)-L-serinate 89. Spectral data
were obtained from a 1:1 mixture of diastereomers. 1H NMR
(400 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.8 Hz, CH2CH3), 1.22-
1.62 (10H, m, (CH2)5CH3), 2.35 (0.5H, dd, J = 14.8 Hz, 9.4 Hz, COCHH’CHOH), 2.36 (1H,
dd, J = 14.7 Hz, 9.3 Hz, COCHH’CHOH), 2.467 (0.5H, d, J = 14.7 Hz, COCHH’CHOH),
2.474 (0.5H, d, J = 14.7 Hz, COCHH’CHOH), 3.54 (0.5H, br s, CHOH or CH2OH), 3.80
(3H, s, OCH3), 3.70-4.10 (4.5H, m, CH2OH or CHOH, CHOH and CH2OH), 4.64-4.72 (1H,
m, CHNH), 7.02 (0.5H, d, J = 7.7 Hz, NH), 7.08 (0.5H, d, J = 7.7 Hz, NH) ppm. 13C NMR
(100 MHz, CDCl3): δ = 14.1 (CH2CH3), 22.6, 25.50, 25.53, 31.8, 37.0, 37.1 ((CH2)5CH3),
43.15, 43.21 (COCH2CHOH), 52.77, 52.84 (OCH3), 54.7 (CHNH), 62.7 (CH2OH), 68.8, 69.0
(CHOH), 171.1, 171.3 (CONH), 172.6, 172.9 (COO) ppm. MS (ESI): m/z (%): 276 (M+H+,
100). HRMS mass calcd.: C13H25NO5H+ 276.1805; found: 276.1804. IR (cm−1) νmax 1061,
1546 (HN-C=O), 1622, 1652 (HN-C=O), 1722, 1742 (C=O), 2854, 2924, 2952, 3290 (N-H
or O-H). Chromatography: EtOAc:petroleum ether 4:1 Rf = 0.24. Melting point: 65-67 ◦C.
Colorless powder. Yield: 53%.
Compound 90 was synthesized by hydrolyzing methyl N-(3-hydroxynonanoyl)-L-serinate 89 (1
equiv, 0.36 mmol, 100 mg) according to general procedure C to yield 86 mg (0.33 mmol, 91%
yield) of compound 90. Diastereomers (ratio 1:1) could not be separated.
OOH
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N-(3-Hydroxynonanoyl)-L-serine 90. Spectral data were ob-
tained from a 1:1 mixture of diastereomers. 1H NMR (400 MHz,
CD3OD): δ = 0.81 (3H, t, J = 6.8 Hz, CH3), 1.10-1.45 (10H, m,
(CH2)5CH3), 2.25-2.35 (2H, m, COCH2CHOH), 3.73 (1H, dd, J = 11.2 Hz, 3.9 Hz, CHH’OH),
3.81 (1H, ddd, J = 11.2 Hz, 4.8 Hz, 1.9 Hz, CHH’OH), 3.83-3.92 (1H, m, CHOH), 4.41 (1H,
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dd, J = 7.8 Hz, 4.0 Hz, CHNH) ppm. 13C NMR (100 MHz, CD3OD): δ = 13.0 (CH3), 22.3,
25.21, 25.22, 29.0, 31.6, 36.8 ((CH2)5CH3), 43.1, 43.2 (COCH2CHOH), 54.7 (CHNH), 61.48,
61.55 (CH2OH), 68.3, 68.4 (CHOH), 172.0 (CONH), 172.96, 173.02 (COO) ppm. MS (ESI):
m/z (%): 262 (M+H+, 100), 284 (M+Na+, 40). HRMS mass calcd.: C12H23NO5H+ 262.1649;
found: 262.1653. IR (cm−1) νmax 1055, 1204, 1414, 1531 (HN-C=O), 1614 (HN-C=O), 1657,
1728 (C=O), 2851, 2920, 3341 (N-H or O-H). Melting point: 112-114 ◦C. Colorless powder.
Yield: 91%.
Synthesis of proline derivatives
Compound 96 was synthesized by reacting L-proline methyl ester hydrochloride 95 (1 equiv,
10 mmol, 1.66 g) with β-hydroxynonanoic acid 58d (1 equiv, 10 mmol, 1.74 g), following
general procedure A. After purification via flash chromatography (ethyl acetate:petroleum ether
1:1), 1.67 g (6.6 mmol, 66% yield) of compound 96 was obtained. Diastereomers (ratio 1:1)
could not be separated via flash chromatography. Both diastereomers existed as a mixture of
two rotamers in a 5:1 ratio.
N
O OMe
O OH
96
Methyl N-(3-hydroxynonanoyl)-L-prolinate 96. Spectral data were
obtained from a 1:1 mixture of diastereomers. 1H NMR (400 MHz,
CDCl3): δ = 0.88 (3H, t, J = 6.5 Hz, CH2CH3), 1.21-1.62 (10H, m,
(CH2)5CH3), 1.88-2.26 (4H, m, (CH2)2CH2N), 2.26-2.55 (2H, m, COCH2CHOH), 3.45-3.75
(2H, m, CH2N), 3.74, 3.75 (2.5H, 2 x s, OCH3), 3.766, 3.772 (0.5H, 2 x s, OCH3), 3.95-4.10
(1H, m, CHOH), 4.37 (0.1H, dd, J = 8.6 Hz, 2.5 Hz, CHN), 4.41 (0.1H, dd, J = 8.4 Hz, 2.6 Hz,
CHN), 4.49 (0.4H, dd, J = 8.6 Hz, 3.7 Hz, CHN), 4.53 (0.4H, dd, J = 8.4 Hz, 3.5 Hz, CHN) ppm.
13C NMR (100 MHz, CDCl3): δ = 14.0 (CH2CH3), 22.5, 29.10, 29.14, 29.2, 29.6, 31.7, 36.4,
36.5 ((CH2)5CH3), 24.5, 24.6, 25.4, 25.5 ((CH2)2CH2N), 40.2, 40.6 (COCH2CHOH), 40.69,
40.71 (COCH2CHOH), 46.1, 46.2 (CH2N), 47.0, 47.1 (CH2N), 52.18, 52.20 (OCH3), 52.5,
52.6 (OCH3), 58.4, 58.5 (CHN), 59.2, 59.4 (CHN), 67.7, 68.0 (CHOH), 68.1, 68.3 (CHOH),
171.7, 171.8 (CON), 171.9, 172.0 (CON), 172.2, 172.3 (COO), 172.6 (COO) ppm. MS (ESI):
m/z (%): 286 (M+H+, 100). HRMS mass calcd.: C15H27NO4H+ 286.2013; found: 286.2012.
IR (cm−1) νmax 1038, 1173, 1196, 1300, 1373, 1393, 1435, 1626 (N-C=O), 1744 (C=O), 2859,
2928, 2953, 3438 (O-H). Chromatography: EtOAc:petroleum ether 1:1 Rf = 0.12. Colorless oil.
Yield: 66%.
Compound 97 was synthesized by hydrolyzing methyl N-(3-hydroxynonanoyl)-L-prolinate 96
(1 equiv, 5 mmol, 1.43 g) according to general procedure C to give 1.21 g (4.45 mmol) of
compound 97 in 89% yield. Both diastereomers existed as a mixture of two rotamers in a 5:1
164
Experimental part
ratio.
N
O OH
O OH
97
N-(3-Hydroxynonanoyl)-L-proline 97. Spectral data were obtained
from a mixture of two diastereomers in a 1:1 ratio. 1H NMR (400
MHz, CDCl3): δ = 0.88 (3H, t, J = 6.4 Hz, CH3), 1.23-1.61 (10H,
m, (CH2)5CH3), 1.88-2.38 (4H, m, (CH2)2CH2N), 2.38-2.56 (2H, m, COCH2CHOH), 3.45-
3.76 (2H, m, CH2N), 4.03-4.11 (1H, m, CHOH), 4.37 (0.1H, dd, J = 6.9 Hz, 4.0 Hz, CHN),
4.46 (0.1H, dd, J = 7.5 Hz, 3.3 Hz, CHN), 4.50-4.58 (0.8H, m, CHN), 7.50 (1H, br s, COOH)
ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1 (CH3), 21.0, 28.7, 28.8, 29.2, 31.8, 36.1, 36.4, 36.5
((CH2)5CH3), 24.5, 24.6, 25.49, 25.51 ((CH2)2CH2N), 40.6, 40.7 (COCH2CHOH), 40.9, 41.1
(COCH2CHOH), 46.4 (CH2N), 47.5, 47.6 (CH2N), 59.02, 58.98 (CHN), 59.4, 59.5 (CHN),
68.0, 68.5 (CHOH), 172.2, 172.4 (CON and COO), 172.7, 172.8 (CON), 174.3 (COO) ppm.
MS (ESI): m/z (%): 272 (M+H+, 100). HRMS mass calcd.: C14H25NO4H+ 272.1856; found:
272.1865. IR (cm−1) νmax 1045, 1173, 1198, 1240, 1373, 1392, 1628 (N-C=O), 1703, 1740
(C=O), 2889, 2930, 2972, 2982, 3448 (O-H), 3651 (O-H). Melting point: 51-53 ◦C. Colorless
powder. Yield: 89%.
Compound 98 was synthesized by ring closing carboxylic acid 97 (1 equiv, 2 mmol, 0.54 g)
according to general procedure D to give 0.43 g of cyclic compound 98 in 84% yield after
flash chromatography (ethyl acetate:petroleum ether 1:1). Diastereomers (ratio 1:1) could not
be separated via flash chromatography.
N
O
O
O
98
(9aS)-3-Hexylhexahydro-1H,5H-pyrrolo[2,1-c][1,4]oxazepine-1,5 -
dione 98. Spectral data were obtained from a mixture of two dia-
stereomers in a 1:1 ratio. 1H NMR (400 MHz, CDCl3): δ = 0.89 (3H, t,
J = 6.5 Hz, CH3), 1.24-1.55 (8H, m, (CH2)4CH3), 1.56-1.80 (2H, m,
CH2(CH2)4CH3), 1.80-2.02 (2H, m, NCH2CH2), 2.15-2.24 (1H, m, NCH2CH2CHH’), 2.55-
2.64 (1H, m, NCH2CH2CHH’), 2.76 (1H, dd, J = 18.5 Hz, 11.5 Hz, COCHH’CH-O), 2.86
(1H, dd, J = 18.5 Hz, 2.4 Hz, COCHH’CH-O), 3.58-3.69 (2H, m, CH2N), 4.67 (1H, dd, J
= 7.0 Hz, 7.0 Hz, CHN), 4.72-4.82 (1H, m, CH-O) ppm. 13C NMR (100 MHz, CDCl3): δ
= 14.0 (CH3), 22.0 (NCH2CH2), 22.5, 25.2, 29.6, 31.6 ((CH2)4CH3), 28.9 (NCH2CH2CH2),
35.0 (CH2(CH2)4CH3), 42.4 (COCH2CH-O), 48.3 (CH2N), 55.7 (CHN), 73.5 (CH-O), 166.9
(CON), 169.6 (COO) ppm. MS (ESI): m/z (%): 254 (M+H+, 100). HRMS mass calcd.:
C14H23NO3H+ 254.1751; found: 254.1763. IR (cm−1) νmax 1223, 1383, 1438, 1616 (N-C=O),
1748 (C=O), 2859, 2902. Melting point: 87-89 ◦C. Colorless powder. Yield: 84%.
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Synthesis of sarcosine derivatives
Compound 106 was synthesized by reacting sarcosine methyl ester hydrochloride 104 (1 equiv,
10 mmol, 1.40 g) with β-hydroxydodecanoic acid 58g (1 equiv, 10 mmol, 2.16 g), following
general procedure A. After flash chromatography (ethyl acetate:petroleum ether 3:1), 1.87 g
(6.2 mmol, 62% yield) of compound 106 was obtained.
OOH
N
OMe
OMe106
Methyl N-(3-hydroxydodecanoyl)sarcosinate 106. Spec-
tral data were obtained from a mixture of two rotamers
in a 4:1 ratio. 1H NMR (400 MHz, CDCl3): δ rotamer
1 (major): 0.88 (3H, t, J = 6.8 Hz, CH2CH3), 1.19-1.61 (16H, m, (CH2)8CH3), 2.40 (1H, dd,
J = 16.5 Hz, 9.4 Hz, COCHH’CHOH), 2.55 (1H, dd, J = 16.5 Hz, 2.4 Hz, COCHH’CHOH),
3.07 (3H, s, NCH3), 3.75 (3H, s, OCH3), 3.93 (1H, br d, J = 2.8 Hz, CHOH), 3.98-4.07 (1H,
m, CHOH), 4.09 (1H, d, J = 17.3 Hz, CHH’N), 4.19 (1H, d, J = 17.4 Hz, CHH’N) ppm; ro-
tamer 2 (minor): 0.88 (3H, t, J = 6.8 Hz, CH2CH3), 1.19-1.61 (16H, m, (CH2)8CH3), 2.25
(1H, dd, J = 16.2 Hz, 9.2 Hz, COCHH’CHOH), 2.35-2.41 (1H, m, COCHH’CHOH), 2.99
(3H, s, NCH3), 3.79 (3H, s, OCH3), 3.98-4.07 (2H, m, CHOH and CHOH), 3.99 (1H, d, J =
18.2 Hz, CHH’N), 4.10 (1H, d, J = 18.2 Hz, CHH’N) ppm. 13C NMR (100 MHz, CDCl3):
δ rotamer 1 (major): 14.1 (CH2CH3), 22.6, 29.3, 29.5, 29.6, 31.9, 36.4 ((CH2)8CH3), 36.5
(NCH3), 39.5 (COCH2CHOH), 49.1 (CH2N), 52.2 (OCH3), 68.7 (CHOH), 169.6 (CON), 173.6
(COO) ppm; rotamer 2 (minor): 14.1 (CH2CH3), 22.6, 29.3, 29.5, 29.6, 31.9, 36.4 ((CH2)8CH3),
34.7 (NCH3), 39.2 (COCH2CHOH), 51.3 (CH2N), 52.5 (OCH3), 68.7 (CHOH), 169.1 (CON),
173.3 (COO) ppm. MS (ESI): m/z (%): 302 (M+H+, 100). HRMS mass calcd.: C16H31NO4H+
302.2326; found: 302.2337. IR (cm−1) νmax 1210, 1418, 1471, 1489, 1634 (N-C=O), 1746
(C=O), 2852, 2922, 2954, 3478 (O-H). Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.29.
Melting point: 52-54 ◦C. Colorless powder. Yield: 62%.
Compound 108 was synthesized by hydrolyzing 1.56 g of methyl ester 106 (1 equiv, 5.2 mmol)
according to general procedure C to yield 1.33 g (4.6 mmol, 89% yield) of compound 108.
OOH
N
OH
OMe108
N-(3-Hydroxydodecanoyl)sarcosine 108. Spectral data
were obtained from a mixture of two rotamers in a 3:1
ratio. 1H NMR (400 MHz, CDCl3): δ rotamer 1 (ma-
jor): 0.89 (3H, t, J = 6.8 Hz, CH2CH3), 1.19-1.65 (16H, m, (CH2)8CH3), 2.49 (1H, dd, J
= 16.3 Hz, 9.2 Hz, COCHH’CHOH), 2.57 (1H, dd, J = 16.2 Hz, 2.7 Hz, COCHH’CHOH),
3.10 (3H, s, NCH3), 3.97-4.21 (3H, m, CHOH and CH2N), 7.85 (1H, br s, COOH) ppm; ro-
tamer 2 (minor): 0.89 (3H, t, J = 6.8 Hz, CH2CH3), 1.19-1.65 (16H, m, (CH2)8CH3), 2.40-
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2.50 (2H, m, COCH2CHOH), 3.01 (3H, s, NCH3), 3.97-4.21 (3H, m, CHOH and CH2N),
7.85 (1H, br s, COOH) ppm. 13C NMR (100 MHz, CDCl3): δ rotamer 1 (major): 14.1
(CH2CH3), 22.7, 25.6, 25.7, 29.3, 29.5, 29.6, 31.9, 35.9, 36.3 ((CH2)8CH3), 36.8 (NCH3), 39.6
(COCH2CHOH), 49.5 (CH2N), 68.2 (CHOH), 172.2 (CON), 174.1 (COO) ppm; rotamer 2
(minor): 14.1 (CH2CH3), 22.7, 25.6, 25.7, 29.3, 29.5, 29.6, 31.9, 35.9, 36.3 ((CH2)8CH3), 35.0
(NCH3), 39.2 (COCH2CHOH), 51.3 (CH2N), 68.7 (CHOH), 171.3 (CON), 173.6 (COO) ppm.
MS (ESI): m/z (%): 288 (M+H+, 100). HRMS mass calcd.: C15H29NO4H+ 288.2169; found:
288.2172. IR (cm−1) νmax 1258, 1402, 1418, 1497, 1638 (N-C=O), 1726 (C=O), 2849, 2918,
3353 (O-H). Melting point: 71-73 ◦C. Colorless powder. Yield: 83%.
Cyclic compound 110 was synthesized by ring closing carboxylic acid 108 (1 equiv, 0.50 mmol,
0.14 g) according to general procedure D. After purification via flash chromatography (ethyl
acetate:petroleum ether 2:1), 84 mg (0.31 mmol, 62% yield) of cyclic compound 110 was ob-
tained.
NO
O
O
Me
110
4-Methyl-7-nonyl-1,4-oxazepane-2,5-dione 110. 1H NMR (400
MHz, CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz, CH2CH3), 1.20-
1.80 (16H, m, (CH2)8CH3), 2.85 (1H, dd, J = 17.5 Hz, 9.5
Hz, COCHH’CH-O), 2.91 (1H, dd, J = 17.5 Hz, 3.7 Hz,
COCHH’CH-O), 3.08 (3H, s, NCH3), 3.96 (1H, d, J = 15.8 Hz, CHH’N), 4.53 (1H, d, J =
15.8 Hz, CHH’N), 4.63-4.71 (1H, m, CH-O) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.3
(CH2CH3), 22.8, 25.2, 29.35, 29.42, 29.57, 29.62, 32.0, 35.7 ((CH2)8CH3), 37.2 (NCH3), 42.3
(COCH2CH-O), 52.7 (CH2N), 76.1 (CH-O), 167.8 (CON), 168.9 (COO) ppm. MS (ESI): m/z
(%): 270 (M+H+, 100). HRMS mass calcd.: C15H27NO3H+ 270.2064; found: 270.2058. IR
(cm−1) νmax 1213, 1339, 1493, 1624 (N-C=O), 1736 (C=O), 2857; 2924. Chromatography:
EtOAc:petroleum ether 2:1 Rf = 0.23. Melting point: 81-83 ◦C. Colorless powder. Yield: 62%.
Synthesis of glycine derivatives
Compound 107 was synthesized by reacting glycine methyl ester hydrochloride 105 (1 equiv,
15 mmol, 1.89 g) with β-hydroxydodecanoic acid 58g (1 equiv, 15 mmol, 3.24 g), following
general procedure A. After purification via flash chromatography (ethyl acetate:petroleum ether
3:1), 2.83 g (9.9 mmol, 66% yield) of compound 107 was obtained.
OOH
N
H
OMe
O107
Methyl N-(3-hydroxydodecanoyl)glycinate 107. 1H
NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.9 Hz,
CH2CH3), 1.19-1.59 (16H, m, (CH2)8CH3), 2.32 (1H,
dd, J = 15.1 Hz, 9.1 Hz, COCHH’CHOH), 2.44 (1H, dd, J = 15.1 Hz, 2.7 Hz, COCHH’CHOH),
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3.34 (1H, br d, J = 3.6 Hz, CHOH), 3.77 (3H, s, OCH3), 3.97-4.05 (1H, m, CHOH), 4.06-
4.14 (2H, m, CH2NH), 6.34 (1H, br s, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.1
(CH2CH3), 22.7, 25.4, 25.5, 29.3, 29.55, 29.59, 31.9, 36.9 ((CH2)8CH3), 41.1 (CH2NH), 42.7
(COCH2CHOH), 52.5 (OCH3), 68.7 (CHOH), 170.6 (CONH), 172.7 (COO) ppm. MS (ESI):
m/z (%): 288 (M+H+, 100). HRMS mass calcd.: C15H29NO4H+ 288.2169; found: 288.2168. IR
(cm−1) νmax 1221, 1379, 1392, 1434, 1442, 1550 (HN-C=O), 1643 (HN-C=O), 1742 (C=O),
2851, 2919, 2956, 3312 (O-H). Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.27. Melt-
ing point: 77-79 ◦C. Colorless powder. Yield: 66%.
Compound 109 was synthesized by hydrolyzing methyl ester 107 (1 equiv, 6.1 mmol, 1.75 g)
according to general procedure C to yield 1.35 g (4.9 mmol, 81% yield) of compound 109.
OOH
N
H
OH
O109
N-(3-Hydroxydodecanoyl)glycine 109. 1H NMR (400
MHz, CD3OD): δ = 0.80 (3H, t, J = 6.9 Hz, CH3), 1.14-
1.43 (16H, m, (CH2)8CH3), 2.25 (1H, dd, J = 14.3 Hz,
7.6 Hz, COCHH’CHOH), 2.30 (1H, dd, J = 14.3 Hz, 5.3 Hz, COCHH’CHOH), 3.78 (1H, d, J =
17.8 Hz, CHH’NH), 3.85 (1H, d, J = 17.8 Hz, CHH’NH), 3.84-3.90 (1H, m, CHOH) ppm. 13C
NMR (100 MHz, CD3OD): δ = 13.1 (CH3), 22.3, 25.3, 29.1, 29.3, 31.7, 36.7 ((CH2)8CH3), 40.4
(CH2NH), 43.2 (COCH2CHOH), 68.3 (CHOH), 171.7 (CONH), 173.3 (COO) ppm. MS (ESI):
m/z (%): 274 (M+H+, 100), 296 (M+Na+, 28). HRMS mass calcd.: C14H27NO4H+ 274.2013;
found: 274.2009. IR (cm−1) νmax 1246, 1262, 1421, 1447, 1556 (HN-C=O), 1640 (HN-C=O),
1708 (C=O), 2849, 2922, 3262 (O-H), 3326 (O-H). Melting point: 92-94 ◦C. Colorless powder.
Yield: 94%.
Synthesis of N-benzyl-1,4-oxazepane-2,5-dione 116
Compound 114 was synthesized by reacting the methyl ester of N-benzyl glycine 113 (1 equiv,
3.0 mmol, 0.59 g) with β-hydroxynonanoic acid 58d (1 equiv, 3.0 mmol, 0.52 g), following
general procedure B to yield 0.55 g (1.6 mmol, 55% yield) of ester 114.
N
OMe
O
OOH
114
Methyl N-benzyl-N-(3-hydroxynonanoyl)glycinate 114. Spec-
tral data were obtained from a mixture of two rotamers in a 7:3
ratio. 1H NMR (400 MHz, CDCl3): δ rotamer 1 (major): 0.87
(3H, t, J = 6.6 Hz, CH2CH3), 1.26-1.61 (10H, m, (CH2)5CH3),
2.49 (1H, dd, J = 16.2 Hz, 9.4 Hz, COCHH’CHOH), 2.62 (1H, dd, J = 16.2 Hz, 2.4 Hz,
COCHH’CHOH), 3.73 (3H, s, OCH3), 3.85-4.15 (4H, m, CHOH and CHOH and CH2COO),
4.55-4.77 (2H, m, C6H5CH2N), 7.16-7.41 (5H, m, 5 x CHarom) ppm; rotamer 2 (minor): 0.87
(3H, t, J = 6.6 Hz, CH2CH3), 1.26-1.61 (10H, m, (CH2)5CH3), 2.32 (1H, dd, J = 16.3 Hz,
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9.3 Hz, COCHH’CHOH), 2.45 (1H, dd, J = 16.3 Hz, 2.3 Hz, COCHH’CHOH), 3.72 (3H, s,
OCH3), 3.85-4.15 (4H, m, CHOH and CHOH and CH2COO), 4.55-4.77 (2H, m, C6H5CH2N),
7.16-7.41 (5H, m, 5 x CHarom) ppm. 13C NMR (100 MHz, CDCl3): δ rotamer 1 (major): 14.1
(CH2CH3), 22.6, 25.5, 29.3, 31.8, 36.4 ((CH2)5CH3), 39.4 (COCH2CHOH), 46.9 (NCH2COO),
52.1 (C6H5CH2N), 52.2 (OCH3), 68.3 (CHOH), 126.7, 128.4, 129.1 (5 x CHarom) 135.6
(Carom), 169.7 (CON), 174.0 (COO) ppm; rotamer 2 (minor): 14.1 (CH2CH3), 22.6, 25.5,
29.3, 31.8, 36.4 ((CH2)5CH3), 39.4 (COCH2CHOH), 48.2 (NCH2COO), 49.5 (C6H5CH2N),
52.5 (OCH3), 68.2 (CHOH), 127.8, 128.0, 128.7 (5 x CHarom) 136.2 (Carom), 169.3 (CON),
173.4 (COO) ppm. MS (ESI): m/z (%): 336 (M+H+, 100). HRMS mass calcd.: C19H29NO4H+
336.2169; found: 336.2176. IR (cm−1) νmax 1001, 1175, 1200, 1368, 1406, 1435, 1452, 1634
(N-C=O), 1709, 1748 (C=O), 2857, 2928, 2953, 3451 (O-H). Yellow oil. Yield: 55%.
Compound 115 was synthesized by hydrolyzing methyl ester 114 (1 equiv, 1.5 mmol, 0.50 g)
according to general procedure C to give 0.41 g (1.3 mmol) of compound 115 in 86% yield.
N
OH
O
OOH
115
N-Benzyl-N-(3-hydroxynonanoyl)glycine 115. Spectral data
were obtained from a mixture of two rotamers in a 1.9:1 ra-
tio. 1H NMR (400 MHz, CDCl3): δ rotamer 1 (major): 0.86-
0.91 (3H, m, CH3), 1.19-1.68 (10H, m, (CH2)5CH3), 2.45-2.65
(2H, m, COCH2CHOH), 3.90-4.21 (3H, m, CHOH and CH2COO), 4.58 (1H, d, J = 16.8 Hz,
C6H5CHH’N), 4.78-4.86 (1H, m, C6H5CHH’N), 7.10-7.41 (5H, m, 5 x CHarom), 7.60 (1H, br
s, COOH) ppm; rotamer 2 (minor): 0.86-0.91 (3H, m, CH3), 1.19-1.68 (10H, m, (CH2)5CH3),
2.45-2.65 (2H, m, COCH2CHOH), 3.90-4.21 (3H, m, CHOH and CH2COO), 4.45-4.55 (1H, m,
C6H5CHH’N), 4.78-4.86 (1H, m, C6H5CHH’N), 7.10-7.41 (5H, m, 5 x CHarom), 7.60 (1H, br
s, COOH) ppm. 13C NMR (100 MHz, CDCl3): δ rotamer 1 (major): 14.1 (CH3), 22.61, 22.64,
25.5, 25.6, 29.2, 31.8, 35.9, 36.3 ((CH2)5CH3), 39.5 (COCH2CHOH), 47.1 (NCH2COO), 52.3
(C6H5CH2N), 68.5 (CHOH), 126.8, 128.4, 129.1 (5 x CHarom) 135.2 (Carom), 172.4 (CON),
174.4 (COO) ppm; rotamer 2 (minor): 14.1 (CH3), 22.61, 22.64, 25.5, 25.6, 29.2, 31.8, 35.9,
36.3 ((CH2)5CH3), 39.5 (COCH2CHOH), 48.0 (NCH2COO), 49.6 (C6H5CH2N), 68.7 (CHOH),
127.8, 128.1, 128.8 (5 x CHarom) 136.2 (Carom), 171.5 (CON), 173.6 (COO) ppm. MS (ESI):
m/z (%): 322 (M+H+, 100). HRMS mass calcd.: C18H27NO4H+ 322.2013; found: 322.2009. IR
(cm−1) νmax 1188, 1213, 1420, 1476, 1626 (N-C=O), 1730 (C=O), 2855, 2927, 3310 (O-H).
Melting point 91-93 ◦C. Colorless powder. Yield: 86%.
Cyclic compound 116 was synthesized by ring closing carboxylic acid 115 (1 equiv, 0.86 mmol,
0.28 g) according to general procedure D. After purification via flash chromatography (ethyl
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acetate:petroleum ether 4:1), 0.20 g (0.65 mmol, 75% yield) of cyclic compound 116 was ob-
tained.
NO
O
O
116
4-Benzyl-7-hexyl-1,4-oxazepane-2,5-dione 116. 1H NMR (400
MHz, CDCl3): δ = 0.88 (3H, t, J = 6.8 Hz, CH3), 1.21-1.55 (8H,
m, (CH2)4CH3), 1.58-1.81 (2H, m, CH2(CH2)4), 2.90-3.02 (2H,
m, COCH2CH-O), 3.94 (1H, d, J = 15.9 Hz, CHH’COO), 4.31
(1H, d, J = 15.9 Hz, CHH’COO), 4.49 (1H, d, J = 14.7 Hz, C6H5CHH’N), 4.67 (1H, tt, J = 12.6
Hz, 4.6 Hz, CH-O), 4.89 (1H, d, J = 14.7 Hz, C6H5CHH’N), 7.23-7.38 (5H, m, 5 x CHarom)
ppm. 13C NMR (100 MHz, CDCl3): δ = 14.0 (CH3), 22.5, 25.0, 28.9, 31.6 ((CH2)4CH3), 35.6
(CH2(CH2)4), 42.2 (COCH2CH-O), 50.2 (CH2COO), 52.1 (C6H5CH2N), 76.0 (CH-O), 128.1,
128.2, 129.0 (5 x CHarom), 135.9 (Carom), 167.5 (CON), 168.8 (COO) ppm. MS (ESI): m/z (%):
304 (M+H+, 100). HRMS mass calcd.: C18H25NO3H+ 304.1907; found: 304.1904. IR (cm−1)
νmax 1134, 1161, 1233, 1296, 1344, 1423, 1439, 1454, 1638 (N-C=O), 1749 (C=O), 2849,
2920, 2951. Chromatography: EtOAc:petroleum ether 4:1 Rf = 0.33. Melting point 53-55 ◦C.
Colorless powder. Yield: 75%.
Synthesis of N-PMB-1,4-oxazepane-2,5-dione 121
Compound 119 was synthesized by reacting the methyl ester of N-PMB glycine 118 (1 equiv, 25
mmol, 5.23 g) with β-hydroxynonanoic acid 58d (1 equiv, 25 mmol, 4.36 g), following general
procedure B to yield 7.1 g (19.5 mmol, 78% yield) of ester 119.
N
OMe
O
OOH
MeO
119
Methyl N-(3-hydroxynonanoyl)-N-(4-methoxybenzyl)glycinate
119. Spectral data were obtained from a mixture of two ro-
tamers in a 2.4:1 ratio. 1H NMR (400 MHz, CDCl3): δ ro-
tamer 1 (major): 0.85-0.90 (3H, m, CH2CH3), 1.21-1.63 (10H,
m, (CH2)5CH3), 2.50 (1H, dd, J = 16.1 Hz, 9.4 Hz, COCHH’CHOH), 2.63 (1H, dd, J = 16.2
Hz, 2.3 Hz, COCHH’CHOH), 3.72 (3H, s, COOCH3), 3.83 (3H, s, CaromOCH3), 3.84-4.03
(2H, m, CH2COO), 4.01-4.11 (1H, m, CHOH), 4.49-4.69 (2H, m, C6H5CH2N), 6.89 (2H,
d, J = 8.6 Hz, 2 x OCCHarom), 7.11 (2H, d, J = 8.6 Hz, 2 x CH2CCHarom) ppm; rotamer
2 (minor): 0.85-0.90 (3H, m, CH2CH3), 1.21-1.63 (10H, m, (CH2)5CH3), 2.30 (1H, dd, J =
16.3 Hz, 9.1 Hz, COCHH’CHOH), 2.43 (1H, dd, J = 16.3 Hz, 2.2 Hz, COCHH’CHOH), 3.71
(3H, s, COOCH3), 3.79 (3H, s, CaromOCH3), 3.84-4.03 (2H, m, CH2COO), 4.01-4.11 (1H, m,
CHOH), 4.49-4.69 (2H, m, C6H5CH2N), 6.85 (2H, d, J = 8.6 Hz, 2 x OCCHarom), 7.15 (2H,
d, J = 8.6 Hz, 2 x CH2CCHarom) ppm. 13C NMR (100 MHz, CDCl3): δ rotamer 1 (major):
14.1 (CH2CH3), 22.6, 25.5, 29.2, 29.3, 31.8, 36.4 ((CH2)5CH3), 39.4 (COCH2CHOH), 46.6
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(NCH2COO), 51.6 (C6H5CH2N), 52.2 (COOCH3), 55.33 (CaromOCH3), 68.3 (CHOH), 114.4
(2 x OCCHarom), 128.2 (2 x CH2CCHarom), 129.9 (CH2Carom), 159.4 (CH3OCarom), 169.7
(CON), 173.8 (COO) ppm; rotamer 2 (minor): 14.1 (CH2CH3), 22.6, 25.5, 29.2, 29.3, 31.8, 36.4
((CH2)5CH3), 39.5 (COCH2CHOH), 47.9 (NCH2COO), 48.9 (C6H5CH2N), 52.5 (COOCH3),
55.29 (CaromOCH3), 68.1 (CHOH), 114.1 (2 x OCCHarom), 127.3 (2 x CH2CCHarom), 128.6
(CH2Carom), 159.3 (CH3OCarom), 169.3 (CON), 173.4 (COO) ppm. MS (ESI): m/z (%): 366
(M+H+, 100). HRMS mass calcd.: C20H31NO5H+ 366.2275; found: 366.2268. IR (cm−1) νmax
1032, 1173, 1200, 1246, 1422, 1437, 1512, 1612, 1632 (N-C=O), 1748 (C=O), 2857, 2928,
2953, 3478 (O-H). Yellow oil. Yield: 78%.
Methyl ester 119 (1 equiv, 19.2 mmol, 7.0 g) was hydrolyzed following general procedure C to
yield 6.4 g (18.2 mmol) of carboxylic acid 120 in 95% yield.
N
OH
O
OOH
MeO
120
N-(3-Hydroxynonanoyl)-N-(4-methoxybenzyl)glycine 120. Spec-
tral data were obtained from a mixture of two rotamers in a
2.3:1 ratio. 1H NMR (400 MHz, CDCl3): δ rotamer 1 (major):
0.87-0.93 (3H, m, CH2CH3), 1.24-1.71 (10H, m, (CH2)5CH3),
2.58 (1H, dd, J = 16.0 Hz, 9.0 Hz, COCHH’CHOH), 2.65 (1H, dd, J = 16.0 Hz, 2.5 Hz,
COCHH’CHOH), 3.83 (3H, s, OCH3), 4.03 (1H, d, J = 17.4 Hz, CHH’COO), 4.11 (1H, d,
J = 17.3 Hz, CHH’COO), 4.01-4.21 (1H, m, CHOH), 4.54 (1H, d, J = 16.3 Hz, C6H5CHH’N),
4.63 (1H, d, J = 16.3 Hz, C6H5CHH’N), 6.92 (2H, d, J = 8.5 Hz, 2 x OCCHarom), 7.13 (2H, d,
J = 8.5 Hz, 2 x CH2CCHarom) ppm; rotamer 2 (minor): 0.87-0.93 (3H, m, CH2CH3), 1.24-1.71
(10H, m, (CH2)5CH3), 2.45-2.54 (2H, m, COCH2CHOH), 3.82 (3H, s, OCH3), 3.89 (1H, d, J =
18.7 Hz, CHH’COO), 3.95 (1H, d, J = 18.7 Hz, CHH’COO), 4.01-4.21 (1H, m, CHOH), 4.42
(1H, d, J = 14.7 Hz, C6H5CHH’N), 4.83 (1H, d, J = 14.8 Hz, C6H5CHH’N), 6.87 (2H, d, J =
8.5 Hz, 2 x OCCHarom), 7.18 (2H, d, J = 8.5 Hz, 2 x CH2CCHarom) ppm. 13C NMR (100 MHz,
CDCl3): δ rotamer 1 (major): 14.1 (CH2CH3), 22.6, 25.5, 25.6, 29.19, 29.23, 31.8, 35.8, 36.4
((CH2)5CH3), 39.6 (COCH2CHOH), 46.9 (NCH2COO), 51.8 (C6H5CH2N), 55.35 (OCH3),
68.4 (CHOH), 114.5 (2 x OCCHarom), 127.0 (CH2Carom), 128.3 (2 x CH2CCHarom), 159.5
(CH3OCarom), 172.4 (CON), 174.3 (COO) ppm; rotamer 2 (minor): 14.1 (CH2CH3), 22.6, 25.5,
25.6, 29.19, 29.23, 31.8, 35.8, 36.4 ((CH2)5CH3), 39.5 (COCH2CHOH), 47.6 (NCH2COO),
48.9 (C6H5CH2N), 55.29 (OCH3), 68.7 (CHOH), 114.2 (2 x OCCHarom), 128.2 (CH2Carom),
129.9 (2 x CH2CCHarom), 159.3 (CH3OCarom), 171.7 (CON), 173.4 (COO) ppm. MS (ESI):
m/z (%): 352 (M+H+, 100). HRMS mass calcd.: C19H29NO5H+ 352.2118; found: 352.2110.
IR (cm−1) νmax 1036, 1175, 1225, 1246, 1398, 1483, 1512, 1620 (N-C=O), 1724 (C=O), 2857,
2920, 3380 (O-H). Melting point: 70-72 ◦C. Colorless powder. Yield: 95%.
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Cyclic compound 121 was synthesized by ring closing carboxylic acid 120 (1 equiv, 17.5 mmol,
6.17 g) according to general procedure D. After purification via flash chromatography (ethyl
acetate:petroleum ether 1:1), 2.33 g (7 mmol, 40% yield) of compound 121 was obtained.
NO
O
O
OMe
121
7-Hexyl-4-(4-methoxybenzyl)-1,4-oxazepane-2,5-dione 121. 1H
NMR (400 MHz, CDCl3): δ = 0.88 (3H, t, J = 6.7 Hz, CH2CH3),
1.21-1.55 (8H, m, (CH2)4CH3), 1.56-1.80 (2H, m, CH2(CH2)4),
2.88-3.00 (2H, m, COCH2CH-O), 3.80 (3H, s, OCH3), 3.94
(1H, d, J = 15.9 Hz, CHH’COO), 4.28 (1H, d, J = 15.9 Hz,
CHH’COO), 4.43 (1H, d, J = 14.6 Hz, C6H5CHH’N), 4.64 (1H, tt, J = 12.7 Hz, 4.5 Hz, CH-O),
4.81 (1H, d, J = 14.6 Hz, C6H5CHH’N), 6.87 (2H, d, J = 8.6 Hz, 2 x OCCHarom), 7.19 (2H,
d, J = 8.6 Hz, 2 x CH2CCHarom) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.0 (CH2CH3),
22.5, 25.0, 28.8, 31.6 ((CH2)4CH3), 35.6 (CH2(CH2)4), 42.1 (COCH2CH-O), 50.0 (CH2COO),
51.4 (C6H5CH2N), 55.3 (OCH3), 76.0 (CH-O), 114.3 (2 x OCCHarom), 127.9 (CH2Carom),
129.6 (2 x CH2CCHarom), 159.4 (CH3OCarom), 167.6 (CON), 168.7 (COO) ppm. MS (ESI):
m/z (%): 334 (M+H+, 100). HRMS mass calcd.: C19H27NO4H+ 334.2013; found: 334.2001.
IR (cm−1) νmax 1032, 1175, 1182, 1204, 1223, 1244, 1306, 1325, 1352, 1512, 1628 (N-C=O),
1730 (C=O), 2855, 2926, 2954. Chromatography: EtOAc:petroleum ether 1:1 Rf = 0.28. Melt-
ing point: 54-56 ◦C. Colorless powder. Yield: 40%.
Removal of the N-PMB group of 121
N-PMB-protected 1,4-oxazepane-2,5-dione 121 (1 equiv, 6.9 mmol, 2.3 g) was dissolved in
250 mL of a 4:1 ethyl acetate-water mixture and cooled to 0 ◦C. Ceric ammonium nitrate
(CAN, 5 equiv, 34.5 mmol, 18.9 g) was added and after 2 h, 150 mL of a saturated solution
of aq. NaHCO3 was added. After a slow phase separation, the aqueous phase was extracted
twice with 150 mL of ethyl acetate. The combined organic phases were washed once with
brine. Drying with MgSO4, filtration and removal of the solvent in vacuo yielded the crude
seven-membered ring, which was purified immediately via column chromatography (ethyl ace-
tate:petroleum ether 1:1), to yield 200 mg of compound 122 as a colorless powder (14% yield).
NHO
O
O
122
7-Hexyl-1,4-oxazepane-2,5-dione 122. 1H NMR (400 MHz, CDCl3):
δ = 0.89 (3H, t, J = 6.5 Hz, CH3), 1.22-1.61 (8H, m, (CH2)4CH3),
1.61-1.83 (2H, m, CH2(CH2)4), 2.83 (2H, d, J = 6.8 Hz, COCH2CH-
O), 3.85 (1H, dd, J = 15.3 Hz, 7.4 Hz, CHH’COO), 4.40 (1H, d,
J = 15.3 Hz, CHH’COO), 4.72 (1H, quint., J = 6.5 Hz, CH-O), 6.18 (1H, d, J = 7.6 Hz,
NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.0 (CH3), 22.5, 25.1, 28.8, 31.6 ((CH2)4CH3),
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35.1 (CH2(CH2)4), 41.7 (COCH2CH-O), 44.5 (CH2COO), 74.7 (CH-O), 167.9 (CONH), 170.5
(COO) ppm. MS (ESI): m/z (%): 214 (M+H+, 100). HRMS mass calcd.: C11H19NO3H+
214.1438; found: 214.1438. IR (cm−1) νmax 1090, 1113, 1348, 1422, 1447, 1489, 1551 (HN-
C=O), 1638 (HN-C=O), 1707, 1738 (C=O), 2849, 2924, 2953, 3256 (N-H). Chromatography:
EtOAc:petroleum ether 1:1 Rf = 0.15. Melting point: 62-64 ◦C. Colorless powder. Yield: 14%.
Synthesis of N-(2-nitrobenzyl)-1,4-oxazepane-2,5-dione 136
To a stirred suspension of glycine methyl ester hydrochloride 105 (1 equiv, 20 mmol, 2.51 g)
in dry methanol (30 mL) under a nitrogen atmosphere and at 0 ◦C, was added triethylamine
(1 equiv, 20 mmol, 2.8 mL) followed by 2-nitrobenzaldehyde 132 (1.1 equiv, 22 mmol, 3.32
g). The bulb was entirely covered with aluminium foil and the reaction mixture was stirred
for 2 h at room temperature and then cooled down to 0 ◦C. Sodium borohydride (2 equiv, 20
mmol, 1.51 g) was portionwise added. The ice bath was removed and after 1 h the reaction was
quenched by the addition of H2O (50 mL). Extraction with diethyl ether (3 x 50 mL), wash-
ing with brine (50 mL), drying (MgSO4) and evaporation of the solvent in vacuo gave methyl
(2-nitrobenzyl)glycinate 133 (3.14 g, 70% crude yield) as a yellow oil. To avoid premature
photolysis, compound 133 was immediately N-acylated, hydrolyzed and cyclized according to
general procedures B, C and D. The resulting 1,4-oxazepane-2,5-dione 136 with a photolabile
N-protecting group was purified via column chromatography (ethyl acetate:petroleum ether 1:1)
to yield 7-hexyl-4-(2-nitrobenzyl)-1,4-oxazepane-2,5-dione 136 as a yellow powder in 40% to-
tal yield.
N
O
O
O
NO2
136
7-Hexyl-4-(2-nitrobenzyl)-1,4-oxazepane-2,5-dione 136. 1H NMR
(400 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.8 Hz, CH3), 1.22-1.56
(8H, m, (CH2)4CH3), 1.59-1.83 (2H, m, CH2(CH2)4), 2.93-3.06
(2H, m, COCH2CH-O), 3.95 (1H, d, J = 15.8 Hz, CHH’COO),
4.44 (1H, d, J = 15.7 Hz, CHH’COO), 4.66-4.72 (1H, m, CH-O), 4.72 (1H, d, J = 15.2
Hz, C6H5CHH’N), 4.86 (1H, d, J = 15.2 Hz, C6H5CHH’N), 7.53-7.63 (2H, m, 2 x CHarom),
8.11-8.20 (2H, m, 2 x CHarom) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.0 (CH3), 22.5,
25.0, 28.8, 31.5 ((CH2)4CH3), 35.6 (CH2(CH2)4), 42.1 (COCH2CH-O), 50.6 (CH2COO), 51.7
(C6H5CH2N), 76.0 (CH-O), 122.8, 123.2, 130.1, 134.0 (4 x CHarom), 138.2 (CH2Carom), 148.6
(O2NCarom), 167.1 (CON), 168.9 (COO) ppm. MS (ESI): m/z (%): 349 (M+H+, 100). IR
(cm−1) νmax 1108, 1215, 1246, 1402 (NO2), 1473, 1512, 1584 (NO2), 1614 (N-C=O), 1725
(C=O), 2867, 2915. Chromatography: EtOAc:petroleum ether 1:1 Rf = 0.19. Melting point:
48-50 ◦C. Yellow powder. Yield: 40%.
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Synthesis of PPG-protected test substrate 146
To a stirred suspension of glycine methyl ester hydrochloride 105 (1 equiv, 2.5 mmol, 0.32 g)
in methanol:DMF 1:1 (20 mL) at room temperature, was added 0.5 g 2-methoxy-6-nitrobenzal-
dehyde 142 (1.1 equiv, 2.8 mmol), followed by the addition of triethylamine (2 equiv, 5 mmol,
0.7 mL). The bulb was entirely covered with aluminium foil and the reaction mixture was stirred
for 1 h at room temperature. The bulb was placed in an ice bath and sodium borohydride (2
equiv, 5 mmol, 0.19 g) was added portionwise. The ice bath was removed and after stirring
overnight, the reaction was quenched by the addition of H2O (20 mL). Extraction with diethyl
ether (3 x 20 mL), washing with brine (2 x 20 mL), drying over MgSO4 and removal of the sol-
vent in vacuo gave methyl (2-methoxy-6-nitrobenzyl)glycinate 145 (0.41 g, 58% crude yield)
as a orange oil. 0.4 g Of methyl (2-methoxy-6-nitrobenzyl)glycinate 145 (1 equiv, 1.6 mmol)
was dissolved in 10 mL THF:H2O 1:1 in an aluminium foil-covered bulb, followed by the addi-
tion of potassium carbonate (2 equiv, 3.2 mmol, 0.44 g) and the dropwise addition of octanoyl
chloride 54e (1 equiv, 1.6 mmol, 0.27 mL). After vigorous stirring for 2 h at room tempera-
ture, the reaction mixture was extracted with ethyl acetate (3 x 15 mL). The combined organic
phases were washed (1 x 30 mL of a saturated aq. NaHCO3-solution, 1 x 30 mL brine) and dried
(MgSO4), followed by evaporation of the solvent in vacuo to yield crude 146. This compound
146 was purified via column chromatography (ethyl acetate:petroleum ether 2:1) to give 285
mg (30% total yield) of N-PPG protected ester 146 as an orange oil.
N
OMe
O
O
OMe
NO2
146
Methyl N-(2-methoxy-6-nitrobenzyl)-N-octanoylglycinate 146.
Spectral data were obtained from a mixture of two rotamers in
a 1.7:1 ratio. 1H NMR (400 MHz, CDCl3): δ rotamer 1 (major):
0.81-0.88 (3H, m, CH2CH3), 1.16-1.39 (8H, m, (CH2)4CH3),
1.61-1.70 (2H, m, CH2(CH2)4CH3), 2.56 (2H, t, J = 7.6 Hz, CH2CON), 3.62 (3H, s, COOCH3),
3.87 (3H, s, CaromOCH3), 3.89 (2H, s, NCH2COO), 4.77-4.80 (2H, m, CH2Carom), 7.05-
7.46 (3H, m, 3 x CHarom) ppm; rotamer 2 (minor): 0.81-0.88 (3H, m, CH2CH3), 1.16-
1.39 (8H, m, (CH2)4CH3), 1.47-1.61 (2H, m, CH2(CH2)4CH3), 2.12 (2H, t, J = 7.6 Hz,
CH2CON), 3.69 (3H, s, COOCH3), 3.84 (3H, s, CaromOCH3), 4.05 (2H, s, NCH2COO),
4.77-4.80 (2H, m, CH2Carom), 7.05-7.46 (3H, m, 3 x CHarom) ppm. 13C NMR (100 MHz,
CDCl3): δ rotamer 1 (major): 14.04 (CH2CH3), 22.6, 29.1, 29.4, 31.7 ((CH2)4CH3), 25.1
(CH2(CH2)4CH3), 32.8 (CH2CON), 42.0 (CH2Carom), 45.6 (NCH2COO), 51.8 (COOCH3),
56.3 (CaromOCH3), 114.8, 116.1, 129.4 (3 x CHarom), 118.0 (CH2Carom), 151.4 (CaromNO2),
158.9 (CaromOCH3), 169.8 (CON), 174.4 (COO) ppm; rotamer 2 (minor): 14.02 (CH2CH3),
22.5, 29.0, 29.2, 31.6 ((CH2)4CH3), 24.9 (CH2(CH2)4CH3), 33.1 (CH2CON), 40.9 (CH2Carom),
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49.7 (NCH2COO), 52.3 (COOCH3), 56.2 (CaromOCH3), 114.1, 115.8, 129.2 (3 x CHarom),
119.4 (CH2Carom), 150.7 (CaromNO2), 158.5 (CaromOCH3), 169.9 (CON), 173.6 (COO) ppm.
MS (ESI): m/z (%): 381 (M+H+, 100). IR (cm−1) νmax 1058, 1175, 1195, 1204, 1223, 1244,
1311, 1333, 1343 (NO2), 1542 (NO2), 1648 (N-C=O), 1720 (C=O), 2844, 2931. Chromatogra-
phy: EtOAc:petroleum ether 2:1 Rf = 0.26. Orange oil. Yield: 30%.
Synthesis of PPG-protected HO-AHL 154a
To a solution of 404 mg of ethyl 3-hydroxynonanoate 55d (1 equiv, 2 mmol) in 10 mL of anhy-
drous THF were added triethylamine (2.2 equiv, 4.4 mmol, 0.613 mL) and chlorotrimethylsilane
(2 equiv, 4 mmol, 0.51 mL). After stirring for 17 h at room temperature, 20 mL of diethyl ether
was added and the reaction mixture was cooled to 0 ◦C. Then 1 mL of a saturated aq. NaHCO3-
solution was added, followed by 25 mL of cold water. After phase separation, the aqueous phase
was washed twice with diethyl ether (2 x 20 mL). The combined organic phases were dried over
MgSO4, the drying agent was removed by filtration and after removal of the solvent in vacuo,
crude trimethyl silyl ether 151a was obtained.
To an ice-cold solution of this silyl ether 151a in anhydrous CH2Cl2 (20 mL) in an aluminium
foil-covered bulb was added 2-methoxy-6-nitrobenzaldehyde 142 (1 equiv, 2 mmol, 362 mg)
and trimethylsilyl triflate (0.1 equiv, 0.2 mmol, 40 µL). The resulting reaction mixture was
stirred at 0 ◦C for 1 h, followed by the addition of 0.32 mL of triethylsilane (1 equiv, 2 mmol).
The reaction mixture was allowed to warm to room temperature and stirred overnight. Then 60
mL of diethyl ether was added, followed by washing of the organic phase with a saturated aq.
NaHCO3-solution (40 mL) and brine (40 mL). Drying and evaporation of the solvent yielded
crude ethyl 3-((2-methoxy-6-nitrobenzyl)oxy)nonanoate 152a as an orange oil. This crude ester
152a was hydrolyzed with 5 equiv of NaOH (10 mmol, 5 mL of a 2M aq. solution) in 15 mL of
THF:MeOH 2:1. The reaction mixture was left to stir at room temperature overnight, followed
by an extraction step with hexane. The aqueous phase was acidified with 2M aq. HCl and ex-
tracted three times with ethyl acetate. After washing with brine, followed by drying (MgSO4)
and removal of the drying agent by filtration, the solvent was removed by rotary evaporation to
yield the crude hydrolyzed product 153a.
The crude PPG-protected fatty acid 153a (1 equiv, 2 mmol) was brought into an aluminium
foil-covered bulb with 5 mL of H2O, followed by the addition of 0.31 mL of Et3N (1 equiv, 2
mmol), 430 mg of EDC.HCl (1 equiv, 2 mmol) and 408 mL of lactone 53 (1 equiv, 2 mmol).
The turbid reaction mixture was stirred overnight at room temperature. Then 10 mL of water
and 10 mL of ethyl acetate were added. After phase separation, the aqueous phase was extracted
twice with 10 mL of ethyl acetate. The combined organic phases were washed with a saturated
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aq. NaHCO3-solution (20 mL) and brine (20 mL) to yield the crude PPG-protected AHL 154a.
Purification via column chromatography (ethyl acetate:petroleum ether 1:1) gave 204 mg of
pure 154a in 24% total yield.
O
N
H O
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N-(3-((2-methoxy-6-nitrobenzyl)oxy)nonanoyl)-L-homoserine
lactone 154a. Spectral data were obtained from a 1:1 mixture
of diastereomers. 1H NMR (400 MHz, CDCl3): δ = 0.90 (3H,
t, J = 6.5 Hz, CH2CH3), 1.23-1.42 (8H, m, (CH2)4CH3), 1.51-
1.75 (2H, m, CH2(CH2)4), 2.16-2.30 (1H, m, OCH2CHH’),
2.45 (1H, dd, J = 15.3 Hz, 6.8 Hz, CHH’CONH), 2.69 (1H, dd, J = 15.3 Hz, 3.3 Hz,
CHH’CONH), 2.68-2.77 (1H, m, OCH2CHH’), 3.76-3.84 (1H, m, CH-OCH2Carom), 3.95 (3H,
s, OCH3), 4.26 (1H, ddd, J = 10.7 Hz, 9.4 Hz, 6.1 Hz, OCHH’CH2), 4.42-4.51 (1H, m,
OCHH’CH2), 4.60-4.74 (1H, m, CHN), 4.78-4.86 (2H, m, OCH2Carom), 6.98 (1H, d, J = 7.1
Hz, NH), 7.17 (1H, d, J = 7.8 Hz, CHarom), 7.39-7.48 (2H, m, 2 x CHarom) ppm. 13C NMR (100
MHz, CDCl3): δ = 14.1 (CH2CH3), 22.6, 25.1, 29.3, 31.7 ((CH2)4CH3), 33.8 (CH2(CH2)4),
41.4 (CH2CONH), 49.2 (NCH), 56.3 (OCH3), 66.0 (CH2CH2O), 70.3 (OCH2Carom), 77.1
(CH-OCH2), 114.7, 116.1, 129.7 (CHarom), 119.8 (CH2Carom), 152.3 (CaromNO2), 158.5
(CaromOCH3), 171.6 (CON), 175.2 (COO) ppm. MS (ESI): m/z (%): 423 (M+H+, 100). IR
(cm−1) νmax 941, 1038, 1050, 1377, 1390 (NO2), 1548 (NO2), 1589 (HN-C=O), 1648 (HN-
C=O), 1771 (C=Olactone), 2832, 2933, 2987, 3212 (N-H). Chromatography: EtOAc:petroleum
ether 1:1 Rf = 0.1. Melting point: 62-64 ◦C. Yellow powder. Yield: 24%.
Synthesis of 2-tbutyloxazolidine protected oxazepane-2,5-dione 160b
tBu-Oxazolidine 157b (1.05 equiv, 4.0 mmol, 0.75 g) was N-acylated according to general pro-
cedure B. The N-acylated 2-tBu-oxazolidine 158b was immediately subjected to a hydrolysis
and cyclization reaction according to general procedures C and D. The crude oxazepane-2,5-
dione 160b, present as a 1:1 mixture of diastereomers, was purified via column chromatography
(Reveleris X2 automated flash chromatography instrument: gradient increase over 5 column vol-
umes (CV) from 100% hexane to 90% hexane 10% ethyl acetate, hold 5 CV, gradient increase
over 10 CV to 50% hexane - 50% ethyl acetate, hold 2 CV, then 2 CV 100% ethyl acetate) fol-
lowed by recrystallization in diethyl ether:hexane to successfully separate both diastereomers
and to give 0.28 g (0.91 mmol, 24% yield) of (RRS)-160b, 0.33 g (1.1 mmol, 28% yield) of
(RSS)-160b and 0.13 g (0.42 mmol, 11% yield) of a mixture of (RRS)/(RSS)-160b
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(S)
N
(R)
O
O
O
O (R)
H
160b
(3R,7R,9aS)-3-(tButyl)-7-hexyltetrahydro-3H,5H,9H-oxazolo[4,3-c]-
[1,4]oxazepine-5,9-dione (RRS)-160b (trans-diastereomer). 1H NMR
(400 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.8 Hz, CH2CH3), 0.95
(9H, s, C(CH3)3), 1.19-1.55 (8H, m, (CH2)4CH3), 1.63-1.84 (2H, m,
CH2(CH2)4CH3), 2.72 (1H, d, J = 16.6 Hz, COCHH’CH-O), 3.14 (1H, dd, J = 16.5 Hz, 11.2
Hz, COCHH’CH-O), 4.44 (1H, dd, J = 9.1 Hz, 9.1 Hz, CHH’-O), 4.52 (1H, dd, J = 9.3 Hz,
8.3 Hz, CHH’-O), 4.68-4.79 (2H, m, CH2CH-O and CH2CHN), 5.36 (1H, s, NCH-O) ppm.
13C NMR (100 MHz, CDCl3): δ = 14.0 (CH2CH3), 22.5, 24.5, 28.9, 31.6 ((CH2)4CH3), 25.9
(C(CH3)3), 37.2 (CH2(CH2)4CH3), 38.7 (C(CH3)3), 42.6 (COCH2CH-O), 59.4 (OOCCHN),
69.2 (CH2-O), 79.7 (CH2CH-O), 96.2 (NCH-O), 166.3 (CON), 171.7 (COO) ppm. MS (ESI):
m/z (%): 312 (M+H+, 100). HRMS mass calcd.: C17H29NO−4 310.2024; found: 310.2016. IR
(cm−1) νmax 1119, 1179, 1215, 1231, 1362, 1369, 1381, 1680 (N-C=O), 1703, 1711 (C=O),
2870, 2930, 2970, 2980. Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.29. Melting point:
94-96 ◦C. Colorless powder. Yield: 24%.
(S)
N
(S)
O
O
O
O (R)
H
160b
(3R,7S,9aS)-3-(tButyl)-7-hexyltetrahydro-3H,5H,9H-oxazolo[4,3-c]-
[1,4]oxazepine-5,9-dione (RSS)-160b (cis-diastereomer). 1H NMR
(400 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.8 Hz, CH2CH3), 0.95
(9H, s, C(CH3)3), 1.21-1.58 (8H, m, (CH2)4CH3), 1.61-1.89 (2H, m,
CH2(CH2)4CH3), 2.85 (1H, dd, J = 17.7 Hz, 9.8 Hz, COCHH’CH-O), 2.97 (1H, dd, J = 17.6
Hz, 2.6 Hz, COCHH’CH-O), 4.36 (1H, dd, J = 9.2 Hz, 8.0 Hz, CHH’-O), 4.62 (1H, dd, J = 9.2
Hz, 9.2 Hz, CHH’-O), 4.71-4.83 (2H, m, CH2CH-O and CH2CHN), 5.44 (1H, s, NCH-O) ppm.
13C NMR (100 MHz, CDCl3): δ = 14.0 (CH2CH3), 22.5, 24.5, 28.8, 31.5 ((CH2)4CH3), 26.4
(C(CH3)3), 35.5 (CH2(CH2)4CH3), 38.9 (C(CH3)3), 42.5 (COCH2CH-O), 55.1 (OOCCHN),
68.6 (CH2-O), 75.2 (CH2CH-O), 97.0 (NCH-O), 167.6 (CON), 168.5 (COO) ppm. MS (ESI):
m/z (%): 312 (M+H+, 100). HRMS mass calcd.: C17H29NO−4 310.2024; found: 310.2028. IR
(cm−1) νmax 1076, 1125, 1175, 1211, 1233, 1354, 1364, 1375, 1396, 1649 (N-C=O), 1738
(C=O), 2889, 2924, 2970, 2982. Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.28. Melt-
ing point: 96-98 ◦C. Colorless needle-like crystals. Yield: 28%.
The absolute configuration of (RSS)-160b was determined as C4 (S), C6 (R) and C1 (S) and con-
firmed by a refined Flack parameter of -0.03(12). Additionally, the C6H13 alkyl chain showed
positional disorder, which could be modeled in two parts with final occupancy factors of 0.502
and 0.498, respectively.
Crystal data for compound (RSS)-160b. C17H29NO4, M = 311.41, orthorhombic, space group
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P212121 (No. 19), a = 5.65117(9) Å, b = 11.07138(12) Å, c = 29.0073(4) Å, V = 1814.88(4)
Å3, Z = 4, T = 293(2) K, ρcalc = 1.140 g cm−3, µ(Cu-Kα) = 0.647 mm−1, F(000) = 680, 62469
reflections measured, 3718 unique (Rint = 0.0826) which were used in all calculations. The final
R1 was 0.0531 (I >2σ (I )) and wR2 was 0.1624 (all data). The asymmetric unit contains two
crystallographic independent molecules.
Synthesis of 2,2-dimethyloxazolidine protected oxazepane-2,5-dione 160c
To methyl N-(3-hydroxynonanoyl)-L-serinate 89 (1 equiv, 2 mmol, 0.55 mg), dissolved in dry
toluene (20 mL) under a nitrogen atmosphere, were sequentially added 2,2-dimethoxypropane
(DMP) (5 equiv, 10 mmol, 1.2 mL) and p-toluenesulfonic acid monohydrate (0.1 equiv, 0.2
mmol, 40 mg). The mixture was heated at reflux in a Dean-Stark apparatus for 3 h to remove
water. After cooling to ambient temperature, water (20 mL) was added. The aqueous phase was
extracted twice with ethyl acetate (2 x 20 mL), the organic phases were combined and washed
with brine (20 mL), dried (MgSO4), filtered and the solvent was removed in vacuo. The crude
oxazolidine 158c was hydrolyzed and cyclized according to the general procedures C and D
to yield compound 160c (0.10 g, 0.36 mmol) in 18% total yield after column chromatography
(Reveleris X2 automated flash chromatography instrument: 5 column volumes (CV) 100% hex-
ane, gradient increase over 15 CV to 50% hexane - 50% ethyl acetate, hold 2 CV, then 2 CV
100% ethyl acetate). Diastereomers (ratio 1.3:1) could not be separated via flash chromatogra-
phy.
N
O
O
O
O
H
160c
(9aS)-7-Hexyl-3,3-dimethyltetrahydro-3H,5H,9H-oxazolo[4,3-c][1,4]-
oxazepine-5,9-dione 160c. Spectral data were obtained from a 1.3:1
mixture of diastereomers. 1H NMR (400 MHz, CDCl3): δ diastereo-
mer 1 (major): 0.91 (3H, t, J = 6.8 Hz, CH2CH3), 1.25-1.82 (10H,
m, (CH2)5CH3), 1.61, 1.64, (2 x 3H, 2 x s, C(CH3)2), 2.63 (1H, dd, J = 15.1 Hz, 2.2 Hz,
COCHH’CH-O), 3.06 (1H, dd, J = 15.1 Hz, 11.7 Hz, COCHH’CH-O), 4.23-4.33 (1H, m,
CHH’-O), 4.59-4.67 (1H, m, CHH’-O), 4.70-4.81 (2H, m, CH-O and CHN) ppm; diastereo-
mer 2 (minor): 0.91 (3H, t, J = 6.8 Hz, CH2CH3), 1.25-1.82 (10H, m, (CH2)5CH3), 1.62, 1.69
(2 x 3H, 2 x s, C(CH3)2), 2.80 (1H, dd, J = 18.5 Hz, 10.8 Hz, COCHH’CH-O), 2.88 (1H, dd,
J = 18.5 Hz, 2.8 Hz, COCHH’CH-O), 4.23-4.33 (1H, m, CHH’-O), 4.51 (1H, dd, J = 9.6 Hz,
7.6 Hz, CHH’-O), 4.59-4.67 (1H, m, CHN), 4.70-4.81 (1H, m, CH-O) ppm. 13C NMR (100
MHz, CDCl3): δ diastereomer 1 (major): 14.0 (CH2CH3), 22.5, 24.5, 28.8, 28.9, 31.6, 34.8,
37.5 ((CH2)5CH3), 23.5, 24.9 (C(CH3)2), 25.1 (C(CH3)2), 43.1 (COCH2CH-O), 59.7 (CHN),
65.8 (CH2-O), 79.8 (CH-O), 96.6 (O-C-N), 164.8 (CON), 167.9 (COO) ppm; diastereomer
2 (minor): 14.0 (CH2CH3), 22.5, 24.5, 28.8, 28.9, 31.6, 34.8, 37.5 ((CH2)5CH3), 23.8, 25.3
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(C(CH3)2), 25.1 (C(CH3)2), 43.4 (COCH2CH-O), 54.6 (CHN), 65.7 (CH2-O), 73.8 (CH-O),
98.3 (O-C-N), 166.9 (CON), 167.1 (COO) ppm. MS (ESI): m/z (%): 284 (M+H+, 100). HRMS
mass calcd.: C15H25NO4H+ 284.1856; found: 284.1856. IR (cm−1) νmax 1072, 1085, 1155,
1209, 1233, 1252, 1335, 1381, 1418, 1632 (N-C=O), 1667, 1703, 1742 (C=O), 2889, 2916,
2932, 2972, 2982. Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.21. Melting point: 88-
90 ◦C. Colorless needle-like crystals. Yield: 18%.
Synthesis of 2-phenyloxazolidine protected oxazepane-2,5-dione 160a
To a stirred solution of L-serine methyl ester hydrochloride 88 (1 equiv, 20 mmol, 3.1 g) in 60
mL of anhydrous CH2Cl2 and 15 mL Et3N at room temperature was added 4.8 g of anhydrous
MgSO4 (2 equiv, 40 mmol), followed by freshly distilled benzaldehyde 112 (1.1 equiv, 22 mmol,
2.24 mL) under a nitrogen atmosphere. The reaction mixture was stirred at room temperature
overnight, filtered and the filtrate was concentrated under reduced pressure. The resulting 2-
phenyloxazolidine 157a was N-acylated analogously to the tBu-derivative 157b, followed by
hydrolysis and cyclization (procedures C and D) to give the 1,4-oxazepane-2,5-dione 160a, as
a 1:1-mixture of diastereomers in 53% overall yield (3.5 g, 10.6 mmol). Diastereomers (ratio
1:1) could not be separated via flash chromatography (ethyl acetate:petroleum ether 3:1).
N
O
O
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160a
(3R,9aS)-7-Hexyl-3-phenyltetrahydro-3H,5H,9H-oxazolo[4,3-c][1,4]-
oxazepine-5,9-dione 160a. Spectral data were obtained from a 1:1
mixture of diastereomers. 1H NMR (400 MHz, CDCl3): δ diastereo-
mer 1: 0.88-0.95 (3H, m, CH3), 1.28-1.90 (10H, m, (CH2)5CH3), 2.75
(1H, d, J = 15.8 Hz, COCHH’CH-O), 3.17 (1H, dd, J = 15.8 Hz, 11.2
Hz, COCHH’CH-O), 4.35-4.44 (1H, m, CHH’-O), 4.47-4.54 (1H, m, CHH’-O), 4.75-4.83 (1H,
m, CH2CH-O), 4.85-4.97 (1H, m, CH2CHN), 6.50 (1H, s, NCH-O), 7.27-7.42 (5H, m, 5 x
CHarom) ppm; diastereomer 2: 0.88-0.95 (3H, m, CH2CH3), 1.28-1.90 (10H, m, (CH2)5CH3),
2.91 (2H, d, J = 6.8 Hz, COCH2CH-O), 4.35-4.44 (1H, m, CHH’-O), 4.47-4.54 (1H, m,
CHH’-O), 4.75-4.83 (1H, m, CH2CH-O), 4.85-4.97 (1H, m, CH2CHN), 6.52 (1H, s, NCH-
O), 7.27-7.42 (5H, m, 5 x CHarom) ppm. 13C NMR (100 MHz, CDCl3): δ diastereomer 1: 14.0
(CH3), 22.5, 24.5, 28.9, 31.57, 35.1 ((CH2)5CH3), 41.9 (COCH2CH-O), 59.0 (CH2CHN), 68.1
(CH2-O), 79.9 (CH2CH-O), 89.9 (O-CHN), 126.1, 128.7, 129.2 (5 x CHarom), 137.2 (Carom),
165.4 (CON), 169.3 (COO) ppm; diastereomer 2: 14.0 (CH3), 22.5, 24.5, 28.8, 31.58, 37.4
((CH2)5CH3), 42.1 (COCH2CH-O), 54.2 (CH2CHN), 67.1 (CH2-O), 74.2 (CH2CH-O), 91.7
(O-CHN), 126.3, 126.8, 129.1 (5 x CHarom) 137.0 (Carom), 166.0 (CON), 167.5 (COO) ppm.
MS (ESI): m/z (%): 332 (M+H+, 100). HRMS mass calcd.: C19H25NO4H+ 332.1856; found:
332.1868. IR (cm−1) νmax 1061, 1117, 1221, 1389, 1425, 1655 (N-C=O), 1676, 1703, 1724
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(C=O), 2857, 2926, 2953. Chromatography: EtOAc:petroleum ether 3:1 Rf = 0.14. Melting
point: 96-98 ◦C. Colorless powder. Yield: 53%.
Debenzylation of 2-phenyloxazolidine 160a
500 mg (1 equiv, 1.5 mmol) of 2-phenyloxazolidine 160a (d.r. 1:1) was dissolved in 30 mL of
ethyl acetate whereafter 250 mg of Pd(OH)2/C (20 wt% loading) was added and the reaction
mixture was stirred under a H2 atmosphere at room temperature for 6 h. Subsequently, the re-
action mixture was filtered through celite and the solvent removed in vacuo. The crude mixture
was purified via column chromatography (ethyl acetate: petroleum ether 1:1 to 100% ethyl ace-
tate) to yield 82 mg (0.32 mmol, 22% yield) of deprotected compound 83, alongside with 334
mg (1 mmol) of recovered 2-phenyloxazolidine 160a (d.r. 1:3).
(S)
HN
(S)
O
O
O
HO
83
(3S,7S)-7-Hexyl-3-(hydroxymethyl)-1,4-oxazepane-2,5-dione (SS)-
83. 1H NMR (400 MHz, CDCl3): δ = 0.89 (3H, t, J = 6.7 Hz, CH3),
1.23-1.57 (8H, m, (CH2)4CH3), 1.58-1.83 (2H, m, CH2(CH2)4CH3),
2.60-2.66 (1H, m, CH2OH), 2.79 (1H, dd, J = 18.7 Hz, 3.0 Hz, COCHH’CH-O), 2.87 (1H, dd,
J = 18.6 Hz, 11.3 Hz, COCHH’CH-O), 3.89 (1H, ddd, J = 12.3 Hz, 8.3 Hz, 4.3 Hz, CHH’OH),
4.06 (1H, ddd, J = 12.0 Hz, 5.0 Hz, 5.0 Hz, CHH’OH), 4.46-4.51 (1H, m, CHN), 4.73-4.81
(1H, m, CH-O), 6.45 (1H, br s, NH) ppm. 13C NMR (100 MHz, CDCl3): δ = 14.0 (CH3,), 22.5,
25.1, 28.8, 31.5 ((CH2)4CH3), 34.9 (CH2(CH2)4CH3), 41.7 (COCH2CH-O), 52.8 (CHN), 61.1
(CH2OH), 73.7 (CH-O), 169.5 (CONH), 171.6 (COO) ppm. MS (ESI): m/z (%): 244 (M+H+,
100). HRMS mass calcd.: C12H21NO4H+ 244.1543; found: 244.1543. IR (cm−1) νmax 1013,
1028, 1072, 1084, 1134, 1186, 1231, 1329, 1391, 1429, 1624 (HN-C=O), 1742 (C=O), 2853,
2916, 2953, 3098 (O-H or N-H), 3206 (O-H or N-H). Chromatography: EtOAc:petroleum ether
1:1 Rf = 0.08. Melting point: 81-83 ◦C. Colorless powder. Yield: 22%.
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5.5 Biotesting
Microorganisms, media and culture conditions
The fluorescent Pseudomonas CMR12a used in this study was previously isolated from the red
cocoyam rhizosphere in Cameroon.347 The studied Pseudomonas strains were routinely main-
tained on Luria-Bertani (LB) medium at 28 ◦C. The different mutant strains were constructed
by Dr. Nam Phuong Kieu.
Table 5.1: Microorganisms used in this study. Abbreviations used: PHZ = phenazine, CLP1 = sessilin, CLP2 =
orfamide.
Strain Relevant characteristics Reference
Pseudomonas
CMR12a PHZ+, CLP1+, CLP2+, wild type (Cameroon) Perneel et al. (2007)347
∆phzR∆cmrR PHZ−, CLP1+, CLP2+, mutant with deletions of the
phzR and the cmrR genes
This study
∆phzI∆cmrI PHZ−, CLP1+, CLP2+, mutant with deletions of the
phzI and the cmrI genes
De Maeyer et al. (2011)361
∆phzI∆cmrIR PHZ−, CLP1+, CLP2+, mutant with deletions of the
phzI, the cmrI and the cmrR genes
This study
∆phzIR∆cmrI PHZ−, CLP1+, CLP2+, mutant with deletions of the
phzI, the phzR and the cmrI genes
This study
∆cmrIR PHZ+, CLP1+, CLP2+, mutant with deletion of the Cmr
operon
This study
∆phzIR PHZ−, CLP1+, CLP2+, mutant with deletion of the
phenazine biosynthesis operon
D’Aes et al. (2011)201
∆phzIR∆cmrIR PHZ−, CLP1+, CLP2+, mutant with deletion of the Phz
and the Cmr operon
This study
NodT2 PHZ+, CLP1+, CLP2+, mutant with deletion of the nodT
gene
This study
∆phzI PHZ−, CLP1+, CLP2+, mutant with deletion of the phzI
gene
De Maeyer et al. (2011)361
∆CLP1 PHZ++, CLP1−, CLP2+, mutant with insertion in CLP1
biosynthesis genes, GmR
D’Aes et al. (2011)201
Plant growth assay
Lettuce (cv. Cobham green) seeds or A. thaliana Col-0 seeds were surface sterilized with 1%
bleach for 45 seconds. After six washes with sterile distilled water, the seeds were germinated on
MS medium (Murashige and Skoog medium including vitamins, Duchefa Biochemie, Haarlem,
the Netherlands) containing 0.8% plant agar (Duchefa Biochemie, Haarlem, the Netherlands).
The plates were covered with aluminium foil and the plants were grown for 3 d in a growth
chamber at 16 ◦C, with a 16 h light cycle and 80% relative humidity.
The compounds to be tested were dissolved in ethanol to obtain a 100 mM stock solution. These
solutions were sterilized by filtration through a Whatman 0.2 µm filter and added to cooled MS
agar medium containing vitamins to obtain the desired 10 µM concentration (25 µL of the
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stock solution to 250 mL of medium). Three-day-old seedlings were transferred to the agar
plates containing the compound to be tested. At least three plates were used per treatment. The
control plates contained the same amount of sterile ethanol. Plants were grown for 14 d in a
growth chamber at 16 ◦C, with a 16 h light cycle and 80% relative humidity. The primary root
length was measured using a ruler.
Fungal growth inhibition assay
The effect of the compounds C10 1g and TA12 11a on fungal growth was evaluated with the
fungi B. cinerea and R. solani. The compounds were added, dissolved in ethanol (100 mM
stock solution) and sterilized by filtration through a Whatman 0.2 µm filter, to the cooled liquid
Difco Potato Dextrose agar medium (250 mL) to reach a concentration of 50 µM. The same
(125 µL) amount of sterile ethanol was added to the medium (250 mL) for the control plates.
An agar cube (diameter = 5 mm), taken from an actively growing fungal colony, was placed in
the center of the plates. After 2 d stored in the dark, the growth was assessed by measuring the
radius of the area covered by the fungal mycelium.
Analysis of phenazine production
A 10 mM stock solution of each AHL was prepared in ethanol and sterilized by filtration through
a Whatman 0.2 µm filter. 50 µL of the applicable stock solution was added to 50 mL of LB
medium to obtain a final concentration of 10 µM of a certain AHL. For the control samples,
an identical amount of sterile ethanol was added. The media were inoculated with the different
strains and incubated overnight on a shaker at 28 ◦C. The phenazine production was quantified
spectrophotometrically via measurement at λ = 369 nm and  = 11393 M−1 cm−1 on the super-
natants of the cultures with pure LB medium as a blank. An estimation of the extinction coef-
ficient was derived before from a standard curve for unsubstituted phenazine (Sigma-Aldrich),
dissolved in water at different concentrations.351 To compare different samples, a correction for
OD620 was made.
Swarming assay
Swarming assays were performed with soft LB agar (0.6% agar) plates. A bacterial colony
was transferred from an agar plate to an Eppendorf tube filled with 1 mL of sterile water. The
suspension was vortexed, then centrifuged for 10 min at 10000 g and the supernatant was dis-
carded to avoid interference of the metabolites produced on agar plates. The bacterial pellet was
resuspended in 1 mL of sterile water and the optical density (OD) was measured at 620 nm.
A dilution to 105 CFU/mL was made and a 5 µL drop was placed in the center of a soft LB
agar plate. To study the effect of different AHLs, agar plates containing 10 µM of AHL were
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prepared via the addition of 500 µL of a sterile 10 mM AHL solution in ethanol to 500 mL of
cooled (50 ◦C) molten medium. The same volume of sterile ethanol was added to the medium
used to prepare the control plates. The plates were placed without cover in a laminar flow for 5
min to allow evaporation of the drop. Three replicates per condition were included. The plates
were incubated at 28 ◦C for 41 h whereafter photos were taken.
HPLC analysis of CLP production
Samples were analyzed at Gembloux Agro-Bio Tech by reverse-phase LC-ESI-MS (HPLC Wa-
ters Alliance 2695/diode array detector, coupled with Waters SQD mass spectrometer) on an
X-terra MS C18 column (100 x 4.6 mm, 3.5 µm, Waters) and eluted with a gradient of acetoni-
trile in water acidified with 0.1% formic acid as described before.201
Analysis of CLP production on agar plates
All cells were scraped off from the agar plate and diluted into 6 mL of water:acetonitrile 1:1.
The resulting suspension was sonicated (Sonoplus, Bandelin Electronic, Berlin) for 1 min, cen-
trifuged for 5 min at 10000 g and the supernatant analyzed on HPLC to determine the amount
of CLP.
Quantification of CLP production
LB medium was freshly prepared and autoclaved. A bacterial colony was transferred from an
agar plate to an Eppendorf tube filled with 1 mL of sterile water. The suspension was vortexed,
then centrifuged for 10 min at 10000 g and the supernatant was discarded. The bacterial pellet
was resuspended in 1 mL of sterile water and the optical density (OD) was measured at 620
nm. From this tube, the required amount was added to the LB medium to obtain a final bacterial
concentration of 105 CFU/mL. This inoculated medium was transferred to a 6-well plate (2.5
mL/well). Three replicates were included for each condition tested. To test the effect of HO8 2e,
a 10 mM stock solution was prepared in ethanol and sterilized by filtration through a Whatman
0.2 µm filter. 50 µL of the applicable stock solution was added to 50 mL of LB medium to
obtain a final concentration of 10 µM of a certain AHL. The same volume of sterile ethanol
was added to the medium used to prepare the control. After the incubation at 28 ◦C for 17, 24,
41, 48 h or 130 h, 3 x 100 µL of medium out of each well was transferred to a 96-well plate
to measure the OD at 620 nm. The remaining suspension was brought into a sterile Eppendorf
and centrifuged for 10 min at 10000 g. The supernatant was filtered through a Whatman 0.2 µm
filter and stored in an LC vial to determine the extracellular amount of CLP. The cell pellet was
resuspended in 1 mL of sterile water and centrifuged once more for 10 min at 10000 g. The
supernatant was removed and the cell pellet resuspended in water:acetonitrile 1:1. This mixture
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was ultra-sonicated (Sonoplus, Bandelin Electronic, Berlin) for 1 min, centrifuged for 5 min at
10000 g and the supernatant analyzed on HPLC to determine the intracellular amount of CLP.
Data analysis
Statistical analysis of data was performed using the software package SPSS 24.0 for Windows
(SPSSinc, Illinois, USA). After controlling the conditions of normality and homogeneity of
variances, Tukey’s test (α = 0.05) was performed.
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Chapter 6
Summary
Nowadays it is generally accepted that microorganisms can communicate with each other and
regulate their gene expression in a cell density-dependent manner. Because this type of gene
regulation is linked with the population density or quorum, the term ‘quorum sensing’ is used
to describe this phenomenon. Gram-negative bacteria rely on N-acylated-L-homoserine lac-
tones (AHLs) for this type of communication. As quorum sensing plays a pivotal role in both
pathogenic and symbiotic bacteria-host interactions, a thorough understanding of this type of
communication will grant mankind many advantages, for example the ability to interfere with
bacterial infections.
In light of the evergrowing human population, an increasing amount of pressure is put on the
agriculture to produce a sufficient amount of food. To combat several plagues, most farmers
rely on synthetic plant protection agents. Confronted with resistance and substantial side effects
on the environment, alternatives need to be sought. One possibility is via the application of
biocontrol agents. Often, these microorganisms rely on secondary metabolites to combat the
malicious organism. Cyclic lipopeptides (CLPs) are examples of such secondary metabolites
with antifungal or antimicrobial properties. Although the production of some CLPs is quorum
sensing-regulated, this is not a general rule. Often, the exact regulation is poorly understood.
Therefore, another advantage of a profound understanding of quorum sensing could be the
ability to fine-tune the secondary metabolite production of biocontrol agents.
In a first part of this research, isotope-labelled AHLs were synthesized. To be able to study the
metabolization of the fatty acid tail of AHLs, the isotope-label was included in the acyl chain of
the AHL. In a first approach, β-oxododecanoic acid i was reduced with sodium borodeuteride to
yield monodeuterated β-hydroxydodecanoic acid ii. This labelled fatty acid ii was coupled to L-
homoserine lactone hydrobromide iii to yield N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine
lactone iv (Scheme 6.1).
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Scheme 6.1. Synthesis of N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine lactone iv.
As only the AHLs bearing the hydroxy moiety can be accessed via this route, an alternative
approach was sought to synthesize AHLs belonging to all the different classes, starting from
one easily available deuterated building block. Aliphatic aldehydes were therefore deuterated at
the α-position via a DMAP-catalyzed H/D-exchange reaction. These labelled aldehydes v were
transformed to the corresponding dideuterated β-hydroxy fatty acids viii via a Reformatsky re-
action with ethyl bromoacetate vi, followed by alkaline hydrolysis (Scheme 6.2). Alternatively,
the deuterated aldehydes v were further elaborated to unfunctionalized [3,3-di-2H]-fatty acids
xi via a chain extension to shift the deuterium label from the acidic α-position to the β-position.
EDC-mediated coupling of these fatty acids xi with Meldrum’s acid yielded the third deuterated
precursor xiii. Reaction of the deuterated precursors viii, xi and xiii with L-homoserine lactone
hydrobromide iii yielded deuterated AHLs ix, xii and xiv (Scheme 6.2).
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Scheme 6.2. Transformation of α,α-dideuterated aldehydes v into deuterated AHLs ix, xii and xiv.
The NMR spectra and MS fragmentation patterns of the labelled analogues iv, ix, xii and xiv
were studied extensively. To be able to compare the spectral data with the unlabelled analogues,
a broad library of natural N-acyl-, N-(3-hydroxyacyl)- and N-(3-oxoacyl)-L-homoserine lac-
186
Summary
tones was synthesized.
In a second part of this research, a hypothetical rearrangement of N-(3-hydroxyacyl)-L-homose-
rine lactones xv toward 1,4-oxazepane-2,5-diones xvi was studied (Scheme 6.3). This rearrange-
ment was not yet reported in literature, but the natural product serratin (xvii) fits in this type of
rearrangement product quite well. Serratin (xvii) had been isolated from a bacterial culture of
Serratia marcescens.
O
N
H
O
O
R
OH
R = alkyl chain
NH
O O
O
OH
NH
O O
O
R OH
A) B)
xv xvi xvii
Scheme 6.3. A) Possible rearrangement of N-(3-hydroxyacyl)-L-homoserine lactones xv toward seven-membered
ring xvi. B) Structure of the bacterial metabolite serratin (xvii).
Several reaction conditions were evaluated but the proposed rearrangement of N-(3-hydroxy-
acyl)-L-homoserine lactones xv was never observed. N-(3-Hydroxynonanoyl)-L-serine xviii
and N-(3-hydroxydodecanoyl)glycine xix failed to cyclize to the desired seven-membered ring
structures xvii and xx as well (Scheme 6.4). However, when repeating this reaction with N-(3-
hydroxynonanoyl)-L-proline xxi and N-(3-hydroxydodecanoyl)sarcosine xxii, 1,4-oxazepane-
2,5-diones xxiii and xxiv were obtained in good yields (Scheme 6.4). This difference in reac-
tivity can be explained by the preference of a secondary amide for the trans-conformation. The
introduction of a third substituent at nitrogen, as is the case for proline and sarcosine derivatives
xxi and xxii, gives rise to an elevated amount of cis-amide structures which are required for the
cyclization to occur. The presence of cis- and trans-rotamers was confirmed via 2D-NOESY
and 1H and 13C NMR analysis. It was therefore decided that a spontaneous rearrangement of a
N-(3-hydroxyacyl) amino acid derivative could not be the origin of serratin-like structures.
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Scheme 6.4. Cyclization of N-(3-hydroxyacyl)amino acid derivatives xviii, xix, xxi, xxii, xxv and xxvi to 1,4-
oxazepane-2,5-diones xvii, xx, xxiii, xxiv, xxvii and xxviii.
From these results it was clear that seven-membered rings, especially those containing two
lactams or one lactam and one lactone bond are extremely difficult to synthesize by cyclization,
and that it is necessary to introduce a third substituent at the amide nitrogen to force the linear
precursor in the correct conformation for cyclization to proceed. However, to obtain the natural
product serratin (xvii), this N-substituent should be a removable one. The intrinsic lability of
the lactone moiety excludes many common protecting groups used for the synthesis of seven-
membered lactams as the reaction conditions needed for their removal will open the lactone
bond. Several reaction conditions were evaluated to remove the N-benzyl group from xxvii but
none was able to deliver the deprotected compound xxix. When ceric ammonium nitrate (CAN)
was used to remove the N-PMB group from xxviii, deprotected 1,4-oxazepane-2,5-dione xxix
was obtained (Scheme 6.5). Attempts to introduce a hydroxymethyl substituent on compound
xxix via reaction with (para)formaldehyde were unsuccessful.
N
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O
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MeO
HN
O
O
O
C6H13
(14%)
5 equiv CAN
EtOAc:H2O 4:1, 0 °C, 2 h
HN
O
O
O
C6H13
OH
CH2O
xxviii xxix xvii
Scheme 6.5. CAN-mediated N-deprotection of xxviii to xxix.
Subsequently, the application of serine-derived oxazolidines (so-called pseudo-prolines) was
evaluated as an alternative. Bicyclic compounds xxx containing a 2-phenyloxazolidine (xxxa),
2-tBu-oxazolidine (xxxb), and a 2,2-dimethyloxazolidine (xxxc) were successfully synthesized
(Scheme 6.6). Although several reaction conditions were evaluated to deprotect the oxazolidine
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moiety from xxxa–c, none was able to deliver serratin (xvii).
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Scheme 6.6. Synthesis of oxazolidine-containing bicyclic structures xxxa–c.
However, the 2-phenyloxazolidine moiety was successfully removed from xxxa via palladium-
catalyzed hydrogenolysis (Scheme 6.7). Remarkably, only the (RSS)-diastereomer of xxxa was
deprotected to yield serratin (xvii).
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H
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xxxa xviixvii
Scheme 6.7. Hydrogenolytic removal of the 2-phenyloxazolidine moiety of xxxa.
When comparing the spectral data of this synthesized analogue (SS)-xvii with those reported
for the isolated serratin, some discrepancies were found. Careful examination of literature data
led to the conclusion that the actual structure of serratin (xvii) is a symmetrical serratamolide
analogue xxxv (Figure 6.1).
NH
O HN
O
O
O
O
O
OH
HO
(S) NH
(S)O
O
O
OH
xvii xxxv
Figure 6.1. Reported structure of serratin (xvii) and proposed actual structure xxxv of this natural product.
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In a third part of this PhD thesis, the biological activity of some AHLs was studied. As the
assays evaluating the effect of the synthesized AHLs on plant growth showed a lot of variation,
this effect was not studied in depth.
Subsequently, the influence of some AHLs on the cyclic lipopeptide (CLP)-production of the
promising biocontrol strain Pseudomonas CMR12a was studied extensively. This strain pro-
duces two types of CLPs, sessilin and orfamide, and possesses two QS systems, PhzI/PhzR and
CmrI/CmrR, but their involvement in the CLP-production was not clear. At first it was studied
whether the fatty acid chain of the AHLs was recycled into the produced CLPs of this strain.
After feeding experiments with isotope-labelled AHL ixa, it was concluded that no such recy-
clation took place. Via swarming assays with different QS mutant strains, it was concluded that
the PhzI/PhzR system was crucial to halt the swarming behavior (Figure 6.2) and that the AHL
N-(3-hydroxyoctanoyl)-L-homoserine lactone (HO8) played a crucial role.
Figure 6.2. Left: typical swarming phenotype observed with an active Phz-operon. Right: typical swarming phe-
notype observed with an inactive Phz-operon.
To further study the effect of HO8 on the CLP-production, a switch to liquid culture was made
to allow quantification of the CLP-production. As orfamide stimulates swarming and sessilin
opposes swarming, it was expected that sessilin production was stimulated via HO8 through the
Phz-operon. However, analysis of the CLP-production of different QS-mutants did not reveal
a difference in sessilin production. On the other hand, the orfamide production was clearly re-
duced in mutants lacking an active Phz-operon. The orfamide production could be restored to
wild type levels after complementation with HO8 to a phzI-mutant (unable to produce HO8 but
able to respond to exogenous added HO8). It was observed that mutants with a high sessilin
to orfamide ratio displayed a stronger swarming phenotype than those with a higher amount of
orfamide. So it was hypothesized that the interaction between sessilin and orfamide determines
the swarming phenotype. This was confirmed by combining a strain (∆CLP1) with a high or-
famide production and a clear swarming behavior and a strain (∆PhzIR) with a high sessilin
production and a clear swarming behavior as well. Combination of these two swarming strains
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resulted in a sessile phenotype (Figure 6.3). It was therefore hypothesized that both orfamide
and sessilin can stimulate swarming, but when they are both present in a high amount, they can
impede each other and inhibit swarming.
Figure 6.3. Observed swarming phenotype of mutant strains ∆CLP1, ∆PhzIR and a co-culture of both strains.
In this PhD thesis isotope-labelled AHLs were synthesized which can be used as a tool to study
the metabolization of AHLs. Secondly, the possible rearrangement of N-(3-hydroxyacyl)-L-
homoserine lactones was investigated and proven to be very unlikely. This investigation resulted
in the successful development of a synthetic entry toward 1,4-oxazepane-2,5-diones, which
are extremely difficult to synthesize due to the presence of a lactam with a preference for the
trans-conformation and a labile lactone moiety in one ring structure. By applying the disclosed
methodology on the synthesis of the natural product serratin, the incorrect structural assignment
of this compound was identified. Thirdly, the profound effect of a QS signal molecule, HO8,
on the swarming behavior of Pseudomonas species CMR12a, was demonstrated. This influence
goes presumably via an elegant fine-tuning of the ratio of the two produced CLPs, orfamide and
sessilin via the control of orfamide production.
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Chapter 7
Samenvatting
Tegenwoordig wordt algemeen aanvaard dat micro-organismen met elkaar kunnen commu-
niceren en hun genexpressie op een populatieafhankelijke manier kunnen coördineren. Aan-
gezien dit type van genregulatie gekoppeld is aan de populatiedensiteit of quorum, wordt de
term ‘quorum sensing’ gebruikt om dit fenomeen te beschrijven. Gram-negatieve bacteriën ge-
bruiken N-geacyleerde-L-homoserine lactonen (AHLs) voor dit type communicatie. Aangezien
quorum sensing een cruciale rol speelt in bacterie-gastheerinteracties van zowel pathogene als
symbiotische bacteriën, zal een diepgaand inzicht in dit soort communicatie de mensheid vele
voordelen bieden, zoals de mogelijkheid om bacteriële infecties te verstoren.
Door de immer groeiende menselijke bevolking wordt steeds meer druk uitgeoefend op de land-
bouw om voldoende voedsel te produceren. Om verschillende plagen te bestrijden, vertrouwen
de meeste boeren op synthetische plantenbeschermingsmiddelen. Door toenemende resistentie
en bepaalde bijwerkingen op het milieu, moeten er echter alternatieven gezocht worden. Een
mogelijk alternatief is het gebruik van micro-organismen als biologische bestrijdingsmiddelen.
Vaak zijn deze micro-organismen afhankelijk van hun secundaire metabolieten om het ziek-
teverwekkende organisme te bestrijden. Cyclische lipopeptiden (CLPs) zijn een voorbeeld van
dergelijke secundaire metabolieten met antifungale en antimicrobiële eigenschappen. Hoewel
de productie van enkele CLPs quorum sensing gereguleerd is, is dit niet altijd het geval. Boven-
dien is het onderliggende controlemechanisme achter de biosynthese van CLPs onvoldoende in
kaart gebracht. Daarom is een ander voordeel van een diepgaand inzicht in quorum sensing de
mogelijkheid om de productie van secundaire metabolieten van deze micro-organismen beter te
begrijpen en te sturen.
In een eerste onderdeel van dit onderzoek werden isotoopgelabelde AHLs gesynthetiseerd. Om
de metabolisatie van de vetzuurstaart van AHLs te kunnen bestuderen, werd het isotooplabel
in de acylketen van het AHL geplaatst. In een eerste benadering werd β-oxododecaanzuur i
gereduceerd met natriumboordeuteride om aldus monogedeutereerd β-hydroxydodecaanzuur
ii te bekomen. Dit gelabelde vetzuur ii werd gekoppeld met L-homoserine lacton waterstof-
bromide iii, waardoor N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine lacton iv bekomen werd
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(Schema 7.1).
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Schema 7.1. Synthese van N-(3-hydroxydodecanoyl-[3-2H])-L-homoserine lacton iv.
Aangezien alleen de AHLs met een hydroxygroep toegankelijk zijn via deze route, werd er
een alternatieve aanpak gezocht om AHLs behorende tot alle verschillende klasses te syn-
thetiseren, vertrekkende vanuit een gemakkelijk beschikbare gedeutereerde bouwsteen. Daarom
werden alifatische aldehyden gedeutereerd op de α-plaats via een DMAP-gekatalyseerde H/D-
uitwisselingsreactie. Deze gelabelde aldehyden v werden omgezet in de overeenkomstige di-
gedeuteerde β-hydroxyvetzuren viii via een Reformatskyreactie met ethylbroomacetaat vi, ge-
volgd door een alkalische hydrolyse (Schema 7.2). Anderzijds werden de gedeutereerde alde-
hyden v verder omgezet tot niet-gefunctionaliseerde [3,3-di-2H]-vetzuren xi via een ketenver-
lenging met als doel het deuteriumlabel van de relatief zure α-plaats te verplaatsen naar de
β-plaats. Koppeling van deze vetzuren xi met Meldrums zuur door middel van EDC leverde de
derde gedeutereerde precuror xiii. Reactie van deze gedeutereerde precursoren viii, xi en xiii
met L-homoserine lacton waterstofbromide iii gaf gedeutereerde AHLs ix, xii en xiv (Schema
7.2).
R
1) 2 equiv NaBH4
    Et2O:MeOH 1:1,
    k.t., 2 h, 88-96%
2) 1,4 equiv Et3N
    1,15 equiv MsCl
    droge Et2O, 0 °C, 
    dan k.t., 2 h
1) 2,5 equiv KCN
    DMSO, 120 °C, o.n.
    86-95%
2) 4 equiv NaOH
    MeOH:H2O 9:1, ∆, o.n.
O
H
D D
R O
D D
S
O
O
Me R
D D O
OH
droge Et2O, ∆, 1 h
1 equiv
1,3 equiv Zn
0,1 equiv TMS-Cl
THF:MeOH:H2O 2:1:1,
 0 °C tot k.t., o.n.
2 equiv LiOH
OH
OH O
R
D D
OEt
OH O
R
D D
OEt
O
Br
(R = C4H9) 
(R = C5H11) 
(R = C8H17) 
(R = C9H19)
(R = C4H9, 96%)
(R = C5H11, 97%)
(R = C8H17, 93%)
(R = C9H19, 92%)
droge CH2Cl2, N2, 
k.t., 20 h
1 equiv 2,2-dimethyl-1,3-
dioxaan-4,6-dion  
(Meldrums zuur) 
1,1 equiv EDC.HCl
2,1 equiv DMAP
O
O
O
O
OH
R
DD
(R = C4H9, 89%)
(R = C5H11, 84%)
(R = C8H17, 89%)
(R = C9H19, 95%)
(R = C5H11, 81%)
(R = C8H17, 77%)
(R = C9H19, 97%)
(R = C5H11, 58%)
(R = C8H17, 80%)
(R = C9H19, 70%)
(R = C5H11, kwant.)
(R = C8H17, kwant.)
(R = C9H19, kwant.)
O
O
N
H
O
R
OH
D D
(R = C4H9, 48%, D-incorp.: 86%, d.r.: 3:2)
(R = C5H11, 58%, D-incorp.: 93%, d.r.: 3:2)
(R = C8H17, 63%, D-incorp.: 95%, d.r.: 5:4)
(R = C9H19, 42%, D-incorp.: 93%, d.r.: 5:4)
O
O
H2NHBr
1 equiv Et3N
1 equiv EDC.HCl
1 equiv
O
O
N
H
R
ODD
(R = C5H11, 55%, D-incorp.: 92%) 
(R = C8H17, 69%, D-incorp.: 95%) 
(R = C9H19, 52%, D-incorp.: 92%)
O
O
H2NHBr
1 equiv Et3N
1 equiv EDC.HCl
1 equiv
H2O, k.t., 3 h
H2O, k.t., 3 h
O
N
H
O
O
(R = C5H11, 49%, D-incorp.: 93%)
(R = C8H17, 66%, D-incorp.: 95%)
(R = C9H19, 54%, D-incorp.: 93%)
O
droge CH3CN, k.t., 2 h, dan ∆, o.n. R
D D
O
O
H2NHBr
1,2 equiv Et3N
1 equiv
va
vb
vc
vd
vi
viia
viib
viic
viid
viiia
viiib
viiic
viiid
iii
iii
iii
ixa
ixb
ixc
ixd
xa
xb
xc
xia
xib
xic
xiia
xiib
xiic
xiiia
xiiib
xiiic
xiva
xivb
xivc
Schema 7.2. Omzetting van α,α-digedeutereerde aldehyden v tot gedeutereerde AHLs ix, xii en xiv.
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De NMR spectra en het MS fragmentatiepatroon van de gelabelde analogen iv, ix, xii en xiv
werden uitvoerig bestudeerd. Om de spectrale gegevens te vergelijken met de niet-gelabelde
analogen, werd een ruime bibliotheek van natuurlijke N-acyl-, N-(3-hydroxyacyl)- en N-(3-
oxoacyl)-L-homoserine lactonen gesynthetiseerd.
In een tweede deel van dit onderzoek werd de mogelijke omlegging van N-(3-hydroxyacyl)-
L-homoserine lactonen xv tot 1,4-oxazepaan-2,5-dionen xvi (Schema 7.3) bestudeerd. Deze
omlegging werd nog niet in de literatuur beschreven, maar het natuurproduct serratine (xvii) past
vrij goed in dit type omleggingsproduct. Serratine (xvii) werd reeds uit een bacteriële cultuur
van Serratia marcescens geïsoleerd.
O
N
H
O
O
R
OH
R = alkylketen
NH
O O
O
OH
NH
O O
O
R OH
A) B)
xv xvi xvii
Schema 7.3. A) De mogelijke omlegging van N-(3-hydroxyacyl)-L-homoserine lactonen xv tot de zevenring xvi.
B) Structuur van het natuurproduct serratine (xvii).
Verscheidene reactieomstandigheden werden geëvalueerd, maar de vooropgestelde omlegging
van N-(3-hydroxyacyl)-L-homoserine lactonen xv werd nooit vastgesteld. N-(3-Hydroxynona-
noyl)-L-serine xviii en N-(3-hydroxydodecanoyl)glycine xix faalden eveneens in de cyclizatie
tot de gewenste zevenringstructuren xvii en xx (Schema 7.4). Echter, wanneer deze reactie werd
herhaald met N-(3-hydroxynonanoyl)-L-proline xxi en N-(3-hydroxydodecanoyl)sarcosine xxii,
werden 1,4-oxazepaan-2,5-dionen xxiii en xxiv verkregen in een goed rendement (Schema 7.4).
Dit verschil in reactiviteit kan verklaard worden door de voorkeur van een secundair amide voor
de trans-conformatie. De invoering van een derde substituent op stikstof, zoals het geval is voor
proline- en sarcosinederivaten xxi en xxii, leidt tot een verhoogd aandeel cis-amide-structuren
die vereist zijn voor de cyclisatie. De aanwezigheid van cis- en trans-rotameren werd bevestigd
via 2D-NOESY en 1H en 13C NMR analyse.
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(R1 = H, R2 = H, R = C9H19)
xviii
xix
xxi
xxii
xxv
xxvi
xvii
xx
xxiii
xxiv
xxvii
xxviii
Schema 7.4. Ringsluiting van N-(3-hydroxyacyl)aminozuurderivaten xviii, xix, xxi, xxii, xxv en xxvi tot 1,4-
oxazepaan-2,5-dionen xvii, xx, xxiii, xxiv, xxvii en xxviii.
Uit deze resultaten bleek dat zevenringen, in het bijzonder deze die twee lactamen of één lactam
en één lacton bevatten, extreem moeilijk te synthetiseren zijn door middel van cyclisatie en het
noodzakelijk is om een substituent te introduceren op het stikstofatoom van de lactambinding
om de lineaire precursor in de correcte conformatie te dwingen zodat cyclisatie kan plaatsvin-
den. Om het natuurproduct serratine (xvii) te verkrijgen, moet deze N-substituent echter ver-
wijderd kunnen worden. De intrinsieke labiliteit van het lacton sluit veel beschermende groepen
uit die vaak gebruikt worden voor de synthese van zevenringbevattende lactamen, aangezien de
omstandigheden die nodig zijn voor de verwijdering ervan de lactonbinding zullen openen.
Verschillende reactieomstandigheden werden getest om de N-benzylgroep van xxvii te verwij-
deren, maar geen methode slaagde erin de ontschermde verbinding xxix te leveren. Wanneer
ceriumammoniumnitraat (CAN) werd gebruikt om de N-PMB groep van xxviii te verwijderen,
werd het ontschermde 1,4-oxazepaan-2,5-dion xxix verkregen (Schema 7.5). Pogingen om een
hydroxymethylgroep op verbinding xxix in te voeren via reactie met (para)formaldehyde waren
niet succesvol.
N
O
O
O
C6H13
MeO
HN
O
O
O
C6H13
(14%)
5 equiv CAN
EtOAc:H2O 4:1, 0 °C, 2 h
HN
O
O
O
C6H13
OH
CH2O
xxviii xxix xvii
Schema 7.5. N-Ontscherming van xxviii tot xxix met CAN.
Vervolgens werd het gebruik van serine-afgeleide oxazolidinen (zogenaamde pseudoprolines)
als een mogelijke oplossing geëvalueerd. Bicyclische verbindingen die een 2-fenyloxazolidine
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(xxxa), een 2-tBu-oxazolidine (xxxb) of een 2,2-dimethyloxazolidine (xxxc) bevatten werden
succesvol gesynthetiseerd (Schema 7.6). Hoewel verscheidene reactieomstandigheden werden
getest om de oxazolidine-eenheid van xxxa–c te verwijderen, kon serratine (xvii) niet verkregen
worden.
N
H
OMe
O
O
C6H13 OH
OOH N
OMe
O
O
O
1) 1 equiv NMM
    1 equiv
    20 min, 0 °C
2) 1,05 equiv
EtOAc, 0 °C, 2 h, dan k.t., o.n.
Cl
O
O
NO Me
HO C6H13
5 equiv NaOH MeOH:H2O 3:1, 
k.t., o.n.
N
OH
O
O
O
HO C6H13
N O
OO
O
C6H13
0,2 equiv DMAP
1,1 equiv EDC.HCl
droge CH2Cl2, k.t., o.n. 
   (verdund, 20 mM)
         (niet geïsoleerd)
H
(R1 = Ph, R2 = H, 53% na 3 stappen, d.r. 1:1)
(R1 = tBu, R2 = H, 63% na 3 stappen, d.r. 1:1)
(R1 = R2 = Me, 18% na 3 stappen, d.r. 1:1,3)
R1
N
H
OMe
O
OH
0,1 equiv PTSA.H2O
5 equiv DMP 
(2,2-dimethoxypropaan)
droge tolueen, ∆, 3 h,
    Dean-Stark
C6H13
OOH
R1
R2
R1
R2
R1
R2
Voor R1 = R2 = MeVoor R1 = Ph of tBu en R2 = H
R2
         (niet geïsoleerd)
xxxi
xxxiia–c
xxxiii
xxxiva–cxxxa
xxxb
xxxc
Schema 7.6. Synthese van oxazolidinebevattende bicyclische structuren xxxa–c.
Echter, de 2-fenyloxazolidinegroep werd succesvol verwijderd door middel van palladium-
gekatalyseerde hydrogenolyse (Schema 7.7). Opmerkelijk genoeg werd alleen het (RSS)-diaste-
reomeer van xxxa ontschermd tot serratine (xvii).
N (S) O
OO
(R)
O
C6H13
HN (S) O
OHO
(S)
O
C6H13
1 atm H2
50 wt% Pd(OH)2/C
HN (S) O
OHO
(R)
O
C6H13
+
(SS)- (SR)-(d.r.: 1:1)
H
(22%) (0%)
EtOAc, k.t., 6 h
xxxa xviixvii
Schema 7.7. Verwijdering van de 2-fenyloxazolidinegroep van xxxa via hydrogenolyse.
Bij het vergelijken van de spectrale data van de gesynthetiseerde verbinding (SS)-xvii met de ge-
rapporteerde data voor het geïsoleerde serratine, werden er een aantal discrepanties opgemerkt.
Zorgvuldige vergelijking met literatuurgegevens leidde tot de conclusie dat de werkelijke struc-
tuur van serratine (xvii) een symmetrisch serratamolide analoog xxxv is (Figuur 7.1).
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xvii xxxv
Figuur 7.1. Gerapporteerde structuur van serratine (xvii) en voorgestelde werkelijke structuur xxxv van dit natu-
urproduct.
In een derde deel van dit doctoraat werd de biologische activiteit van sommige AHLs bestudeerd.
Aangezien de experimenten die het effect van de gesynthetiseerde AHLs op plantengroei moesten
testen, veel variatie vertoonden, werd dit effect niet verder in detail bestudeerd.
De invloed van sommige AHLs op de cyclische lipopeptiden (CLP)-productie van de veel-
belovende biocontrolestam Pseudomonas CMR12a werd daarentegen uitgebreid bestudeerd.
Deze stam produceert twee soorten CLPs, sessiline en orfamide, en beschikt over twee QS-
systemen, PhzI/PhzR en CmrI/CmrR. De rol van deze QS systemen in de CLP-productie was
echter nog niet duidelijk. Aanvankelijk werd onderzocht of de vetzuurketen van de AHLs her-
bruikt werd voor de biosynthese van de CLPs. Na het uitvoeren van een experiment met het
isotoopgelabelde AHL ixa werd geconcludeerd dat er geen dergelijke recyclage plaatsvond. Via
swarming assays met verschillende QS mutantstammen werd geconcludeerd dat het PhzI/PhzR
systeem van cruciaal belang is om het swarmgedrag van deze stam tegen te gaan (Figuur 7.2) en
dat het AHL N-(3-hydroxyoctanoyl)-L-homoserine lacton (HO8) hierbij een cruciale rol speelt.
Figuur 7.2. Links: het typische swarmingfenotype dat vastgesteld wordt wanneer er een actief Phz-operon aan-
wezig is. Rechts: het typische swarmingfenotype dat vastgesteld wordt wanneer er geen actief Phz-operon aan-
wezig is.
Om het effect van HO8 op de CLP-productie verder te bestuderen werd er overgeschakeld
naar vloeibare bacteriële culturen om aldus de kwantificatie van de CLP-productie mogelijk
te maken. Aangezien orfamide swarming stimuleert en sessiline geassocieerd is met het in-
hiberen van swarming, werd verwacht dat HO8 de productie van sessiline zou stimuleren via
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het Phz-operon. Bij analyse van de sessilineproductie werden er echter geen verschillen tussen
de verschillende QS-mutanten waargenomen. De productie van orfamide was echter duidelijk
gedaald in mutanten zonder een actief Phz-operon. De productie van orfamide kon hersteld
worden tot het wildtype-niveau na complementatie met HO8 aan een phzI-mutant (niet in staat
om HO8 te produceren maar wel in staat te reageren op exogeen toegevoegd HO8). Er werd
vastgesteld dat mutanten met een hoge sessiline ten opzichte van orfamide ratio een sterker
swarmingfenotype vertoonden dan mutanten met een hoger orfamidegehalte. Hierdoor werd
verondersteld dat de interactie tussen sessiline en orfamide het uiteindelijke swarmingfenotype
bepaalt. Deze hypothese werd bevestigd door een stam (∆CLP1) met een hoge orfamidepro-
ductie en een duidelijk swarminggedrag te combineren met een andere stam (∆PhzIR) met een
hoge sessilineproductie en eveneens een duidelijk swarminggedrag. Combinatie van deze twee
swarmende stammen resulteerde in een sessiel fenotype (Figuur 7.3). Derhalve werd de hy-
pothese vooropgesteld dat zowel orfamide als sessiline swarmen kunnen stimuleren, maar als
ze beide in een hoge concentratie aanwezig zijn, ze elkaar belemmeren en swarmen verhinderd
wordt.
Figuur 7.3. Het geobserveerde swarmingfenotype van mutantstammen ∆CLP1, ∆PhzIR en een co-cultuur van
beide stammen.
In dit doctoraatsonderzoek werden isotoopgelabelde AHLs gesynthetiseerd die gebruikt kun-
nen worden om de metabolisering van AHLs te bestuderen. Ten tweede werd de mogelijke
omlegging van N-(3-hydroxyacyl)-L-homoserine lactonen onderzocht maar deze bleek zeer on-
waarschijnlijk. Dit onderzoek resulteerde in de succesvolle ontwikkeling van een methode voor
de synthese van 1,4-oxazepaan-2,5-dionen, die uiterst moeilijk te synthetiseren zijn door de
aanwezigheid van een lactam met een voorkeur voor de trans-conformatie en een labiel lacton
in één ringstructuur. Door de ontwikkelde methodologie toe te passen op de synthese van het
natuurproduct serratine, werd de foutieve structurele toewijzing van deze verbinding geïdenti-
ficeerd. Daarnaast werd de invloed van een QS-signaalmolecule, HO8, op het swarminggedrag
van Pseudomonas CMR12a aangetoond. Deze verbinding oefent vermoedelijk zijn effect uit
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door een elegante controle van de verhouding van de twee geproduceerde CLPs, orfamide en
sessiline, via de controle van de orfamideproductie.
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